---
document_datetime: 2023-09-21 20:43:36
document_pages: 163
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/keytruda-h-c-3820-ii-0099-epar-assessment-report-variation_en.pdf
document_name: keytruda-h-c-3820-ii-0099-epar-assessment-report-variation_en.pdf
version: success
processing_time: 522.8523583
conversion_datetime: 2025-12-22 09:42:01.293311
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

16 September 2021 EMA/CHMP/563896/2021 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Keytruda

International non-proprietary name: pembrolizumab

Procedure No. EMEA/H/C/003820/II/0099

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure..............................................                                   | 7                                                                                                         |
|----------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation ..................................................................................................7 |                                                                                                           |
| 1.2. Steps taken for the assessment of the product                                                                         | ........................................................8                                                 |
| 2. Scientific discussion................................................................................                   | 8                                                                                                         |
| 2.1. Introduction                                                                                                          | ........................................................................................................8 |
| 2.1.1. Problem statement                                                                                                   | ............................................................................................8             |
| 2.1.2. About the product                                                                                                   | ........................................................................................... 11            |
| 2.1.3. The development programme/compliance with CHMP guidance/scientific advice......                                     | 11                                                                                                        |
| 2.1.4. General comments on compliance with GCP........................................................                     | 12                                                                                                        |
| 2.2. Non-clinical aspects............................................................................................      | 12                                                                                                        |
| 2.2.1. Ecotoxicity/environmental risk assessment.........................................................                  | 12                                                                                                        |
| 2.3. Clinical aspects                                                                                                      | .................................................................................................. 12     |
| 2.3.1. Introduction....................................................................................................    | 12                                                                                                        |
| 2.3.2. Pharmacokinetics                                                                                                    | ............................................................................................ 14           |
| 2.3.3. Pharmacodynamics..........................................................................................          | 19                                                                                                        |
| 2.3.4. PK/PD modelling                                                                                                     | ............................................................................................. 19          |
| 2.3.5. Discussion on clinical                                                                                              | pharmacology................................................................... 20                        |
| 2.3.6. Conclusions on clinical pharmacology.................................................................               | 20                                                                                                        |
| 2.4. Clinical efficacy                                                                                                     | .................................................................................................. 21     |
| 2.4.1. Dose response study(ies)                                                                                            | ................................................................................. 21                      |
| 2.4.2. Main study                                                                                                          | ..................................................................................................... 21  |
| 2.4.3. Discussion on clinical efficacy............................................................................         | 85                                                                                                        |
| 2.4.4. Conclusions on the clinical efficacy ....................................................................           | 92                                                                                                        |
| 2.5. Clinical safety                                                                                                       | .................................................................................................... 92   |
| 2.5.1. Discussion on clinical safety............................................................................           | 152                                                                                                       |
| 2.5.2. Conclusions on clinical safety..........................................................................            | 155                                                                                                       |
| 2.5.3. PSUR cycle                                                                                                          | ................................................................................................... 155   |
| 2.6. Risk management plan                                                                                                  | ..................................................................................... 155                 |
| 2.7. Update of the Product information......................................................................               | 157                                                                                                       |
| 2.7.1. User consultation ..........................................................................................        | 157                                                                                                       |
| 3. Benefit-Risk Balance...........................................................................                         | 158                                                                                                       |
| 3.1. Therapeutic Context .........................................................................................         | 158                                                                                                       |
| 3.1.1. Disease or condition                                                                                                | ...................................................................................... 158                |
| 3.1.2. Available therapies and unmet medical need.....................................................                     | 158                                                                                                       |
| 3.1.3. Main clinical studies.......................................................................................        | 158                                                                                                       |
| 3.2. Favourable effects............................................................................................        | 158                                                                                                       |
| 3.3. Uncertainties and limitations about favourable effects...........................................                     | 159                                                                                                       |
| 3.4. Unfavourable effects.........................................................................................         | 159                                                                                                       |
| 3.5. Uncertainties and limitations about unfavourable effects                                                              | ....................................... 160                                                               |
| 3.6. Effects Table....................................................................................................     | 160                                                                                                       |
| 3.7. Benefit-risk assessment and discussion...............................................................                 | 161                                                                                                       |
| 3.7.1. Importance of favourable and unfavourable effects............................................                       | 161                                                                                                       |
| 3.7.2. Balance of benefits and risks                                                                                       | .......................................................................... 161                            |

<div style=\"page-break-after: always\"></div>

3.7.3. Additional considerations on the benefit-risk balance ......................................... 161

3.8. Conclusions  ..................................................................................................... 162

4. Recommendations  ............................................................................... 163

<div style=\"page-break-after: always\"></div>

## List of abbreviations

1L First-line AE Adverse event(s) AEOSI  Adverse event(s) of special interest ALT Alanine aminotransferase ASaT All Subjects as Treated AST Aspartate aminotransferase AUC Area under the curve BICR Blinded independent central radiology review Cavg Average concentration over the dosing interval CD8+ Cluster of differentiation 8 positive cHL Classic Hodgkin lymphoma CI Confidence interval Cmax Observed maximum (peak) concentration Cmin Minimal (trough) plasma concentration CNS Central nervous system CPS Combined positive score CR Complete Response CRC Colorectal cancer CSR Clinical Study Report cSSC Cutaneous squamous cell carcinoma CTCAE  Common Terminology Criteria for Adverse Events DMC Data monitoring committee dMMR  Mismatch repair deficient DOR Duration of response ECOG PS Eastern Cooperative Oncology Group performance status EMA European Medicines Agency E-R Exposure-response ER Estrogen receptor ESMO European Society for Medical Oncology EU European Union FAS Full analysis set FDA US Food and Drug Administration

<div style=\"page-break-after: always\"></div>

FoxP3 Forkhead box P3 gBRCAm Germline breast cancer susceptibility gene-mutated GCP Good Clinical Practice HCC Hepatocellular carcinoma HER2 Human epidermal growth factor receptor 2 HNSCC Head and neck squamous cell carcinoma HR Hazard ratio IA1 First interim efficacy analysis IA2 Second interim efficacy analysis IC PD-L1 stained tumor-infiltrating immune cells IFNγ Interferon gamma IgG4 Immunoglobulin G4 IHC Immunohistochemistry IL-2 Interleukin-2 ITT Intent-to-treat IV Intravenous KM Kaplan-Meier mAb Monoclonal antibody MCC Merkel cell carcinoma MSI-H  Microsatellite instability-high NAC Neoadjuvant chemotherapy NCCN National Comprehensive Cancer Network NKC Natural killer cells NSCLC  Non-small cell lung cancer ORR Objective response rate OS Overall survival PARP Poly (ADP-ribose) polymerase PD Progressive disease PD-1 Programmed cell death 1 PD-L1 Programmed cell death 1 ligand 1 PD-L2 Programmed cell death 1 ligand 2 PFS Progression-free survival PgR Progesterone receptor

<div style=\"page-break-after: always\"></div>

- PI Prediction interval PK Pharmacokinetic(s) PMBCL  Primary mediastinal B-cell lymphoma PR Partial Response PRO Patient-reported outcome PTs Preferred terms Q2W Every 2 weeks Q3W Every 3 weeks Q6W Every 6 weeks QoL Quality of life RCC Renal cell carcinoma RECIST 1.1 Response Evaluation Criteria in Solid Tumors version 1.1 RSD Reference Safety Dataset SAE Serious adverse event(s) SAP Statistical Analysis Plan sBLA Supplemental Biologics License Application SCLC Small cell lung cancer SD Stable Disease SmPC Summary of product characteristics SOC System Organ Class sPMA Supplemental Premarket Approval sSAP Supplemental Statistical Analysis Plan TILs Tumor-infiltrating lymphocytes TMB Tumor mutational burden TNBC Triple negative breast cancer TNFα Tumor necrosis factor alpha US United States USPI United States prescribing information WBC White blood cells

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Merck Sharp &amp; Dohme B.V. submitted to the European Medicines Agency on 19 November 2020 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication for Keytruda to include in combination with chemotherapy, treatment of locally recurrent unresectable or metastatic triple negative breast cancer in adults whose tumours express PD L1 with a CPS ≥ 10 and who have not received prior chemotherapy for metastatic disease; as a consequence, sections 4.1, 4.2 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 31.1 of the RMP has also been submitted.

The variation requested amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included EMA Decision P/0043/2018 on the agreement of a paediatric investigation plan (PIP).

At the time of submission of the application, the PIP (EMEA-001474-PIP01-13-M01) covering the condition 'Treatment of all conditions included in the category of malignant neoplasms (except nervous system, haematopoietic and lymphoid tissue)' was not yet completed as some measures were deferred.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the MAH did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## Scientific advice

The MAH did not seek Scientific Advice at the CHMP.

<div style=\"page-break-after: always\"></div>

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Armando Genazzani

Co-Rapporteur:

Jan Mueller-Berghaus

| Timetable                                            | Actual dates      |
|------------------------------------------------------|-------------------|
| Submission date                                      | 19 November 2020  |
| Start of procedure:                                  | 26 December 2020  |
| CHMP Rapporteur Assessment Report                    | 26 February 2021  |
| CHMP Co-Rapporteur Assessment Report                 | 19 February 2021  |
| PRAC Rapporteur Assessment Report                    | 25 February 2021  |
| PRAC Outcome                                         | 11 March 2021     |
| CHMP members comments                                | 15 March 2021     |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report | 20 March 2021     |
| Request for supplementary information (RSI)          | 25 March 2021     |
| CHMP Rapporteur Assessment Report                    | 28 May 2021       |
| CHMP members comments                                | 14 June 2021      |
| Updated CHMP Rapporteur Assessment Report            | 17 June 2021      |
| Request for supplementary information (RSI)          | 24 June 2021      |
| CHMP Rapporteur Assessment Report                    | 1 September 2021  |
| CHMP members comments                                | 6 September 2021  |
| Updated CHMP Rapporteur Assessment Report            | 9 September 2021  |
| Opinion                                              | 16 September 2021 |

## 2. Scientific discussion

## 2.1. Introduction

## 2.1.1. Problem statement

## Disease or condition

The claimed therapeutic indication is: 'KEYTRUDA, in combination with chemotherapy, is indicated for the treatment of locally recurrent unresectable or metastatic triple negative breast cancer in adults whose tumours express PD-L1 with a CPS ≥ 10 and who have not received prior chemotherapy for metastatic disease.'

<div style=\"page-break-after: always\"></div>

## Epidemiology

Breast cancer is the most common cancer and the leading cause of cancer mortality in women. In Europe, the expected number of new cases and deaths from breast cancer is 522,500 and 137,700, respectively 1 . TNBC represents 15% to 20% of all breast cancers 2 .

## Biologic features

TNBC is phenotypically defined by a lack of ER and PgR expression and the absence of HER2 overexpression and/or amplification 4   3 . TNBC is overlapping, but not synonymous, with the basal-like subtype defined by gene expression, as about 70% of TNBCs have basal-like characteristics according to gene-expression profiling 4 . TNBC is a heterogeneous entity that encompasses several subtypes with distinct molecular characteristics (basal-like 1 and 2, mesenchymal, mesenchymal stem-like, immunomodulatory, luminal androgen receptor) 5 . Actionable somatic mutations are generally lowfrequency events in TNBC 6 . TNBCs are significantly associated with BRCA1-germline mutations and high levels of genomic instability, TP53 (82%) and PIK3CA (10%) being the two most frequently mutated somatic genes 7 . Approximately 15% of subjects with TNBC carry deleterious BRCA mutations 8 .

TNBC is characterized by the presence of TILs and gene signatures enriched for cytotoxic CD8+ T cell and NKC activity, suggesting that this cancer subtype may be an immunoreactive disease and may be amenable to immune modulation of the tumor microenvironment 9 . Published studies report PD-L1 positivity ranging from 20% to 60% in all breast cancers 10   11 , which have been associated to good or bad prognosis in different studies 12 . In addition, PD-L1 positivity in breast cancer is often associated with TILs or TIL activity 9  and the presence of other immune regulators 13 , although there is a noteworthy heterogeneity between breast tumors even within the same molecular subtype 14 .

## Clinical presentation, diagnosis and stage/prognosis

TNBC occur more frequently in younger patients and it is associated with higher tumor grade at diagnosis, a higher risk of distant disease recurrence, occurring earlier with a peak of recurrence within 1

1  Ferlay J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018;103:356 -87.

2  Bauer KR, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer. 2007 May 1;109(9):1721 -8.

3  Arnedos M, Bihan C, Delaloge S, Andre F. Triple-negative breast cancer: are we making headway at least? Ther Adv Med Oncol. 2012 Jul;4(4):195 -210.

4  Badve S, et al. Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol. 2011 Feb;24(2):157 -67.

5  Lehmann BD, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750 -67.

6  Bareche Y, et al. Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis. Ann Oncol 2018;29:895 -902.

7  Lehmann BD, Pietenpol JA. Clinical implications of molecular heterogeneity in TNBC. Breast 2015;24: S36-S40.

8  Sharma P, et al. Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing. Breast Cancer Res Treat . 2014; 145:707-714.

9  Stagg J, Allard B. Immunotherapeutic approaches in triple negative breast cancer: latest research and clinical prospects. Ther Adv Med Oncol. 2013 May;5(3):169 -81.

10  Mittendorf EA, et al. PD-L1 expression in triple- negative breast cancer. Cancer Immunol Res. 2014 Apr;2(4):36

1-70.

11  Ghebeh H, et al. FOXP3+Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy. BMC Cancer. 2008 Feb 23;8:57.

12  Solinas C, et al. Targeting PD-1 in cancer: Biological insights with a focus on breast cancer. Crit Rev Oncol Hematol. 2019 Oct;142:35 -43.

13  Basu GD, et al. Expression of novel immunotherapeutic targets in triple-negative breast cancer. 2014 ASCO (American Society of Clinical Oncology) Annual Meeting; 2014 May 30June 3; Chicago, IL.

14  Solinas C, et al. Immune Checkpoint Molecules on Tumor-Infiltrating Lymphocytes and Their Association with Tertiary Lymphoid Structures in Human Breast Cancer. Front Immunol. 2017 Oct 30;8:1412.

<div style=\"page-break-after: always\"></div>

to 3 years after initial diagnosis, more likely develop of visceral and CNS metastases, and poorer OS compared to other breast cancer subtypes 15 .

## Management

Treatment of TNBC is challenging, as these tumors lack therapeutic targets, such as ER and HER2. Chemotherapy is considered the standard of care, although become rapidly resistant to chemotherapy upon local recurrence and/or metastasis, even though they are often sensitive to cytotoxic drugs at initial presentation 5 .

When KEYNOTE-355 started in 2016, recommendations for advanced TNBC included sequential monotherapy as the preferred choice, reserving combination chemotherapy to patients with rapid clinical progression, life-threatening visceral metastases, or need for rapid symptom and/or disease control. Anthracyclines and taxanes were the preferred option. Anthracyclines and taxanes were also suggested as rechallenge regimens in patients with 6-12 months of disease free survival following completion of neoadjuvant or adjuvant chemotherapy, whichever was completed last. In patients with advanced HER2negative breast cancer, who were pre-treated in the adjuvant or metastatic setting with anthracycline and taxane and not in need of combination chemotherapy, single agent capecitabine, vinorelbine or eribulin were possible choices. As TNBC was a putatively BRCA-deficient population, platinum doublets were studied with some evidence of activity 16   17 .

According to the latest European treatment guidelines 18 , for most patients with advanced TNBC, chemotherapy remains the only available non-investigational systemic treatment option for non-BRCAmutated, with no specific recommendations regarding types of agents, with the possible exception of platinum compounds for patients with BRCA-mutated.

Based on the results of IMpassion130 study, atezolizumab in combination with nab-paclitaxel may be considered an option in the 1L setting for de-novo advanced/metastatic disease or disease that has developed at least 12 months after completion of (neo)adjuvant ChT in tumours that have PD-L1 expression≥1% on immune cells. This treatment was approved in EU in 2019 based on PFS advantage [updated PFS analysis in PD-L1 positive population: median PFS 7.46 (95%CI 6.7, 9.23) vs 5.29 (95%CI 3.81, 5.55), HR 0.63 (95%CI 0.5, 0.8), p&lt;0.0001] and positive OS trend [not formally tested; median OS in the PD-L1 positive population 25.03 (95%CI 19.55, 30.65) vs 17.97 months (95%CI 13.63, 20.07), HR 0.71 (95%CI 0.54, 0.93)] 19 .

In contrast, atezolizumab + paclitaxel did not improve PFS or OS in participants with a recurrence-free interval of ≥ 12 months and PD-L1 positive tumors (IC ≥ 1%) enrolled in IMpassion131.

In patients with germline BRCA mutation, a PARP inhibitor is a preferred treatment option. Olaparib and talazoparib were approved in EU in 2019 for the treatment of germline BRCA1/2-mutations HER2 negative locally a dvanced or metastatic breast cancer; patients should have been previously treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless not suitable for these treatments.

15  Dent R, et al. Triple-negative b reast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34.

16  Andre F, Zielinski CC. Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. Ann Oncol. 2012 Aug;23 Suppl 6:vi46 -51.

17  Cardoso F, et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Breast 2014 Oct;23(5):489 -502.

18  Cardoso F, et al. 5th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 5). Ann Oncol 2020;31:1623 -49.

19  EPAR Tecentriq X-17, EMA/CHMP/425313/2019.

<div style=\"page-break-after: always\"></div>

Table: Efficacy of Chemotherapy as 1L Treatment for mTNBC

| Study/Breast Cancer Subtype/Reference                                                                     | Line   | Drug                                                    | ORR%/PFSm/OSmo   |
|-----------------------------------------------------------------------------------------------------------|--------|---------------------------------------------------------|------------------|
| Metanalysis of 3 PhaseIII trials: E2100,AVAD0,RIBB0N 1 -MCB TNBC subgroup analysis Miles et al. 2013 [78] | 1L     | Paclitaxel or docetaxel or capecitabine or (A/EC,FA/EC) | 23/5.4/17.5      |
| E2100-Phase III - MCB TNBC subgroup analysis Gray et al. 2009 [79]                                        | 1L     | Paclitaxel                                              | 22/5.3/16.3      |
| Phase III - TNBC 1L subgroup analysis O'Shaughnessy et al. 2014 [71]                                      | 1L     | Gemcitabine+ carboplatin                                | NR/4.6/13.9      |
| Phase III -MBC TNBC subgroup analysis                                                                     | 1L     | Paclitaxel + bevacizumab                                | NR/6.5/NR        |
| Rugo et al. 2015 [77]                                                                                     | 1L     | Nab-paclitaxel+bevacizumab                              | NR/7.4/NR        |

Note: In all studies included in Table 1, paclitaxel and nab-paclitaxel were both given on Days 1, 8, and 15 every 28 days.

Table from KEYNOTE-355 study protocol

## 2.1.2. About the product

Keytruda (pembrolizumab) is a humanized mAb IgG4/kappa isotype directed against PD-1. By blocking the interaction between PD-1 and its ligands PD-L1/2, pembrolizumab enhances T cell lymphocyte activity with consequent stimulation of the immune-mediated anti-tumour activity. Pembrolizumab also modulates the level of IL2, TNFα, IFNγ, and other cytokines. The antibody potentiates existing immune responses in the presence of antigen only; it do es not non-specifically activate T cells.

Pembrolizumab is currently EU approved as monotherapy and in combination with chemotherapy or other agents for the treatment of melanoma, NSCLC, RCC, HNSCC, urothelial cancer, cHL and MSI-H mCRC.

## 2.1.3. The development programme/compliance with CHMP guidance/scientific advice

The MAH for Keytruda applied for an extension of indication of pembrolizumab in combination with chemotherapy for the 1L treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥ 10). This application is based on the efficacy and safety results of IA2 (data cutoff date 11-DEC-2019) of the pivotal phase III double-blind randomized KEYNOTE-355 study which evaluated pembrolizumab plus chemotherapy compared with placebo plus chemotherapy as treatment for locally recurrent inoperable or metastatic TNBC who had recurrence-free interval of ≥ 6 months from completion of treatment with curative intent. In both arms, chemotherapy was a physician's choice between paclitaxel, nab-paclitaxel, or gemcitabine plus carboplatin. During the procedure, the MAH submitted also the results of the final analysis for overall survival of KEYNOTE-355 (data cut-off date 15JUN-2021).

No scientific advice was requested to CHMP on the design of the pivotal study KEYNOTE-355, which was obtained from the US FDA. A pre-submission TC meeting was held with Rapporteurs and EMA on 26 October 2020 regarding content and format of the submission.

<div style=\"page-break-after: always\"></div>

## 2.1.4. General comments on compliance with GCP

The MAH stated that all studies were conducted according to current standard research approaches and following appropriate GCP standards and considerations for the ethical treatment of human participants that were in place at the time the studies were performed.

## 2.2. Non-clinical aspects

No new non-clinical data have been submitted in this application, which was considered acceptable by the CHMP.

## 2.2.1. Ecotoxicity/environmental risk assessment

According to the Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use (EMEA/CHMP/SWP/4447/00) proteins are exempted from the submission of ERA studies because they are unlikely to result in significant risk to the environment. Pembrolizumab is a protein, therefore an ERA has not been submitted by the MAH. This is acceptable.

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the MAH.

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

<div style=\"page-break-after: always\"></div>

<!-- image -->

| StudyID                                     | Phase   | Country/Region                                                                                                                                                                                                                         | Study Tile                                                                                                                                                                                                       | Study design                                                  | Dosing regimen                                                                                                                                                                                                                                                                       | Study population                                                                                                                                    | Participant exposure                                        |
|---------------------------------------------|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|
| P355V01MK3475 MK3475] [Ref 5.3.5.1: P355V01 |         | USA Brazil Mexico Canada Argentina Chile Colombia Spain Belgium UK Ireland France Italy Germany Netherlands Denmark Ukraine Hungary Russia Poland Czech Republic Tukey Japan Taiwan SouthKorea Malaysia Hong Kong Austalia New Zealand | A Randomized,Double- BlindPhaseII Study ofPembrolizumab (MK-3475) plus Chemotherapy vs Placebo plus Chemotherapy for Previously Untreated LocallyRecurent Inoperable or Metastatic Tniple Negative Breast Cancer | Randomized, parallel-group, controlled placebo- double-blind, | Pembrolizumab: 200mgQ3W Paclitaxel: 90 mg/m²on Days 1, 8, and15ofevery 28-day cycle Placebo:normal saline or dextrose Q3W Nab-paclitaxel: 100mg/m²on Days 1, 8, and 15 ofevery 28-day cycle Gemcitabine and carboplatin: 1000 mg/m² and AUC 2 on Days 1 and 8 of every 21-day cycle. | Adult male and inoperable or metastatic TNBC, not female participants with locally recuwrent (18 years of age) previously treated with chemotherapy | Pembrolizmab+ chemotherapy. Placebo + chemotherapy. 562 281 |

| TrialID                                | Phase   | Country/Region                                                                                                                                                                                                                                                                | Trial Title                                                                                                                                                                                                                                                                                                                                 | Trial desigu                                         | Dosing regimen                                                                                                                                                | Trial population                                            | Subject exposure                               |
|----------------------------------------|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|------------------------------------------------|
| 3475-119 [Ref 5.3.5.1: P119V01 MK3475] |         | Argentina Australia Belgium Brazil Colombia France Germany Guatemala Hong Kong Ireland Italy Japan Malaysia Mexico Netherlands New Zealand Peru Philippines Poland Russia Singapore South Afica SouthKorea Spain Sweden Switzerland Taiwan Thailand Turkey United Kingdom USA | A Randomized Open- LabelPhase IlI Study of Single Agent Pembrolizumab versus Single Agent Chemotherapy per Physician’s Choice for Metastatic Iniple Negative Breast Cancer (mINBC)- (KEYNOTE-119) EMfcacy and safety in participants receiving second line (2L) or third line (3L) intervention for metastatic tiple negative breast cancer | Randomized, unblinded, open-label, active controlled | Am 1: Pembrolizumab 200 mg IV Q3W35adminishatons (approximately 2 years) Am 2: Capecitabine Or Enbulin Or Gemcitabine Or Vinorelbine (local standard of care) | Male and female paticipants≥18 years with Stage IV/Ml mTNBC | Am 1: 309 participants Arm 2: 292 participants |

<!-- image -->

| Study ID                       |   Phase | Country                                                                                                                                                                                                                                  | Study Title                                                                                                                                                                                                                                                                                                                                                                                                                                     | Study desigu                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Dosing regimen                                                                | Study population                                                                                                                                                                                                                                                                                   | Participant exposure                                                                                  |
|--------------------------------|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|
| [Ref. 5.3.5.2: P086V01 MK3475] |       2 | CohortA Aushalia Belgium Canada France, Gemany Israel Italy Japan New Zealand South Afica Spain, United Kingdom, United States Cohort B Aushalia Belgium Canada Gemany Lsrael Italy Japan South Afica Spain United Kingdom United States | A Phase 2 Clinical Trial ofPembrolizumab (MK-3475) a5 Monotherapy for Metastatic Tniple- negative Breast Cancer (mTNBC)- (KEYNOTE-086) A safety and effcacy study ofpembrolizumab as second line or above (2L+)monotherapy in tumors with programmed cell death receptor-ligand 1 (PD- Ll)positive (+) expression and independent ofPD.L1 expression; and as furst line (IL) monotherapy in tumors with PD.L1 (+) and PD-L1 shrong(+)expression | Open-label, nomrandomized, single- a, 2-pant, multicenter, multicohort Part 1:Cohort A paticipants with PD-L1 (+) tumors and allcomers, and Cohort Bpaticipants with PD-L1 (+) tumors; Cohorts A and Benrolled in parallel; 2 interm analyses (IA 1 and IA 2) for CohortA IA-1: Fuility analysis on the PD.L1 negative subpopulation of CohortA IA-2:Efficacy analysis ofresponses in at least 10 participants with PD. L1 strong (+) tumors in CohortA Part2:CohortC participants compnising at least 1 responder in 10-15 participants with PD-L1 strong(+) tumors from CohortAand~40-45 paticipants with PD-L1 strong(+) tumors | Pembrolizumab 200 mg IV Q3Wfor up to 24 weeks from the date of the furst dose | Females/males ≥18 years of age mINBC paticipants previously treated with at least 1 systemic treatment for metastatic breast cancer and documented progression after the most recent therapy; and previously treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting | ~285paticipants CohortA(2L+) ~160participants CohortB (IL) ~80paticipants CohortC(2L+) ~45paticipants |

<div style=\"page-break-after: always\"></div>

## 2.3.2. Pharmacokinetics

Comprehensive review of the key clinical pharmacology findings for pembrolizumab as monotherapy (200 mg Q3W dosing regimen) from melanoma, NSCLC, HNSCC, HL, UC, GEJ adenocarcinoma, HCC, MSI-H mCRC and HL indications have been discussed extensively in previous submissions. The key clinical pharmacology characteristics are summarized in the SmPC.

## Absorption

Pembrolizumab is dosed via the intravenous route and therefore is immediately and completely bioavailable.

## Distribution

Consistent with a limited extravascular distribution, the volume of distribution of pembrolizumab at steady state is small (6.0 L; coefficient of variation [CV]: 20%). As expected for an antibody, pembrolizumab does not bind to plasma proteins in a specific manner.

## Elimination

Pembrolizumab CL is approximately 23% lower (geometric mean, 195 mL/day [CV%: 40%]) after achieving maximal change at steady state compared with the first dose (252 mL/day [CV%: 37%]); this decrease in CL with time is not considered clinically meaningful. The geometric mean value (CV%) for the terminal half-life is 22 days (32%) at steady-state.

## Pharmacokinetic in target population

A substantial characterization of the key clinical pharmacology and immunogenicity findings of pembrolizumab as monotherapy has been provided in previous submissions.

The updated clinical pharmacology results pertaining to the current submission include:

- PK data from subjects with from subjects with previously untreated locally recurrent inoperable or metastatic triple negative breast cancer (TNBC) (KEYNOTE-355)
- A comparison of KEYNOTE-355 observed PK data with reference model (TDPK) predicted PK.
- A comparison of KEYNOTE-355 observed PK concentrations with observed PK concentrations from subjects from historical data.

## Pembrolizumab PK data from KEYNOTE-355 study

PK samples with a 15-June-2020 visit cut-off date were measured for a total of 221 subjects in KEYNOTE355. The PK analysis dataset was constructed from the final locked SDTM datasets using SAS version 9.4 and contains observed MK-3475 serum concentrations and actual elapsed blood sampling times relative to the corresponding time of dose.

Summary statistics were calculated based on nominal time after first dose. Safety follow up and discontinuation visits, as well as PK results from subjects dosed with placebo instead of pembrolizumab were omitted from the PK analysis.

<div style=\"page-break-after: always\"></div>

PK sampling schedule in KEYNOTE-355 for pembrolizumab: pre infusion pembrolizumab serum concentrations (Ctrough) were obtained within 24 hours prior to dosing at Cycle 1, 2, 4, and 8 and every 8 cycles (6 months) thereafter.

PK samples were also collected at discontinuation and at 30 days after discontinuation of trial treatment.

Phoenix™ WinNonlin® (Version 8.1.0.3530) software was used for pharmacokinetic analysis.

## RESULTS

Individual predose serum pembrolizumab concentration-time profiles with mean ± SE profile overlaid are shown in [Figure 1], mean predose serum pembrolizumab concentration-time profile is shown in [Figure 2].

Figure 1 Individual and Arithmetic Mean Predose Serum Concentrations of Pembrolizumab Following Administration of Multiple I.V. doses of 200 mg Q3W Pembrolizumab in KEYNOTE-355 (a) Linear scale, (b) Log scale

<!-- image -->

Note: Grey lines represent individual concentration observations. Black dashed lines represent arithmetic mean concentrations and error bars are associated +/- SE. Actual times were used for this analysis.

Data Source: [05M6YJ: analysis-adpc]

<div style=\"page-break-after: always\"></div>

Figure 2 Arithmetic Mean (±SE) Predose Serum Concentrations of Pembrolizumab Following Administration of Multiple I.V. doses of 200 mg Q3W Pembrolizumab in KEYNOTE-355, Linear scale

<!-- image -->

Data Source: [05M6YJ: analysis-adpc]

Summary descriptive statistics of the predose concentrations by Cycle are presented in the following table:

Table 2 Summary Statistics of Pembrolizumab Predose (Ctrough) Serum Concentration Values Following Administration of Multiple I.V. doses of 200 mg Q3W Pembrolizumab in KEYNOTE-355

| Cycle             | NOMTAFD   | N   | GM (%CV)    | GM (SD)     | AM (SD)     | Min    | Median   | Max    |
|-------------------|-----------|-----|-------------|-------------|-------------|--------|----------|--------|
|                   | (fep)     |     | (g/mL)      | (g/mL)      | (g/mL)      | (g/mL) | (g/mL)   | (g/mL) |
| Predose (Ctrough) |           |     |             |             |             |        |          |        |
| Cycle 2 (Week3)   | 21.0      | 195 |             |             | 16.7 (7.6)  | 0.00   | 15.8     | 62.7   |
| Cycle 4 (Week9)   | 63.0      | 148 |             |             | 32.1 (9.5)  | 0.00   | 32.5     | 54.0   |
| Cycle 8 (Week21)  | 147       | 64  | 38.9 (46.4) | 38.9 (15.3) | 42.2 (15.3) | 8.31   | 42.0     | 75.9   |
| Cycle 16 (Week45) | 315       | 6   | 39.9 (29)   | 39.9 (10.9) | 41.2 (10.9) | 24.7   | 40.9     | 57.4   |

NOMTAFD = Nominal time after first pembrolizumab administration;

GM = Geometric Mean;

CV%= Geometric Coefficient of Variation;

SD = Standard Deviation;

AM = Arithmetic Mean;

Results reported for time points with N &gt; 5.

Data Source: [05M6YJ: analysis-adpc]

Over the course of clinical development of pembrolizumab, PK has been robustly characterized. Using a dataset with sample size of 2993 participants, a time-dependent PK model was created to describe the PK profile as indicated in the USPI and EU SmPC. This model is used as the reference PK model to support pembrolizumab submissions across indications worldwide.

Observed pembrolizumab concentration data in KEYNOTE-355 for pembrolizumab + Chemotherapy group are overlaid on the simulated profile using the reference PK model as shown in [Figure 3]. While the majority of the observed serum concentration values in KEYNOTE-355 are above the median of the predicted interval, most are contained within the boundaries of the predicted interval using the reference PK model.

<div style=\"page-break-after: always\"></div>

Figure 3 Observed Concentration Data in KEYNOTE-355 Subjects Receiving 200 mg Q3W Pembrolizumab with Reference Model-Predicted Pharmacokinetic Profile for 200 mg Q3W Dose Regimen

<!-- image -->

<!-- image -->

a) after 1\"t dose on log scale; b) at and after dose number 8 (21 weeks) on log scale;

Symbols are individual observed data (nominal time) from KEYNOTE-355 200 mg Q3W subjects; black line is median predicted concentrations from the model for a regimen of 200 mg Q3W and the grey shaded area represents the 90% prediction interval.

Data Source: [05M6YJ: analysis-adpe]

## COMPARISON KEYNOTE-355

Tabular summaries of descriptive statistics and boxplots from Cycle 2 and steady-state dosing at Cycle 8, comparing observed pembrolizumab concentrations of 200 mg every 3 weeks (Q3W) from participants with previously untreated locally recurrent inoperable or metastatic triple negative breast cancer (TNBC) KEYNOTE-355 and monotherapy trials in non-small cell lung cancer (NSCLC, KEYNOTE-024), urothelial

<div style=\"page-break-after: always\"></div>

cancer (UC, KEYNOTE-045 and KEYNOTE-052), melanoma (MEL, KEYNOTE-054), head and neck squamous cell cancer (HNSCC, KEYNOTE-055), gastric cancer (GC, KEYNOTE-059), classical Hodgkin Lymphoma (HL, KEYNOTE-087), microsatellite instability-high cancer (MSI-H, KEYNOTE-164), primary mediastinal large B-cell lymphoma (PMBCL, KEYNOTE-170) and hepatocellular carcinoma (HCC, KEYNOTE-224), are presented for all subjects in [Table 3] and [Figure 4]. In addition, the comparison of observed PK data is also shown across studies/indications by gender in [Table 3] and for female subjects only in [Figure 5], to provide a more balanced comparison across studies, considering KEYNOTE-355 has only female subjects due to the breast cancer indication, as gender was a significant covariate in the PK model.

Table 3 SummaryStatisticsof ObservedPembrolizumabTroughConcentrations at Cycle 2and Cycle8(Steady-state) in Various Trials (KEYNOTE-024,-045,-052,-054,-055,-059,-087,-164,-170,-224 and-355)

|       |            |            | Total   | Total               | Total                 | Female    | Female              | Female               | Male      | Male                | Male                  |
|-------|------------|------------|---------|---------------------|-----------------------|-----------|---------------------|----------------------|-----------|---------------------|-----------------------|
| CYCLE | STUDYID    | Indication | N       | GM (%CV) (ug/mL)    | AM (SD) (ug/mL)       | N         | GM (%CV) (ug/mL)    | AM (SD) (ug/mL)      | N         | GM (%CV) (ug/mL)    | AM (SD) (ug/mL)       |
| 2 8   | MK3475-024 | NSCLC      | 131 82  | 11.1 (54) 30.6 (50) | 12.2 (4.7) 33.6 (13)  | 52 30     | 13.5 (51) 37.2 (43) | 14.6 (5.1) 40.0 (14) | 79 52     | 9.80 (52) 27.4 (49) | 10.7 (3.7) 29.9 (11)  |
| 2 8   | MK3475-045 | UC         | 233 104 | 13.1 (47) 33.4 (64) | 14.2 (4.9) 37.8 (17)  | 60 26     | 16.0 (42) 47.7 (37) | 17.1 (5.7) 50.5 (17) | 173 78    | 12.3 (47) 29.7 (66) | 13.2 (4.2) 33.6 (14)  |
| 2 8   | MK3475-052 | UC         | 83 28   | 10.9 (44) 28.8 (35) | 11.8 (4.4) 30.4 (9.7) | 20 5      | 14.4 (37) 36.6 (35) | 15.3 (4.9) 38.1 (11) | 63 23     | 9.93 (42) 27.3 (33) | 10.6 (3.6) 28.7 (8.6) |
| 2 8   | MK3475-054 | MEL        | 467 362 | n.c. 40.2 (34)      | 16.5 (5.8) 42.3 (13)  | 170 130   | n.c. 47.8 (32)      | 19.1 (4.8) 50.0 (14) | 297 232   | n.c. 36.5 (30)      | 15.0 (5.8) 38.0 (11)  |
| 2 8   | MK3475-055 | HNSCC      | 40 7    | 10.7 (47) 27.8 (41) | 11.8 (5.2) 29.6 (11)  | n.a. n.a. | n.a. n.a.           | n.a. n.a.            | n.a. n.a. | n.a. n.a.           | n.a. n.a.             |
| 2 8   | MK3475-059 | GC         | 221 49  | 10.6 (46) 25.3 (62) | 11.6 (4.6) 28.7 (13)  | n.a. n.a. | n.a. n.a.           | n.a. n.a.            | n.a. n.a. | n.a. n.a.           | n.a. n.a.             |
| 2 8   | MK3475-087 | HL         | 200 68  | 14.4 (40) 43.9 (43) | 15.4 (5.1) 47.4 (17)  | 93 37     | 17.7 (29) 49.5 (38) | 18.3 (4.8) 52.5 (16) | 107 31    | 12.1 (38) 38.1 (45) | 12.8 (3.9) 41.3 (16)  |
| 2 8   | MK3475-164 | MSI-H      | 56 34   | 12.5 (35) 33.6 (43) | 13.2 (4.6) 36.2 (14)  | 22 16     | 15.8 (29) 42.3 (34) | 16.5 (4.7) 44.4 (14) | 34 18     | 10.7 (29) 27.4 (39) | 11.1 (3.0) 29.0 (8.7) |
| 2 8   | MK3475-170 | PMBCL      | 38 10   | 17.9 (45) 64.1 (29) | 19.3 (6.3) 66.4 (18)  | n.a. n.a. | n.a. n.a.           | n.a. n.a.            | n.a. n.a. | n.a. n.a.           | n.a. n.a.             |
| 2 8   | MK3475-224 | HCC        | 96 40   | 13.0 (45) 25.9 (46) | 14.2 (7.1) 28.5 (13)  | 17 6      | 15.9 (31) 30.8 (56) | 16.5 (4.6) 34.6 (20) | 79 34     | 12.4 (46) 25.2 (44) | 13.7 (7.4) 27.4 (12)  |
| 2 8   | MK3475-355 | TNBC       | 195 64  | n.c. 38.9 (46)      | 16.7 (7.6) 42.2 (15)  | 195 64    | n.c. 38.9 (46)      | 16.7 (7.6) 42.2 (15) | 0 0       |                     |                       |

GM=Geometric Mean;CV%=Geometric Coefficient ofVariation;SD=StandardDeviation;AM=ArithmeticMean;n.c.=not calculated;n.a.=information not available; TNBC = triple negative breast cancer, NSCLC = non-small cell lung cancer; UC = urothelial cancer; MEL = melanoma; HNSCC = head and neck squamous cell cancer GC = gastric cancer, HL = classical Hodgkin Lymphoma; MSI-H = microsatellite instability-high cancer, PMBCL =primary mediastinal large B-celllymphoma; HCC = hepatocellular carcinoma.

Data Source: [05M6YJ: analysis-adpc]

Figure 4 ObservedTroughPembrolizumabConcentrations atCycle 2andCycle8(Steady-state)Across Studies/Indications,All Subjects

<!-- image -->

Data Source: [05M6YJ: analysis-adpc]

<div style=\"page-break-after: always\"></div>

Figure 5 ObservedTroughPembrolizumabConcentrationsatCycle2andCycle8(Steady-state)Across Studies/Indications,FemaleSubjectsOnly

<!-- image -->

Data Source:[05M6YJ: analysis-adpc]

## 2.3.3. Pharmacodynamics

## Mechanism of action

KEYTRUDA is an antibody that binds to the programmed death-1 (PD-1) receptor and blocks its interaction with ligands PD-L1 and PD-L2. The PD-1 receptor is a negative regulator of T-cell activity that has been shown to be involved in the control of T-cell immune responses. KEYTRUDA potentiates T-cell responses, including anti-tumour responses, through blockade of PD-1 binding to PD-L1 and PD-L2, which are expressed in antigen presenting cells and may be expressed by tumours or other cells in the tumour microenvironment.

## Dose regimen

Pembrolizumab is approved at a 2 mg/kg or 200 mg Q3W dosing regimen for multiple indications as monotherapy and in combination with small molecule or chemotherapy worldwide (e.g., melanoma, NSCLC, HNSCC, HL, UC, gastric cancer, MSI-H cancer, HCC and RCC).

Pembrolizumab is also approved at 400 mg Q6W in the EU for monotherapy and combination indications.

A dosing regimen of 200 mg Q3W or 400 mg Q6W is recommended for pembrolizumab in the treatment of adult subjects with TNBC in combination with chemotherapy. The 200 mg Q3W dosing regimen is approved for use in multiple indications globally as monotherapy as well as in combination with small molecule or chemotherapy based on a large, integrated body of evidence at this dose level across indications.

## 2.3.4. PK/PD modelling

No new information regarding PK/PD modelling for pembrolizumab is available within this extension of indication.

## Immunogenicity

The existing immunogenicity assessment for pembrolizumab for the monotherapy setting is based on a sufficiently large dataset of patients across several indications, with very low observed rates of total treatment ADA across different pembrolizumab regimens (1.4 - 3.8%) as well as of neutralizing antibodies (0.4 - 1.6%). This analysis has not demonstrated impact on efficacy or safety, as currently summarized in the SmPC. This low rate of immunogenicity has been shown to be consistent across tumor

<!-- image -->

<div style=\"page-break-after: always\"></div>

type and no clinically meaningful consequences have been observed in the subjects with a positive immunogenicity reading. Based on the existing robust characterization of immunogenicity potential, alignment has been obtained with the US FDA and EMA that the current assessment of immunogenicity for pembrolizumab is adequate for non-adjuvant monotherapy settings.

No new ADA data are provided in this submission based on the robust characterization of immunogenicity potential with trials in non-adjuvant monotherapy setting.

## 2.3.5. Discussion on clinical pharmacology

Clinical pharmacology results in support of the current extension of indication of pembrolizumab in combination with chemotherapy for the treatment of locally recurrent inoperable or metastatic TNBC derive from study KEYNOTE-355. Data were collected on a total of 221 subjects with a visit cut-off date of 15-June-2020.

The MAH presented a descriptive PK analysis based on predose pembrolizumab serum concentrations (Ctrough) obtained within 24 hours prior to dosing at Cycles 1, 2, 4, 8 and every 8 cycles (6 months) thereafter. The observed pembrolizumab serum concentration values at cycle 2 and cycle 8 are consistent with other globally approved studies in different cancer indications.

A comparison was conducted between the observed PK of pembrolizumab for the current indication and the predictions from the reference PK model developed with pembrolizumab monotherapy data (KEYNOTE-001, -002, -006, -010, and -024). The observed concentrations in patients with advanced/metastatic TNBC with Pembrolizumab 200 mg Q3W generally fall within the 90% CI of the model predicted median concentration, both after first dose and at steady state.

In a comparative exercise with prior conducted clinical studies of pembrolizumab in monotherapy, the PK data at both Cycle 2 and Cycle 8 from KEYNOTE-355 show consistency with the established PK profile observed across the different clinical settings for which approval has been granted. Similarity in PK profile between KEYNOTE-355 and other clinical trials has also been confirmed in an analysis restricted to female subjects only.

Overall, the PK in participants with metastatic TNBC in KEYNOTE-355 after combination therapy of pembrolizumab with chemotherapy is generally consistent with monotherapy PK, as previously established. This refers also to the comparison of female patients only.

## 2.3.6. Conclusions on clinical pharmacology

Pharmacokinetics and immunogenicity of pembrolizumab has been sufficiently investigated for the extension of the indication of pembrolizumab 200 mg every 3 weeks in combination with chemotherapy for the treatment of TNBC. The PK profile that emerges from KEYNOTE-355 testing pembrolizumab 200 mg Q3W in combination with chemotherapy in patients with locally recurrent inoperable or metastatic TNBC is consistent with the established pharmacology of pembrolizumab as observed across different cancer subtypes.

<div style=\"page-break-after: always\"></div>

## 2.4. Clinical efficacy

## 2.4.1. Dose response study(ies)

No specific dose response study have been performed. Pembrolizumab dose and regimen used in the pivotal KEYNOTE-355 study 200 mg Q3W IV is one of the dosages currently approved in combination with chemotherapy for other indications (NSCLC, HNSCC).

## 2.4.2. Main study

A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) plus Chemotherapy vs Placebo plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (KEYNOTE-355)

The study included 2 parts:

- Part 1 - safety run-in : unblinded, open-label, safety run-in that monitored participants (N=35) for unacceptable toxicities to study treatment (pembrolizumab + chemotherapy). Participants were assigned by forced randomization to ensure at least 10 participants were included in each treatment group (pembrolizumab + gemcitabine/carboplatin or pembrolizumab + taxane [paclitaxel or nabpaclitaxel]).
- Part 2 - phase 3 study : double-blind, placebo-controlled study on a background of chemotherapy, with 847 eligible participants randomly assigned in a 2:1 ratio to receive pembrolizumab + chemotherapy or placebo + chemotherapy, respectively.

The efficacy data are based on Part 2 results (all data described in the efficacy section below are related to Part 2) .

Figure: Study Design for KEYNOTE-355 Part 2

<!-- image -->

1.Chemotherapytreatmentonstudy(taxanevsgemcitabine/carboplatin)

Stratificationfactors

2.PD-L1tumor status(CPS≥1vsCPS&lt;1)

<div style=\"page-break-after: always\"></div>

## Methods

## Study participants

Key inclusion criteria:

- Have previously untreated metastatic TNBC or locally recurrent inoperable breast cancer which could not be treated with curative intent.
- Have centrally confirmed TNBC, as defined by the most recent ASCO/CAP guidelines.
- Have completed treatment for Stage I-III breast cancer, if indicated, and ≥ 6 months elapsed between the completion of treatment with curative intent and first documented local or distant disease recurrence. (Note: Subjects who received taxane, gemcitabine, or platinum agents in the (neo)adjuvant setting can be treated with same class of chemotherapy (taxane or gemcitabine/carboplatin), if ≥12 months have elapsed between the completion of treatment with curative intent (e.g., date of primary breast tumor surgery or date of last adjuvant chemotherapy administration, whichever occurred last) and first documented local or distant disease recurrence).
- Have been treated with (neo)adjuvant anthracycline, if they had received systemic treatment in that setting, unless anthracycline was contraindicated or not considered the best treatment option for the participant in the opinion of the treating physician. ( Note: Subjects presenting with de novo metastatic TNBC are eligible for the study, if anthracycline is contraindicated or not considered the best treatment option for the subject in the opinion of the treating physician).
- Have measurable disease based on RECIST 1.1 as determined by local radiology review.
- Have at least 18 years of age.
- Have ECOG PS of 0 or 1, as assessed within 10 days prior to the start of study treatment.
- Have predicted life expectancy ≥ 12 weeks from randomization.
- Have provided recently or newly obtained core or excisional biopsy from a locally recurrent inoperable or metastatic tumor lesion for central determination of TNBC status and PD-L1 expression, unless contraindicated due to site inaccessibility and/or subject safety concerns.
- Demonstrate adequate organ function, within 10 days prior to the start of study treatment, as defined in the protocol
- Female subjects of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study treatment.

Key exclusion criteria:

- Had an active autoimmune disease that had required systemic treatment in the past 2 years. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment.
- Had a diagnosis of immunodeficiency or was receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to randomization.
- Had a known active CNS metastases and/or carcinomatous meningitis. Participants with known brain metastases may have participated provided the brain metastases had been previously treated (except with chemotherapy) and were radiographically stable. (Note: Known brain metastases are considered active, if any of the following criteria are applicable: a. Brain imaging during screening demonstrates progression of existing metastases and/or appearance of new lesions compared to brain imaging

<div style=\"page-break-after: always\"></div>

performed at least 4 weeks earlier. b. Neurological symptoms attributed to brain metastases have not returned to baseline c. Steroids were used for management of symptoms related to brain metastases within 28 days of randomization).

- Had a history of (non-infectious) pneumonitis that required steroids or current pneumonitis.
- Had active, or a history of, interstitial lung disease.
- Had a history of class II-IV congestive heart failure or myocardial infarction within 6 months of randomization.
- Had received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another co-inhibitory T cell receptor (such as CTLA-4, OX-40, CD137) or has previously participated in Merck pembrolizumab clinical studies.
- Has a known additional malignancy that progressed or required active treatment within the last 5 years. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy, and in situ cervical cancer.
- Has a known history of human immunodeficiency virus (HIV), known active hepatitis B or C, history of active TB.
- Has received a live vaccine within 30 days prior to randomization.
- Has a known history of hypersensitivity or allergy to pembrolizumab and any of its components and/or to any of the study chemotherapies.
- Is pregnant or breastfeeding.

## Treatments

## Table: study treatments

| Drug                     | Dose/ Potency    | Dose Frequency    | Route of Administration   | Treatment Period   | Use                                  |
|--------------------------|------------------|-------------------|---------------------------|--------------------|--------------------------------------|
| Pembrolizumab            | 200 mg           | Day 1             | IV infusion               | Every 21 days      | Experimental                         |
| Placebo (normal saline)  | N/A              | Day 1             | IV infusion               | Every 21 days      | Placebo for pembrolizumab            |
| Nab-paclitaxel           | 100 mg/m²        | Days 1, 8, and 15 | IV infusion               | Every 28 days      | Chemotherapy background intervention |
| Paclitaxel               | 90 mg/m²         | Days 1, 8, and 15 | IV infusion               | Every 28 days      | Chemotherapy background intervention |
| Gemcitabine/ Carboplatin | 1000 mg/m2 AUC 2 | Days 1 and 8      | IV infusion               | Every 21 days      | Chemotherapy background intervention |

Chemotherapy was administered unblinded. Participants, investigators, other study site staff (except for an unblinded pharmacist), and the Sponsor were blinded to pembrolizumab/placebo administration.

## Objectives

Primary objectives:

<div style=\"page-break-after: always\"></div>

The combination of pembrolizumab and chemotherapy was compared to placebo and chemotherapy for the treatment of previously untreated locally recurrent inoperable or metastatic centrally confirmed TNBC:

- To compare progression-free survival (PFS) based on RECIST 1.1 as assessed by a blinded central imaging vendor (CIV) in all subjects.
- To compare PFS based on RECIST 1.1 as assessed by a blinded CIV in subjects with PD-L1 positive tumors (CPS ≥ 1).
- To compare PFS based on RECIST 1.1 as assessed by a blinded CIV in subjects with PD-L1 positive tumors (CPS ≥ 10).
- To compare overall survival (OS) in all subjects.
- To compare OS in subjects with PD-L1 positive tumors (CPS ≥ 1).
- To compare OS in subjects with PD-L1 positive tumors (CPS ≥ 10).

The study is considered to have met its primary objective if the combination of pembrolizumab and chemotherapy is superior to placebo and chemotherapy in either PFS or OS in either all subjects or in subjects with PD-L1 positive tumors (CPS ≥ 1 or CPS ≥ 10) at either an interim analysis or the final analysis (OS only).

## Secondary objectives:

- To compare objective response rate (ORR) based on RECIST 1.1 as assessed by a blinded CIV in all subjects and in subjects with PD-L1 positive tumors (CPS ≥ 1 and CPS ≥ 10).
- To evaluate duration of response (DOR) based on RECIST 1.1 as assessed by a blinded CIV in all subjects and in subjects with PD-L1 positive tumors (CPS ≥ 1 and CPS ≥ 10).
- To compare DCR based on RECIST 1.1 as assessed by a blinded CIV in all subjects and in subjects with PD-L1 positive tumors (CPS ≥ 1 and CPS ≥ 10).
- To evaluate the safety and tolerability of 3 pembrolizumab + chemotherapy combinations.
- To evaluate changes in health-related quality-of-life (QoL) assessments from baseline in all subjects and in subjects with PD-L1 positive tumors (CPS ≥ 1 and CPS ≥ 10) using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and EORTC Breast Cancer-Specific Quality of Life Questionnaire (EORTC QLQ-BR23).

## Exploratory Objectives:

- To characterize utilities in all subjects and in subjects with PD-L1 positive tumors (CPS ≥ 1 and CPS ≥ 10) using EuroQol-5 Dimension Questionnaire (EQ-5D™).
- To investigate association(s) between anti-tumor activity of study treatments and efficacy/resistance biomarkers, utilizing tumor and blood specimens obtained before randomization, during treatment, and at disease progression.
- To identify molecular (genomic, metabolic, and/or proteomic) determinants of response or resistance to pembrolizumab and other treatments in this study, so as to define novel predictive and pharmacodynamic biomarkers and understand the mechanism of action of pembrolizumab.

<div style=\"page-break-after: always\"></div>

## Outcomes/endpoints

The dual primary endpoints, evaluated for all participants and for those participants whose tumors express PD-L1 (CPS ≥ 1 and CPS ≥ 10), were the following:

- PFS, defined as the time from randomization to the first documented disease progression as measured by BICR per RECIST 1.1 or death due to any cause, whichever occurred first.
- OS, defined as the time from randomization to death due to any cause.

Secondary efficacy and PRO endpoints, evaluated for all participants and for those participants whose tumors express PD-L1 (CPS ≥ 1 and CPS ≥ 10), were as follows:

- ORR, defined as the proportion of participants in the analysis population who had a response (CR or PR) as measured by BICR per RECIST 1.1.
- DOR, defined as the time from the first documented evidence of CR or PR until disease progression as measured by BICR per RECIST 1.1 or death due to any cause, whichever occurred first.
- DCR, defined as the percentage of participants who had achieved CR or PR or had demonstrated SD for at least 24 weeks, as measured by BICR per RECIST 1.1.
- QoL, defined as changes from baseline using the EORTC QLQ-C30 and EORTC QLQ BR23 questionnaires.

## Imaging assessment:

Tumor imaging were acquired by computed tomography (CT, strongly preferred). Brain imaging (MRI preferred) was required at screening and during the study for subjects with known brain metastases and those with worsening and/or new neurological symptoms. A bone scan was required prior to study entry if a subject had a history of bone metastases and/or suggestive symptoms/signs, and during the study if clinically indicated or if the site believed a subject attained a CR.

Baseline tumor imaging were performed during the 28-day screening window prior to randomization to confirm measurable disease based on RECIST 1.1 as assessed by local radiology review, then submitted to central imaging vendor (CIV) for retrospective review. Post-baseline imaging assessments were be performed at 8, 16, and 24 weeks post randomization, and then every 9 weeks during the first year. After 1 year, imaging were performed every 12 weeks. Imaging were not discontinued until PD verified by CIV or start of new anti-cancer treatment, consent withdrawal, death, or end of study, whichever occurs first.

RECIST 1.1 were applied by local radiology for assessing subject eligibility and by CIV as the primary measure for assessing efficacy parameters, allowing a maximum of 10 target lesions in total and 5 per organ. irRECIST, adapted to account for the unique tumor response seen with immunotherapeutic drugs, were used by site/investigator to assess tumor response and make treatment decisions both before and after PD is verified by CIV.

Based on RECIST 1.1, PRs and CRs were confirmed by repeat tumor imaging studies at ≥ 4 weeks from the date response was first documented.

Site/investigator-assessed first radiologic evidence of PD was also evaluated by the CIV in real time, and the results of central imaging review were expeditiously communicated to the study site and the Sponsor. Imaging flow algorithm for verification of PD by CIV for clinically stable subjects is illustrated in figure below.

<div style=\"page-break-after: always\"></div>

Figure: Imaging and Treatment for Clinically Stable Subjects After First Radiologic Evidence of PD Based on RECIST 1.1 and as Assessed by Site/Investigator

<!-- image -->

Note: Verified refers to centrally verified.

PD-L1 status assessment: PD-L1 expression status was determined from a core or excisional biopsy and assessed centrally using the investigational PD-L1 IHC 22C3 pharmDx kit.

## Sample size

- Part 1 : Approximately 30 subjects will be enrolled.
- Part 2 : It was expected that ~ 664 OS events among all subjects, ~ 482 OS events among subjects with CPS ≥ 1, and ~ 240 OS events among subjects with CPS ≥ 10 have been observed at the FA. The planned sample size was approximately 828 subjects:
- (1) PFS in all subjects: at IA2 the analysis has ~ 89% power at a one-sided 0.111% alpha level, if the true HR is 0.70. At IA2, with ~ 634 events the HR at boundary for success is ~ 0.77 (~ 1.6 months

<div style=\"page-break-after: always\"></div>

improvement over control median PFS of 5.5 months). At IA2, PFS in all subjects can only be tested if both hypotheses of PFS in subjects with CPS ≥ 10 and PFS in subjects with CPS ≥ 1 are supported.

(2) PFS in subjects with CPS ≥ 1: at IA2 the analysis has ~ 97% power at a one-sided 0.111% alpha level, if the true HR is 0.62. At IA2, with ~ 463 events the HR at boundary for success is ~ 0.74 (~ 1.9 months improvement over control median PFS of 5.5 months). At IA2, PFS in all subjects with CPS ≥ 1 can only be tested if the hypothesis of PFS in subjects with CPS ≥ 10 is supported.

(3) PFS in subjects with CPS ≥ 10: at IA2 the analysis has ~ 86% power at a one-sided 0.411% alpha level, if the true HR is 0.60. At IA2, with ~ 235 events the HR at boundary for success is ~ 0.69 (~ 2.4 months improvement over control median PFS of 5.5 months).

(4) OS in all subjects: the trial has ~ 60% power at a one-sided 0.75% alpha level, if the true HR is 0.80. With ~ 664 events, the HR at boundary for success at FA is ~ 0.81 (~ 4.0 months improvement over control median OS of 17.5 months). After IA1, OS in all subjects can be tested if hypothesis of OS in subjects with CPS ≥ 1 is supported.

(5) OS in subjects with CPS ≥ 1: the trial has ~ 87% power at a one-sided 0.75% alpha level, if the true HR is 0.71. With ~ 482 events, the HR at boundary for success at FA is ~ 0.78 (~ 4.8 months improvement over control median OS of 17.5 months).

(6) OS in subjects with CPS ≥ 10: the trial has ~ 79% power at a one-sided 1.011% alpha level, if the true HR is 0.65. With ~ 240 events, the HR at boundary for success at FA is ~ 0.72 (~ 6.8 months improvement over control median OS of 17.5 months).

## Randomisation

Treatment allocation/randomization occurred centrally using an interactive voice response system / integrated web response system (IVRS/IWRS).

Part 1 used partial randomization with forced allocation depending on prior (neo)adjuvant treatment and disease-free interval, to stop enrollment into a specific treatment once ≥ 10 subjects are enrolled in that treatment.

In Part 2 randomization was stratified for:

- chemotherapy on study (paclitaxel or nab-paclitaxel vs gemcitabine/carboplatin),
- tumor programmed cell death-ligand 1 (PD-L1) status (combined positive score [CPS] ≥ 1 vs CPS &lt;1),
- prior treatment with same class of chemotherapy in the (neo)adjuvant setting (yes vs no).

## Blinding (masking)

Part 1 was open label.

Part 2 was double-blinded. Details regarding trial blinding/unblinding including unblinding required for operational purposes (e.g., unblinded pharmacist) were described in Protocol and Statistical analysis plan.

## Statistical methods

Part 1 and part 2 were planned to be analysed separately.

## Part 1:

<div style=\"page-break-after: always\"></div>

The efficacy population were all subjects as treated (ASaT), who received at least one dose of study treatment. Patients were analysed in the treatment group correspondingly to the study treatment they actually received. The primary objective of safety and tolerability were addressed by performing descriptive summary statistics for safety endpoints by treatment. One interim analysis was planned for safety evaluation after the last subject have completed the first 21 or 28 days of study treatment, which was approximately 3 months after the first subject randomized reviewed by the DMC. Continuous safety monitoring were performed by the study team. No multiplicity correction was performed. Efficacy endpoints were secondary endpoints and analysed descriptively.

## Part 2:

There are three planned interim analyses (IA) in addition to the final analysis for this study. The trial continues until the number of death is approximately equal to the targeted number for the final analysis, irrespective of the outcome from the interim analyses. The analyses planned, endpoints evaluated, and drivers of timing are summarized in the table below.

| Analysis   | Criteria                                                                                                                                                                         | Endpoint         | Time after last Subject Randomized      | Primary Purpose of Analysis      |
|------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|-----------------------------------------|----------------------------------|
| IA1        | IA1 was to be conducted when: (1) enrolment is completed, and (2) ~ 9 months after first 640 subjects are randomized in Part 2                                                   | • ORR • PFS • OS | ~ 4 months (Actual LPLV: 18Oct2018)     | Final ORR Interim PFS Interim OS |
| IA2        | IA2 was to be conducted after ~ 185 OS events among subjects with CPS ≥10 have been observed                                                                                     | • PFS • OS       | ~ 18 months (Actual LPLV: 11Dec2019)    | Interim OS Final PFS             |
| IA3*       | IA3 was to be conducted after ~ 210 OS events among subjects with CPS ≥10 have been observed                                                                                     | • OS             | ~24 months (Actual LPLV: 15Jun2020)     | Interim OS                       |
| FA         | FA will be conducted after : ~ 664 OS events among all subjects, ~ 482 OS events among subjects with CPS ≥1, and ~ 240 OS events among subjects with CPS ≥10 have been observed. | • OS             | ~ 31-36 months (Actual LPLV: 15Jun2021) | Final OS                         |

IA2 was performed after approximately 185 OS events had been observed among participants with PD-L1 positive tumors (CPS ≥ 10). A multiplicity strategy was applied to the 6 primary hypotheses (superiority of pembrolizumab + chemotherapy with respect to PFS and OS in All Participants, and in the PD-L1 positive subgroups [CPS ≥ 1 and CPS ≥ 10]), and the 2 secondary hypotheses of superiority of pembrolizumab + chemotherapy in ORR in All Participants and in the PD-L1 positive subgroup (CPS ≥ 1). The family-wise Type-I error rate over the 6 primary hypotheses and 2 secondary hypotheses was strongly controlled at 2.5% (1-sided). The OS hypotheses were tested following a group sequential approach, with 3 IAs and a final analysis planned. The PFS hypotheses were tested with an interim analysis performed at IA1 and a final analysis at IA2. The ORR hypotheses were tested with a single analysis each at IA1.

Based on emerging biomarker data external to this study, the initial alpha allocation among the 6 primary hypotheses and 2 secondary hypotheses was revised in Protocol Amendment 05. The revision of the alpha

<div style=\"page-break-after: always\"></div>

allocation occurs after the conduct of efficacy IA1. The family-wise Type-I error rate for this study was strongly controlled at 2.5% (one-sided) across all 6 primary hypotheses on PFS and OS as well as 2 secondary hypotheses on ORR. Figure below displays the revised multiplicity strategy diagram of the study. The initial one-sided alpha allocation for each hypothesis is shown in the rectangle representing the hypothesis. The weights for re-allocation from each hypothesis to the others are represented in the numbers along the lines connecting hypotheses. Overall, a total of 0.5% alpha was allocated to PFS endpoints, a total of 1.8% alpha was allocated to OS endpoints, and a total of 0.2% alpha was allocated to ORR endpoints.

Figure: multiplicity strategy (protocol 05)

<!-- image -->

- a) Nominal alpha for testing will be calculated based on Spiessens and Debois method accounting for correlation between ORR in all subjects and ORR in subjects with CPS ≥ 1. Of note, while the nominal alpha will be calculated and used for testing, the allocated alpha (0.001) will be passed to H7 when applicable.

b) H5 α=0.0075 which includes 0.00036 already spent at IA1. Note: The shaded boxes in this figure represent alpha that has already been spent at IA1 and will be considered lost for future analyses. These alphas will no longer be re-allocated to other hypotheses under the graphical approach, nor can they be used to account for correlation among group sequential tests within each endpoint across different time points.

The study uses the graphical method of Maurer and Bretz to control multiplicity for multiple hypotheses as well as interim analyses. According to this approach, study hypotheses may be tested more than once, and when a particular null hypothesis is rejected, the alpha allocated to that hypothesis can be reallocated to other hypothesis tests.

The boundary properties for each of these alpha-levels for the OS interim analyses were derived using a Lan-DeMets O'Brien-Fleming spending function.

Further details of statistical analyses were described in the SAP.

The Part 2 ITT population served as the population for the primary efficacy analyses. All randomly assigned participants were included in this population. The efficacy analyses in this submission were based on IA2, which was the final analysis of PFS and second interim analysis for OS. Participants enrolled in Part 1 were excluded from the efficacy analyses.

A summary of the analysis strategy for key efficacy endpoints is presented in the following table:

<div style=\"page-break-after: always\"></div>

| Endpoint/Variable (Description, Time Point)                                                                                          | Statistical Method a                                                                             | Analysis Population                                                           | Missing Approach                                         | Data                                      |
|--------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|----------------------------------------------------------|-------------------------------------------|
| Primary Hypothesis 1                                                                                                                 | Primary Hypothesis 1                                                                             | Primary Hypothesis 1                                                          | Primary Hypothesis 1                                     | Primary Hypothesis 1                      |
| PFS based on RECIST 1.1 assessed by BICR in all participants                                                                         | Test: Stratified log-rank test Estimation: Stratified Cox model with Efron's tie handling method | ITT                                                                           | See Table 11 of the study protocol                       | See Table 11 of the study protocol        |
| Primary Hypothesis 2                                                                                                                 | Primary Hypothesis 2                                                                             | Primary Hypothesis 2                                                          | Primary Hypothesis 2                                     | Primary Hypothesis 2                      |
| PFS based on RECIST 1.1 assessed by BICR in participants with tumors that express PD-L1 with CPS ≥1                                  | Test: Stratified log-rank test Estimation: Stratified Cox model with Efron's tie handling method | ITT                                                                           | See Table 11 of the study protocol                       | See Table 11 of the study protocol        |
| Primary Hypothesis 3                                                                                                                 | Primary Hypothesis 3                                                                             | Primary Hypothesis 3                                                          | Primary Hypothesis 3                                     | Primary Hypothesis 3                      |
| PFS based on RECIST 1.1 assessed by BICR in participants with tumors that express PD-L1 with CPS ≥10                                 | Test: Stratified log-rank test Estimation: Stratified Cox model with Efron's tie handling method | ITT                                                                           | See Table 11 of the study protocol                       | See Table 11 of the study protocol        |
| Primary Hypothesis 4                                                                                                                 | Primary Hypothesis 4                                                                             | Primary Hypothesis 4                                                          | Primary Hypothesis 4                                     | Primary Hypothesis 4                      |
| OS in all participants                                                                                                               | Test: Stratified log-rank test Estimation: Stratified Cox model with Efron's tie handling method | ITT                                                                           | Censored at last known alive date                        | Censored at last known alive date         |
| Primary Hypothesis 5                                                                                                                 | Primary Hypothesis 5                                                                             | Primary Hypothesis 5                                                          | Primary Hypothesis 5                                     | Primary Hypothesis 5                      |
| OS in participants with tumors that express PD- L1 with CPS ≥1                                                                       | Test: Stratified log-rank test Estimation: Stratified Cox model with Efron's tie handling method | ITT                                                                           | Censored at last known alive date                        | Censored at last known alive date         |
| Primary Hypothesis 6                                                                                                                 | Primary Hypothesis 6                                                                             | Primary Hypothesis 6                                                          | Primary Hypothesis 6                                     | Primary Hypothesis 6                      |
| OS in participants with tumors that express PD- L1 with CPS ≥10                                                                      | Test: Stratified log-rank test Estimation: Stratified Cox model with Efron's tie handling method | ITT                                                                           | Censored at last known alive date                        | Censored at last known alive date         |
| Key Secondary Hypothesis 1 (Hypothesis 7)                                                                                            | Key Secondary Hypothesis 1 (Hypothesis 7)                                                        | Key Secondary Hypothesis 1 (Hypothesis 7)                                     | Key Secondary Hypothesis 1 (Hypothesis 7)                | Key Secondary Hypothesis 1 (Hypothesis 7) |
| ORR based on RECIST 1.1 assessed by BICR in all participants                                                                         | Stratified M & N method b                                                                        | The first ~ 640 participants randomized in Part 2 (a subset of ITT, IA1 only) | Participants relevant missing considered non-responders. | with data are                             |
| Key Secondary Hypothesis 2 (Hypothesis 8)                                                                                            | Key Secondary Hypothesis 2 (Hypothesis 8)                                                        | Key Secondary Hypothesis 2 (Hypothesis 8)                                     | Key Secondary Hypothesis 2 (Hypothesis 8)                | Key Secondary Hypothesis 2 (Hypothesis 8) |
| ORR based on RECIST 1.1 assessed by BICR in participants with tumors that express PD-L1 with CPS ≥1                                  | Stratified M & N method b                                                                        | The first ~ 640 participants randomized in Part 2 (a subset of ITT, IA1 only) | Participants relevant missing considered non-responders. | with data are                             |
| Other Secondary Endpoints                                                                                                            | Other Secondary Endpoints                                                                        | Other Secondary Endpoints                                                     | Other Secondary Endpoints                                | Other Secondary Endpoints                 |
| ORR based on RECIST 1.1 assessed by BICR in participants with tumors that express PD-L1 with CPS ≥10                                 | Stratified M & N method b                                                                        | ITT                                                                           | Participants relevant missing considered non-responders. | with data are                             |
| DCR based on RECIST 1.1 assessed by BICR in all participants and in participants with tumors that express PD-L1 (CPS ≥1 and CPS ≥10) | Stratified M & N method b                                                                        | ITT                                                                           | Participants relevant missing considered non-responders. | with data are                             |

<div style=\"page-break-after: always\"></div>

| Endpoint/Variable (Description, Time Point)                                                                                          | Statistical Method a                         | Analysis Population   | Missing Data Approach               |
|--------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------|-----------------------|-------------------------------------|
| DOR based on RECIST 1.1 assessed by BICR in all participants and in participants with tumors that express PD-L1 (CPS ≥1 and CPS ≥10) | Summary statistics using Kaplan-Meier method | All responders in ITT | See Table 12 of the study protocol. |

BICR=blinded independent central review; CPS=combined positive score; DCR=disease control rate; DOR=duration of response; IA1 = Interim Analysis 1; ITT=intention-to-treat; M &amp; N=Miettinen and Nurminen; ORR=objective response rate; OS=overall survival; PD-L1=programmed cell death ligand 1; PFS=progression-free survival; RECIST 1.1= Response Evaluation Criteria in Solid Tumors version 1.1.

a. Statistical models are described in further detail in Section 8.6 of the protocol [Ref. 5.3.5.1: P355V01MK3475: 16.1.1]. For stratified analyses, the stratification factors used for randomization were used as stratification factors for analysis.

Table 11 Censoring Rules for Primary and Sensitivity Analyses of PFS

| Situation                                                                                                                   | Primary Analysis                                                                                                                          | Sensitivity Analysis 1                       | Sensitivity Analysis 2                                                                                                                                                                       |
|-----------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| No PD and no death; andnewanticancer treatmentis notinitiated                                                               | Censored at last disease assessment                                                                                                       | Censored at last disease assessment          | Progressed at treatment discontinuation due to reasons other than complete response; otherwise censored at last disease assessment if still on study treatment or completed study treatment. |
| NoPD and no death; new anticancer treatment is initiated                                                                    | Censored at last disease assessment before new anticancer treatment                                                                       | Censored at last disease assessment          | Progressed at date of new anticancer treatment                                                                                                                                               |
| PD or death documented after ≤1 missed disease assessment,andbefore new anti-cancer therapy, if any                         | Progressed at date of documented PD or death                                                                                              | Progressed at date of documented PD or death | Progressed at date of documented PD or death                                                                                                                                                 |
| PD or death documented immediately after ≥2 consecutive missed disease assessments or after new anti-cancer therapy, if any | Censored at last disease assessment prior to theearlierdateof≥2 consecutive missed disease assessment and new anti-cancer therapy, if any | Progressed at date of documented PD or death | Progressed at date of documented PD or death                                                                                                                                                 |

Table 12 Censoring Rules for DOR

| Situation                                                                                                                        | Date of Progression or Censoring                                                                                                   | Outcome                                                                                                                          |
|----------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------|
| No progression nor death, no new anti-cancer therapy initiated                                                                   | Last adequate disease assessment                                                                                                   | Censor (non-event)                                                                                                               |
| No progression nor death, new anti- cancer therapy initiated                                                                     | Lastadequatediseaseassessment before new anti-cancer therapy initiated                                                             | Censor (non-event)                                                                                                               |
| Death or progression immediately after≥2consecutivemisseddisease assessmentsorafternewanti-cancei therapy, if any                | Earlier date of last adequate disease assessment tpriorto≥2missed adequate disease assessments and new anti-cancer therapy, if any | Censor (non-event)                                                                                                               |
| Death or progression after ≤1 missed disease assessments and before new anti-cancer therapy, if any                              | PD or death                                                                                                                        | End of response (Event)                                                                                                          |
| A missed disease assessment includes any assessment that is not obtained or is considered inadequate for evaluation of response. | A missed disease assessment includes any assessment that is not obtained or is considered inadequate for evaluation of response.   | A missed disease assessment includes any assessment that is not obtained or is considered inadequate for evaluation of response. |

<div style=\"page-break-after: always\"></div>

PRO analyses were based on the PRO FAS population, defined as all randomized participants who received at least 1 dose of study intervention and had completed at least 1 PRO assessment. Participants were included in the treatment arm to which they were randomly assigned in the PRO analyses.

The safety analyses were based on the ASaT populations.

The non-parametric Kaplan-Meier method was used to estimate the PFS and OS curve in each treatment group. The treatment difference in PFS and OS was assessed by the stratified log-rank test. For PFS and OS a stratified Cox proportional hazard model with Efron's method of tie handling was used to assess the magnitude of the treatment difference between the treatment arms. The hazard ratio and its 95% confidence interval from the stratified Cox model with Efron's method of tie handling and with a single treatment covariate was reported. The same stratification factors used for randomization were applied to both the stratified log-rank test and the stratified Cox model. The PFS and OS HRs were estimated for several subgroups based on baseline prognostic variables and demographic characteristics.

In order to evaluate the robustness of the PFS endpoint per RECIST 1.1 by a blinded independent central imaging vendor, sensitivity analyses with a different set of censoring rules was applied.

The stratified Miettinen and Nurminen method was used for the comparison of the ORR and DCR between the two treatment groups. The difference in ORR/DCR and its 95% confidence interval from the stratified Miettinen and Nurminen method with strata weighting by sample size with a single treatment covariate was reported. The stratification factors used for randomization were applied to the analysis.

If sample size permits, it was planned to summarize DOR descriptively using Kaplan-Meier medians and quartiles. Only the subset of patients who show a complete response or partial response were to be included in this analysis.

The analysis of safety results followed a tiered approach. There were no Tier 1 endpoints in this study, and Tier 2 parameters were assessed via point estimates with 95% confidence intervals (CIs) provided for betweengroup comparisons; only point estimates by intervention arm were provided for Tier 3 safety parameters. The 95% CIs for the between-treatment differences in percentages were provided using the Miettinen and Nurminen method.

## Results

Note : Efficacy analyses to support this extension of indication are based on the Part 2 ITT population (N = 847). Participants enrolled in Part 1 (safety runin; n=35) were excluded from the efficacy analyses. Therefore, the following sections are focused on the presentation of Part 2 results.

<div style=\"page-break-after: always\"></div>

## Participant flow (all subjects)

<!-- image -->

Table: Disposition of Subjects (Part 2 All Subjects) (ITT Population)

|                                                                        | Pembrolizumab Chemotherapy                                             | Pembrolizumab Chemotherapy                                             | +                                                                      | Placebo + Chemotherapy Total                                           | Placebo + Chemotherapy Total                                           |                                                                        |                                                                        |
|------------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|
|                                                                        | n                                                                      | (%)                                                                    |                                                                        | n                                                                      | (%)                                                                    | n                                                                      | (%)                                                                    |
| Subjects in population                                                 | 566                                                                    |                                                                        |                                                                        | 281                                                                    |                                                                        | 847                                                                    |                                                                        |
| Status for Study Medication in Trial Segment of First Course Treatment | Status for Study Medication in Trial Segment of First Course Treatment | Status for Study Medication in Trial Segment of First Course Treatment | Status for Study Medication in Trial Segment of First Course Treatment | Status for Study Medication in Trial Segment of First Course Treatment | Status for Study Medication in Trial Segment of First Course Treatment | Status for Study Medication in Trial Segment of First Course Treatment | Status for Study Medication in Trial Segment of First Course Treatment |
| Started                                                                | 562                                                                    |                                                                        |                                                                        | 281                                                                    |                                                                        | 843                                                                    |                                                                        |
| Completed                                                              | 16                                                                     | (2.8)                                                                  |                                                                        | 5                                                                      | (1.8)                                                                  | 21                                                                     | (2.5)                                                                  |
| Discontinued                                                           | 513                                                                    | (91.3)                                                                 |                                                                        | 264                                                                    | (94.0)                                                                 | 777                                                                    | (92.2)                                                                 |
| Adverse Event                                                          | 46                                                                     | (8.2)                                                                  |                                                                        | 16                                                                     | (5.7)                                                                  | 62                                                                     | (7.4)                                                                  |
| Clinical Progression                                                   | 70                                                                     | (12.5)                                                                 |                                                                        | 41                                                                     | (14.6)                                                                 | 111                                                                    | (13.2)                                                                 |
| Complete Response                                                      | 4                                                                      | (0.7)                                                                  |                                                                        | 1                                                                      | (0.4)                                                                  | 5                                                                      | (0.6)                                                                  |
| Physician Decision                                                     | 12                                                                     | (2.1)                                                                  |                                                                        | 3                                                                      | (1.1)                                                                  | 15                                                                     | (1.8)                                                                  |
| Progressive Disease                                                    | 349                                                                    | (62.1)                                                                 |                                                                        | 193                                                                    | (68.7)                                                                 | 542                                                                    | (64.3)                                                                 |
| Withdrawal By Subject                                                  | 32                                                                     | (5.7)                                                                  |                                                                        | 10                                                                     | (3.6)                                                                  | 42                                                                     | (5.0)                                                                  |
| Status Not Recorded                                                    | 33                                                                     | (5.9)                                                                  |                                                                        | 12                                                                     | (4.3)                                                                  | 45                                                                     | (5.3)                                                                  |
| Status for Trial                                                       | Status for Trial                                                       | Status for Trial                                                       | Status for Trial                                                       | Status for Trial                                                       | Status for Trial                                                       | Status for Trial                                                       | Status for Trial                                                       |
| Discontinued                                                           | 386                                                                    | (68.2)                                                                 |                                                                        | 203                                                                    | (72.2)                                                                 | 589                                                                    | (69.5)                                                                 |
| Death                                                                  | 367                                                                    | (64.8)                                                                 |                                                                        | 197                                                                    | (70.1)                                                                 | 564                                                                    | (66.6)                                                                 |
| Withdrawal By Subject                                                  | 19                                                                     | (3.4)                                                                  |                                                                        | 6                                                                      | (2.1)                                                                  | 25                                                                     | (3.0)                                                                  |
| Status Not Recorded                                                    | 180                                                                    | (31.8)                                                                 |                                                                        | 78                                                                     | (27.8)                                                                 | 258                                                                    | (30.5)                                                                 |

(2.5)

(92.2)

(7.4)

(13.2)

(0.6)

(1.8)

(64.3)

(5.0)

(5.3)

(69.5)

(66.6)

(3.0)

(30.5)

Clinical Progression and Progressive Disease are based on Investigator´s assessment and may be different from the data used in the primary analysis.

Progressive Disease refers to disease progression based on RECIST 1.1 and does not include Clinical Progression.

<div style=\"page-break-after: always\"></div>

Study medication discontinuation refers to discontinuation of all study medications.

Status Not Recorded: Subjects without a completed study medication discontinuation form or without a completed study disposition form.

Database Cutoff Date: 11DEC2019

Table: Disposition of Subjects (Part 2 Subjects with PD-L1 CPS ≥10 ) (ITT Population)

|                                                                    | Pembrolizumab + Chemotherapy                                       | Pembrolizumab + Chemotherapy                                       | Placebo+ Chemotherapy                                              | Placebo+ Chemotherapy                                              | Total                                                              | Total                                                              |
|--------------------------------------------------------------------|--------------------------------------------------------------------|--------------------------------------------------------------------|--------------------------------------------------------------------|--------------------------------------------------------------------|--------------------------------------------------------------------|--------------------------------------------------------------------|
|                                                                    | n                                                                  | (%)                                                                | n                                                                  | (%)                                                                |                                                                    | (%)                                                                |
| Subjects in population                                             | 220                                                                |                                                                    | 103                                                                |                                                                    | 323                                                                |                                                                    |
| Status forStudy MedicationinTrial Segment of First CourseTreatment | Status forStudy MedicationinTrial Segment of First CourseTreatment | Status forStudy MedicationinTrial Segment of First CourseTreatment | Status forStudy MedicationinTrial Segment of First CourseTreatment | Status forStudy MedicationinTrial Segment of First CourseTreatment | Status forStudy MedicationinTrial Segment of First CourseTreatment | Status forStudy MedicationinTrial Segment of First CourseTreatment |
| Started                                                            | 219                                                                |                                                                    | 103                                                                |                                                                    | 322                                                                |                                                                    |
| Completed                                                          | 14                                                                 | (6.4)                                                              | 2                                                                  | (1.9)                                                              | 16                                                                 | (5.0)                                                              |
| Discontinued                                                       | 190                                                                | (86.8)                                                             | 95                                                                 | (92.2)                                                             | 285                                                                | (88.5)                                                             |
| AdverseEvent                                                       | 20                                                                 | (9.1)                                                              | 5                                                                  | (4.9)                                                              | 25                                                                 | (7.8)                                                              |
| Clinical Progression                                               | 21                                                                 | (9.6)                                                              | 12                                                                 | (11.7)                                                             | 33                                                                 | (10.2)                                                             |
| Complete Response                                                  | 3                                                                  | (1.4)                                                              | 1                                                                  | (1.0)                                                              | 4                                                                  | (1.2)                                                              |
| Physician Decision                                                 | 7                                                                  | (3.2)                                                              | 3                                                                  | (2.9)                                                              | 10                                                                 | (3.1)                                                              |
| Progressive Disease                                                | 125                                                                | (57.1)                                                             | 70                                                                 | (68.0)                                                             | 195                                                                | (60.6)                                                             |
| Withdrawal By Subject                                              | 14                                                                 | (6.4)                                                              | 4                                                                  | (3.9)                                                              | 18                                                                 | (5.6)                                                              |
| Status Not Recorded                                                | 15                                                                 | (6.8)                                                              | 6                                                                  | (5.8)                                                              | 21                                                                 | (6.5)                                                              |
| StatusforTrial                                                     | StatusforTrial                                                     | StatusforTrial                                                     | StatusforTrial                                                     | StatusforTrial                                                     | StatusforTrial                                                     | StatusforTrial                                                     |
| Discontinued                                                       | 128                                                                | (58.2)                                                             | 72                                                                 | (69.9)                                                             | 200                                                                | (61.9)                                                             |
| Death                                                              | 119                                                                | (54.1)                                                             | 70                                                                 | (68.0)                                                             | 189                                                                | (58.5)                                                             |
| WithdrawalBySubject                                                | 9                                                                  | (4.1)                                                              | 2                                                                  | (1.9)                                                              | 11                                                                 | (3.4)                                                              |
| StatusNotRecorded                                                  | 92                                                                 | (41.8)                                                             | 31                                                                 | (30.1)                                                             | 123                                                                | (38.1)                                                             |

ClinicalProgression andProgressiveDisease arebased onInvestigator's assessmentand maybedifferentfrom the data used in the primary analysis.

Progressive Disease refers to disease progression based on RECIST 1.1 and does not include Clinical Progression. Studymedicationdiscontinuationreferstodiscontinuationof allstudymedications.

Status Not Recorded: Subjects without a completed study medication discontinuation form or without a completed study dispositionform.

DatabaseCutoffDate:11DEC2019

## Recruitment

This study was conducted at 251 centers in 29 countries. First subject in part 2 was randomized on 9-Jan 2017, last subject randomized was on 12 Jun 2018.

A total of 525 patients were not randomized due to screen failure, the most common being not having centrally confirmed TNBC (38%) and not having measurable disease based on RECIST 1.1 as determined by local radiology review (10.5%). About 7% of subjects were not included due to ECOG ≥ 2 and about 6% due to symptomatic/unstable CNS disease.

A total of 847 participants were randomly assigned in a 2:1 ratio to pembrolizumab + chemotherapy (566 participants) or placebo + chemotherapy (281 participants). Enrolment in Part 2 of the study was from 09-JAN-2017 to 12-JUN-2018.

## Conduct of the study

Protocol amendments: a total of 5 protocol amendments were released. Main changes are summarised below:

Original protocol (21-Apr-2016)

Amendment 1 (06-Dec-2016)

<div style=\"page-break-after: always\"></div>

- Update of pneumonitis exclusion criterion and permanent discontinuation of subjects with Grade 2 pneumonitis
- Clarifications  regarding  visit  schedule,  review  of  safety  labs  and  washout  period  for  prior  radiation therapy
- Clarification that adjuvant radiation therapy is not considered treatment with curative intent for the purpose of calculating the ≥ 6 month interval requirement between completion of surgery or adjuvant chemotherapy (whichever occurred last) and first disease recurrence. Therefore, a subject who was treated with adjuvant radiation therapy within the 6-month interval requirement may be eligible for study participation.

## Amendment 2 (05-Feb-2018)

- Added guidelines for dose modification in the event of myocarditis and updated guidelines for several other conditions to align with the most current label and safety information for pembrolizumab.
- Clarification regarding the imaging assessments required to demonstrate stable brain metastases
- Clarification for requirements of non-emergent unblindings, imaging assessments and survival FU

## Amendment 3 (31-Aug-2018)

- To allow testing of the hypotheses for ORR at IA1 independent of the outcome of the other hypotheses, the allocation of alpha was adjusted over the dual primary and key secondary endpoints.
- The timing of Interim analysis 1 (IA1) was changed from being driven by PFS events to occur ~9 months after 640 subjects were randomly assigned in Part 2 to ensure adequate follow-up time for the ORR analysis.
- Updated the censoring rules for PFS and DOR, to closely follows recent regulatory guidance (primary PFS analysis), and the 'intent-to-treat complete follow-up principle' (first PFS sensitivity analysis).
- Interim analysis 2 (IA2) was changed from OS event driven (estimated ~28 months after the first subject randomized) to calendar time driven (~12 months after the last subject randomized) to allow IA2 be conducted at a pre-specified time point so that subjects will have sufficient follow-up time for analysis.
- The final analysis timing was changed from '~39.5 months after the first subject randomized' to '~23 months after the last subject randomized' to accommodate the new assumptions for the enrollment period.
- To prevent alpha over-spending at interim, alpha and beta-spending were updated to use the time spending approach.
- Power for ORR, PFS and OS have been updated to be in alignment with the updated multiplicity strategy, and to accommodate the new assumptions for the enrollment duration and the prevalence of PD-L1 positivity (from 60% to 75%) in mTNBC subjects updated based on recent available data.
- QoL evaluation has been promoted from an exploratory to a secondary objective.
- Removal of exploratory evaluation of efficacy endpoints based on irRECIST.

## Amendment 4 (20-Mar-2019)

- The timing of the final analysis was changed from OS event driven to both OS event and follow-up time driven to ensure adequate follow-up duration at time of the final analysis.

<div style=\"page-break-after: always\"></div>

- Addition of a third efficacy interim analysis (IA3) between IA2 and FA. The added IA3 also matched the timing of a periodical safety interim analysis.

## Amendment 5 (04-Oct-2019)

- Data from external studies, including other indications of pembrolizumab monotherapy, demonstrated an enriched treatment effect with increasing PD-L1 expression. To identify an enriched population of subjects  that  could  potentially  benefit  more  from  pembrolizumab  plus  chemotherapy  in  metastatic TNBC, the objectives, hypotheses, and statistical analysis plan was revised to include primary and secondary endpoints in participants with PDL1 positive tumors with CPS≥10 .
- Revised efficacy interim analyses plan, and updated multiplicity strategy to allocate initial alpha to PFS and OS in subjects with CPS ≥ 10 to allow testing of added primary endpoints.
- Extended trial follow-up time, to ensure adequate power for the testing of OS and PFS endpoints in the smaller CPS≥10 population.
- Revised multiplicity strategy to allocate initial alpha to PFS and OS in subjects with CPS ≥ 10, to allow testing of added primary endpoints.
- Revised hazard ratio, trial follow-up duration, and PFS dropout rate assumptions for power calculations to  reflect  information  from  latest  external  data  and  updated  statistical  analysis  plan  and  strategy. Revised power calculation based on the revised statistical analysis plan.
- Added subgroup analysis to  examine  different  CPS  cutoffs,  and  to  align  with  the  updated  analysis strategy.

## Additional information regarding protocol amendment 5 and the choice of the PDL1 CPS≥10 cut -off:

Amendment 05 (4-Oct-2019) was initiated and finalized after efficacy IA1 had occurred (actual LPLV: 18 Oct 2018). Following review and recommendation by an independent, external DMC at IA1, the study continued to IA2. Per protocol, the Sponsor remained blinded to IA1 efficacy and safety study results, including individual treatment assignment and CPS scores. A conservative Bonferroni approach was implemented for Type-I error control in amendment 05 by eliminating alpha spent at IA1. The MAH stated that the timing of amendment 05 had no impact on the results or integrity of the study.

To minimize bias, all images for PFS (primary endpoint) evaluation were assessed by independent central reviewer who was blinded to both treatment assignment and PD-L1 status. Therefore, the MAH stated that the integrity of the study was preserved.

The MAH stated that the DMC decision, based on IA1, did not drive the decision to proceed with amendment 05. Amendment 05 was based on the totality of scientific evidence from emerging clinical data from studies in metastatic TNBC external to KEYNOTE-355, namely KEYNOTE-119 and IMpassion130, which were not fully available to the Sponsor until June 2019. Both studies demonstrated an enriched treatment effect of PD-1/L1 inhibition in a PD-L1-enriched patient population.

An enriched treatment effect in OS with increasing PD-L1 level was seen in other indications (HNSCC, urothelial carcinoma, gastric cancer). KEYNOTE-355 prospectively included the CPS cut-off ≥ 1 based on preliminary evidence from KEYNOTE-086 (Coho rt B, 1L mTNBC CPS≥1). The addition of the additional cut-off CPS ≥ 10 was related to data from 2 studies in the metastatic setting becoming available while KEYNOTE-355 was being conducted. KEYNOTE-119 demonstrated that pembrolizumab monotherapy provided a trend for improved OS with enrichment of tumor PD-L1 expression levels (CPS ≥ 1 to CPS ≥ 10) in recurrent locally advanced or metastatic TNBC tumors. In addition, as noted above, IMpassion130 demonstrated that atezolizumab + nab-paclitaxel significantly prolonged PFS in PD-L1 positive tumors,

<div style=\"page-break-after: always\"></div>

defined as PD-L1 stained tumor-infiltrating immune cells of any intensity covering ≥ 1% of the tumor area by the VENTANA PD-L1 (SP142) assay. The PD-L1 IHC 22C3 pharmDx assay used in KEYNOTE-355 uses the combined score of tumor and immune cells that stain positive for PD-L1 expression. Previous studies have shown that the VENTANA PD-L1 (SP142) assay produces lower PD-L1 numerical scores compared with the PD-L1 IHC 22C3 pharmDx assay 20   21   22 , expected based on differences in the antibodies and IHC platforms as well as intrinsic differences in the definitions of the scores (IC vs CPS) themselves; therefore, it is not possible to substitute cut-offs across assays. The prevalence of participants identified as PDL1 positive (IC≥ 1%) in IMpassion130 by the VENTANA PD-L1 (SP142) assay and the prevalence of participants with tumors that express PD-L1 with CPS ≥ 10 by the PD-L1 IHC 22C3 pharmDx assay in KEYNOTE-355 was similar between the 2 studies.

## Protocol deviations:

Important protocol deviations (i.e. 'those that may significantly impact the quality or integrity of key study data or that may significantly affect a participant's rights, safety, or well-being') were reported for 83 (9.8%) participants in Part 2 of the study (10.6% vs 8.2% in the pembrolizumab + chemo vs chemo arm). Seven participants received incorrect study intervention (pembrolizumab or placebo); 6 participants received the incorrect study invention for 1 cycle and 1 participant for 6 cycles.

Of the important protocol deviations, 27 (3.2%) participants had deviations that were considered to be clinically important (i.e. 'deviations that may compromise critical data analyses pertaining to primary efficacy and/or safety endpoints or the participant's safety') (see table below).

Table: Summary of Important Protocol Deviations Considered to be Clinically Important (Part 2 All Subjects) (ITT Population)

20  Buttner R, et al. Programmed death-ligand 1 immunohistochemistry testing: a review of analytical assays and clinical implementation in non-smallcell lung cancer. J Clin Oncol. 2017 Dec 1;35(34):3867 -76.

21  Hirsch FR, et al. PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project. J Thorac Oncol. 2017 Feb;12(2):208 -22.

22  Rugo HS, et al. Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple negative breast cancer (mTNBC): posthoc analysis of IMpassion130 [abstract]. Presented at: ESMO Congress; 2019 Sep 27Oct 1; Barcelona (Spain). Ann Oncol. 2019 Oct;30(suppl 5):v858 -9. Abstract no. LBA20.

<div style=\"page-break-after: always\"></div>

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Pembrolizumab+ Chemotherapy   | Pembrolizumab+ Chemotherapy   | Placebo + Chemotherapy       | Placebo + Chemotherapy       | Total                        | Total                        |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------|-------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | n                             | (%)                           | n                            | (%)                          | 1n                           | (%)                          |
| Subjects in population                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 566                           |                               | 281                          |                              | 847                          |                              |
| With one or more clinically important protocol deviations                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 20                            | (3.5)                         | 7                            | (2.5)                        | 27                           | (3.2)                        |
| With no clinically important protocol deviations                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 546                           | (96.5)                        | 274                          | (97.5)                       | 820                          | (96.8)                       |
| Inclusion/ExclusionCriteria                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 17                            | (3.0)                         | 5                            | (1.8)                        | 22                           | (2.6)                        |
| Participants who do not have centrally confirmed TNBC, as defined by the most recent ASCO/CAP guidelines.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 3                             | (0.5)                         | 1                            | (0.4)                        | 4                            | (0.5)                        |
| Participantswhodonothavecompleted treatment for StageI-II breast cancer,if indicated,andgreaterthanorequalto6months elapsedbetweenthecompletionoftreatment withcurativeintent(dateofprimarybreast tumor surgery or date of last adjuvant chemotherapy administration, whichever occurredlast)andfirst documentedlocalor distant disease recurrence.Note:Subjects who received taxane,gemcitabine,orplatinum agents in the (neo)adjuvant setting can only be treated with same class of chemotherapy, if greater than or equal to 12 months have elapsed betweenthecompletionoftreatmentwith curative intent (date of primary breast tumor surgery or date of last adjuvant chemotherapy administration,whicheveroccurredlast)and firstdocumentedlocalordistantdisease | 11                            | (1.9)                         | 3                            | (1.1)                        | 14                           | (1.7)                        |
| recurence. Participantswhodonot havelocallyrecurrent inoperable breast cancer not previously treated with chemotherapy andwhich cannot be treated with curativeintent ORdonot havemetastatic breast cancer not previously treated with chemotherapy.Note:Some subjects with a history oflocallyrecurrentbreastcancer,which was previously treated with curative intent,                                                                                                                                                                                                                                                                                                                                                                                               |                               | (0.5)                         |                              | (0.4)                        | 4                            | (0.5)                        |
| InformedConsent                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 2                             | (0.4)                         | 1                            | (0.4)                        | 3                            | (0.4)                        |
| Participant had no documented initial consent to enter the trial.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 2                             | (0.4)                         | 1                            | (0.4)                        | 3                            | (0.4)                        |
| Safety Reporting                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 1                             | (0.2)                         | 1                            | (0.4)                        | 2                            | (0.2)                        |
| Participant had a reportable Safety Event and/or followupSafetyEventinformationthatwas notreportedperthetimelines outlinedinthe protocol.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 1                             | (0.2)                         | 1                            | (0.4)                        | 2                            | (0.2)                        |
| DatabaseCutoffDate:11DEC2019                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | DatabaseCutoffDate:11DEC2019  | DatabaseCutoffDate:11DEC2019  | DatabaseCutoffDate:11DEC2019 | DatabaseCutoffDate:11DEC2019 | DatabaseCutoffDate:11DEC2019 | DatabaseCutoffDate:11DEC2019 |

No participant's data were excluded from the Part 2 analyses due to an important protocol deviation.

Overall, in the PD-L1 CPS ≥10 subgroup 9.6% of patients had an important protocol deviation, and 3.6% had a clinically important protocol deviation, which were similarly distributed in both treatment arms and were similar to the ITT population,

No important protocol deviations that occurred during Part 2 of the study were classified as a serious GCP compliance issue.

## Premature unblinding

A total of 125 participants were prematurely unblinded during Part 2, as follows:

- Sponsor-approved  non-emergency  unblinding  requests  for  discontinued  participants  to  determine subsequent therapy in participants failing study intervention; N = 102
- Inadverten t unblinding; N = 11
- Emergency unblinding through the call centre; N = 12.

<div style=\"page-break-after: always\"></div>

## Baseline data

Note: Baseline characteristics data are presented below for the PDL1 positive population CPS≥10 (sought indication), CPS≥1, and all patients (ITT population).

Table: Subject Characteristics (Part 2 Subjects with PDL1 CPS≥10 ) (ITT Population)

323

323

257

66

52.7

12.7

53.0

22 to 83

2

64

15

9

223

10

58

250

10

4

1

56

160

7

45

55

99

44

180

97

44

181

1

|                                  | Pembrolizumab                  | Pembrolizumab   | Placebo + Chemotherapy   | Placebo + Chemotherapy   | Total    | Total   |
|----------------------------------|--------------------------------|-----------------|--------------------------|--------------------------|----------|---------|
|                                  |                                | (%)             |                          | (%)                      | n        | (%)     |
| Subjects in population           | 220                            | 220             | 103                      |                          | 323      |         |
| Gender                           |                                |                 |                          |                          |          |         |
| Female                           | 220                            | (100.0)         | 103                      | (100.0)                  | 323      | (100.0) |
| Age (Years)                      |                                |                 |                          |                          |          |         |
| < 65                             | 178                            | (80.9)          | 79                       | (76.7)                   | 257      | (79.6)  |
| >= 65                            | 42                             | (19.1)          | 24                       | (23.3)                   | 66       | (20.4)  |
| Mean                             | 52.5                           |                 | 53.3                     |                          | 52.7     |         |
| SD                               | 12.5                           |                 | 13.2                     |                          | 12.7     |         |
| Median                           | 52.0                           |                 | 55.0                     |                          | 53.0     |         |
| Range                            | 25 to 83                       |                 | 22 to 77                 |                          | 22 to 83 |         |
| Race                             |                                |                 |                          |                          |          |         |
| American Indian Or Alaska Native | 2                              | (0.9)           | 0                        | (0.0)                    | 2        | (0.6)   |
| Asian                            | 44                             | (20.0)          | 20                       | (19.4)                   | 64       | (19.8)  |
| Black Or African American        | 9                              | (4.1)           | 6                        | (5.8)                    | 15       | (4.6)   |
| Multiple                         | 6                              | (2.7)           | 3                        | (2.9)                    | 9        | (2.8)   |
| White                            | 153                            | (69.5)          | 70                       | (68.0)                   | 223      | (69.0)  |
| Missing                          | 6                              | (2.7)           | 4                        | (3.9)                    | 10       | (3.1)   |
| Ethnicity                        |                                |                 |                          |                          |          |         |
| Hispanic Or Latino               | 37                             | (16.8)          | 21                       | (20.4)                   | 58       | (18.0)  |
| Not Hispanic Or Latino           | 174                            | (79.1)          | 76                       | (73.8)                   | 250      | (77.4)  |
| Not Reported                     | 6                              | (2.7)           | 4                        | (3.9)                    | 10       | (3.1)   |
| Unknown                          | 2                              | (0.9)           | 2                        | (1.9)                    | 4        | (1.2)   |
| Missing                          | 1                              | (0.5)           | 0                        | (0.0)                    | 1        | (0.3)   |
| Geographic Region                |                                |                 |                          |                          |          |         |
| Asia                             | 38                             | (17.3)          | 18                       | (17.5)                   | 56       | (17.3)  |
| Europe                           | 108                            | (49.1)          | 52                       | (50.5)                   | 160      | (49.5)  |
| Australia                        | 5                              | (2.3)           | 2                        | (1.9)                    | 7        | (2.2)   |
| North America                    | 33                             | (15.0)          | 12                       | (11.7)                   | 45       | (13.9)  |
| Rest of the World                | 36                             | (16.4)          | 19                       | (18.4)                   | 55       | (17.0)  |
| Chemotherapy on Study (IVRS)     | Chemotherapy on Study (IVRS)   |                 |                          |                          |          |         |
| Nab-Paclitaxel                   | 63                             | (28.6)          | 36                       | (35.0)                   | 99       | (30.7)  |
| Paclitaxel                       | 33                             | (15.0)          | 11                       | (10.7)                   | 44       | (13.6)  |
| Gemcitabine/Carboplatin          | 124                            | (56.4)          | 56                       | (54.4)                   | 180      | (55.7)  |
| Chemotherapy on Study (Actual)   | Chemotherapy on Study (Actual) |                 |                          |                          |          |         |
| Nab-Paclitaxel                   | 61                             | (27.7)          | 36                       | (35.0)                   | 97       | (30.0)  |
| Paclitaxel                       | 33                             | (15.0)          | 11                       | (10.7)                   | 44       | (13.6)  |
| Gemcitabine/Carboplatin          | 125                            | (56.8)          | 56                       | (54.4)                   | 181      | (56.0)  |
| Missing                          | 1                              | (0.5)           | 0                        | (0.0)                    | 1        | (0.3)   |

<div style=\"page-break-after: always\"></div>

65

258

61

261

1

103

206

13

1

196

127

233

90

11

312

108

215

103

66

153

1

166

110

37

10

297

70.2

48.9

59.0

11.0 to 290.0

320

77.6

56.2

60.0

10.0 to 352.0

| Prior Treatment with Same Yes                                                                | Class 46                                                                                     | Chemotherapy in (20.9)                                                                       | Neoadjuvant 19                                                                               | or Adjuvant (18.4)                                                                           | Setting (IVRS) 65                                                                            | (20.1)                                                                                       |
|----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|
| No                                                                                           | 174                                                                                          | (79.1)                                                                                       | 84                                                                                           | (81.6)                                                                                       | 258                                                                                          | (79.9)                                                                                       |
| Prior Treatment with Same Class Chemotherapy in the Neoadjuvant or Adjuvant Setting (Actual) | Prior Treatment with Same Class Chemotherapy in the Neoadjuvant or Adjuvant Setting (Actual) | Prior Treatment with Same Class Chemotherapy in the Neoadjuvant or Adjuvant Setting (Actual) | Prior Treatment with Same Class Chemotherapy in the Neoadjuvant or Adjuvant Setting (Actual) | Prior Treatment with Same Class Chemotherapy in the Neoadjuvant or Adjuvant Setting (Actual) | Prior Treatment with Same Class Chemotherapy in the Neoadjuvant or Adjuvant Setting (Actual) | Prior Treatment with Same Class Chemotherapy in the Neoadjuvant or Adjuvant Setting (Actual) |
| Yes                                                                                          | 44                                                                                           | (20.0)                                                                                       | 17                                                                                           | (16.5)                                                                                       | 61                                                                                           | (18.9)                                                                                       |
| No                                                                                           | 175                                                                                          | (79.5)                                                                                       | 86                                                                                           | (83.5)                                                                                       | 261                                                                                          | (80.8)                                                                                       |
| Missing                                                                                      | 1                                                                                            | (0.5)                                                                                        | 0                                                                                            | (0.0)                                                                                        | 1                                                                                            | (0.3)                                                                                        |
| Disease Status                                                                               | Disease Status                                                                               | Disease Status                                                                               | Disease Status                                                                               | Disease Status                                                                               | Disease Status                                                                               | Disease Status                                                                               |
| Metastatic, De Novo                                                                          | 68                                                                                           | (30.9)                                                                                       | 35                                                                                           | (34.0)                                                                                       | 103                                                                                          | (31.9)                                                                                       |
| Metastatic, Recurrence                                                                       | 144                                                                                          | (65.5)                                                                                       | 62                                                                                           | (60.2)                                                                                       | 206                                                                                          | (63.8)                                                                                       |
| Locally Recurrent Inoperable                                                                 | 7                                                                                            | (3.2)                                                                                        | 6                                                                                            | (5.8)                                                                                        | 13                                                                                           | (4.0)                                                                                        |
| Missing                                                                                      | 1                                                                                            | (0.5)                                                                                        | 0                                                                                            | (0.0)                                                                                        | 1                                                                                            | (0.3)                                                                                        |
| ECOG                                                                                         | ECOG                                                                                         | ECOG                                                                                         | ECOG                                                                                         | ECOG                                                                                         | ECOG                                                                                         | ECOG                                                                                         |
| 0                                                                                            | 134                                                                                          | (60.9)                                                                                       | 62                                                                                           | (60.2)                                                                                       | 196                                                                                          | (60.7)                                                                                       |
| 1                                                                                            | 86                                                                                           | (39.1)                                                                                       | 41                                                                                           | (39.8)                                                                                       | 127                                                                                          | (39.3)                                                                                       |
| HER2 Status                                                                                  | HER2 Status                                                                                  | HER2 Status                                                                                  | HER2 Status                                                                                  | HER2 Status                                                                                  | HER2 Status                                                                                  | HER2 Status                                                                                  |
| 0-1+ by IHC                                                                                  | 153                                                                                          | (69.5)                                                                                       | 80                                                                                           | (77.7)                                                                                       | 233                                                                                          | (72.1)                                                                                       |
| 2+ by IHC                                                                                    | 67                                                                                           | (30.5)                                                                                       | 23                                                                                           | (22.3)                                                                                       | 90                                                                                           | (27.9)                                                                                       |
| History of Brain Metastasis                                                                  | History of Brain Metastasis                                                                  | History of Brain Metastasis                                                                  | History of Brain Metastasis                                                                  | History of Brain Metastasis                                                                  | History of Brain Metastasis                                                                  | History of Brain Metastasis                                                                  |
| Yes                                                                                          | 5                                                                                            | (2.3)                                                                                        | 6                                                                                            | (5.8)                                                                                        | 11                                                                                           | (3.4)                                                                                        |
| No                                                                                           | 215                                                                                          | (97.7)                                                                                       | 97                                                                                           | (94.2)                                                                                       | 312                                                                                          | (96.6)                                                                                       |
| Menopausal Status                                                                            | Menopausal Status                                                                            | Menopausal Status                                                                            | Menopausal Status                                                                            | Menopausal Status                                                                            | Menopausal Status                                                                            | Menopausal Status                                                                            |
| Pre-menopausal                                                                               | 74                                                                                           | (33.6)                                                                                       | 34                                                                                           | (33.0)                                                                                       | 108                                                                                          | (33.4)                                                                                       |
| Post-menopausal                                                                              | 146                                                                                          | (66.4)                                                                                       | 69                                                                                           | (67.0)                                                                                       | 215                                                                                          | (66.6)                                                                                       |
| Disease Free Interval                                                                        | Disease Free Interval                                                                        | Disease Free Interval                                                                        | Disease Free Interval                                                                        | Disease Free Interval                                                                        | Disease Free Interval                                                                        | Disease Free Interval                                                                        |
| de novo metastasis                                                                           | 68                                                                                           | (30.9)                                                                                       | 35                                                                                           | (34.0)                                                                                       | 103                                                                                          | (31.9)                                                                                       |
| < 12 months                                                                                  | 49                                                                                           | (22.3)                                                                                       | 17                                                                                           | (16.5)                                                                                       | 66                                                                                           | (20.4)                                                                                       |
| >= 12 months                                                                                 | 102                                                                                          | (46.4)                                                                                       | 51                                                                                           | (49.5)                                                                                       | 153                                                                                          | (47.4)                                                                                       |
| Unknown                                                                                      | 1                                                                                            | (0.5)                                                                                        | 0                                                                                            | (0.0)                                                                                        | 1                                                                                            | (0.3)                                                                                        |
| Baseline Lactate Dehydrogenase (LDH)                                                         | Baseline Lactate Dehydrogenase (LDH)                                                         | Baseline Lactate Dehydrogenase (LDH)                                                         | Baseline Lactate Dehydrogenase (LDH)                                                         | Baseline Lactate Dehydrogenase (LDH)                                                         | Baseline Lactate Dehydrogenase (LDH)                                                         | Baseline Lactate Dehydrogenase (LDH)                                                         |
| Normal                                                                                       | 115                                                                                          | (52.3)                                                                                       | 51                                                                                           | (49.5)                                                                                       | 166                                                                                          | (51.4)                                                                                       |
| > ULN and < 2 x ULN                                                                          | 75                                                                                           | (34.1)                                                                                       | 35                                                                                           | (34.0)                                                                                       | 110                                                                                          | (34.1)                                                                                       |
| >= 2 x ULN                                                                                   | 25                                                                                           | (11.4)                                                                                       | 12                                                                                           | (11.7)                                                                                       | 37                                                                                           | (11.5)                                                                                       |
| Missing                                                                                      | 5                                                                                            | (2.3)                                                                                        | 5                                                                                            | (4.9)                                                                                        | 10                                                                                           | (3.1)                                                                                        |
| Sum of Target Lesion Size at Baseline (Central) (mm)                                         | Sum of Target Lesion Size at Baseline (Central) (mm)                                         | Sum of Target Lesion Size at Baseline (Central) (mm)                                         | Sum of Target Lesion Size at Baseline (Central) (mm)                                         | Sum of Target Lesion Size at Baseline (Central) (mm)                                         | Sum of Target Lesion Size at Baseline (Central) (mm)                                         | Sum of Target Lesion Size at Baseline (Central) (mm)                                         |
| Subjects with data                                                                           | 199                                                                                          |                                                                                              | 98                                                                                           |                                                                                              | 297                                                                                          |                                                                                              |
| Mean                                                                                         | 69.2                                                                                         |                                                                                              | 72.4                                                                                         |                                                                                              | 70.2                                                                                         |                                                                                              |
| SD                                                                                           | 47.6                                                                                         |                                                                                              | 51.4                                                                                         |                                                                                              | 48.9                                                                                         |                                                                                              |
| Median                                                                                       | 57.0                                                                                         |                                                                                              | 59.5                                                                                         |                                                                                              | 59.0                                                                                         |                                                                                              |
| Range                                                                                        | 11.0 to 290.0                                                                                |                                                                                              | 15.0 to 271.0                                                                                |                                                                                              | 11.0 to 290.0                                                                                |                                                                                              |
| Sum of Target Lesion Size at Baseline (Investigator) (mm)                                    | Sum of Target Lesion Size at Baseline (Investigator) (mm)                                    | Sum of Target Lesion Size at Baseline (Investigator) (mm)                                    | Sum of Target Lesion Size at Baseline (Investigator) (mm)                                    | Sum of Target Lesion Size at Baseline (Investigator) (mm)                                    | Sum of Target Lesion Size at Baseline (Investigator) (mm)                                    | Sum of Target Lesion Size at Baseline (Investigator) (mm)                                    |
| Subjects with data                                                                           | 217                                                                                          |                                                                                              | 103                                                                                          |                                                                                              | 320                                                                                          |                                                                                              |
| Mean                                                                                         | 77.3                                                                                         |                                                                                              | 78.1                                                                                         |                                                                                              | 77.6                                                                                         |                                                                                              |
| SD                                                                                           | 59.9                                                                                         |                                                                                              | 47.8                                                                                         |                                                                                              | 56.2                                                                                         |                                                                                              |
| Median                                                                                       | 60.0                                                                                         |                                                                                              | 66.0                                                                                         |                                                                                              | 60.0                                                                                         |                                                                                              |
| Range                                                                                        | 10.0 to 352.0                                                                                |                                                                                              | 10.0 to 237.1                                                                                |                                                                                              | 10.0 to 352.0                                                                                |                                                                                              |

<div style=\"page-break-after: always\"></div>

|                                            | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Placebo + Chemotherapy   | Placebo + Chemotherapy   | Total   | Total   |
|--------------------------------------------|--------------------------------|--------------------------------|--------------------------|--------------------------|---------|---------|
|                                            | 1n                             | (%)                            | 1n                       | (%)                      | n       | (%)     |
| Subjects in Population                     | 220                            |                                | 103                      |                          | 323     |         |
| No. of Metastatic Organ Sites              |                                |                                |                          |                          |         |         |
| 0                                          | 7                              | (3.2)                          | 6                        | (5.8)                    | 13      | (4.0)   |
| 1                                          | 39                             | (17.7)                         | 21                       | (20.4)                   | 60      | (18.6)  |
| 2                                          | 76                             | (34.5)                         | 35                       | (34.0)                   | 111     | (34.4)  |
| V3                                         | 97                             | (44.1)                         | 41                       | (39.8)                   | 138     | (42.7)  |
| Missing                                    | 1                              | (0.5)                          | 0                        | (0.0)                    | 1       | (0.3)   |
| Metastatic Organ Sitest                    |                                |                                |                          |                          |         |         |
| Subjects with metastatic disease           | 212                            |                                | 97                       |                          | 309     |         |
| Bone                                       | 52                             | (23.6)                         | 22                       | (21.4)                   | 74      | (22.9)  |
| Brain                                      | 5                              | (2.3)                          | 6                        | (5.8)                    | 11      | (3.4)   |
| Breast                                     | 17                             | (7.7)                          | 7                        | (6.8)                    | 24      | (7.4)   |
| Chest Wall                                 | 56                             | (25.5)                         | 15                       | (14.6)                   | 71      | (22.0)  |
| Liver                                      | 62                             | (28.2)                         | 32                       | (31.1)                   | 94      | (29.1)  |
| Lung                                       | 120                            | (54.5)                         | 55                       | (53.4)                   | 175     | (54.2)  |
| Lymph Nodes                                | 169                            | (76.8)                         | 79                       | (76.7)                   | 248     | (76.8)  |
| Other Metastasis                           | 46                             | (20.9)                         | 17                       | (16.5)                   | 63      | (19.5)  |
| Visceral Disease                           |                                |                                |                          |                          |         |         |
| Non-Visceral Only                          | 13                             | (5.9)                          | 9                        | (8.7)                    | 22      | (6.8)   |
| With brain metastasis                      | 0                              | (0.0)                          | 0                        | (0.0)                    | 0       | (0.0)   |
| Without brain metastasis                   | 13                             | (5.9)                          | 9                        | (8.7)                    | 22      | (6.8)   |
| Any Visceral                               | 206                            | (93.6)                         | 94                       | (91.3)                   | 300     | (92.9)  |
| With brain metastasis                      | 5                              | (2.3)                          | 6                        | (5.8)                    | 11      | (3.4)   |
| Without brain metastasis                   | 201                            | (91.4)                         | 88                       | (85.4)                   | 289     | (89.5)  |
| Missing                                    | 1                              | (0.5)                          | 0                        | (0.0)                    | 1       | (0.3)   |
| Prior Neoadjuvant or Adjuvant Chemotherapy |                                |                                |                          |                          |         |         |
| Yes                                        | 131                            | (59.5)                         | 62                       | (60.2)                   | 193     | (59.8)  |
| Taxanes                                    | 107                            | (48.6)                         | 50                       | (48.5)                   | 157     | (48.6)  |
| Platinum                                   | 13                             | (5.9)                          | 6                        | (5.8)                    | 19      | (5.9)   |
| Anthracyclines                             | 115                            | (52.3)                         | 50                       | (48.5)                   | 165     | (51.1)  |
| Other                                      | 118                            | (53.6)                         | 55                       | (53.4)                   | 173     | (53.6)  |
| No                                         | 89                             | (40.5)                         | 41                       | (39.8)                   | 130     | (40.2)  |

↑ Breast, chest wall and lymph node also include locally recurrent lesions.

Database Cutoff Date: 11DEC2019.

Table: Subject Characteristics (Part 2 Subjects with PD-L1 CPS ≥ 1) (ITT Population)

<div style=\"page-break-after: always\"></div>

|                                  | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Placebo + Chemotherapy   | Placebo + Chemotherapy   | Total    | Total   |
|----------------------------------|--------------------------------|--------------------------------|--------------------------|--------------------------|----------|---------|
|                                  | n                              | (%)                            | n                        | (%)                      | n        | (%)     |
| Subjects in population           | 425                            |                                | 211                      |                          | 636      |         |
| Gender                           |                                |                                |                          |                          |          |         |
| Female                           | 425                            | (100.0)                        | 211                      | (100.0)                  | 636      | (100.0) |
| Age (Years)                      |                                |                                |                          |                          |          |         |
| <65                              | 337                            | (79.3)                         | 168                      | (79.6)                   | 505      | (79.4)  |
| >= 65                            | 88                             | (20.7)                         | 43                       | (20.4)                   | 131      | (20.6)  |
| Mean                             | 52.8                           |                                | 52.6                     |                          | 52.8     |         |
| SD                               | 12.9                           |                                | 12.8                     |                          | 12.9     |         |
| Median                           | 52.0                           |                                | 52.0                     |                          | 52.0     |         |
| Range                            | 25 to 83                       |                                | 22 to 77                 |                          | 22 to 83 |         |
| Race                             |                                |                                |                          |                          |          |         |
| American Indian Or Alaska Native | 7                              | (1.6)                          | 0                        | (0.0)                    | 7        | (1.1)   |
| Asian                            | 89                             | (20.9)                         | 41                       | (19.4)                   | 130      | (20.4)  |
| Black Or African American        | 16                             | (3.8)                          | 10                       | (4.7)                    | 26       | (4.1)   |
| Multiple                         | 9                              | (2.1)                          | 7                        | (3.3)                    | 16       | (2.5)   |
| White                            | 291                            | (68.5)                         | 146                      | (69.2)                   | 437      | (68.7)  |
| Missing                          | 13                             | (3.1)                          | 7                        | (3.3)                    | 20       | (3.1)   |
| Ethnicity                        |                                |                                |                          |                          |          |         |
| Hispanic Or Latino               | 81                             | (19.1)                         | 36                       | (17.1)                   | 117      | (18.4)  |
| Not Hispanic Or Latino           | 324                            | (76.2)                         | 163                      | (77.3)                   | 487      | (76.6)  |
| Not Reported                     | 12                             | (2.8)                          | 8                        | (3.8)                    | 20       | (3.1)   |
| Unknown                          | 7                              | (1.6)                          | 4                        | (1.9)                    | 11       | (1.7)   |
| Missing                          | 1                              | (0.2)                          | 0                        | (0.0)                    | 1        | (0.2)   |
| Geographic Region                |                                |                                |                          |                          |          |         |
| Asia                             | 81                             | (19.1)                         | 36                       | (17.1)                   | 117      | (18.4)  |
| Europe                           | 204                            | (48.0)                         | 111                      | (52.6)                   | 315      | (49.5)  |
| Australia                        | 10                             | (2.4)                          | 7                        | (3.3)                    | 17       | (2.7)   |
| North America                    | 54                             | (12.7)                         | 25                       | (11.8)                   | 79       | (12.4)  |
| Rest of the World                | 76                             | (17.9)                         | 32                       | (15.2)                   | 108      | (17.0)  |
| Chemotherapy onStudy (IVRS)      | Chemotherapy onStudy (IVRS)    |                                |                          |                          |          |         |
| Nab-Paclitaxel                   | 130                            | (30.6)                         | 74                       | (35.1)                   | 204      | (32.1)  |
| Paclitaxel                       | 62                             | (14.6)                         | 22                       | (10.4)                   | 84       | (13.2)  |

<div style=\"page-break-after: always\"></div>

| Gemcitabine/Carboplatin                                                                       | 233                                                                                           | (54.8)                                                                                        | 115                                                                                           | (54.5)                                                                                        | 348                                                                                           | (54.7)                                                                                        |
|-----------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|
| Chemotherapy on Study (Actual)                                                                | Chemotherapy on Study (Actual)                                                                | Chemotherapy on Study (Actual)                                                                | Chemotherapy on Study (Actual)                                                                | Chemotherapy on Study (Actual)                                                                | Chemotherapy on Study (Actual)                                                                | Chemotherapy on Study (Actual)                                                                |
| Nab-Paclitaxel                                                                                | 129                                                                                           | (30.4)                                                                                        | 74                                                                                            | (35.1)                                                                                        | 203                                                                                           | (31.9)                                                                                        |
| Paclitaxel                                                                                    | 61                                                                                            | (14.4)                                                                                        | 22                                                                                            | (10.4)                                                                                        | 83                                                                                            | (13.1)                                                                                        |
| Gemcitabine/Carboplatin                                                                       | 231                                                                                           | (54.4)                                                                                        | 115                                                                                           | (54.5)                                                                                        | 346                                                                                           | (54.4)                                                                                        |
| Missing                                                                                       | 4                                                                                             | (0.9)                                                                                         | 0                                                                                             | (0.0)                                                                                         | 4                                                                                             | (0.6)                                                                                         |
| Prior Treatment with Same Class Chemotherapy in the Neoadjuvant or Adjuvant Setting (IVRS)    | Prior Treatment with Same Class Chemotherapy in the Neoadjuvant or Adjuvant Setting (IVRS)    | Prior Treatment with Same Class Chemotherapy in the Neoadjuvant or Adjuvant Setting (IVRS)    | Prior Treatment with Same Class Chemotherapy in the Neoadjuvant or Adjuvant Setting (IVRS)    | Prior Treatment with Same Class Chemotherapy in the Neoadjuvant or Adjuvant Setting (IVRS)    | Prior Treatment with Same Class Chemotherapy in the Neoadjuvant or Adjuvant Setting (IVRS)    | Prior Treatment with Same Class Chemotherapy in the Neoadjuvant or Adjuvant Setting (IVRS)    |
| Yes                                                                                           | 91                                                                                            | (21.4)                                                                                        | 45                                                                                            | (21.3)                                                                                        | 136                                                                                           | (21.4)                                                                                        |
| No                                                                                            | 334                                                                                           | (78.6)                                                                                        | 166                                                                                           | (78.7)                                                                                        | 500                                                                                           | (78.6)                                                                                        |
| Prior Treatiment with Same Class Chemotherapy in the Neoadjuvant or Adjuvant Setting (Actual) | Prior Treatiment with Same Class Chemotherapy in the Neoadjuvant or Adjuvant Setting (Actual) | Prior Treatiment with Same Class Chemotherapy in the Neoadjuvant or Adjuvant Setting (Actual) | Prior Treatiment with Same Class Chemotherapy in the Neoadjuvant or Adjuvant Setting (Actual) | Prior Treatiment with Same Class Chemotherapy in the Neoadjuvant or Adjuvant Setting (Actual) | Prior Treatiment with Same Class Chemotherapy in the Neoadjuvant or Adjuvant Setting (Actual) | Prior Treatiment with Same Class Chemotherapy in the Neoadjuvant or Adjuvant Setting (Actual) |
| Yes                                                                                           | 92                                                                                            | (21.6)                                                                                        | 42                                                                                            | (19.9)                                                                                        | 134                                                                                           | (21.1)                                                                                        |
| No                                                                                            | 329                                                                                           | (77.4)                                                                                        | 169                                                                                           | (80.1)                                                                                        | 498                                                                                           | (78.3)                                                                                        |
| Missing                                                                                       | 4                                                                                             | (0.9)                                                                                         | 0                                                                                             | (0.0)                                                                                         | 4                                                                                             | (0.6)                                                                                         |
| Disease Status                                                                                | Disease Status                                                                                | Disease Status                                                                                | Disease Status                                                                                | Disease Status                                                                                | Disease Status                                                                                | Disease Status                                                                                |
| Metastatic, De Novo                                                                           | 135                                                                                           | (31.8)                                                                                        | 65                                                                                            | (30.8)                                                                                        | 200                                                                                           | (31.4)                                                                                        |
| Metastatic,Recurrence                                                                         | 274                                                                                           | (64.5)                                                                                        | 135                                                                                           | (64.0)                                                                                        | 409                                                                                           | (64.3)                                                                                        |
| Locally Recurrent Inoperable                                                                  | 13                                                                                            | (3.1)                                                                                         | 11                                                                                            | (5.2)                                                                                         | 24                                                                                            | (3.8)                                                                                         |
| Missing                                                                                       | 3                                                                                             | (0.7)                                                                                         | 0                                                                                             | (0.0)                                                                                         | 3                                                                                             | (0.5)                                                                                         |
| ECOG                                                                                          | ECOG                                                                                          | ECOG                                                                                          | ECOG                                                                                          | ECOG                                                                                          | ECOG                                                                                          | ECOG                                                                                          |
| 0                                                                                             | 253                                                                                           | (59.5)                                                                                        | 134                                                                                           | (63.5)                                                                                        | 387                                                                                           | (60.8)                                                                                        |
| 1                                                                                             | 171                                                                                           | (40.2)                                                                                        | 77                                                                                            | (36.5)                                                                                        | 248                                                                                           | (39.0)                                                                                        |
| Missing                                                                                       | 1                                                                                             | (0.2)                                                                                         | 0                                                                                             | (0.0)                                                                                         | 1                                                                                             | (0.2)                                                                                         |
| HER2Status                                                                                    | HER2Status                                                                                    | HER2Status                                                                                    | HER2Status                                                                                    | HER2Status                                                                                    | HER2Status                                                                                    | HER2Status                                                                                    |
| 0-1+ by IHC                                                                                   | 309                                                                                           | (72.7)                                                                                        | 159                                                                                           | (75.4)                                                                                        | 468                                                                                           | (73.6)                                                                                        |
| 2+ by IHC                                                                                     | 116                                                                                           | (27.3)                                                                                        | 52                                                                                            | (24.6)                                                                                        | 168                                                                                           | (26.4)                                                                                        |
| History of Brain Metastasis                                                                   | History of Brain Metastasis                                                                   | History of Brain Metastasis                                                                   | History of Brain Metastasis                                                                   | History of Brain Metastasis                                                                   | History of Brain Metastasis                                                                   | History of Brain Metastasis                                                                   |
| Yes                                                                                           | 14                                                                                            | (3.3)                                                                                         | 8                                                                                             | (3.8)                                                                                         | 22                                                                                            | (3.5)                                                                                         |
| No                                                                                            | 410                                                                                           | (96.5)                                                                                        | 203                                                                                           | (96.2)                                                                                        | 613                                                                                           | (96.4)                                                                                        |
| Missing                                                                                       | 1                                                                                             | (0.2)                                                                                         | 0                                                                                             | (0.0)                                                                                         | 1                                                                                             | (0.2)                                                                                         |
| Menopausal Status                                                                             | Menopausal Status                                                                             | Menopausal Status                                                                             | Menopausal Status                                                                             | Menopausal Status                                                                             | Menopausal Status                                                                             | Menopausal Status                                                                             |
| Pre-menopausal                                                                                | 146                                                                                           | (34.4)                                                                                        | 76                                                                                            | (36.0)                                                                                        | 222                                                                                           | (34.9)                                                                                        |
| Post-menopausal                                                                               | 278                                                                                           | (65.4)                                                                                        | 135                                                                                           | (64.0)                                                                                        | 413                                                                                           | (64.9)                                                                                        |
| Missing                                                                                       | 1                                                                                             | (0.2)                                                                                         | 0                                                                                             | (0.0)                                                                                         | 1                                                                                             | (0.2)                                                                                         |
| DiseaseFreeInterval                                                                           | DiseaseFreeInterval                                                                           | DiseaseFreeInterval                                                                           | DiseaseFreeInterval                                                                           | DiseaseFreeInterval                                                                           | DiseaseFreeInterval                                                                           | DiseaseFreeInterval                                                                           |
| de novo metastasis                                                                            | 135                                                                                           | (31.8)                                                                                        | 65                                                                                            | (30.8)                                                                                        | 200                                                                                           | (31.4)                                                                                        |
| <12 months                                                                                    | 92                                                                                            | (21.6)                                                                                        | 37                                                                                            | (17.5)                                                                                        | 129                                                                                           | (20.3)                                                                                        |
| >= 12 months                                                                                  | 195                                                                                           | (45.9)                                                                                        | 109                                                                                           | (51.7)                                                                                        | 304                                                                                           | (47.8)                                                                                        |
| Unknown                                                                                       | 3                                                                                             | (0.7)                                                                                         | 0                                                                                             | (0.0)                                                                                         | 3                                                                                             | (0.5)                                                                                         |
| BaselineLactateDehydrogenase(LDH)                                                             | BaselineLactateDehydrogenase(LDH)                                                             | BaselineLactateDehydrogenase(LDH)                                                             | BaselineLactateDehydrogenase(LDH)                                                             | BaselineLactateDehydrogenase(LDH)                                                             | BaselineLactateDehydrogenase(LDH)                                                             | BaselineLactateDehydrogenase(LDH)                                                             |
| Normal                                                                                        | 202                                                                                           | (47.5)                                                                                        | 99                                                                                            | (46.9)                                                                                        | 301                                                                                           | (47.3)                                                                                        |
| >ULN and< 2 x ULN                                                                             | 142                                                                                           | (33.4)                                                                                        | 75                                                                                            | (35.5)                                                                                        | 217                                                                                           | (34.1)                                                                                        |
| >= 2 x ULN                                                                                    | 70                                                                                            | (16.5)                                                                                        | 29                                                                                            | (13.7)                                                                                        | 66                                                                                            | (15.6)                                                                                        |
| Missing                                                                                       | 11                                                                                            | (2.6)                                                                                         | 8                                                                                             | (3.8)                                                                                         | 19                                                                                            | (3.0)                                                                                         |
| Sumof Target Lesion Size atBaseline(Central)(mm)                                              | Sumof Target Lesion Size atBaseline(Central)(mm)                                              | Sumof Target Lesion Size atBaseline(Central)(mm)                                              | Sumof Target Lesion Size atBaseline(Central)(mm)                                              | Sumof Target Lesion Size atBaseline(Central)(mm)                                              | Sumof Target Lesion Size atBaseline(Central)(mm)                                              | Sumof Target Lesion Size atBaseline(Central)(mm)                                              |
| Subjects with data                                                                            | 394                                                                                           |                                                                                               | 193                                                                                           |                                                                                               | 587                                                                                           |                                                                                               |
| Mean                                                                                          | 70.1                                                                                          |                                                                                               | 71.6                                                                                          |                                                                                               | 70.6                                                                                          |                                                                                               |
| SD                                                                                            | 50.7                                                                                          |                                                                                               | 52.9                                                                                          |                                                                                               | 51.4                                                                                          |                                                                                               |
| Median                                                                                        | 56.0                                                                                          |                                                                                               | 55.0                                                                                          |                                                                                               | 56.0                                                                                          |                                                                                               |
| Range                                                                                         | 11.0 to 352.0                                                                                 |                                                                                               | 12.0 to 271.0                                                                                 |                                                                                               | 11.0 to 352.0                                                                                 |                                                                                               |
| Sum of Target Lesion Size at Baseline (Investigator) (mm)                                     | Sum of Target Lesion Size at Baseline (Investigator) (mm)                                     | Sum of Target Lesion Size at Baseline (Investigator) (mm)                                     | Sum of Target Lesion Size at Baseline (Investigator) (mm)                                     | Sum of Target Lesion Size at Baseline (Investigator) (mm)                                     | Sum of Target Lesion Size at Baseline (Investigator) (mm)                                     | Sum of Target Lesion Size at Baseline (Investigator) (mm)                                     |
| Subjects with data                                                                            | 420                                                                                           |                                                                                               | 211                                                                                           |                                                                                               | 631                                                                                           |                                                                                               |
| Mean                                                                                          | 78.6                                                                                          |                                                                                               | 75.5                                                                                          |                                                                                               | 77.6                                                                                          |                                                                                               |
| SD                                                                                            | 60.0                                                                                          |                                                                                               | 57.2                                                                                          |                                                                                               | 59.1                                                                                          |                                                                                               |
| Median Range                                                                                  | 62.4 10.0 to 352.0                                                                            |                                                                                               | 58.0                                                                                          |                                                                                               | 60.0                                                                                          |                                                                                               |
| 10.0 to 410.0 10.0 to 410.0 DatabaseCutoff Date:11DEC2019                                     | 10.0 to 410.0 10.0 to 410.0 DatabaseCutoff Date:11DEC2019                                     | 10.0 to 410.0 10.0 to 410.0 DatabaseCutoff Date:11DEC2019                                     | 10.0 to 410.0 10.0 to 410.0 DatabaseCutoff Date:11DEC2019                                     | 10.0 to 410.0 10.0 to 410.0 DatabaseCutoff Date:11DEC2019                                     | 10.0 to 410.0 10.0 to 410.0 DatabaseCutoff Date:11DEC2019                                     | 10.0 to 410.0 10.0 to 410.0 DatabaseCutoff Date:11DEC2019                                     |

Table: Subject Characteristics (Part 2 All Subjects) (ITT Population)

<div style=\"page-break-after: always\"></div>

|                                  | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Placebo + Chemotherapy   | Placebo + Chemotherapy   | Total    | Total   |
|----------------------------------|--------------------------------|--------------------------------|--------------------------|--------------------------|----------|---------|
|                                  | n                              | (%)                            | n                        | (%)                      | n        | (%)     |
| Subjects in population           | 566                            |                                | 281                      |                          | 847      |         |
| Gender                           |                                |                                |                          |                          |          |         |
| Female                           | 566                            | (100.0)                        | 281                      | (100.0)                  | 847      | (100.0) |
| Age (Years)                      |                                |                                |                          |                          |          |         |
| <65                              | 443                            | (78.3)                         | 224                      | (79.7)                   | 667      | (78.7)  |
| >=65                             | 123                            | (21.7)                         | 57                       | (20.3)                   | 180      | (21.3)  |
| Mean                             | 53.5                           |                                | 53.0                     |                          | 53.3     |         |
| SD                               | 12.7                           |                                | 12.7                     |                          | 12.7     |         |
| Median                           | 53.0                           |                                | 53.0                     |                          | 53.0     |         |
| Range                            | 25 to 85                       |                                | 22 to 77                 |                          | 22 to 85 |         |
| Race                             |                                |                                |                          |                          |          |         |
| American Indian Or Alaska Native | 11                             | (6: 1)                         | 1                        | (0.4)                    | 12       | (1.4)   |
| Asian                            | 123                            | (21.7)                         | 52                       | (18.5)                   | 175      | (20.7)  |
| Black Or African American        | 20                             | (3.5)                          | 17                       | (6.0)                    | 37       | (4.4)   |
| Multiple                         | 11                             | (1.9)                          | 8                        | (2.8)                    | 19       | (2.2)   |
| White                            | 384                            | (67.8)                         | 195                      | (69.4)                   | 579      | (68.4)  |
| Missing                          | 17                             | (3.0)                          | 8                        | (2.8)                    | 25       | (3.0)   |
| Ethnicity                        |                                |                                |                          |                          |          |         |
| Hispanic Or Latino               | 116                            | (20.5)                         | 48                       | (17.1)                   | 164      | (19.4)  |
| Not Hispanic Or Latino           | 423                            | (74.7)                         | 218                      | (77.6)                   | 641      | (75.7)  |
| Not Reported                     | 17                             | (3.0)                          | 10                       | (3.6)                    | 27       | (3.2)   |
| Unknown                          | 9                              | (1.6)                          | 5                        | (1.8)                    | 14       | (1.7)   |
| Missing                          | 1                              | (0.2)                          | 0                        | (0.0)                    | 1        | (0.1)   |
| Geographic Region                |                                |                                |                          |                          |          |         |
| Asia                             | 113                            | (20.0)                         | 47                       | (16.7)                   | 160      | (18.9)  |
| Europe                           | 263                            | (46.5)                         | 144                      | (51.2)                   | 407      | (48.1)  |
| Australia                        | 13                             | (2.3)                          | 8                        | (2.8)                    | 21       | (2.5)   |
| North America                    | 68                             | (12.0)                         | 40                       | (14.2)                   | 108      | (12.8)  |
| Rest of the World                | 109                            | (19.3)                         | 42                       | (14.9)                   | 151      | (17.8)  |
| Chemotherapy on Study (IVRS)     | Chemotherapy on Study (IVRS)   |                                |                          |                          |          |         |
| Nab-Paclitaxel                   | 173                            | (30.6)                         | 95                       | (33.8)                   | 268      | (31.6)  |
| Paclitaxel                       | 82                             | (14.5)                         | 32                       | (11.4)                   | 114      | (13.5)  |

<div style=\"page-break-after: always\"></div>

| Gemcitabine/Carboplatin                                                                      | 311                                                                                          | (54.9)                                                                                       | 154                                                                                          | (54.8)                                                                                       | 465                                                                                          | (54.9)                                                                                       |
|----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|
| Chemotherapy on Study (Actual)                                                               | Chemotherapy on Study (Actual)                                                               | Chemotherapy on Study (Actual)                                                               | Chemotherapy on Study (Actual)                                                               | Chemotherapy on Study (Actual)                                                               | Chemotherapy on Study (Actual)                                                               | Chemotherapy on Study (Actual)                                                               |
| Nab-Paclitaxel                                                                               | 172                                                                                          | (30.4)                                                                                       | 95                                                                                           | (33.8)                                                                                       | 267                                                                                          | (31.5)                                                                                       |
| Paclitaxel                                                                                   | 81                                                                                           | (14.3)                                                                                       | 32                                                                                           | (11.4)                                                                                       | 113                                                                                          | (13.3)                                                                                       |
| Gemcitabine/Carboplatin                                                                      | 309                                                                                          | (54.6)                                                                                       | 154                                                                                          | (54.8)                                                                                       | 463                                                                                          | (54.7)                                                                                       |
| Missing                                                                                      | 4                                                                                            | (0.7)                                                                                        | 0                                                                                            | (0.0)                                                                                        | 4                                                                                            | (0.5)                                                                                        |
| PD-L1Status(CPSCutoffof1)                                                                    | PD-L1Status(CPSCutoffof1)                                                                    | PD-L1Status(CPSCutoffof1)                                                                    | PD-L1Status(CPSCutoffof1)                                                                    | PD-L1Status(CPSCutoffof1)                                                                    | PD-L1Status(CPSCutoffof1)                                                                    | PD-L1Status(CPSCutoffof1)                                                                    |
| PD-L1 CPS >=1                                                                                | 425                                                                                          | (75.1)                                                                                       | 211                                                                                          | (75.1)                                                                                       | 636                                                                                          | (75.1)                                                                                       |
| PD-L1 CPS<1                                                                                  | 141                                                                                          | (24.9)                                                                                       | 70                                                                                           | (24.9)                                                                                       | 211                                                                                          | (24.9)                                                                                       |
| PD-L1Status(CPSCutoff of5)                                                                   | PD-L1Status(CPSCutoff of5)                                                                   | PD-L1Status(CPSCutoff of5)                                                                   | PD-L1Status(CPSCutoff of5)                                                                   | PD-L1Status(CPSCutoff of5)                                                                   | PD-L1Status(CPSCutoff of5)                                                                   | PD-L1Status(CPSCutoff of5)                                                                   |
| PD-L1CPS>=5                                                                                  | 312                                                                                          | (55.1)                                                                                       | 140                                                                                          | (49.8)                                                                                       | 452                                                                                          | (53.4)                                                                                       |
| PD-L1CPS<5                                                                                   | 254                                                                                          | (44.9)                                                                                       | 141                                                                                          | (50.2)                                                                                       | 395                                                                                          | (46.6)                                                                                       |
| PD-L1Status(CPSCutoffof10)                                                                   | PD-L1Status(CPSCutoffof10)                                                                   | PD-L1Status(CPSCutoffof10)                                                                   | PD-L1Status(CPSCutoffof10)                                                                   | PD-L1Status(CPSCutoffof10)                                                                   | PD-L1Status(CPSCutoffof10)                                                                   | PD-L1Status(CPSCutoffof10)                                                                   |
| PD-L1 CPS>=10                                                                                | 220                                                                                          | (38.9)                                                                                       | 103                                                                                          | (36.7)                                                                                       | 323                                                                                          | (38.1)                                                                                       |
| PD-L1 CPS<10                                                                                 | 346                                                                                          | (61.1)                                                                                       | 178                                                                                          | (63.3)                                                                                       | 524                                                                                          | (61.9)                                                                                       |
| PD-L1Status(CPSCutoff of15)                                                                  | PD-L1Status(CPSCutoff of15)                                                                  | PD-L1Status(CPSCutoff of15)                                                                  | PD-L1Status(CPSCutoff of15)                                                                  | PD-L1Status(CPSCutoff of15)                                                                  | PD-L1Status(CPSCutoff of15)                                                                  | PD-L1Status(CPSCutoff of15)                                                                  |
| PD-L1 CPS>=15                                                                                | 160                                                                                          | (28.3)                                                                                       | 73                                                                                           | (26.0)                                                                                       | 233                                                                                          | (27.5)                                                                                       |
| PD-L1CPS<15                                                                                  | 406                                                                                          | (71.7)                                                                                       | 208                                                                                          | (74.0)                                                                                       | 614                                                                                          | (72.5)                                                                                       |
| PD-L1 Status (CPS Cutoff of20)                                                               | PD-L1 Status (CPS Cutoff of20)                                                               | PD-L1 Status (CPS Cutoff of20)                                                               | PD-L1 Status (CPS Cutoff of20)                                                               | PD-L1 Status (CPS Cutoff of20)                                                               | PD-L1 Status (CPS Cutoff of20)                                                               | PD-L1 Status (CPS Cutoff of20)                                                               |
| PD-L1CPS>=20                                                                                 | 140                                                                                          | (24.7)                                                                                       | 64                                                                                           | (22.8)                                                                                       | 204                                                                                          | (24.1)                                                                                       |
| PD-L1 CPS<20                                                                                 | 426                                                                                          | (75.3)                                                                                       | 217                                                                                          | (77.2)                                                                                       | 643                                                                                          | (75.9)                                                                                       |
| PriorTreatmentwithSameClassChemotherapyintheNeoadjuvant orAdjuvantSetting(IVRS)              | PriorTreatmentwithSameClassChemotherapyintheNeoadjuvant orAdjuvantSetting(IVRS)              | PriorTreatmentwithSameClassChemotherapyintheNeoadjuvant orAdjuvantSetting(IVRS)              | PriorTreatmentwithSameClassChemotherapyintheNeoadjuvant orAdjuvantSetting(IVRS)              | PriorTreatmentwithSameClassChemotherapyintheNeoadjuvant orAdjuvantSetting(IVRS)              | PriorTreatmentwithSameClassChemotherapyintheNeoadjuvant orAdjuvantSetting(IVRS)              | PriorTreatmentwithSameClassChemotherapyintheNeoadjuvant orAdjuvantSetting(IVRS)              |
| Yes                                                                                          | 124                                                                                          | (21.9)                                                                                       | 62                                                                                           | (22.1)                                                                                       | 186                                                                                          | (22.0)                                                                                       |
| No                                                                                           | 442                                                                                          | (78.1)                                                                                       | 219                                                                                          | (77.9)                                                                                       | 661                                                                                          | (78.0)                                                                                       |
| Prior Treatment with Same Class Chemotherapy in the Neoadjuvant or Adjuvant Setting (Actual) | Prior Treatment with Same Class Chemotherapy in the Neoadjuvant or Adjuvant Setting (Actual) | Prior Treatment with Same Class Chemotherapy in the Neoadjuvant or Adjuvant Setting (Actual) | Prior Treatment with Same Class Chemotherapy in the Neoadjuvant or Adjuvant Setting (Actual) | Prior Treatment with Same Class Chemotherapy in the Neoadjuvant or Adjuvant Setting (Actual) | Prior Treatment with Same Class Chemotherapy in the Neoadjuvant or Adjuvant Setting (Actual) | Prior Treatment with Same Class Chemotherapy in the Neoadjuvant or Adjuvant Setting (Actual) |
| Yes                                                                                          | 124                                                                                          | (21.9)                                                                                       | 56                                                                                           | (6:61)                                                                                       | 180                                                                                          | (21.3)                                                                                       |
| No                                                                                           | 438                                                                                          | (77.4)                                                                                       | 225                                                                                          | (80.1)                                                                                       | 663                                                                                          | (78.3)                                                                                       |
| Missing                                                                                      | 4                                                                                            | (0.7)                                                                                        | 0                                                                                            | (0.0)                                                                                        | 4                                                                                            | (0.5)                                                                                        |
| Disease Status                                                                               | Disease Status                                                                               | Disease Status                                                                               | Disease Status                                                                               | Disease Status                                                                               | Disease Status                                                                               | Disease Status                                                                               |
| Metastatic,DeNovo                                                                            | 167                                                                                          | (29.5)                                                                                       | 84                                                                                           | (29.9)                                                                                       | 251                                                                                          | (29.6)                                                                                       |
| Metastatic,Recurrence                                                                        | 383                                                                                          | (67.7)                                                                                       | 185                                                                                          | (65.8)                                                                                       | 568                                                                                          | (67.1)                                                                                       |
| Locally Recurrent Inoperable                                                                 | 13                                                                                           | (2.3)                                                                                        | 12                                                                                           | (4.3)                                                                                        | 25                                                                                           | (3.0)                                                                                        |
| Missing                                                                                      | 3                                                                                            | (0.5)                                                                                        | 0                                                                                            | (0.0)                                                                                        | 3                                                                                            | (0.4)                                                                                        |
| ECOG                                                                                         | ECOG                                                                                         | ECOG                                                                                         | ECOG                                                                                         | ECOG                                                                                         | ECOG                                                                                         | ECOG                                                                                         |
| 0                                                                                            | 332                                                                                          | (58.7)                                                                                       | 173                                                                                          | (61.6)                                                                                       | 505                                                                                          | (59.6)                                                                                       |
| 1                                                                                            | 232                                                                                          | (41.0)                                                                                       | 108                                                                                          | (38.4)                                                                                       | 340                                                                                          | (40.1)                                                                                       |
| 2                                                                                            | 1                                                                                            | (0.2)                                                                                        | 0                                                                                            | (0.0)                                                                                        | 1                                                                                            | (0.1)                                                                                        |
| Missing                                                                                      | 1                                                                                            | (0.2)                                                                                        | 0                                                                                            | (0.0)                                                                                        | 1                                                                                            | (0.1)                                                                                        |
| HER2 Status                                                                                  | HER2 Status                                                                                  | HER2 Status                                                                                  | HER2 Status                                                                                  | HER2 Status                                                                                  | HER2 Status                                                                                  | HER2 Status                                                                                  |
| 0-1+byIHC                                                                                    | 414                                                                                          | (73.1)                                                                                       | 214                                                                                          | (76.2)                                                                                       | 628                                                                                          | (74.1)                                                                                       |
| 2+ by IHC                                                                                    | 152                                                                                          | (26.9)                                                                                       | 67                                                                                           | (23.8)                                                                                       | 219                                                                                          | (25.9)                                                                                       |
| HistoryofBrainMetastasis                                                                     | HistoryofBrainMetastasis                                                                     | HistoryofBrainMetastasis                                                                     | HistoryofBrainMetastasis                                                                     | HistoryofBrainMetastasis                                                                     | HistoryofBrainMetastasis                                                                     | HistoryofBrainMetastasis                                                                     |
| Yes                                                                                          | 19                                                                                           | (3.4)                                                                                        | 9                                                                                            | (3.2)                                                                                        | 28                                                                                           | (3.3)                                                                                        |
| No                                                                                           | 546                                                                                          | (96.5)                                                                                       | 272                                                                                          | (96.8)                                                                                       | 818                                                                                          | (96.6)                                                                                       |
| Missing                                                                                      | 1                                                                                            | (0.2)                                                                                        | 0                                                                                            | (0.0)                                                                                        | 1                                                                                            | (0.1)                                                                                        |
| Menopausal Status                                                                            | Menopausal Status                                                                            | Menopausal Status                                                                            | Menopausal Status                                                                            | Menopausal Status                                                                            | Menopausal Status                                                                            | Menopausal Status                                                                            |
| Pre-menopausal                                                                               | 178                                                                                          | (31.4)                                                                                       | 92                                                                                           | (32.7)                                                                                       | 270                                                                                          | (31.9)                                                                                       |
| Post-menopausal                                                                              | 387                                                                                          | (68.4)                                                                                       | 189                                                                                          | (67.3)                                                                                       | 576                                                                                          | (68.0)                                                                                       |
| Missing                                                                                      | 1                                                                                            | (0.2)                                                                                        | 0                                                                                            | (0.0)                                                                                        | 1                                                                                            | (0.1)                                                                                        |
| DiseaseFreeInterval                                                                          | DiseaseFreeInterval                                                                          | DiseaseFreeInterval                                                                          | DiseaseFreeInterval                                                                          | DiseaseFreeInterval                                                                          | DiseaseFreeInterval                                                                          | DiseaseFreeInterval                                                                          |
| de novo metastasis                                                                           | 167                                                                                          | (29.5)                                                                                       | 84                                                                                           | (29.9)                                                                                       | 251                                                                                          | (29.6)                                                                                       |
| <12months                                                                                    | 126                                                                                          | (22.3)                                                                                       | 50                                                                                           | (17.8)                                                                                       | 176                                                                                          | (20.8)                                                                                       |
| >=12 months                                                                                  | 270                                                                                          | (47.7)                                                                                       | 147                                                                                          | (52.3)                                                                                       | 417                                                                                          | (49.2)                                                                                       |
| Unknown                                                                                      | 3                                                                                            | (0.5)                                                                                        | 0                                                                                            | (0.0)                                                                                        | 3                                                                                            | (0.4)                                                                                        |
| BaselineLactateDehydrogenase(LDH)                                                            | BaselineLactateDehydrogenase(LDH)                                                            | BaselineLactateDehydrogenase(LDH)                                                            | BaselineLactateDehydrogenase(LDH)                                                            | BaselineLactateDehydrogenase(LDH)                                                            | BaselineLactateDehydrogenase(LDH)                                                            | BaselineLactateDehydrogenase(LDH)                                                            |
| Normal                                                                                       | 261                                                                                          | (46.1)                                                                                       | 135                                                                                          | (48.0)                                                                                       | 396                                                                                          | (46.8)                                                                                       |
| >ULN and<2xULN                                                                               | 195                                                                                          | (34.5)                                                                                       | 94                                                                                           | (33.5)                                                                                       | 289                                                                                          | (34.1)                                                                                       |
| >=2 x ULN                                                                                    | 98                                                                                           | (17.3)                                                                                       | 42                                                                                           | (14.9)                                                                                       | 140                                                                                          | (16.5)                                                                                       |
| Sum of Target LesionSizeatBaseline(Central)(mm)                                              | Sum of Target LesionSizeatBaseline(Central)(mm)                                              | Sum of Target LesionSizeatBaseline(Central)(mm)                                              | Sum of Target LesionSizeatBaseline(Central)(mm)                                              | Sum of Target LesionSizeatBaseline(Central)(mm)                                              | Sum of Target LesionSizeatBaseline(Central)(mm)                                              | Sum of Target LesionSizeatBaseline(Central)(mm)                                              |
| Subjects with data                                                                           | 524                                                                                          |                                                                                              | 253                                                                                          |                                                                                              | 777                                                                                          |                                                                                              |
| Mean SD                                                                                      | 70.1 52.9                                                                                    |                                                                                              | 70.9 53.8                                                                                    |                                                                                              | 70.3 53.2                                                                                    |                                                                                              |

<div style=\"page-break-after: always\"></div>

| Median Range                                              | 55.0 11.0 to 368.0                                        | 54.0 11.0 to 289.0                                        | 55.0 11.0 to 368.0                                        |
|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|
| Sum of Target Lesion Size at Baseline (Investigator) (mm) | Sum of Target Lesion Size at Baseline (Investigator) (mm) | Sum of Target Lesion Size at Baseline (Investigator) (mm) | Sum of Target Lesion Size at Baseline (Investigator) (mm) |
| Subjects with data                                        | 561                                                       | 281                                                       | 842                                                       |
| Mean                                                      | 77.1                                                      | 72.6                                                      | 75.6                                                      |
| SD                                                        | 59.3                                                      | 55.4                                                      | 58.0                                                      |
| Median                                                    | 61.0                                                      | 56.0                                                      | 59.8                                                      |
| Range                                                     | 10.0 to 406.8                                             | 10.0 to 410.0                                             | 10.0 to 410.0                                             |
| DatabaseCutoffDate:11DEC2019                              | DatabaseCutoffDate:11DEC2019                              | DatabaseCutoffDate:11DEC2019                              | DatabaseCutoffDate:11DEC2019                              |

|                                                                             | Pembrolizumab + Chemotherapy                                                | Pembrolizumab + Chemotherapy                                                | Placebo + Chemotherapy                                                      | Placebo + Chemotherapy                                                      | Total                                                                       | Total                                                                       |
|-----------------------------------------------------------------------------|-----------------------------------------------------------------------------|-----------------------------------------------------------------------------|-----------------------------------------------------------------------------|-----------------------------------------------------------------------------|-----------------------------------------------------------------------------|-----------------------------------------------------------------------------|
| Subjects in Population                                                      | n 566                                                                       | (%)                                                                         | n 281                                                                       | (%)                                                                         | n 847                                                                       | (%)                                                                         |
| No. of Metastatic Organ Sites                                               |                                                                             |                                                                             |                                                                             |                                                                             |                                                                             |                                                                             |
| 0                                                                           | 13                                                                          | (2.3)                                                                       | 12                                                                          | (4.3)                                                                       | 25                                                                          | (3.0)                                                                       |
| 1                                                                           | 109                                                                         | (19.3)                                                                      | 59                                                                          | (21.0)                                                                      | 168                                                                         | (19.8)                                                                      |
| 2                                                                           | 191                                                                         | (33.7)                                                                      | 95                                                                          | (33.8)                                                                      | 286                                                                         | (33.8)                                                                      |
| B3                                                                          | 250                                                                         | (44.2)                                                                      | 115                                                                         | (40.9)                                                                      | 365                                                                         | (43.1)                                                                      |
| Missing                                                                     | 3                                                                           | (0.5)                                                                       | 0                                                                           | (0.0)                                                                       | 3                                                                           | (0.4)                                                                       |
| Metastatic Organ Sitest                                                     |                                                                             |                                                                             |                                                                             |                                                                             |                                                                             |                                                                             |
| Subjects with metastatic disease                                            | 550                                                                         |                                                                             | 269                                                                         |                                                                             | 819                                                                         |                                                                             |
| Bone                                                                        | 169                                                                         | (29.9)                                                                      | 85                                                                          | (30.2)                                                                      | 254                                                                         | (30.0)                                                                      |
| Brain                                                                       | 17                                                                          | (3.0)                                                                       | 9                                                                           | (3.2)                                                                       | 26                                                                          | (3.1)                                                                       |
| Breast                                                                      | 35                                                                          | (6.2)                                                                       | 18                                                                          | (6.4)                                                                       | 53                                                                          | (6.3)                                                                       |
| Chest Wall                                                                  | 132                                                                         | (23.3)                                                                      | 45                                                                          | (16.0)                                                                      | 177                                                                         | (20.9)                                                                      |
| Liver                                                                       | 171                                                                         | (30.2)                                                                      | 78                                                                          | (27.8)                                                                      | 249                                                                         | (29.4)                                                                      |
| Lung                                                                        | 324                                                                         | (57.2)                                                                      | 162                                                                         | (57.7)                                                                      | 486                                                                         | (57.4)                                                                      |
| Lymph Nodes                                                                 | 417                                                                         | (73.7)                                                                      | 206                                                                         | (73.3)                                                                      | 623                                                                         | (73.6)                                                                      |
| Other Metastasis                                                            | 110                                                                         | (19.4)                                                                      | 51                                                                          | (18.1)                                                                      | 161                                                                         | (19.0)                                                                      |
| Visceral Disease                                                            |                                                                             |                                                                             |                                                                             |                                                                             |                                                                             |                                                                             |
| Non-Visceral Only                                                           | 31                                                                          | (5.5)                                                                       | 23                                                                          | (8.2)                                                                       | 54                                                                          | (6.4)                                                                       |
| With brain metastasis                                                       | 0                                                                           | (0.0)                                                                       | 0                                                                           | (0.0)                                                                       | 0                                                                           | (0.0)                                                                       |
| Without brain metastasis                                                    | 31                                                                          | (5.5)                                                                       | 23                                                                          | (8.2)                                                                       | 54                                                                          | (6.4)                                                                       |
| Any Visceral                                                                | 532                                                                         | (94.0)                                                                      | 258                                                                         | (91.8)                                                                      | 790                                                                         | (93.3)                                                                      |
| With brain metastasis                                                       | 17                                                                          | (3.0)                                                                       | 9                                                                           | (3.2)                                                                       | 26                                                                          | (3.1)                                                                       |
| Without brain metastasis                                                    | 515                                                                         | (91.0)                                                                      | 249                                                                         | (88.6)                                                                      | 764                                                                         | (90.2)                                                                      |
| Missing                                                                     | 3                                                                           | (0.5)                                                                       | 0                                                                           | (0.0)                                                                       | 3                                                                           | (0.4)                                                                       |
| Prior Neoadjuvant or Adjuvant Chemotherapy                                  | Prior Neoadjuvant or Adjuvant Chemotherapy                                  | Prior Neoadjuvant or Adjuvant Chemotherapy                                  | Prior Neoadjuvant or Adjuvant Chemotherapy                                  | Prior Neoadjuvant or Adjuvant Chemotherapy                                  | Prior Neoadjuvant or Adjuvant Chemotherapy                                  | Prior Neoadjuvant or Adjuvant Chemotherapy                                  |
| Yes                                                                         | 357                                                                         | (63.1)                                                                      | 181                                                                         | (64.4)                                                                      | 538                                                                         | (63.5)                                                                      |
| Taxanes                                                                     | 290                                                                         | (51.2)                                                                      | 156                                                                         | (55.5)                                                                      | 446                                                                         | (52.7)                                                                      |
| Platinum                                                                    | 41                                                                          | (7.2)                                                                       | 24                                                                          | (8.5)                                                                       | 65                                                                          | (7.7)                                                                       |
| Anthracyclines                                                              | 318                                                                         | (56.2)                                                                      | 155                                                                         | (55.2)                                                                      | 473                                                                         | (55.8)                                                                      |
| Other                                                                       | 329                                                                         | (58.1)                                                                      | 169                                                                         | (60.1)                                                                      | 498                                                                         | (58.8)                                                                      |
| No                                                                          | 209                                                                         | (36.9)                                                                      | 100                                                                         | (35.6)                                                                      | 309                                                                         | (36.5)                                                                      |
| t Breast, chest wall and lymph node also include locally recurrent lesions. | t Breast, chest wall and lymph node also include locally recurrent lesions. | t Breast, chest wall and lymph node also include locally recurrent lesions. | t Breast, chest wall and lymph node also include locally recurrent lesions. | t Breast, chest wall and lymph node also include locally recurrent lesions. | t Breast, chest wall and lymph node also include locally recurrent lesions. | t Breast, chest wall and lymph node also include locally recurrent lesions. |
| Database Cutoff Date:11DEC2019.                                             | Database Cutoff Date:11DEC2019.                                             | Database Cutoff Date:11DEC2019.                                             | Database Cutoff Date:11DEC2019.                                             | Database Cutoff Date:11DEC2019.                                             | Database Cutoff Date:11DEC2019.                                             | Database Cutoff Date:11DEC2019.                                             |

BRCA mutations: Of the 847 enrolled subjects, 100 have known BRCA mutational status assessed locally (12%), of whom 17 were BRCA positive. Most of the BRCA mutant patients have PD-L1 positive tumors. BRCA mutational status is under investigation as part of the planned exploratory biomarker research, which is due to be completed and provided in 2023.

## Concomitant treatments :

The reported concomitant interventions were generally balanced between the 2 treatment groups, except for the following that were higher ( ≥ 5% point difference) in the pembrolizumab + chemotherapy group:

- Antidiarrheals, intestinal anti-inflammatory/anti-infective medications (16.9% vs 9.3%)
- Medications for constipation (30.4% vs 24.6%)

<div style=\"page-break-after: always\"></div>

- Systemic antibacterial medications (55.2% vs 47.3%)
- Topical corticosteroids (18.1% vs 12.5%)

## Subsequent anticancer treatments :

Subsequent anticancer treatments were received by 57.5% vs 66.2% of participants in the pembrolizumab + chemotherapy group vs placebo + chemotherapy group, respectively. The most common type of therapy administered in both treatment groups were antineoplastic agents, including capecitabine (29.4% vs 33.8%), carboplatin (10.7% vs 13.2%), cyclophosphamide (13.0% vs 15.3%), eribulin mesylate (13.7% vs 16%), gemcitabine (8.9% vs 12.1%), and paclitaxel (13.3% vs 12.8%). More participants in the placebo + chemotherapy group received subsequent immunotherapy, including atezolizumab (0.4% vs 2.1%), pembrolizumab (1.1% vs 4.3%) and nivolumab (0% vs 1.1%).

## Numbers analysed

Efficacy analyses were based on the Part 2 ITT population ( n=847 ), which included participants in the treatment arm to which they were randomly assigned, regardless of whether they received treatment. Participants enrolled in Part 1 were excluded from the efficacy analyses. According to PD-L1 expression, CPS≥1 patients were n=636 , and CPS≥10 patients were n=323 .

PRO analyses were based on the PRO FAS population, defined as all randomized participants who received at least 1 dose of study intervention and had completed at least 1 PRO assessment.

## Outcomes and estimation

The efficacy analyses were based on IA2, which was the final analysis of PFS and the second interim analysis of OS. Data cut-off date was 11-Dec-2019, approximately 18 months after the last participant was randomized. Median follow-up duration was 16.8 months (range 0.2, 35) in the ITT population (n=847) and 19.2 months (range 0.3, 35) in the CPS≥10 population (n=323).

For the dual primary endpoints PFS and OS, PFS in the CPS≥10 population was statistically significant. OS in CPS≥10, as well as PFS and OS in CPS≥1 did not cross the prespecified efficacy boundary at IA2. PFS and OS in the ITT population were not statistically tested at the IA2 per the prespecified multiplicity strategy.

For the secondary endpoint ORR, ORR in all participants and in the CPS ≥ 1 population were only tested at IA1 and the success criterion were not met. ORR in all the three populations was not formally tested at IA2 per the prespecified multiplicity strategy.

During the procedure, the MAH submitted the results of the final analysis for Overall Survival with data cut-off date 15-JUN-2021 (summarised at the end of this section).

## PD-L1 with CPS ≥10

Table: Summary of Efficacy Results in Participants with CPS ≥10 (ITT Population)

<div style=\"page-break-after: always\"></div>

| Endpoint                             | Pembrolizumab Chemotherapy (N=220)   | Placebo + Chemotherapy (N=103)   |
|--------------------------------------|--------------------------------------|----------------------------------|
| PFS a                                |                                      |                                  |
| Number of Events (%)                 | 136 (61.8)                           | 79 (76.7)                        |
| Median PFS, months (95% CI)          | 9.7 (7.6, 11.3)                      | 5.6 (5.3, 7.5)                   |
| HR (95% CI), p-value                 | 0.65 (0.49, 0.86) p=0.0012           |                                  |
| PFS at 6 months (95% CI)             | 65.0 (58.1, 71.2)                    | 46.9 (36.5, 56.6)                |
| PFS at 9 months (95% CI)             | 53.0 (45.8, 59.8)                    | 36.6 (26.9, 46.4)                |
| PFS at 12 months (95% CI)            | 39.1 (32.0, 46.0)                    | 23.0 (14.7, 32.3)                |
| OS                                   |                                      |                                  |
| Number of Events (%)                 | 121 (55.0)                           | 71 (68.9)                        |
| Median OS, months (95% CI)           | 23.0 (18.8, 27.5)                    | 16.1 (12.6, 18.8)                |
| HR (95% CI), p-value                 | 0.69 (0.51, 0.93) p=0.0066 b         |                                  |
| OS at 12 months (95% CI)             | 70.5 (64.0, 76.1)                    | 64.1 (54.0, 72.5)                |
| OS at 18 months (95% CI)             | 58.1 (51.2, 64.3)                    | 44.7 (34.9, 53.9)                |
| OS at 24 months (95% CI)             | 49.1 (42.2, 55.7)                    | 32.4 (23.3, 41.8)                |
| Objective Response c                 |                                      |                                  |
| ORR %(95% CI) a                      | 53.2 (46.4, 59.9)                    | 39.8 (30.3, 49.9)                |
| ORR Difference %(95% CI), p-value    | 13.6 (1.9, 24.8) p=0.0115            |                                  |
| CR, n (%)                            | 37 (16.8)                            | 13 (12.6)                        |
| PR, n (%)                            | 80 (36.4)                            | 28 (27.2)                        |
| DCR, n (%)                           | 143 (65.0)                           | 56 (54.4)                        |
| DOR (months), median (range) a, d, e | 19.3 (1.6+ - 29.8)                   | 7.3 (1.5 - 32.5+)                |

Abbreviations:  BICR  =  blinded  independent  central  review;  CI  =  confidence  interval;  CPS = combined  positive  score;  CR  = complete  response,  DCR = disease  control  rate;  DOR = duration  of  response;  HR = hazard  ratio;  IA2 = Interim  Analysis  2; ITT = intent-to-treat; ORR = objective response rate; OS = overall survival; PD = progressive disease; PD-L1 = programmed cell death  1  ligand  1;  PFS = progression-free  survival;  PR = partial  response  RECIST  1.1  =  Response  Evaluation  Criteria  in  Solid Tumors version 1.1.

- a. Response assessed by BICR per RECIST 1.1; only confirmed responses are included.
- b. The observed p-value of p=0.0066 did not cross the prespecified efficacy boundary at IA2 (the multiplicity adjusted, one-sided nominal alpha level was 0.00472).
- c. ORR was not formally tested at IA2 per the prespecified multiplicity strategy.
- d. From product-limit (Kaplan-Meier) method for censored data.
- e. '+' indicated there is no PD by the time of last disease assessment.

One-sided p-values based on stratified log-rank test (PFS and OS) or stratified Miettinen &amp; Nurminen method (ORR).

Data cutoff: 11DEC2019

## PFS - Dual primary endpoint

Pembrolizumab + chemotherapy demonstrated a statistically significant improvement in PFS compared with placebo + chemotherapy in participants with tumors that express PD-L1 with CPS ≥ 10. With about 67% of events/patients, the PFS HR was 0.65 (95%CI 0.49, 0.86), p=0.0012 [pre-specified boundary 0.00411] ; median PFS was 9.7 (95%CI 7.6, 11.3) vs 5.6 (95%CI 5.3, 7.5) months in the pembrolizumab + chemotherapy vs placebo + chemotherapy, respectively.

<div style=\"page-break-after: always\"></div>

## Table: Analysis of PFS by BICR per RECIST 1.1 (Subjects with PDL1 CPS ≥10) (ITT)

|                                   | Pembrolizumab + Chemotherapy (N=220)   | Placebo + Chemotherapy (N=103)   |
|-----------------------------------|----------------------------------------|----------------------------------|
| Number of Events (%)              | 136 (61.8)                             | 79 (76.7)                        |
| Kaplan-Meier Estimates (Months)t  |                                        |                                  |
| Median (95% CI)                   | 9.7 (7.6, 11.3)                        | 5.6 (5.3, 7.5)                   |
| [Q1, Q3]                          | [3.9, 31.4]                            | [3.6, 11.8]                      |
| Person-Months                     | 2232.5                                 | 821.7                            |
| Event Rate/100Person-Months       | 6.1                                    | 9.6                              |
| vs Placebo + Chemotherapy         |                                        |                                  |
| Hazard Ratio (95% CI)+            | 0.65 (0.49, 0.86)                      |                                  |
| p-values                          | 0.0012                                 |                                  |
| PFS Rate at Month 3 (%) (95% CI)  | 81.8 (76.0, 86.4)                      | 80.2 (71.0, 86.8)                |
| PFS Rate at Month 6 (%) (95% CI)  | 65.0 (58.1, 71.2)                      | 46.9 (36.5, 56.6)                |
| PFS Rate at Month 9 (%) (95% CI)  | 53.0 (45.8, 59.8)                      | 36.6 (26.9, 46.4)                |
| PFS Rate at Month 12 (%) (95% CI) | 39.1 (32.0, 46.0)                      | 23.0 (14.7, 32.3)                |

From product-limit (Kaplan-Meier) method for censored data.

+ Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by chemotherapy on study (taxane vs gemcitabine/carboplatin) and prior treatment with same class of chemotherapy in the (neo)adjuvant setting (yes vs no).

One-sided p-value based on log-rank test stratified by chemotherapy on study (taxane vs gemcitabine/carboplatin) and prior treatment with same class of chemotherapy in the (neo)adjuvant setting (yes vs no).

BICR = Blinded Independent Central Review.

Database CutoffDate:11DEC2019

Kaplan-Meier Estimates of Progression-Free Survival Based on BICR Assessment per RECIST 1.1 (Part 2 Subjects with PD-L1 CPS ≥10) (ITT Population)

Progression-Free-Survival(%)

<!-- image -->

## Number of subjects at risk

Pembrolizumab +

220

173

Placebo +

Chemotherapy

Chemotherapy

103

80

122

41

96

30

DatabseCutoffDate:11DEC2019

## Additional analyses of PFS:

- PFS based on investigator assessment per RECIST 1.1: HR 0.71 (0.54, 0.93), median PFS 8.0 months vs. 5.6 months
- Sensitivity Analysis 1: HR 0.69 [0.53, 0.90], median PFS 9.5 months vs. 5.7 months

63

18

52

15

44

12

37

8

25

8

12

7

5

3

0

0

0

<div style=\"page-break-after: always\"></div>

- Sensitivity Analysis 2: HR 0.78 [0.61, 1.0], median PFS 8.0 months vs. 5.7 months

## OS - Dual Primary Endpoint

Pembrolizumab + chemotherapy showed a numerical improvement in OS compared with placebo + chemotherapy in participants with PDL1 positive tumors (CPS≥ 10): HR 0.69 (95%CI 0.51, 0.93), median OS 23 months (95%CI 18.8, 27.5) vs 16.1 (95%CI 12.6, 18.8), number of events 55% vs 68.9% in the pembrolizumab + chemotherapy vs placebo + chemotherapy arm. However, the observed p-value of p=0.0066 did not cross the prespecified efficacy boundary at IA2 (the multiplicity adjusted, one-sided nominal alpha level was 0.00472).

## Table: Analysis of Overall Survival (Subjects with PD-L1 CPS ≥ 10) (ITT Population)

|                                  | Pembrolizumab + Chemotherapy (N=220)   | Placebo + Chemotherapy (N=103)   |
|----------------------------------|----------------------------------------|----------------------------------|
| Number of Events (%)             | 121 (55.0)                             | 71 (68.9)                        |
| Kaplan-Meier Estimates (Months)  |                                        |                                  |
| Median (95% CI)                  | 23.0 (18.8, 27.5)                      | 16.1 (12.6, 18.8)                |
| [Q1, Q3]                         | [10.3, NR]                             | [8.6, 30.6]                      |
| Person-Months                    | 4074.4                                 | 1680.9                           |
| Event Rate / 100 Person-Months   | 3.0                                    | 4.2                              |
| vs Placebo + Chemotherapy        |                                        |                                  |
| Hazard Ratio (95% CI)+           | 0.69 (0.51, 0.93)                      |                                  |
| p-values                         | 0.0066                                 |                                  |
| OS Rate at Month 6 (%) (95% CI)  | 88.5 (83.5, 92.1)                      | 88.3 (80.4, 93.2)                |
| OS Rate at Month 12 (%) (95% CI) | 70.5 (64.0, 76.1)                      | 64.1 (54.0, 72.5)                |
| OS Rate at Month 18 (%) (95% CI) | 58.1 (51.2, 64.3)                      | 44.7 (34.9, 53.9)                |
| OS Rate at Month 24 (%) (95% CI) | 49.1 (42.2, 55.7)                      | 32.4 (23.3, 41.8)                |

t From product-limit (Kaplan-Meier) method for censored data.

+ Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by chemotherapy on study (taxane vs gemcitabine/carboplatin) and prior treatment with same class of chemotherapy in the (neo)adjuvant setting (yes vs no).

s One-sided p-value based on log-rank test stratified by chemotherapy on study (taxane vs gemcitabine/carboplatin) and prior treatment with same class of chemotherapy in the (neo)adjuvant setting (yes vs no).

NR = Not reached.

Database Cutoff Date: 11DEC2019

<div style=\"page-break-after: always\"></div>

Kaplan-Meier Estimates of Overall Survival (Part 2 Subjects with PD-L1 CPS ≥10) (ITT Population)

<!-- image -->

## Secondary endpoints

## · ORR

Pembrolizumab + chemotherapy provides an improvement in ORR (per RECIST 1.1 by BICR) compared with placebo + chemotherapy (53.2% vs 39.8%) in participants with tumors that express PD-L1 with CPS ≥ 10 (difference 13.6% [1.9, 24.8]; p=0.0115). ORR was only tested at IA1 and not formally tested at IA2 per the prespecified multiplicity strategy, therefore the results of IA2 data may only be interpreted in exploratory manner.

Table: Summary of Best Overall Response by BICR per RECIST 1.1 (Subjects with PD-L1 CPS ≥ 10)

| Response Evaluation                   | Pembrolizumab + Chemotherapy (N=220)   | Pembrolizumab + Chemotherapy (N=220)   | Pembrolizumab + Chemotherapy (N=220)   | Placebo + Chemotherapy (N=103)   | Placebo + Chemotherapy (N=103)   | Placebo + Chemotherapy (N=103)   |
|---------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------|----------------------------------|----------------------------------|
|                                       | n                                      | (%)                                    | 95% CIt                                | n                                | (%)                              | 95% CIt                          |
| Complete Response (CR)                | 37                                     | (16.8)                                 | (12.1, 22.4)                           | 13                               | (12.6)                           | (6.9, 20.6)                      |
| Partial Response (PR)                 | 80                                     | (36.4)                                 | (30.0, 43.1)                           | 28                               | (27.2)                           | (18.9, 36.8)                     |
| Objective Response (CR+PR)            | 117                                    | (53.2)                                 | (46.4, 59.9)                           | 41                               | (39.8)                           | (30.3, 49.9)                     |
| Stable Disease (SD)                   | 62                                     | (28.2)                                 | (22.3, 34.6)                           | 45                               | (43.7)                           | (33.9, 53.8)                     |
| Disease Control (SD ≥ 24 Weeks+CR+PR) | 143                                    | (65.0)                                 | (58.3, 71.3)                           | 56                               | (54.4)                           | (44.3, 64.2)                     |
| No Evidence of Disease (NED)tt        | 2                                      | (0.9)                                  | (0.1, 3.2)                             | 0                                | (0.0)                            | (0.0, 3.5)                       |
| Progressive Disease (PD)              | 31                                     | (14.1)                                 | (9.8, 19.4)                            | 12                               | (11.7)                           | (6.2, 19.5)                      |
| Not Evaluable (NE)t                   | 2                                      | (0.9)                                  | (0.1, 3.2)                             | 0                                | (0.0)                            | (0.0, 3.5)                       |
| No Assessments                        | 6                                      | (2.7)                                  | (1.0, 5.8)                             | 5                                | (4.9)                            | (1.6, 11.0)                      |

ft No Evidence of Disease (NED) includes subjects without evidence of disease at baseline and at least one post-baseline time point.

↑ Based on the binomial exact confidence interval method for binomial data.

+ Not Evaluable (NE) includes subjects with insufficient data for assessment of response per RECIST 1.1.

$ No Assessment includes subjects without post-baseline assessment on the data cutoff date.

Stable Disease (SD) includes both SD and Non-CR/Non-PD.

Confirmed responses are included.

BICR = Blinded Independent Central Review

Database Cutoff Date: 11DEC2019.

<div style=\"page-break-after: always\"></div>

The results by Investigator assessment per RECIST 1.1 for confirmed responses were similar (ORR 53.2% vs. 34.0% in the pembrolizumab + chemotherapy group vs. the placebo + chemotherapy group; difference 19.1%); however reported ORR rates in the placebo + chemotherapy arm were numerically lower compared to the independent assessment.

## · DOR

In responders with tumors that express PD-L1 with CPS ≥ 10, the responses in the pembrolizumab + chemotherapy group were durable relative to those observed in the placebo + chemotherapy group (median DOR, 19.3 months vs 7.3 months).

Summary of Time to Response and Duration of Response Based on BICR Assessment per RECIST 1.1 in Subjects with Confirmed Response (Part 2 Subjects with PD-L1 CPS ≥10) (ITT Population)

|                                                                                                                                                                                                                                                                                                    | Pembrolizumab+ Chemotherapy (N=220)                                                                                                                                                                                                                                                                | Placebo + Chemotherapy (N=103)                                                                                                                                                                                                                                                                     |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Number of subjects with responset                                                                                                                                                                                                                                                                  | 117                                                                                                                                                                                                                                                                                                | 41                                                                                                                                                                                                                                                                                                 |
| Time to Response(months)                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                    |
| Mean (SD)                                                                                                                                                                                                                                                                                          | 2.4 (1.5)                                                                                                                                                                                                                                                                                          | 2.7 (1.5)                                                                                                                                                                                                                                                                                          |
| Median (Range)                                                                                                                                                                                                                                                                                     | 1.9 (1.2-11.7)                                                                                                                                                                                                                                                                                     | 1.9 (1.3-7.9)                                                                                                                                                                                                                                                                                      |
| Response Duration+ (months)                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                    |
| Median (Range)                                                                                                                                                                                                                                                                                     | 19.3 (1.6+ - 29.8)                                                                                                                                                                                                                                                                                 | 7.3 (1.5 -32.5+)                                                                                                                                                                                                                                                                                   |
| Number(%+)of Subjects withExtended ResponseDuration:                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                    |
| ≥6 months                                                                                                                                                                                                                                                                                          | 84 (82.8)                                                                                                                                                                                                                                                                                          | 22 (58.5)                                                                                                                                                                                                                                                                                          |
| ≥12months                                                                                                                                                                                                                                                                                          | 49 (55.9)                                                                                                                                                                                                                                                                                          | 14 (39.0)                                                                                                                                                                                                                                                                                          |
| Includes subjects with confirmed complete response or partial response.  From product-limit (Kaplan-Meier) method for censored data. \"+\" indicates there is no progressive disease by the time of last disease assessment. BICR = Blinded Independent Central Review. DatabaseCutoffDate:11DEC2019 | Includes subjects with confirmed complete response or partial response.  From product-limit (Kaplan-Meier) method for censored data. \"+\" indicates there is no progressive disease by the time of last disease assessment. BICR = Blinded Independent Central Review. DatabaseCutoffDate:11DEC2019 | Includes subjects with confirmed complete response or partial response.  From product-limit (Kaplan-Meier) method for censored data. \"+\" indicates there is no progressive disease by the time of last disease assessment. BICR = Blinded Independent Central Review. DatabaseCutoffDate:11DEC2019 |

Kaplan-Meier Estimates of Duration of Response in Subjects with Confirmed Response Based on BICR Assessment per RECIST 1.1 (Part 2 Subjects with PD-L1 CPS ≥10)(IT1 Population)

<!-- image -->

The results for DOR based on investigator assessment per RECIST 1.1 for confirmed responses in participants with PD-L1 positive tumors (CPS ≥ 10) showed the same trend as the primary results for DOR by BICR (median response duration 11.3 months vs. 8.0 months in the pembrolizumab + chemotherapy group vs. the placebo + chemotherapy group), but the difference between the treatment arms were smaller.

## Subgroup analyses

- PFS

Figure: Forest Plot of PFS HR by BICR per RECIST 1.1 by Subgroup Factors (PD-L1 CPS ≥ 10)

<div style=\"page-break-after: always\"></div>

Forest Plot of Progression-Free Survival Hazard Ratio Based on BICR Assessment per RECIST 1.1 by Subgroup Factor (Part 2 Subjects with PD-L1 CPS ≥10)

(ITT Population)

<!-- image -->

|                                                                                                         | #Event/N              | Median Progresson Free Survival (mo) Pembro+Chemo   | Pbo+Chemo               | HR (95% CI)                       | HR                  | I%96                                  |
|---------------------------------------------------------------------------------------------------------|-----------------------|-----------------------------------------------------|-------------------------|-----------------------------------|---------------------|---------------------------------------|
| Overall                                                                                                 | 215/323               | 9.7                                                 | 5.6                     | 王                                 | 0.65                | (0.49, 0.86)                          |
| Age (years) <65 yeers                                                                                   | 171/257               | 9.5                                                 | 5.5                     | 王                                 | 0.63                | (0.46,0.87)                           |
| 265 yeers                                                                                               | 44/66                 | 10.7                                                | 7.6                     |                                   | 0.67                | (0.37,1.23)                           |
| Ethnidty Hispanic or Latino                                                                             | 43/58                 | 7.5                                                 | 6.2                     |                                   | 1.02                | (0.53, 1.93)                          |
| Not Hispanic or Latino                                                                                  | 163/250               | 9.9                                                 | 5.5                     |                                   | 0.55                | (0.40, 0.76)                          |
| Geographicregion Europe/North America/Australia                                                         | 142/212               | 9.6                                                 | 5.7                     |                                   | 0.69                | (0.49,0.97)                           |
| Asia                                                                                                    | 34/56                 | 17.3                                                | 5.6                     |                                   | 0.45                | (0.22,0.91)                           |
| Rest of the World                                                                                       | 39/55                 | 7.6                                                 | 6.2                     |                                   | 0.79                | (0.40, 1.55)                          |
| Chemotherapy on study(IVRS) Nab-Paditaxe                                                                | 66/L9                 | 66                                                  | 5.5                     |                                   | 0.57                | (0.34,0.95)                           |
| Paditaxel                                                                                               | 27/44 127/180         | 9.6 8.0                                             | 3.6 7.2                 |                                   | 0.33 0.77           | (0.14, 0.76) (0.53, 1.11)             |
| Gemaitabine/Caboplatin Chemotherapy on study (Actual) Nab-Paditaxe Paditaxel GamaitabindCaboplain       | 60/97 28/44 127/181   | 66 9.6 9.5                                          | 5.5 3.6 7.2             |                                   | 0.57 0.35 0.76 0.65 | (0.34,0.96) (0.15, 0.78) (0.52, 1.09) |
| GemaitabinelCaboplatin gemaitabine/carboplatin){(Actual) faxane                                         | 172/258 41/61 174/261 | 7.7 9.7                                             | 5.7                     | T 1                               | 0.77 0.59           | (0.48,0.90)                           |
| Yes No in the (neo)adjuvant setting (Actual) Yes No Prioradjuvantorneoadjuvantchemotherapy              | 88/141 127/181 43/65  | 8.0 9.9                                             | 5.7 5.4 6.6 5.7 5.4 5.6 | T                                 | 0.74 0.50 0.71 0.51 | (0.32, 1.15) (0.30, 1.15) (0.48,0.89) |
| gemaitabinecarboplatin)(IVRS) Taxane                                                                    | 127/180               | 66                                                  | 5.4                     | T                                 |                     | (0.52,1.09)                           |
| Gemaitabine/Caboplatin                                                                                  | 88/143                | 7.6                                                 |                         |                                   |                     |                                       |
| Priortroatmontwithsamedassofchamotharapy in the(neo)adjuvant setting (IVRS)                             |                       |                                                     |                         |                                   | 0.52 0.76           | (0.33,0.78) (0.53,1.11)               |
|                                                                                                         |                       |                                                     | 5.4 7.2 5.4             | T⊥                                | 0.51                | (0.34, 0.79)                          |
|                                                                                                         |                       | 9.5                                                 | 7.2                     |                                   |                     |                                       |
| No treatment No Premenopausa                                                                            |                       |                                                     |                         |                                   | 0.60 0.66           |                                       |
| 2+ by IHC denovometastasis                                                                              | 161/233 54/90         | 9.8                                                 | 9.0                     |                                   |                     |                                       |
| 0 1 HER2status 0-1+ by IHC Disease freeinterval (DFI) <12months ≥12 months No.of metastatic organ sites |                       | 7.5 9.9                                             |                         | 1                                 | 0.48 1.00           | (0.55, 1.12) (0.30, 0.74)             |
| <2× ULN >2 x ULN                                                                                        | 111/157 104/166       | 10.7 3.7                                            |                         | 0.1 10 Pembro+ChemoFavorPbo+Chemo | 0.78                |                                       |
| Yes No Prioradjuvantorneoadjuvanttaxanetreatment Yes                                                    | 130/193 85/130        | 7.9 11.0                                            |                         |                                   | 0.47                |                                       |
|                                                                                                         |                       |                                                     |                         |                                   |                     | (0.51, 1.12)                          |
|                                                                                                         |                       | 7.5                                                 | 6.2                     | {1                                | 0.76                | (0.38, 0.84)                          |
| Prioradjuvant orneoadjuvantplatinum                                                                     |                       | 11.8                                                |                         |                                   | 0.56                |                                       |
|                                                                                                         | 203/304 76/108        | 9.6 7.6                                             | 5.5                     | 王                                 | 0.65                | (0.49,0.86) (0.46, 1.18)              |
| Menopausal status Post-menopausa                                                                        | 139/215               | 9.9                                                 | 5.7                     |                                   | 0.74 0.59           | (0.42,0.84)                           |
|                                                                                                         | 127/196 88/127        | 7.6                                                 | 7.5 3.9                 |                                   |                     | (0.51, 1.07) (0.33,0.78)              |
| ECOG                                                                                                    |                       |                                                     |                         |                                   |                     |                                       |
|                                                                                                         |                       | 7.7 14.6                                            | 5.6                     | T                                 |                     | (0.52,0.98)                           |
|                                                                                                         | 66/103                | 9.7                                                 | 7.4 5.3                 |                                   |                     | (0.29, 0.90)                          |
|                                                                                                         | 43/66                 | 7.5                                                 | 7.2                     |                                   |                     | (0.29, 0.79)                          |
| <3                                                                                                      | 106/153               | 9.9                                                 | 6.6                     |                                   | 0.64                | (0.51, 1.95) (0.43,0.95)              |
|                                                                                                         | 109/184               | 11.8                                                |                         | T                                 |                     |                                       |
| 23                                                                                                      |                       |                                                     |                         | T1                                | 0.52                | (0.46, 1.00) (0.34,0.78)              |
| Visoral disease Yes                                                                                     | 106/138               |                                                     | 4.5                     |                                   | 0.68                |                                       |
|                                                                                                         |                       | 9.5                                                 | 5.5                     | 王                                 | 0.58                | (0.44, 0.77)                          |
|                                                                                                         | 206/300               |                                                     |                         |                                   |                     |                                       |
| Baslinelactate dehydrogenase (L DH)                                                                     | 175/276               |                                                     |                         | 王                                 |                     |                                       |
|                                                                                                         | 34/37                 |                                                     | 5.6                     |                                   | 0.61                | (0.45, 0.83)                          |
|                                                                                                         |                       |                                                     | 4.6                     |                                   | 0.97                | (0.47, 1.99)                          |

Pembro+Chemovs.Pbo+Chemo

Analysis (HR and 95% CI) in the overall population is based on the stratified Cox regression model with Efron's method of tie handling stratified by chemotherapy on study (taxane vs gemcitabine/carboplatin) and prior treatment with same class of chemotherapy in the (neo)adjuvant setting (yes vs no); analysis in the subgroups is based on the unstratified Cox model. If any level of a subgroup variable has  fewer  than  30  subjects,  subgroup  analysis  is  not  performed  in  that  level  of  the  subgroup  variable.    Database  Cutoff  Date: 11DEC2019

## · OS

<div style=\"page-break-after: always\"></div>

Figure: Forest Plot of OS HR by Subgroup Factors (Subjects with PDL1 CPS ≥10) (ITT)

Forest Plot of Overall Survival Hazard Ratio by Subgroup Factors (Part 2 Subjects with PD-L1 CPS ≥10) (ITT Population)

<!-- image -->

|                                                                                                                                                             | #Event/N                     | Median Overall Survival (mo) Pembro+Chemo   | Pbo+Chemo           | HR (95% CI)                         | HR                            | Q%96                                  |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------|---------------------------------------------|---------------------|-------------------------------------|-------------------------------|---------------------------------------|
| Overall                                                                                                                                                     | 192/323                      | 23.0                                        | 16.1                | ?                                   | 0.69                          | (0.51, 0.93)                          |
| Age (years) <65yers                                                                                                                                         | 155/257                      | 21.8                                        | 16.8                | T                                   | 0.78                          | (0.56, 1.08)                          |
| ≥65years                                                                                                                                                    | 37/66                        | 31.2                                        | 12.6                |                                     | 0.46                          | (0.24, 0.87)                          |
| Ethnidty Hispanic or Latino                                                                                                                                 | 40/58                        | 14.7                                        | 22.0                |                                     | 1.24                          | (0.63, 2.41)                          |
| Not Hispanic or Latino                                                                                                                                      | 142/250                      | 25.8                                        | 15.2                |                                     | 0.57                          | (0.40,0.80)                           |
| Geographic region Europe/North America/Australia                                                                                                            | 127/212                      | 23.0                                        | 15.2                | T                                   | 0.69                          | (0.48, 0.99)                          |
| Asia                                                                                                                                                        | 31/56                        | 27.5                                        | 17.4                |                                     | 0.44                          | (0.21,0.93)                           |
| Rest of the World                                                                                                                                           | 34/55                        | 18.0                                        | 22.0                |                                     | 0.99                          | (0.49, 2.00)                          |
| Chemotherapy on study (IVRS)                                                                                                                                | 54/99                        | 26.7                                        | 18.4                |                                     | 0.58                          | (0.34,1.00)                           |
| Nab-Paditaxe Paditaxel                                                                                                                                      | 25/44                        | 28.6                                        | 8.5                 |                                     | 0.28                          | (0.13, 0.64)                          |
| Gemaitabine/Caboplatin Chemotherapy on study (Adtual) Nab-Paditaxe                                                                                          | 113/180 54/97 24/44          | 19.0                                        | 16.2                |                                     | 0.93                          | (0.62, 1.38)                          |
| Paditaxel Gamaitabing/Caboplatin gemaitabinecarboplatin)(IVRS) Taxane                                                                                       |                              | 26.7 28.6                                   | 18.4 8.5 16.2       |                                     | 0.60 0.27 0.93                | (0.35, 1.02) (0.12, 0.62)             |
| Taxane Gemaitabine/Caboplatin Prior treatmant withsamedassofchemotharapy in the (neo)adjuvant seting (IVRS) Yes Priortreatmentwithsamedassofchemotherapy No | 113/180 78/141 41/65 151/258 | 28.3 19.2 23.5 23.0                         | 14.9 16.9 14.8 16.9 |                                     | 0.55 0.73 0.63 0.71 0.90 0.46 | (0.62, 1.38) (0.30,0.73) (0.52, 1.01) |
|                                                                                                                                                             | 114/181                      | 19.2                                        | 16.2 16.1 16.2      |                                     | 0.47 0.93                     |                                       |
| Gemaitabine/Caboplatin                                                                                                                                      | 79/143                       |                                             | 16.1                |                                     |                               |                                       |
|                                                                                                                                                             |                              | 28.3 19.0                                   |                     |                                     | 0.93                          | (0.62, 1.38)                          |
| gemcitabine/carboplatin)(Actual)                                                                                                                            |                              |                                             |                     |                                     | 0.47                          | (0.30, 0.73)                          |
|                                                                                                                                                             | 37/61 155/261                | 23.5 23.0                                   |                     | T                                   |                               | (0.32, 1.24) (0.51,0.98)              |
| 0-1+ by IHC 2+ by IHC denovometastasis                                                                                                                      | 117/193                      |                                             |                     |                                     |                               | (0.62,1.38)                           |
| No Prior adjuvant orneoadjuvant chemotherapy Yes No Yes                                                                                                     | 114/181                      |                                             | 17.6 10.3           | 0.1 1 10 Pembro+ChemoFavorPbo+Chemo |                               | (0.29, 1.05)                          |
| in the(neo)adjuvant setting (Actual) Yes                                                                                                                    | 75/130                       | 20.3 28.3                                   | 13.0                |                                     |                               | (0.61,1.32) (0.29, 0.73)              |
|                                                                                                                                                             |                              |                                             | 17.1                |                                     |                               |                                       |
| Prioradjuvantorneoadjuvanttaxanetreatment                                                                                                                   |                              |                                             |                     |                                     |                               |                                       |
| No                                                                                                                                                          | 102/157 90/166               | 17.7 28.6                                   | 15.8 16.1           |                                     | 0.91                          | (0.60, 1.38) (0.35, 0.80)             |
| Prioradjuvantorneoadjuvantplatinum treatment No                                                                                                             |                              | 23.0                                        | 16.4                |                                     | 0.53                          | (0.50, 0.92)                          |
| Menopausal status                                                                                                                                           | 179/304 64/108               | 21.2 23.5                                   | 16.0 16.1           | T T                                 | 0.68 0.71                     | (0.43, 1.19)                          |
| Pre-menopausa Post-menopausa ECOG                                                                                                                           | 128/215                      |                                             |                     | 王                                   | 0.69                          | (0.48, 0.98)                          |
| 0 1                                                                                                                                                         | 101/196 91/127               | 27.5                                        | 19.8 10.6           | T                                   | 0.70                          | (0.47, 1.05) (0.42, 1.00)             |
|                                                                                                                                                             |                              | 17.7                                        |                     |                                     | 0.65                          |                                       |
| HER2status                                                                                                                                                  | 143/233 49/90                | 21.8 27.5                                   | 15.2                | T                                   | 0.70 0.72                     | (0.50,0.98)                           |
| Diseasefreeinterval (DFI)                                                                                                                                   | 44/66                        |                                             | 18.6 12.5           | +                                   | 0.47                          | (0.39, 1.34)                          |
|                                                                                                                                                             | 63/103                       | 28.3                                        |                     |                                     |                               | (0.28, 0.78)                          |
| <12months ≥12months                                                                                                                                         | 85/153                       | 17.4 25.8                                   | 19.7 17.1           |                                     | 1.19 0.70                     | (0.59, 2.40)                          |
| No.of metastaticorgan sites <3                                                                                                                              | 93/184 99/138                | 29.0                                        | 18.8                | T                                   | 0.60                          | (0.45, 1.09) (0.40, 0.91)             |
| ≥3                                                                                                                                                          |                              | 13.2                                        | 10.5                | T                                   |                               | (0.49, 1.14)                          |
| Visoaral disease                                                                                                                                            |                              |                                             |                     |                                     | 0.75                          |                                       |
| Yes                                                                                                                                                         | 184/300                      | 22.8                                        | 15.0                | 王                                   | 0.63                          | (0.46, 0.84)                          |
| Baselineladtate dehydrogenase(L DH)                                                                                                                         | 151/276                      | 26.3                                        |                     |                                     | 0.66                          | (0.47, 0.92)                          |
| < 2 x ULN                                                                                                                                                   | 32/37                        | 8.3                                         |                     |                                     |                               | (0.52, 2.29)                          |
| ≥2 × ULN                                                                                                                                                    |                              |                                             |                     |                                     |                               |                                       |
|                                                                                                                                                             |                              |                                             |                     |                                     | 1.09                          |                                       |

Pembro+Chemovs.Pbo+Chemo

Analysis (HR and 95% CI) in the overall population is based on the stratified Cox regression model with Efron's method of tie handling stratified by chemotherapy on study (taxane vs gemcitabine/carboplatin) and prior treatment with same class of chemotherapy in the (neo)adjuvant setting (yes vs no); analysis in the subgroups is based on the unstratified Cox model. If any level of a subgroup variable has fewer than 30 subjects, subgroup analysis is not performed in that level of the subgroup variable. Database Cutoff Date: 11DEC2019

<div style=\"page-break-after: always\"></div>

## · ORR

## Figure: Forest Plot of ORR by Subgroup Factors by BICR per RECIST 1.1 (PD-L1 CPS ≥ 10)

Forest Plot of Objective Response Rate by Subgroup Factors Based on BICR Assessments per RECIST 1.1 (Part 2 Subjects with PD-L1 CPS ≥10) (ITT Population)

<!-- image -->

|                                                               | #Responder/N                                    |                | ObjectiveResponse Rate (%) Pembro+Chemo   | Pbo+Chemo      | ORR Diff (95% CI)   | ORR Diff      | I%56                                |
|---------------------------------------------------------------|-------------------------------------------------|----------------|-------------------------------------------|----------------|---------------------|---------------|-------------------------------------|
| Overall                                                       | 158/323                                         |                | 53.2                                      | 39.8           |                     | 13.6          | (1.9, 24.8)                         |
| Age (years)                                                   | 121/257                                         | 51.1           |                                           | 38.0           |                     | 13.1          | (-0.1, 25.6)                        |
| <65yeers 265 years Ethnidty                                   | 37/66                                           |                | 61.9                                      | 45.8           |                     | 16.1          | (-8.8, 39.3)                        |
| Hispanic or Latino                                            | 29/58                                           |                | 54.1                                      | 42.9           |                     | 11.2          | (-15.4, 36.0)                       |
| Not Hispanic or Latino                                        | 122/250                                         |                | 53.4                                      | 38.2           |                     | 15.3          | (1.8, 27.9)                         |
| Geographicregion                                              |                                                 |                |                                           |                |                     |               |                                     |
| Europe/North America/Australia                                | 100/212                                         |                | 50.7                                      | 39.4           |                     | 11.3          | (-3.3, 25.0)                        |
| Asia                                                          | 29/56                                           |                | 57.9                                      | 38.9           |                     | 19.0          | (-9.1, 43.8)                        |
| Rest ofthe World                                              | 29/55                                           |                | 58.3                                      | 42.1           |                     | 16.2          | (-11.4, 41.5)                       |
| Nab-Padlitaxe                                                 | 47/99                                           |                | 54.0                                      | 36.1           |                     | 17.9          | (-2.7, 36.5)                        |
| Padlitaxe                                                     | 24/44                                           |                | 63.6                                      | 27.3           |                     | 36.4          | (1.9, 61.1)                         |
| Gemaitebine/Carboplain                                        | 87/180                                          |                | 50.0                                      |                |                     | 5.4           | (-10.4, 20.6)                       |
| Chemotherapy on study (Adtual)                                |                                                 |                |                                           | 44.6           |                     |               |                                     |
| Nab-Padlitaxel                                                | 46/97                                           |                | 54.1                                      | 36.1           |                     | 18.0          | (-2.7, 36.8)                        |
| Padlitaxe                                                     | 24/44                                           |                | 63.6                                      | 27.3           |                     | 36.4          | (1.9,61.1)                          |
| GemcitabineCarboplain                                         | 88/181                                          |                | 50.4                                      | 44.6           |                     | 5.8           | (-10.0, 21.0)                       |
| gemaitabinecarboplatin)(IVRS) Taxane                          | 71/143                                          |                | 57.3                                      | 34.0           |                     | 23.2          | (5.8, 38.9)                         |
| Gemaitabine/Carboplatin                                       | 87/180                                          |                | 50.0                                      | 44.6           |                     | 5.4           | (-10.4, 20.6)                       |
| gemcitabinelcarboplatin)(Acual) Taxane Gemcitabine/Caboplatin | 70/141 88/181                                   |                | 57.4 50.4                                 | 34.0 44.6      |                     | 23.4 5.8      | (5.9, 39.1) (-10.0, 21.0)           |
| Prior treatmentwith samedassofchemotherapy                    |                                                 |                |                                           |                |                     |               |                                     |
| in the (neo)adjuvant setting (IVRS)                           |                                                 | 27/65          | 50.0                                      | 21.1           |                     | 28.9          | (2.5, 49.1)                         |
| Yes Priortreatment withsamedassofchemotheapy No               | Yes Priortreatment withsamedassofchemotheapy No | 131/258        | 54.0                                      | 44.0           |                     | 10.0          | (-3.1, 22.6)                        |
| in the (neo)adjuvant setting (Actual)                         | Yes No                                          | 26/61 132/261  | 47.7 54.9                                 | 29.4 41.9      |                     | 18.3          | (-9.7, 41.2) (0.1, 25.4)            |
| Prior adjuvant orneoadjuvant chemotherapy                     |                                                 |                | 47.3 61.8                                 | 34.1           |                     | 13.0          |                                     |
| Prior adjuvant or neoadjuvant taxanetreatment                 | Yes No                                          | 89/193 69/130  |                                           | 43.5           |                     | 3.8 27.7      | (-11.3,18.4) (9.2, 44.0)            |
| Prior adjuvantorneoadjuvantplatinum                           | Yes No                                          | 68/157 90/166  | 43.9 61.9                                 | 42.0 37.7      |                     | 1.9 24.2      | (-14.8,18.0) (7.9,39.1)             |
| treatment                                                     | No                                              | 149/304        |                                           |                | 1                   |               | (0.9, 24.5)                         |
| Menopausal status                                             |                                                 |                | 53.1                                      | 40.2           |                     | 12.9          |                                     |
| Premenopausa Post-menopausa                                   | ECOG                                            | 51/108 107/215 | 51.4 54.1                                 | 38.2 40.6      |                     | 13.1 13.5     | (-7.2, 31.8) (-0.8,27.1)            |
| HER2status 0-1+ by IHC 2+ by IHC                              | 0                                               | 103/196 55/127 | 56.0 48.8 51.6                            | 45.2 31.7 42.5 |                     | 10.8          | (-4.2,25.3)                         |
|                                                               | 1                                               | 113/233 45/90  |                                           | 30.4           |                     | 17.1 9.1 26.3 | (-1.4,33.6) (-4.4, 22.2) (2.5,45.8) |
| Disease freeinterval (DFI) denovo metastasis                  |                                                 | 56/103         | 56.7                                      | 52.9           |                     |               |                                     |
|                                                               |                                                 |                |                                           |                |                     | 13.7          |                                     |
| ≥12 months                                                    |                                                 | 74/153         |                                           |                |                     |               | (-3.1, 29.5)                        |
|                                                               |                                                 |                | 64.7                                      | 34.3           |                     | 30.4          | (10.0,48.1)                         |
| <12months                                                     |                                                 | 28/66          | 38.8                                      |                |                     | -14.2         | (-39.5, 12.5)                       |
|                                                               |                                                 |                | 52.9                                      | 39.2           |                     |               |                                     |
| No.of metastatic organ sites                                  |                                                 |                |                                           |                |                     |               |                                     |
| <3                                                            | 105/184                                         |                | 60.7                                      | 50.0           |                     | 10.7          | (-4.4, 25.5)                        |
| ≥3                                                            |                                                 | 53/138         | 44.3                                      | 24.4           |                     | 19.9          | (2.2, 35.0)                         |
| Visoral disease Yes                                           |                                                 | 143/300        | 53.4                                      | 35.1           | T⊥                  | 18.3          | (6.1, 29.6)                         |
| Baslineladtate dehydrogenase (L DH)                           |                                                 |                |                                           |                |                     |               |                                     |
| < 2 × ULN                                                     | 141/276                                         |                | 57.4                                      | 37.2           | 1                   | 20.2          | (7.4, 32.0)                         |
| ≥ 2 × ULN                                                     |                                                 |                |                                           |                |                     | -9.7          |                                     |
|                                                               |                                                 | 13/37          | 32.0                                      | 41.7           | H                   |               | (-41.8, 21.5)                       |
|                                                               |                                                 |                |                                           |                | -50-25 0 25 50 75   |               |                                     |

Pembro+Chemovs.Pbo+Chemo

Analysis  (ORR  difference  and  95%  CI)  in  the  overall  population  is  based  on  the  Miettinen  and  Nurminen  method  stratified  by chemotherapy on study (taxane vs gemcitabine/carboplatin) and prior treatment with same class of chemotherapy in the (neo)adjuvant setting (yes vs no); analysis in the subgroups is based on the unstratified Miettinen &amp; Nurminen method. If any level of a subgroup variable has fewer than 30 subjects, subgroup analysis is not performed in that level of the subgroup variable. Database Cutoff Date: 11DEC2019

## PDL1 with CPS ≥1

<div style=\"page-break-after: always\"></div>

Numerical improvements in PFS, OS and ORR for pembrolizumab + chemotherapy compared with placebo + chemotherapy in the PD-L1 CPS ≥ 1 population were not statistically significant .

Table: Summary of Efficacy Results in Participants with PD-L1 CPS ≥ 1 (ITT Population)

| Endpoint                             | Pembrolizumab + Chemotherapy (N=425)   | Placebo + Chemotherapy (N=211)   |
|--------------------------------------|----------------------------------------|----------------------------------|
| PFS a                                |                                        |                                  |
| Number of Events (%)                 | 288 (67.8)                             | 162 (76.8)                       |
| Median PFS, months (95% CI)          | 7.6 (6.6, 8.0)                         | 5.6 (5.4, 7.4)                   |
| HR (95% CI), p-value                 | 0.74 (0.61, 0.90) p=0.0014 b           |                                  |
| OS                                   |                                        |                                  |
| Number of Events (%)                 | 273 (64.2)                             | 155 (73.5)                       |
| Median OS, months (95% CI)           | 17.6 (15.5, 19.5)                      | 16.0 (12.8, 17.4)                |
| HR (95% CI), p-value                 | 0.82 (0.68, 1.00) p=0.0263 c           |                                  |
| Objective Response d                 |                                        |                                  |
| ORR %(95% CI) a                      | 45.2 (40.4, 50.0)                      | 37.9 (31.3, 44.8)                |
| ORR Difference %(95% CI), p-value    | 7.3 (-0.9, 15.2) p=0.0408              |                                  |
| CR, n (%)                            | 53 (12.5)                              | 18 (8.5)                         |
| PR, n (%)                            | 139 (32.7)                             | 62 (29.4)                        |
| DOR (months), median (range) a, e, f | 10.1 (1.0+ - 29.8)                     | 6.5 (1.5 - 32.5+)                |

Abbreviations: BICR = blinded independent central review; CI = confidence interval; CPS = combined positive score; CR = complete response, DOR = duration of response; HR = hazard ratio; IA2 = Interim Analysis 2; ITT = intent-to-treat; ORR = objective response rate; OS = overall survival; PD = progressive disease; PD-L1 = programmed cell death 1 ligand 1; PFS = progression-free survival; PR = partial response; RECIST 1.1 = Response Evaluation Criteria in Solid Tumors version 1.1.

- a. Response assessed by BICR per RECIST 1.1; only confirmed responses are included.
- b. The observed p-value of p=0.0014 did not cross the prespecified efficacy boundary at IA2 (the multiplicity adjusted, one-sided nominal alpha level was 0.00111).
- c. The observed p-value of p=0.0263 did not cross the prespecified efficacy boundary at IA2 (the multiplicity adjusted, one-sided nominal alpha level was 0.00221).
- d. ORR was not formally tested at IA2 per the prespecified multiplicity strategy.
- e. From product-limit (Kaplan-Meier) method for censored data.
- f. '+' indicated there is no PD by the time of last disease assessment.

One-sided p-values based on stratified log-rank test (PFS and OS) or stratified Miettinen &amp; Nurminen method (ORR).

Data cutoff: 11DEC2019

<div style=\"page-break-after: always\"></div>

Kaplan-Meier Estimates of Progression-Free Survival Based on BICR Assessment per RECIST 1.1 (Part 2 Subjects with PD-L1 CPS ≥1) (ITT Population)

<!-- image -->

Kaplan-Meier Estimates of Overall Survival (Part 2 Subjects with PD-L1 CPS ≥1) (ITT Population)

<!-- image -->

## All subjects

<div style=\"page-break-after: always\"></div>

Per the multiplicity schema, the primary hypotheses pertaining to PFS and OS in All Participants were not formally tested because the success criteria for the primary hypotheses of PFS and OS in participants with tumors that express PD-L1 with CPS ≥ 1 were not met.

Table: Summary of Efficacy Results in All Participants (ITT Population)

| Endpoint                             | Pembrolizumab + Chemotherapy (N=566)   | Placebo + Chemotherapy (N=281)   |
|--------------------------------------|----------------------------------------|----------------------------------|
| PFS a, b                             |                                        |                                  |
| Number of Events (%)                 | 391 (69.1)                             | 211 (75.1)                       |
| Median PFS, months (95% CI)          | 7.5 (6.3, 7.7)                         | 5.6 (5.4, 7.3)                   |
| HR (95% CI), p-value                 | 0.82 (0.69, 0.97) p=0.0112             |                                  |
| OS b                                 |                                        |                                  |
| Number of Events (%)                 | 374 (66.1)                             | 201 (71.5)                       |
| Median OS, months (95% CI)           | 17.2 (15.3, 19.0)                      | 15.5 (13.9, 17.2)                |
| HR (95% CI), p-value                 | 0.87 (0.73, 1.03) p=0.0579             |                                  |
| Objective Response                   |                                        |                                  |
| ORR %(95% CI) a, c                   | 41.0 (36.9, 45.2)                      | 35.9 (30.3, 41.9)                |
| ORR Difference %(95% CI), p-value    | 5.1 (-1.9, 11.8) p=0.0768              |                                  |
| CR, n (%)                            | 60 (10.6)                              | 20 (7.1)                         |
| PR, n (%)                            | 172 (30.4)                             | 81 (28.8)                        |
| DOR (months), median (range) a, d, e | 10.1 (1.0+ - 29.8)                     | 6.4 (1.5 - 32.5+)                |

Abbreviations:  BICR  =  blinded  independent  central  review;  CI  =  confidence  interval;  CPS = combined  positive  score;  CR  = complete response, DOR  =  duration of response; HR = hazard ratio; IA2 = Interim Analysis 2; ITT = intent-to-treat; ORR = objective  response  rate;  OS = overall  survival;  PD = progressive  disease;  PD-L1 = programmed  cell  death  1  ligand  1; PFS = progression-free survival; PR = partial response; RECIST 1.1 = Response Evaluation Criteria in Solid Tumors version 1.1.

- a. Response assessed by BICR per RECIST 1.1; only confirmed responses are included.
- b. Per the prespecified multiplicity strategy, the primary hypotheses pertaining to PFS and OS in All Participants were not formally tested because the success criterion for the primary hypotheses of PFS and OS in participants with tumors that express PD-L1 with CPS ≥1 were not met.
- c. ORR was not formally tested at IA2 per the prespecified multiplicity strategy.
- d. From product-limit (Kaplan-Meier) method for censored data.
- e. '+' indicated there is no PD by the time of last disease assessment.

One-sided p-values based on stratified log-rank test (PFS and OS) or stratified Miettinen &amp; Nurminen method (ORR). Data cutoff: 11DEC2019

<div style=\"page-break-after: always\"></div>

Kaplan-Meier Estimates of Progression-Free Survival Based on BICR Assessment per RECIST 1.1 (Part 2 All Subjects) (ITT Population)

<!-- image -->

Kaplan-Meier Estimates of Overall Survival (Part 2 All Subjects) (ITT Population)

<!-- image -->

## Subgroup analyses for all participants

<div style=\"page-break-after: always\"></div>

## Figures: forest plot of PFS based on BICR assessment per RECIST 1.1 by subgroup factors

Forest Plot of Progression-Free Survival Hazard Ratio Based on BICR Assessment per RECIST 1.1 by Subgroup Factors (Part 2 All Subjects) (ITT Population)

|                                                                      | #Event/N   | Median Progression Free Survival (mo) Pembro+Chemo   | Pbo+Chemo   | HR (95% CI)   | HR   | 95%CI        |
|----------------------------------------------------------------------|------------|------------------------------------------------------|-------------|---------------|------|--------------|
| Overall                                                              | 602/847    | 7.5                                                  | 5.6         |               | 0.82 | (0.69, 0.97) |
| Age (years)                                                          |            |                                                      |             |               |      |              |
| <65 years                                                            | 485/667    | 7.3                                                  | 5.6         |               | 0.83 | (0.69, 1.00) |
| 265 yeers                                                            | 117/180    | 9.2                                                  | 6.2         | T             | 0.72 | (0.49, 1.05) |
| Ethnidty                                                             |            |                                                      |             |               |      |              |
| Hi spanic or Latino                                                  | 125/164    | 5.6                                                  | 5.6         |               | 1.25 | (0.83, 1.87) |
| Not Hispanic or Latino                                               | 448/641    | 7.7                                                  | 5.6         | 王             | 0.70 | (0.58,0.85)  |
| Geographic region                                                    |            |                                                      |             |               |      |              |
| Europe/North America/Australia                                       | 376/536    | 7.5                                                  | 5.7         |               | 0.83 | (0.67, 1.02) |
| Asia                                                                 | 111/160    | 8.8                                                  | 6.7         | 工⊥            | 0.61 | (0.41, 0.90) |
| Rest of the World                                                    | 115/151    | 5.8                                                  | 5.4         |               | 1.01 | (0.67, 1.54) |
| Chemotherapy on study(IVRS)                                          |            |                                                      |             |               |      |              |
| Nab-Paditaxe                                                         | 182/268    | 7.5                                                  | 5.4         | 王             | 0.69 | (0.51,0.93)  |
| Paditaxel                                                            | 76/114     | 8.0                                                  | 3.8         |               | 0.57 | (0.35, 0.93) |
| Gemaitabine/Caboplatin                                               | 344/465    | 7.4                                                  | 7.4         |               | 0.93 | (0.74, 1.16) |
| Chemotherapy on study (Adtual)                                       |            |                                                      |             |               |      |              |
| Nab-Paditaxd                                                         | 182/267    | 7.5                                                  | 5.4         | 王             | 0.69 | (0.51, 0.93) |
| Paditaxel                                                            | 76/113     | 8.0                                                  | 3.8         |               | 0.58 | (0.35, 0.94) |
| Gamaitabino/Caboplatin                                               | 343/463    | 7.4                                                  | 7.4         |               | 0.92 | (0.73, 1.15) |
| gemaitabinefcarboplatin)(IVRS)                                       |            |                                                      |             |               |      |              |
| Taxane                                                               | 258/382    | 7.6                                                  | 5.3         | 王             | 0.66 | (0.51, 0.86) |
| Gemaitabine/Caboplatin                                               | 344/465    | 7.4                                                  | 7.4         | 王             | 0.93 | (0.74, 1.16) |
| Chemotherapyonstudy(taxanevs. gemaitabine/carboplatin){Acual) Taxane | 258/380    | 7.6                                                  | 5.3         |               | 0.67 | (0.52,0.86)  |
| Gemaitabine/Caboplatin                                               | 343/463    | 7.4                                                  | 7.4         |               | 0.92 | (0.73, 1.15) |
| PD-L1 status (CPS autoff of 1)                                       |            |                                                      |             |               |      |              |
| PD-L1 CPS ≥1                                                         | 450/636    | 7.6                                                  | 5.6         | M             | 0.74 | (0.61, 0.89) |
| PD-L1 CPS <1                                                         | 152/211    | 6.3                                                  | 6.2         |               | 1.08 | (0.77, 1.53) |
| PD-L1 status (CPS autoff of 5)                                       |            |                                                      |             |               |      |              |
| PD-L1 CPS ≥5                                                         | 311/452    | 7.7                                                  | 5.6         |               | 0.73 | (0.57,0.92)  |
| PD-L1 CPS <5                                                         | 291/395    | 6.1                                                  | 5.7         |               | 0.93 | (0.73, 1.19) |
| PD-L1 status (CPS autoff of 10)                                      |            |                                                      |             |               |      |              |
| PD-L1 CPS ≥10                                                        | 215/323    | 9.7                                                  | 5.6         | 王             | 0.65 | (0.49, 0.86) |
| PD-L1 CPS<10                                                         | 387/524    | 5.8                                                  | 5.7         |               | 0.94 | (0.76, 1.16) |
| PD-L1 status (CPS autoff of 15)                                      |            |                                                      |             |               |      |              |
| PD-L1 CPS ≥15                                                        | 159/233    | 9.6                                                  | 5.4         |               | 0.60 | (0.43, 0.83) |
| PD-L1 CPS <15                                                        | 443/614    | 6.6                                                  | 5.8         | H             | 0.92 | (0.75, 1.11) |
| PD-L1 status (CPS cutoff of 20)                                      |            |                                                      |             |               |      |              |
| PD-L1 CPS ≥20                                                        | 135/204    | 9.5                                                  | 5.4         | 王             | 0.61 | (0.43, 0.87) |
| PD-L1CPS<20                                                          | 467/643    | 6.6                                                  | 5.8         |               | 0.89 | (0.73, 1.07) |
| Priortreatmentwithsamedassofchemotherapy                             |            |                                                      |             |               |      |              |
| in the (neo)adjuvant setting (IVRS)                                  | 137/186    | 7.5                                                  | 5.4         | T⊥            | 0.56 | (0.39, 0.80) |
| Ycs No                                                               | 465/661    | 7.6                                                  | 6.6         |               | 0.89 | (0.73, 1.07) |
| Priortreatmentwithsamedassofchemotherapy                             |            |                                                      |             |               |      |              |
| in the(neo)adjuvant setting (Adtual) Yes                             | 133/180    | 6.3                                                  | 5.4         |               | 0.67 | (0.47, 0.96) |
| No                                                                   | 468/663    | 7.6                                                  | 6.6         |               | 0.83 | (0.69,1.01)  |
| Prioradjuvantorneoadjuvantchemotherapy                               |            |                                                      |             |               |      |              |
| Yes                                                                  | 402/538    | 6.3                                                  | 5.7         |               | 0.92 | (0.75, 1.13) |
| No                                                                   | 200/309    | 8.0                                                  | 5.5         |               | 0.62 | (0.47, 0.83) |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Prioradjuvantorneoadjuvanttaxanetreatment    | Prioradjuvantorneoadjuvanttaxanetreatment   | Prioradjuvantorneoadjuvanttaxanetreatment   | Prioradjuvantorneoadjuvanttaxanetreatment   | Prioradjuvantorneoadjuvanttaxanetreatment   | Prioradjuvantorneoadjuvanttaxanetreatment   | Prioradjuvantorneoadjuvanttaxanetreatment   |
|----------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|
| Yes                                          | 339/446                                     | 6.3                                         | 5.6                                         |                                             | 0.89                                        | (0.71, 1.11)                                |
| No                                           | 263/401                                     | 7.9                                         | 5.7                                         |                                             | 0.72                                        | (0.56,0.93)                                 |
| Prioradjuvantorneoadjuvantplatinum treatment |                                             |                                             |                                             |                                             |                                             |                                             |
| Yes                                          | 48/65                                       | 5.8                                         | 5.4                                         |                                             | 0.76                                        | (0.42, 1.37)                                |
| No                                           | 554/782                                     | 7.6                                         | 5.7                                         |                                             | 0.81                                        | (0.68, 0.96)                                |
| Menopausal status                            |                                             |                                             |                                             |                                             |                                             |                                             |
| Premenopausal                                | 202/270                                     | 5.6                                         | 5.6                                         | TH                                          | 0.91                                        | (0.68, 1.22)                                |
| Post-menopausal                              | 399/576                                     | 7.7                                         | 5.7                                         |                                             | 0.76                                        | (0.62, 0.93)                                |
| ECOG                                         |                                             |                                             |                                             |                                             |                                             |                                             |
| 0                                            | 358/505                                     | 7.6                                         | 6.6                                         |                                             | 0.83                                        | (0.67,1.03)                                 |
| 1                                            | 243/340                                     | 6.8                                         | 5.5                                         | T                                           | 0.75                                        | (0.57, 0.97)                                |
| HER2status                                   |                                             |                                             |                                             |                                             |                                             |                                             |
| 0-1+ by IHC                                  | 458/628                                     | 7.4                                         | 5.7                                         | M                                           | 0.86                                        | (0.71, 1.05)                                |
| 2+ by IHC                                    | 144/219                                     | 9.3                                         | 5.6                                         |                                             | 0.66                                        | (0.46, 0.94)                                |
| Diseasefreeinterval (DFI)                    |                                             |                                             |                                             |                                             |                                             |                                             |
| denovometastasis                             | 165/251                                     | 7.7                                         | 5.5                                         | T                                           | 0.66                                        | (0.48,0.91)                                 |
|                                              | 132/176                                     | 5.6                                         | 5.6                                         |                                             | 0.90                                        | (0.62, 1.31)                                |
| ≥12months                                    | 304/417                                     | 7.6                                         | 6.6                                         |                                             | 0.83                                        | (0.66, 1.05)                                |
| No. of metastatic organ sites                |                                             |                                             |                                             |                                             |                                             |                                             |
| >                                            | 317/479                                     | 8.0                                         | 7.2                                         |                                             | 0.83                                        | (0.66, 1.04)                                |
| ≥3                                           | 284/365                                     | 5.9                                         | 5.3                                         |                                             | 0.73                                        | (0.57, 0.94)                                |
| Visoaraldisease                              |                                             |                                             |                                             |                                             |                                             |                                             |
| Yes                                          | 576/790                                     | 7.5                                         | 5.6                                         | M                                           | 0.78                                        | (0.65, 0.92)                                |
| No                                           | 25/54                                       | 14.5                                        | 12.9                                        |                                             | 0.94                                        | (0.42, 2.07)                                |
| Baselinelactate dehydrogenase(LDH)           |                                             |                                             |                                             |                                             |                                             |                                             |
| <2xULN                                       |                                             |                                             | 6.6                                         |                                             | 0.76                                        | (0.63, 0.92)                                |
| ≥2 × ULN                                     |                                             |                                             | 3.7                                         |                                             |                                             |                                             |
|                                              | 466/685                                     | 7.7                                         |                                             | Mi                                          |                                             |                                             |
|                                              | 123/140                                     | 3.5                                         |                                             |                                             | 0.93                                        | (0.63, 1.37)                                |

Pembro+Chemovs.Pbo+Chemo

Analysis (HR and 95% CI) in the overall population is based on the stratified Cox regression model with Efron's method of tie handling stratified by chemotherapy on study (taxane vs gemcitabine/carboplatin), tumor PDL1 status (CPS ≥1 vs CPS &lt;1) and prior treatment with same class of chemotherapy in the (neo)adjuvant setting (yes vs no); analysis in the subgroups is based on the unstratified Cox model. If any level of a subgroup variable has fewer than 30 subjects, subgroup analysis is not performed in that level of the subgroup variable. Database Cutoff Date: 11DEC2019

## Figures: forest plot of OS by subgroup factors

<div style=\"page-break-after: always\"></div>

Forest Plot of Overall Survival Hazard Ratio by Subgroup Factors (Part 2 All Subjects) (ITT Population)

<!-- image -->

|                                                                                                                         | #Event/N                | Median Overall Survival (mo) Pembro+Chemo   | Pbo+Chemo      | HR (95% CI)   | HR             | 95%CI                                           |     |             |                 |
|-------------------------------------------------------------------------------------------------------------------------|-------------------------|---------------------------------------------|----------------|---------------|----------------|-------------------------------------------------|-----|-------------|-----------------|
| Overall                                                                                                                 | 575/847                 | 17.2                                        | 15.5           |               | 0.87           | (0.73,1.03)                                     |     |             |                 |
| Age (years) <65yeas                                                                                                     | 458/667                 | 17.1                                        | 16.0           |               | 0.93           | (0.76, 1.12)                                    |     |             |                 |
| ≥65 yeers Ethnidity                                                                                                     | 117/180                 | 19.0                                        | 13.0 12.8      | ！             | 0.70           | (0.48, 1.02) (0.90,1.99)                        |     |             |                 |
| Hispenic or Latino Not Hispanic or Latino Geographicregion                                                              | 126/164 419/641         | 12.3 19.6 16.8                              | 15.3 15.4      |               | 1.33 0.77      | (0.63,0.93)                                     |     |             |                 |
| Europe/North America/Australia Asia Rest of the World                                                                   | 367/536 95/160 113/151  | 24.7 12.5                                   | 17.2 12.8      |               | 0.90 0.52 1.21 | (0.73, 1.12) (0.34,0.79) (0.79, 1.85)           |     |             |                 |
| Chemotherapy on study (IVRS) Nab-Paditaxe Padlitaxel Gemcitabine/Caboplatin Chemotherapy on study (Adual)               | 171/268 74/114 330/465  | 18.3 20.7 15.9                              | 17.1 16.6 14.7 | 王 T 王         | 0.79 0.74 0.96 | (0.58,1.07) (0.45, 1.21) (0.76, 1.21)           |     |             |                 |
| Nab-Padlitaxe Paditaxdl Gamaitabind/Caboplatin gemcitabine/carboplatin)(IVRS)                                           | 172/267 72/113 328/463  | 18.3 20.7 15.9                              | 17.1 16.6 14.7 | 王 1 王         | 0.80 0.72 0.95 | (0.59,1.09) (0.44, 1.17) (0.76, 1.20)           |     |             |                 |
| faxane Gemaitabine/Caboplain gemaitabinelcarboplatin)(Adual) Taxane                                                     | 245/382 330/465 244/380 | 19.2 15.9                                   | 17.1 14.7      | 王 王           | 0.77 0.96      | (0.59,0.99) (0.76, 1.21)                        |     |             |                 |
| Gemditabine/Caboplatin PD-L1 CPS ≥1                                                                                     | 328/463 428/636         | 19.2 15.9                                   | 17.1 14.7      |               | 0.76 0.95      | (0.59,0.99) (0.76,1.20)                         |     |             |                 |
| PD-L1 status (CPS autoff of 1) PD-L1 CPS <1 PD-L1 status (CPS cutoff of 5) PD-L1 CPS ≥5 PD-L1 CPS <5                    | 147/211 290/452 285/395 | 17.6 16.5 19.5 14.7                         | 16.0 14.7 14.4 | ? 王           | 0.82 1.04      | (0.68, 1.00) (0.73, 1.47) 0.71 (0.56,0.91) 1.12 |     | (0.88,1.43) |                 |
| PD-L1 status (CPS autoff of 10) PD-L1 CPS ≥10 PD-L1 CPS <10 PD-L1 status (CPS autoff of 15) PD-L1 CPS ≥15 PD-L1 CPS <15 | 136/233 439/614         | 23.0 14.7                                   | 16.7 16.1 15.2 |               | 0.69 1.01      | (0.52,0.93) (0.82, 1.25)                        |     |             | 192/323 383/524 |
|                                                                                                                         |                         | 25.2                                        | 16.4 15.3      | 1             | 0.62           | (0.44,0.88) (0.81, 1.20)                        |     |             |                 |
| PD-L1 status (CPS cutoff of 20) PD-L1 CPS ≥20 PD-L1CPS<20                                                               | 118/204                 | 15.3                                        | 15.6 15.5      |               | 0.99 0.64 0.96 | (0.44,0.93) (0.79, 1.17)                        |     |             | 457/643         |
| Priortreatmentwithsamedassofchemotherapy in the (neo)adjuvant setting (IVRS) Ycs No                                     | 120/186 455/661         | 25.8 15.9 17.4                              | 17.4 14.7      |               | 0.79 0.90      | (0.55, 1.15) (0.74, 1.09)                       |     |             |                 |
| Priortreatment withsamedassofchemotherapy in the (neo)adjuvant setting (Actual)                                         | 117/180                 | 17.2                                        | 17.4           |               | 0.94           | (0.64, 1.39)                                    |     |             |                 |
| Yes No Prior adjuvant orneoadjuvant chemotherapy Yes No                                                                 | 455/663 372/538 203/309 | 16.2 17.6 16.5 19.2                         | 14.7 16.1 14.8 | 王 王           | 0.85 0.94      | (0.70, 1.03) (0.76, 1.17) 0.77 (0.58, 1.02)     |     |             |                 |
|                                                                                                                         | 314/446                 | 16.2                                        | 15.3 15.5      | 王             | 0.92           | (0.73, 1.16) (0.64, 1.07)                       |     |             |                 |
| Prioradjuvantorneoadjuvanttaxanetreatment Yes Prioradjuvantorneoadjuvantplatinum No. treatment                          | 261/401 46/65 529/782   | 19.0 15.5 17.6                              | 16.8 15.3      | √             | 0.83 1.11      | (0.61,2.02) (0.71, 1.02)                        |     |             |                 |
| Yes No Menopausal status Pre-menopausal Post-menopausal                                                                 | 191/270 383/576 321/505 | 15.9 17.7 19.3                              | 15.3 15.5 17.6 |               | 0.85 0.88      | 0.85 (0.64, 1.15) (0.71, 1.09)                  |     |             |                 |
| ECOG 0 1 HER2status 0-1+ by IHC                                                                                         | 252/340                 | 14.0                                        | 11.4           |               | 0.88 0.83      | (0.70, 1.10) (0.64,1.08)                        |     |             |                 |
| 2+ by IHC <12 months                                                                                                    | 432/628 143/219 171/251 | 16.5 19.6                                   | 14.9 17.1 14.7 |               | 0.90 0.80      | (0.74, 1.10) (0.57, 1.14)                       |     |             |                 |
| Diseasefreeinterval (DFI) de novometastasis                                                                             | 137/176 265/417         | 18.8 12.9 18.5                              | 13.7 17.2      | 王             | 0.75 0.95 0.88 | (0.55, 1.02) (0.66,1.38) (0.69,1.13)            |     |             |                 |
| ≥12 months No.of metastaticorgan sites <3                                                                               | 292/479 281/365         | 20.5                                        | 17.6           | 王             | 0.81           | (0.64,1.03)                                     |     |             |                 |
| ≥3 Visoeral disease Yes No                                                                                              | 546/790 27/54           | 12.6 17.2 24.7                              | 10.5 14.9 NR   |               | 0.83 1.31      | 0.90 (0.70, 1.16) (0.70,0.99) (0.60, 2.87)      |     |             |                 |
| Baslinelactate dehydrogenase (L DH)                                                                                     |                         |                                             |                |               |                | (0.69, 1.03)                                    |     |             |                 |
|                                                                                                                         | 424/685                 |                                             |                | 王             | 0.84           |                                                 |     |             |                 |
| < 2× ULN                                                                                                                |                         | 20.2                                        | 17.2           |               |                | (0.67, 1.40)                                    |     |             |                 |
| ≥2 × ULN                                                                                                                | 132/140                 | 9.0                                         | 9.3            |               |                |                                                 |     |             |                 |
|                                                                                                                         |                         |                                             |                | T⊥            |                |                                                 |     |             |                 |
|                                                                                                                         |                         |                                             |                |               | 0.97           |                                                 |     |             |                 |
|                                                                                                                         |                         |                                             |                | 1             |                |                                                 |     |             |                 |
|                                                                                                                         |                         |                                             |                |               | 10             |                                                 |     |             |                 |
|                                                                                                                         |                         |                                             |                |               |                |                                                 | 0.1 |             |                 |

Pembro+ChemoFa/orPbo+Chemo

Pembro+Chemo vs.Pbo+Chemo

Analysis (HR and 95% CI) in the overall population is based on the stratified Cox regression model with Efron's method of tie handling stratified by chemotherapy on study (taxane vs gemcitabine/carboplatin), tumor PDL1 status (CPS ≥1 vs CPS &lt;1) and prior treatment with same class of chemotherapy in the (neo)adjuvant setting (yes vs no); analysis in the subgroups is based on the unstratified Cox

<div style=\"page-break-after: always\"></div>

model. If any level of a subgroup variable has fewer than 30 subjects, subgroup analysis is not performed in that level of the subgroup variable. Database Cutoff Date: 11DEC2019

## Figures: forest plot of ORR based on BICR per RECIST 1.1 by subgroup factors

Forest Plot of Objective Response Rate by Subgroup Factors Based on BICR Assessments per RECIST 1.1 (Part 2 All Subjects) (ITT Population)

|                                                                                                     | #Responder/N                  | Objective Response Rate (%)   | Pbo+Chemo      | ORR Diff (95% CI)   | ORR Diff   | %56                                                  |
|-----------------------------------------------------------------------------------------------------|-------------------------------|-------------------------------|----------------|---------------------|------------|------------------------------------------------------|
| Overall                                                                                             | 333/847                       | 41.0                          | 35.9           |                     | 5.1        | (-1.9, 11.8)                                         |
| Age (years) <65years                                                                                | 259/667                       | 40.0                          | 36.6           |                     | 3.3        | (-4.5, 11.0)                                         |
| ≥65 yeers                                                                                           | 74/180                        | 44.7                          | 33.3           |                     | 11.4       | (-4.2, 25.7)                                         |
| Ethnidty Hispanic or Latino                                                                         | 56/164                        | 31.9                          | 39.6           |                     | -7.7       | (-24.1, 7.9)                                         |
| Not Hispanic or Latino                                                                              | 259/641                       | 43.5                          | 34.4           |                     | 9.1        | (1.1, 16.8)                                          |
| Geographic region Europe/North America/Australia                                                    | 204/536                       | 40.4                          | 33.9           |                     | 6.6        | (-2.1, 14.8)                                         |
| Asia                                                                                                | 76/160                        | 48.7                          | 44.7           |                     | 4.0        | (-12.9, 20.4)                                        |
| Rest ofthe World                                                                                    | 53/151                        | 34.9                          | 35.7           |                     | -0.9       | (-18.3, 15.2)                                        |
| Chemotherapy on study (IVRS) Nab-Padlitaxel                                                         | 97/268                        | 40.5                          | 28.4           |                     | 12.0       | (-0.0, 23.2) (-3.2, 34.2)                            |
| Padlitaxe Gemcitabine/Caboplatin                                                                    | 46/114 190/465                | 45.1 40.2                     | 28.1 42.2      |                     | 17.0 -2.0  | (-11.6, 7.4)                                         |
| Chemotherapy on study (Adtual)                                                                      | 96/267                        | 40.1                          | 28.4           |                     | 11.7       | (-0.4, 22.9)                                         |
| Nab-Padlitaxel Padlitaxe                                                                            | 46/113                        |                               |                |                     |            |                                                      |
| Gemcitabine/Caboplain                                                                               | 191/463                       | 45.7 40.8                     | 28.1 42.2      |                     | 17.6 -1.4  | (-2.7, 34.8) (-11.0, 8.0)                            |
| Chemotherapyonstudy(taxanevs. gemditabinecarboplatin)(IVRS) Taxane                                  | 143/382                       | 42.0                          | 28.3           |                     | 13.6       | (3.4, 23.1)                                          |
| Gemaitabine/Carboplain gemcitabinelcarboplatin)(Acual)                                              | 190/465                       | 40.2                          | 42.2           |                     | -2.0       | (-11.6, 7.4)                                         |
| Taxane                                                                                              | 142/380 191/463               | 41.9 40.8                     | 28.3 42.2      |                     | 13.6       | (3.3, 23.1) (-11.0, 8.0)                             |
| Gemcitabine/Carboplatin                                                                             |                               |                               |                |                     | -1.4       |                                                      |
| PD-L1 status (CPS autoff of 1) PD-L1 CPS ≥1 PD-L1 CPS <1                                            | 272/636 61/211                | 45.2 28.4                     | 37.9 30.0      |                     | 7.3 -1.6   | (-0.9,15.2) (-15.2, 10.9)                            |
| PD-L1 status (CPS autoff of 5) PD-L1 CPS 25 PD-L1 CPS <5                                            | 205/452 128/395               | 47.1 33.5                     | 41.4 30.5      |                     | 5.7 3.0    | (-4.3, 15.3) (-6.8,12.3)                             |
| PD-L 1 status (CPS cutoff of 10) PD-L1 CPS ≥10 PD-L1 CPS <10                                        | 158/323 175/524               | 53.2 33.2                     | 39.8 33.7      |                     | 13.4 -0.5  | (1.7,24.6) (-9.2, 7.9)                               |
| PD-L 1 status (CPS cutoff of 15) PD-L1 CPS ≥15 PD-L1 CPS <15                                        | 107/233 226/614               | 52.5 36.5                     | 31.5 37.5      |                     | 21.0 -1.0  | (7.3,33.4) (-9.2,6.9)                                |
| PD-L1 status (CPS autoff of 20) PD-L1 CPS ≥20                                                       | 95/204 238/643                | 52.9                          | 32.8 36.9      |                     | 20.0 0.2   | (5.3, 33.4) (-7.8,8.0)                               |
| PD-L1CPS<20                                                                                         |                               | 37.1                          | 25.8           |                     |            | (3.0,30.9) (-6.5,9.2)                                |
| in the(neo)adjuvant setting (IVRS) Yes No                                                           | 70/186 263/661                | 43.5 40.3                     | 38.8 28.6      |                     | 17.7 1.5   |                                                      |
| Prior adjuvant or neoadjuvant chemotherapy Yes No                                                   |                               |                               | 37.8           |                     | 3.8        | (-4.2, 11.5)                                         |
| In the(neo)adjuvant setting (Actual) Yes No                                                         | 66/180 267/663                | 40.3 41.6                     |                |                     | 11.8       | (-3.6,25.5)                                          |
|                                                                                                     | 201/538 132/309               |                               | 37.6           |                     | -0.3 14.4  | (-9.1,8.2) (2.6,25.3)                                |
|                                                                                                     |                               | 37.3 47.4                     | 33.0 36.5      |                     | 2.4        |                                                      |
| Prioradjuvantorneoadjuvanttaxanetreatment Yes Prioradjuvant orneoadjuvant platinum No treatment Yes | 170/446 163/401 23/65 310/782 | 39.0 43.1 36.6 41.3           | 35.2 33.3 36.2 |                     | 7.9 3.3    | (-7.1, 11.7) (-2.5, 17.8) (-21.3, 25.8) (-2.2, 12.2) |
| No Menopausal status Premenopausd Post-menopaused ECOG                                              | 105/270 228/576               | 38.8 42.1                     | 39.1 34.4      |                     | 5.1 -0.4   |                                                      |
|                                                                                                     |                               |                               |                |                     | 7.7        | (-12.8, 11.6) (-0.8, 15.9)                           |
| 0 1                                                                                                 |                               |                               | 36.4 35.2      |                     |            |                                                      |
| HER2status 0-1+ by IHC                                                                              | 202/505 130/340               | 41.9 39.7                     | 37.9           |                     | 5.5 4.5    | (-3.6, 14.2) (-6.7, 15.1)                            |
| 2+by IHC                                                                                            | 242/628 91/219                | 38.9 46.7                     | 29.9           |                     | 1.0        | (-7.1, 8.9) (2.7, 29.6)                              |
|                                                                                                     |                               |                               |                |                     | 16.9       |                                                      |
| Disease free interval (DFI) denovo metastasis                                                       | 106/251                       | 46.1                          | 34.5           |                     | 11.6       | (-1.4, 23.8)                                         |
| <12months ≥12 months                                                                                | 56/176 171/417                | 31.7 42.6                     | 32.0 38.1      |                     | -0.3 4.5   | (-16.1, 14.1) (-5.4, 14.1)                           |
| No.of metastaticorgan sites                                                                         | 213/479                       | 47.6                          |                |                     |            |                                                      |
| <3                                                                                                  | 120/365                       | 33.2                          | 38.6 32.2      |                     | 9.0 1.0    | (-0.3, 18.1) (-9.6, 11.0)                            |
| 23 Visoeral disease                                                                                 |                               |                               |                |                     | 5.7        | (-1.6, 12.8)                                         |
| Yes                                                                                                 | 315/790                       | 41.7                          | 36.0           |                     |            |                                                      |
| No                                                                                                  | 18/54                         | 32.3                          | 34.8           |                     | -2.5       | (-28.0, 22.2)                                        |

<div style=\"page-break-after: always\"></div>

<!-- image -->

Pembro+Chemovs.Pbo+Chemo

Analysis  (ORR  difference  and  95%  CI)  in  the  overall  population  is  based  on  the  Miettinen  and  Nurminen  method  stratified  by chemotherapy on study (taxane vs gemcitabine/carboplatin), tumor PD-L1 stat us (CPS ≥1 vs CPS &lt;1) and prior treatment with same class of chemotherapy in the (neo)adjuvant setting (yes vs no); analysis in the subgroups is based on the unstratified Miettinen &amp; Nurminen method. If any level of a subgroup variable has fewer than 30 subjects, subgroup analysis is not performed in that level of the subgroup variable. Database Cutoff Date: 11DEC2019

A tabular summary of the overall data presented by the MAH according to PD-L1 expression at various cutoffs is presented below:

| Endpoint   | CPS   | Number of subjects   | Number of subjects   | Median (95%CI, months)   | Median (95%CI, months)   | HR (95%CI)        |
|------------|-------|----------------------|----------------------|--------------------------|--------------------------|-------------------|
| Endpoint   | CPS   | Pembro               | Placebo              | Pembro                   | Placebo                  | HR (95%CI)        |
| PFS        | ≥ 20  | 140                  | 64                   | 9.5 (7.6, 11.8)          | 5.4 (3.9, 7.2)           | 0.61 (0.43, 0.87) |
|            | ≥ 15  | 160                  | 73                   | 9.6                      | 5.4                      | 0.60 (0.43, 0.83) |
|            | ≥ 10  | 220                  | 103                  | 9.7 (7.6, 11.3)          | 5.6 (5.3, 7.5)           | 0.65 (0.49, 0.86) |
|            | ≥ 5   | 312                  | 140                  | 7.7                      | 5.6                      | 0.73 (0.57, 0.92) |
|            | ≥ 1   | 425                  | 211                  | 7.6 (6.6, 8.0)           | 5.6 (5.4, 7.4)           | 0.74 (0.61, 0.90) |
|            | < 1   | 141                  | 70                   | 6.3                      | 6.2                      | 1.08 (0.77, 1.53) |
|            | < 5   | 254                  | 141                  | 6.1                      | 5.7                      | 0.93 (0.73, 1.19) |
|            | < 10  | 346                  | 178                  | 5.8                      | 5.7                      | 0.94 (0.76, 1.16) |
|            | < 15  | 406                  | 208                  | 6.6                      | 5.8                      | 0.92 (0.75, 1.11) |
|            | < 20  | 426                  | 217                  | 6.6 (5.7, 7.6)           | 5.8 (5.5, 7.5)           | 0.89 (0.73, 1.07) |
|            | ALL   | 566                  | 281                  | 7.5 (6.3, 7.7)           | 5.6 (5.4, 7.3)           | 0.82 (0.69, 0.97) |
| OS         | ≥ 20  | 140                  | 64                   | 25.8 (18.8, 31.2)        | 15.6 (12.3, 20.8)        | 0.64 (0.44, 0.93) |
|            | ≥ 15  | 160                  | 73                   | 25.2                     | 16.4                     | 0.62 (0.44, 0.88) |
|            | ≥ 10  | 220                  | 103                  | 23.0 (18.8, 27.5)        | 16.1 (12.6, 18.8)        | 0.69 (0.51, 0.93) |
|            | ≥ 5   | 312                  | 140                  | 19.5                     | 14.4                     | 0.71 (0.56, 0.91) |
|            | ≥ 1   | 425                  | 211                  | 17.6 (15.5, 19.5)        | 16.0 (12.8, 17.4)        | 0.82 (0.68, 1.00) |
|            | < 1   | 141                  | 70                   | 16.5                     | 14.7                     | 1.04 (0.73, 1.47) |
|            | < 5   | 254                  | 141                  | 14.7                     | 16.7                     | 1.12 (0.88, 1.43) |
|            | <10   | 346                  | 178                  | 14.7                     | 15.2                     | 1.01 (0.82, 1.25) |
|            | <15   | 406                  | 208                  | 15.3                     | 15.3                     | 0.99 (0.81, 1.20) |
|            | <20   | 426                  | 217                  | 15.9 (14.0, 17.7)        | 15.5 (12.6, 17.6)        | 0.96 (0.79, 1.17) |

<div style=\"page-break-after: always\"></div>

| ALL   | 566   | 281   | 17.2 (15.3, 19.0)   | 15.5 (13.9, 17.2)   | 0.87 (0.73, 1.03)   |
|-------|-------|-------|---------------------|---------------------|---------------------|

The analyses of PFS and OS with CPS as a continuous score (after square root transformation) in a Cox regression model using IA1 data suggest that CPS score is a strong predictive factor in the pembrolizumab + chemotherapy group, while there is no evidence suggesting CPS affects the efficacy in the placebo + chemotherapy group (tables not shown).

## Ancillary analyses

## Patients reported outcomes

Completion rates of the EORTC QLQ-C30 were above 93% in both the pembrolizumab + chemotherapy and placebo + chemotherapy groups at baseline among participants with PD-L1 positive tumors (CPS ≥ 10 and CPS ≥ 1) and in All Participants, and remained high at Week 15 (between 70 and 77%).

Compliance rates of the EORTC QLQ-C30, defined as the percentage of participants completing the measure among those expected to complete the measure (i.e. not missing by design) were similar at baseline in both arms among participants with CPS ≥ 10 and CPS ≥ 1 and in All Participants (above 93%) and remained high at Week 15 (between 81% and 88%). In the PDL1 CPS≥10 population, at week 51 compliance rate was approximately 90% in both arms.

Similar rates of completion and compliance were observed for the EORTC QLQ-BR23 and EQ-5D.

The time frame of 15 weeks for the change from baseline analysis was selected based on a prespecified required minimum completion rate of 60% and compliance rate of 80% to minimize the impact of missing data.

## EORTC QLQ-C30 Analysis

- Change from Baseline

Baseline EORTC QLQ-C30 global health status/QoL scores were similar between the 2 treatment groups among participants with PD-L1 positive tumors (CPS ≥ 10 and CPS ≥ 1) and in All Participants. Over 15 weeks of follow-up, there was either no decrease or a similar decrease in the pre-specified global health status/QoL, Physical Functioning and Emotional Functioning scores observed for both treatment groups.

<!-- formula-not-decoded -->

|                                                   | Baseline                                          | Baseline                                          | Week15   | Week15         | ChangefromBaselineatWeek15   | ChangefromBaselineatWeek15      | ChangefromBaselineatWeek15   |
|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|----------|----------------|------------------------------|---------------------------------|------------------------------|
| Treatment                                         | N                                                 | Mean (SD)                                         | N        | Mean (SD)      | N                            | LS Mean (95%CI                  |                              |
| Pembrolizumab+Chemotherapy                        | 201                                               | 67.54 (21.865)                                    | 166      | 66.32 (19.318) | 216                          | -2.69 (-5.86, 0.48)             |                              |
| Placebo+ Chemotherapy                             | t6                                                | 64.54 (21.514)                                    | 70       | 66.07 (22.085) | 100                          | -0.88 (-5.41,3.64)              |                              |
| PairwiseComparison                                |                                                   |                                                   |          |                |                              | Difference in LS Means (95% CI) | p-Value                      |
| Pembrolizumab+Chemotherapyvs.Placebo+Chemotherapy | Pembrolizumab+Chemotherapyvs.Placebo+Chemotherapy | Pembrolizumab+Chemotherapyvs.Placebo+Chemotherapy |          |                |                              | -1.81 (-6.92, 3.30)             | 0.4865                       |

Based on cLDA model with thePROscores as theresponse variable,and treatment by timepoint interaction,andstratum(defined by stratificationfactors of chemotherapy on study[taxanevsgemcitabine/carboplatin]and prior treatmentwithsame class of chemotherapyin the(neo)adjuvant setting[yes vs no])as covariates.

For baseline andWeek15,N is the number of subjects in each treatment group with non-missing assessments at the specific time point;for change frombaseline,N is the number of subjects in the analysis population in each treatment group.

Two-sidedp-value.

DatabaseCutoffDate:11DEC2019

<div style=\"page-break-after: always\"></div>

Change from Baseline for EORTC QLQ-C30 Global Health Status/QoL and Functional Scales at Week15 (LS Mean Change and 95% CI) (Part 2Subjects withPD-L1 CPS≥10) (FAS Population)

<!-- image -->

Forglobalhealthstatus/qualityoflifescore and allfunctionalscales,ahigherscoredenotes better health related quality of life (HRQOL) or function. For symptoms scales/items, a higher score denotes worse symptoms.

N is the number of subjects in the analysis population in each treatment group. DatabaseCutoffDate:11DEC2019.

## · Time to Deterioration (TTD)

In participants with PD-L1 positive tumors (CPS ≥ 10), there were no differences in TTD in the EORTC QLQ-C30 global health status/QoL [median TTD 6.4 vs. 5.6 months, HR 0.99] and Physical Functioning scores [median TTD 5.6 vs. 6.2 months, HR 1.27] between the pembrolizumab + chemotherapy and placebo + chemotherapy groups. A directional difference in favor of the placebo + chemotherapy group was observed for the TTD in the Emotional Functioning score [median TTD 9.6 vs. 15.3 months, HR 1.26 [0.86, 1.84]; however, the 95% CI for the HR includes 1.

TTD analyses in participants with PD-L1 positive tumors using the cutoff of CPS ≥ 1 and in All Participants showed similar trends for global health status/QoL, Physical Functioning, and Emotional Functioning scores.

ChangefromBaseline for EORTC QLQ-C30SymptomScales/Items at Week 15 (LS Mean Change and 95% CI) (Part 2 Subjects with PD-L1 CPS ≥10) (FAS Population)

<!-- image -->

For functional scales/items, a higher score denotes better function. For symptom scales/items, a higher score denotes worse symptom.

N is the number of subjects in the analysis population in each treatment group. DatabaseCutoffDate:11DEC2019.

<div style=\"page-break-after: always\"></div>

## AnalysisofTimetoDeteriorationforEORTCQLQ-C30GlobalHealthStatus/QoL (Part 2 Subjects with PD-L1 CPS ≥10) (FAS Population)

|                                                           | Pembrolizumab + Chemotherapy (N=217)   | Placebo + Chemotherapy (N=100)   |
|-----------------------------------------------------------|----------------------------------------|----------------------------------|
| Number of Events (%)                                      | 116 (53.5)                             | 47 (47.0)                        |
| Kaplan-Meier Estimates (Months)t Median (95% CI) [Q1, Q3] | 6.4 (3.8, 9.3)                         | 5.6 (3.7, 14.3)                  |
|                                                           | [1.4, 20.5]                            | [1.4, 17.7]                      |
| vs Placebo + Chemotherapy Hazard Ratio (95% CI)t p-values | 0.99 (0.70,1.39) 0.4834                |                                  |

From product-limit (Kaplan-Meier)method for censored data.

- Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by chemotherapy on study (taxane vs.gemcitabine/carboplatin) and prior treatment with same class of chemotherapy in the (neo)adjuvant setting (yes vs. no).

One-sided p-valuebased onlog-rank test stratified by chemotherapy onstudy(taxanevs. gemcitabine/carboplatin) and prior treatment with same class of chemotherapy in the (neo)adjuvant setting (yes vs. no).

- Time todeterioration(event)isdefined astime tofirstonset of10pointsor moreworseningfrom baseline.

DatabaseCutoffDate:11DEC2019

KaplanMeier Estimate of Time toDeteriorationfor EORTC QLQ-C30 Global Health Status/QoL (Part 2 Subjects with PD-L1 CPS ≥10) (FAS Population)

<!-- image -->

## EORTC QLQ-BR23

In participants with PD-L1 positive tumors (CPS ≥ 10 and CPS ≥ 1) and in All Participants, the LS mean change from baseline to Week 15 in scores for EORTC QLQBR23 functional scales/items (Body Image, Sexual Functioning, Sexual Enjoyment and Future Perspective) and in symptom scales (Systemic Therapy Side Effects, Breast Symptoms, Arm Symptoms and Upset by Loss of Hair) were similar between the 2 treatment groups.

## Exploratory Subgroup Analyses- EU Region

The prespecified subgroups for geographic region was North America/Europe/New Zealand + Australia vs Asia vs Rest of World. Post-hoc analyses of the EU subpopulation are presented to further examine the treatment effect in this group. EU participants in the CPS ≥ 10 population were n=64 in the pembrolizumab

<div style=\"page-break-after: always\"></div>

+ c hemotherapy group vs n=28 in the placebo + chemotherapy group; the results of these exploratory analyses should be interpreted with caution.

## Demographics and Other Baseline Characteristics

For participants with tumors that express PD-L1 with CPS ≥ 10 enrolled in the EU, intervention groups were generally balanced for most baseline characteristics and prognostic factors and were generally similar to the overall population of participants with tumors that express PD-L1 with CPS ≥ 10. Some differences are noted for participants enrolled in the EU:

- More participants in the pembrolizumab + chemotherapy group received paclitaxel (14.1%) compared with the placebo + chemotherapy group (7.1%)
- Fewer  participants  in  the  pembrolizumab  +  chemotherapy  group  received  gemcitabine/carboplatin (43.8%) compared with the placebo + chemotherapy group (57.1%)
- More participants in the pembrolizumab + chemotherapy group had de novo metastatic disease (25.0% vs 17.9%) whereas more participants in the placebo + chemotherapy group had recurrent metastatic disease (68.8% vs 75.0%)
- More participants in the pembrolizumab + chemotherapy group had an ECOG of 1 (37.5%) compared with the placebo + chemotherapy group (28.6%)
- Fewer participants in the pembrolizumab + chemotherapy had an LDH level within normal limits at baseline (45.3%) compared with the placebo + chemotherapy group (60.7%)
- Fewer participants in the pembrolizumab + chemotherapy group received prior neoadjuvant or adjuvant chemotherapy (60.9%) compared with the placebo + chemotherapy group (75%).

## Efficacy Results in the EU Subgroup

Table: Summary of Efficacy Results in Participants with PD-L1 CPS ≥ 10 - EU Participants

| Endpoint                           | Pembrolizumab + Chemotherapy (N=64)   | Placebo + Chemotherapy (N=28)   |
|------------------------------------|---------------------------------------|---------------------------------|
| PFSa                               |                                       |                                 |
| Median PFS, months (95% CI)        | 5.7 (3.7, 11.0)                       | 7.4 (3.9, 11.1)                 |
| HR (95% CI)                        | 1.02 (0.60, 1.72)                     | 1.02 (0.60, 1.72)               |
| OS                                 |                                       |                                 |
| Median OS, months (95% CI)         | 15.8 (11.7, 22.8)                     | 19.3 (16.1, NR)                 |
| HR (95% CI)                        | 1.41 (0.80, 2.48)                     | 1.41 (0.80, 2.48)               |
| Objective Response                 |                                       |                                 |
| ORR % (95% CI)a                    | 40.6 (28.5, 53.6)                     | 46.4 (27.5, 66.1)               |
| ORR Difference % (95% CI)          | -5.8 (-27.4, 15.5)                    | -5.8 (-27.4, 15.5)              |
| CR, n (%)                          | 8 (12.5)                              | 3 (10.7)                        |
| PR, n (%)                          | 18 (28.1)                             | 10 (35.7)                       |
| DOR (months), median (range)a b. c | 12.6 (1.6+ to 29.6+)                  | 6.5 (2.3 to 26.3+)              |

Abbreviations: CI = confidence interval; CR = complete response, DOR = duration of response; NR = not reached; ORR = objective response rate; OS = overall survival; PD = progressive disease; PFS = progressionfree survival; PR = partial response.

- a. Response assessed by BICR per RECIST 1.1; only confirmed responses (CR or PR) are included.

b. From product-limit (Kaplan-Meier) method for censored data.

C. \"+\" indicated there is no PD by the time of last disease assessment.

Data cutoff: 11DEC2019

<div style=\"page-break-after: always\"></div>

Figure: KM Estimates of PFS and OS (Subjects with PD-L1 CPS ≥ 10 - EU Subjects)

<!-- image -->

Table: Summary of Efficacy Results in All Participants - Participants Enrolled in EU and non-EU Countries (ITT Population)

| Endpoint                         | EU Participants                      | EU Participants               | Non-EU Participants                  | Non-EU Participants            |
|----------------------------------|--------------------------------------|-------------------------------|--------------------------------------|--------------------------------|
| Endpoint                         | Pembrolizumab + Chemotherapy (N=165) | Placebo + Chemotherapy (N=94) | Pembrolizumab + Chemotherapy (N=401) | Placebo + Chemotherapy (N=187) |
| PFS a                            |                                      |                               |                                      |                                |
| Median PFS, months (95% CI) b    | 5.8 (5.1, 7.7)                       | 5.7 (5.1, 7.5)                | 7.6 (7.4, 8.0)                       | 5.6 (5.4, 7.5)                 |
| HR (95% CI) c                    | 1.01 (0.75, 1.36)                    | 1.01 (0.75, 1.36)             | 0.73 (0.60, 0.89)                    | 0.73 (0.60, 0.89)              |
| PFS rate at 6 months,% (95% CI)  | 47.0 (38.7, 54.9)                    | 47.9 (36.9, 58.0)             | 58.7 (53.5, 63.6)                    | 47.9 (40.2, 55.2)              |
| PFS rate at 9 months,% (95% CI)  | 37.1 (29.0, 45.2)                    | 36.2 (25.9, 46.5)             | 44.3 (39.0, 49.5)                    | 31.8 (24.6, 39.2)              |
| PFS rate at 12 months, %(95% CI) | 25.3 (18.0, 33.2)                    | 26.8 (17.3, 37.2)             | 31.6 (26.6, 36.6)                    | 18.2 (12.3, 25.0)              |
| OS                               |                                      |                               |                                      |                                |
| Median OS, months (95% CI) b     | 14.2 (12.9, 17.4)                    | 18.0 (14.6, 20.4)             | 18.3 (16.0, 20.4)                    | 14.7 (12.4, 16.6)              |
| HR (95% CI) c                    | 1.18 (0.87, 1.61)                    | 1.18 (0.87, 1.61)             | 0.76 (0.62, 0.93)                    | 0.76 (0.62, 0.93)              |
| OS rate at 12 months,% (95% CI)  | 62.2 (54.2, 69.2)                    | 64.9 (54.3, 73.6)             | 65.5 (60.6, 69.9)                    | 60.8 (53.4, 67.4)              |
| OS rate at 18 months,% (95% CI)  | 40.2 (32.6, 47.7)                    | 50.0 (39.5, 59.6)             | 51.0 (46.0, 55.8)                    | 37.6 (30.7, 44.6)              |
| OS rate at 24 months,% (95% CI)  | 28.9 (21.7, 36.4)                    | 33.3 (23.6, 43.2)             | 37.9 (32.9, 42.8)                    | 27.1 (20.6, 34.0)              |
| Objective Response               |                                      |                               |                                      |                                |
| ORR %(95% CI) a                  | 38.8 (31.3, 46.7)                    | 35.1 (25.5, 45.6)             | 41.9 (37.0, 46.9)                    | 36.4 (29.5, 43.7)              |
| ORR Difference% (95% CI) d       | 3.7 (-8.7, 15.5)                     | 3.7 (-8.7, 15.5)              | 5.5 (-3.0, 13.8)                     | 5.5 (-3.0, 13.8)               |

Abbreviations: BICR = blinded independent central review; CI = confidence interval; ORR = objective response rate; OS = overall survival; PFS = progression-free survival; RECIST 1.1 = Response Evaluation Criteria in Solid Tumors version 1.1.

a. Response assessed by BICR per RECIST 1.1; only confirmed responses are included.

<div style=\"page-break-after: always\"></div>

- b. From product-limit (Kaplan-Meier) method for censored data.
- c. Based on Cox regression model with Efron's method of tie handling with treatment as a covariate.
- d. Based on Miettinen &amp; Nurminen method

Data cutoff: 11DEC2019

Source: Table 1, Table 3, and Table 5 of [Annex 6] [Ref. 5.3.5.1: P355V01MK3475: Table 14.2-37] [Ref. 5.3.5.1:

P355V01MK3475: Table 14.2-66] [Ref. 5.3.5.1: P355V01MK3475: Table 14.2-111]

## Efficacy by chemotherapy backbone

A  summary  of  the  most  notable  differences  in  baseline  characteristics  of  subjects  treated  with  each chemotherapy backbone is presented in the table below:

## Table: differences in baseline characteristics by backbone chemotherapy

|                                                       | Treatment with Carboplatin/Gemcitabine   | Treatment with Nab-Paclitaxel   | Treatment with Paclitaxel   |
|-------------------------------------------------------|------------------------------------------|---------------------------------|-----------------------------|
| De novo metastatic disease                            | 22%                                      | 35.6%                           | 46.9%                       |
| Prior (neo)adjuvant chemotherapy                      | 72.8%                                    | 58.1%                           | 40.7%                       |
| Prior Treatment with Same Class Chemotherapy (Actual) | 6.3%                                     | 45.3%                           | 26.5%                       |
| Disease free interval < 12 months                     | 29.6%                                    | 10.1%                           | 10.6%                       |
| LDH ≥2 x ULN                                          | 18.1%                                    | 14.2%                           | 15.0%                       |
| No. of metastatic organ sites ≥3                      | 46.4%                                    | 37.1%                           | 44.2%                       |
| Median target lesion size (central)                   | 53 mm                                    | 57 mm                           | 61.5 mm                     |
| Median age (years)                                    | 50                                       | 55                              | 59                          |

Summary table prepared by the assessment team

The subgroups by backbone chemotherapy were not individually powered to demonstrate treatment effect. The results of these exploratory analyses should be interpreted with caution.

Efficacy in the Placebo + Carboplatin/Gemcitabine Group

Figures: Kaplan-Meier Estimates of PFS Based on BICR Assessment per RECIST 1.1 (Part 2 Subjects with PD-L1 CPS ≥10 by Actual Chemotherapy Treatment (ITT Population)

<div style=\"page-break-after: always\"></div>

<!-- image -->

Figures: Kaplan-Meier Estimates of Overall Survival (Part 2 Subjects with PD-L1 CPS ≥ 10 by Actual Chemotherapy Treatment (ITT Population)

<!-- image -->

Table: Summary of Efficacy Results for Carboplatin/Gemcitabine as a First-line Treatment for Metastatic TNBC

| Treatment (Study)                                | Median PFS, Months   | Median OS, Months   | ORR,%   |
|--------------------------------------------------|----------------------|---------------------|---------|
| Placebo + carboplatin/ gemcitabine (KEYNOTE-355) | 7.2                  | 16.2                | 44.6    |
| Carboplatin/gemcitabine (tnAcity)                | 6.0                  | 12.6                | 44.0    |
| Carboplatin/gemcitabine (BSI- 201) a             | 4.6                  | 13.9                | NR      |
| Carboplatin/gemcitabine (Phase 2 study)          |                      |                     |         |
| HER2- (no taxane) b                              | NR                   | 21.7                | 27.0    |

<div style=\"page-break-after: always\"></div>

| HER2- (prior taxane) c   | NR   | 11.0   | 30.6   |
|--------------------------|------|--------|--------|

Abbreviations: DOR = duration of response, NR = not reported; ORR = objective response rate; OS = overall survival; PFS = progression-free survival.

- a. Results from the subgroup analysis of patients receiving first-line treatment.
- b. Patients had not received prior treatment for metastatic breast cancer but could have received prior treatment (docetaxel or paclitaxel ≥2 years prior) in the adjuvant setting.
- c. Patients could had received &lt;2 prior treatment for metastatic breast cancer and received prior treatment (docetaxel or paclitaxel &lt;2 years prior) in the adjuvant setting.

## Table: Summary of Efficacy Results for Paclitaxel as a First-line Treatment for Metastatic TNBC

| Treatment (Study)                  |   Median PFS, Months |   Median OS, Months |   ORR,% |
|------------------------------------|----------------------|---------------------|---------|
| Placebo + paclitaxel (KEYNOTE-355) |                  3.6 |                 8.5 |    27.3 |
| Paclitaxel alone (Phase 2 study )  |                  3.5 |                13.1 |    32   |
| Placebo + paclitaxel (LOTUS )      |                  4.9 |                18.4 |    20   |
| Placebo + Paclitaxel (PAKT )       |                  4.2 |                12.6 |    28.8 |

Abbreviations: DOR = duration of response, ORR = objective response rate; OS = overall survival; PFS = progression-free survival.

## Efficacy by prior (neo) adjuvant therapy

## Table: subgroup analysis of PFS (subjects with PDL1 CPS≥10)

| Prior adjuvant or neoadjuvant chemotherapy     | Prior adjuvant or neoadjuvant chemotherapy     | Prior adjuvant or neoadjuvant chemotherapy     | Prior adjuvant or neoadjuvant chemotherapy     | Prior adjuvant or neoadjuvant chemotherapy     | Prior adjuvant or neoadjuvant chemotherapy     | Prior adjuvant or neoadjuvant chemotherapy     | Prior adjuvant or neoadjuvant chemotherapy     |
|------------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|
| Yes                                            | 131                                            | 84                                             | (64.1)                                         | 62                                             | 46                                             | (74.2)                                         | 0.78 (0.55, 1.12)                              |
| No                                             | 89                                             | 52                                             | (58.4)                                         | 41                                             | 33                                             | (80.5)                                         | 0.47 (0.30, 0.74)                              |
| Prior adjuvant or neoadjuvant taxane treatment | Prior adjuvant or neoadjuvant taxane treatment | Prior adjuvant or neoadjuvant taxane treatment | Prior adjuvant or neoadjuvant taxane treatment | Prior adjuvant or neoadjuvant taxane treatment | Prior adjuvant or neoadjuvant taxane treatment | Prior adjuvant or neoadjuvant taxane treatment | Prior adjuvant or neoadjuvant taxane treatment |
| Yes                                            | 107                                            | 72                                             | (67.3)                                         | 50                                             | 39                                             | (78.0)                                         | 0.76 (0.51, 1.12)                              |
| No                                             | 113                                            | 64                                             | (56.6)                                         | 53                                             | 40                                             | (75.5)                                         | 0.56 (0.38, 0.84)                              |
| Prior adjuvant orneoadjuvantplatinun treatment | Prior adjuvant orneoadjuvantplatinun treatment | Prior adjuvant orneoadjuvantplatinun treatment | Prior adjuvant orneoadjuvantplatinun treatment | Prior adjuvant orneoadjuvantplatinun treatment | Prior adjuvant orneoadjuvantplatinun treatment | Prior adjuvant orneoadjuvantplatinun treatment | Prior adjuvant orneoadjuvantplatinun treatment |
| No                                             | 207                                            | 128                                            | (61.8)                                         | 97                                             | 75                                             | (77.3)                                         | 0.65 (0.49, 0.86)                              |

## Table: subgroup analysis of OS (subjects with PD- L1 CPS≥10)

<div style=\"page-break-after: always\"></div>

| Prior adjuvant or neoadjuvant cheimotherapy        | Prior adjuvant or neoadjuvant cheimotherapy        | Prior adjuvant or neoadjuvant cheimotherapy        | Prior adjuvant or neoadjuvant cheimotherapy        | Prior adjuvant or neoadjuvant cheimotherapy        | Prior adjuvant or neoadjuvant cheimotherapy        | Prior adjuvant or neoadjuvant cheimotherapy        | Prior adjuvant or neoadjuvant cheimotherapy        |
|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|
| Yes                                                | 131                                                | 78                                                 | (59.5)                                             | 62                                                 | 39                                                 | (62.9)                                             | 0.90 (0.61, 1.32)                                  |
| No                                                 | 89                                                 | 43                                                 | (48.3)                                             | 41                                                 | 32                                                 | (78.0)                                             | 0.46 (0.29, 0.73)                                  |
| Prior adjuvant or neoadjuvant taxane treatment     | Prior adjuvant or neoadjuvant taxane treatment     | Prior adjuvant or neoadjuvant taxane treatment     | Prior adjuvant or neoadjuvant taxane treatment     | Prior adjuvant or neoadjuvant taxane treatment     | Prior adjuvant or neoadjuvant taxane treatment     | Prior adjuvant or neoadjuvant taxane treatment     | Prior adjuvant or neoadjuvant taxane treatment     |
| Yes                                                | 107                                                | 69                                                 | (64.5)                                             | 50                                                 | 33                                                 | (66.0)                                             | 0.91 (0.60, 1.38)                                  |
| No                                                 | 113                                                | 52                                                 | (46.0)                                             | 53                                                 | 38                                                 | (71.7)                                             | 0.53 (0.35, 0.80)                                  |
| Prior adjuvant or neoadjuvant platinuin treatiment | Prior adjuvant or neoadjuvant platinuin treatiment | Prior adjuvant or neoadjuvant platinuin treatiment | Prior adjuvant or neoadjuvant platinuin treatiment | Prior adjuvant or neoadjuvant platinuin treatiment | Prior adjuvant or neoadjuvant platinuin treatiment | Prior adjuvant or neoadjuvant platinuin treatiment | Prior adjuvant or neoadjuvant platinuin treatiment |
| No                                                 | 207                                                | 112                                                | (54.1)                                             | 97                                                 | 67                                                 | (69.1)                                             | 0.68 (0.50, 0.92)                                  |

## Table: Subgroup Analysis of Objective Response Based on BICR Assessment per RECIST 1.1 (subjects with PD-L1 CPS ≥ 10)

| Prior adjuvant or neoadjuvant chemotherapy       | Prior adjuvant or neoadjuvant chemotherapy       | Prior adjuvant or neoadjuvant chemotherapy       | Prior adjuvant or neoadjuvant chemotherapy       | Prior adjuvant or neoadjuvant chemotherapy       | Prior adjuvant or neoadjuvant chemotherapy       | Prior adjuvant or neoadjuvant chemotherapy       | Prior adjuvant or neoadjuvant chemotherapy       | Prior adjuvant or neoadjuvant chemotherapy       | Prior adjuvant or neoadjuvant chemotherapy       | Prior adjuvant or neoadjuvant chemotherapy       |
|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|
| Yes                                              | 131                                              | 62                                               | (47.3)                                           | (38.5, 56.2)                                     | 62                                               | 27                                               | (43.5)                                           | (31.0, 56.7)                                     | (3.8)                                            | (-11.3, 18.4)                                    |
| No                                               | 89                                               | 55                                               | (61.8)                                           | (50.9, 71.9)                                     | 41                                               | 14                                               | (34.1)                                           | (20.1, 50.6)                                     | (27.7)                                           | (9.2,44.0)                                       |
| Prior adjuvant or neoadjuvant taxane treatment   | Prior adjuvant or neoadjuvant taxane treatment   | Prior adjuvant or neoadjuvant taxane treatment   | Prior adjuvant or neoadjuvant taxane treatment   | Prior adjuvant or neoadjuvant taxane treatment   | Prior adjuvant or neoadjuvant taxane treatment   | Prior adjuvant or neoadjuvant taxane treatment   | Prior adjuvant or neoadjuvant taxane treatment   | Prior adjuvant or neoadjuvant taxane treatment   | Prior adjuvant or neoadjuvant taxane treatment   | Prior adjuvant or neoadjuvant taxane treatment   |
| Yes                                              | 107                                              | 47                                               | (43.9)                                           | (34.3, 53.9)                                     | 50                                               | 21                                               | (42.0)                                           | (28.2, 56.8)                                     | (1.9)                                            | (-14.8, 18.0)                                    |
| No                                               | 113                                              | 70                                               | (61.9)                                           | (52.3, 70.9)                                     | 53                                               | 20                                               | (37.7)                                           | (24.8, 52.1)                                     | (24.2)                                           | (7.9, 39.1)                                      |
| Prior adjuvant or neoadjuvant platinum treatment | Prior adjuvant or neoadjuvant platinum treatment | Prior adjuvant or neoadjuvant platinum treatment | Prior adjuvant or neoadjuvant platinum treatment | Prior adjuvant or neoadjuvant platinum treatment | Prior adjuvant or neoadjuvant platinum treatment | Prior adjuvant or neoadjuvant platinum treatment | Prior adjuvant or neoadjuvant platinum treatment | Prior adjuvant or neoadjuvant platinum treatment | Prior adjuvant or neoadjuvant platinum treatment | Prior adjuvant or neoadjuvant platinum treatment |
| No                                               |                                                  |                                                  | 207110 (53.1)                                    | (46.1, 60.1)                                     | 97                                               | 39                                               | (40.2)                                           | (30.4, 50.7)                                     | (12.9)                                           | (0.9,24.5)                                       |

## PFS by Investigator and PFS sensitivity analyses

Table: PFS results in all populations (table prepared by assessment team)

| PFS primary analysis by BICR per RECIST 1.1 HR (95%CI)   | PFS by Investigator per RECIST 1.1 HR (95%CI)   | PFS Sensitivity analysis 1 * HR (95%CI)   | PFS Sensitivity analysis 2 ** HR (95%CI)   | PFS Sensitivity analysis with actual stratum HR (95%CI)   |
|----------------------------------------------------------|-------------------------------------------------|-------------------------------------------|--------------------------------------------|-----------------------------------------------------------|
| All subjects                                             | All subjects                                    | All subjects                              | All subjects                               | All subjects                                              |
| 0.82 (0.69, 0.97)                                        | 0.83 (0.71, 0.97)                               | 0.84 (0.71, 0.98)                         | 0.90 (0.77, 1.04)                          | 0.81 (0.69, 0.96)                                         |
| PD- L1 CPS≥1                                             | PD- L1 CPS≥1                                    | PD- L1 CPS≥1                              | PD- L1 CPS≥1                               | PD- L1 CPS≥1                                              |
| 0.74 (0.61, 0.90)                                        | 0.79 (0.66, 0.95)                               | 0.77 (0.64, 0.92)                         | 0.84 (0.71, 1.00)                          | 0.73 (0.60, 0.89)                                         |
| PD- L1 CPS≥10                                            | PD- L1 CPS≥10                                   | PD- L1 CPS≥10                             | PD- L1 CPS≥10                              | PD- L1 CPS≥10                                             |
| 0.65 (0.49, 0.86)                                        | 0.71 (0.54, 0.93)                               | 0.69 (0.53, 0.90)                         | 0.78 (0.61, 1.00)                          | 0.64 (0.49, 0.85)                                         |

* Sensitivity analysis 1: PD or death after ≥ 2 consecutive missed disease assessments or after new anticancer therapy is an event.

** Sensitivity analysis 2: treatment discontinuation if no PD, no death and no new anticancer treatment is an event; if no PD, no death, start of new anticancer treatment is an event; PD or death after ≥ 2 consecutive missed disease assessments or after new anticancer therapy is an event.

## EFFICACY RESULTS - FINAL ANALISIS (data cut-off 15-JUN2021)

<div style=\"page-break-after: always\"></div>

The MAH presented during the procedure the Final Analysis (FA) for overall survival with a data cutoff date of 15-JUN-2021, with a median follow-up of 16.7 months (range 0.2, 53.1) in the ITT population (n=847) and 20.2 months (range 0.3, 53.1) in the CPS≥10 population (n=323).

The testing of the primary hypotheses of PFS was completed at interim analysis 2 (FA of PFS) and was met at the IA2; PFS was not tested at the FA, although updated descriptive PFS analyses have been also provided. The key secondary hypotheses of ORR were only tested at IA1.

Per protocol, this eventdriven FA was triggered by ~240 OS events in participants with CPS≥10, ~482 OS events in parti cipants with CPS≥1, and ~664 OS events in All Participants.

The overall type I error over the primary endpoints PFS and OS and the secondary endpoint ORR was strongly controlled at 2.5% (one-sided), with initially 0.5% allocated to the PFS hypothesis, 1.8% to the OS hypothesis, and 0.2% to the ORR hypothesis.

At the FA, the primary endpoint of OS in participants with CPS≥10 was met. OS in the CPS≥1 population was not met at the FA, while OS in the ITT population was not statistically tested per multiplicity strategy.

Table: Outcomes of the Primary Endpoints of OS at FA

| Endpoint                      | Numberof Events/N   | HR (95% CI)       | p-value Boundary   |   p-value | Success Criterionfor OS Hypothesis   |
|-------------------------------|---------------------|-------------------|--------------------|-----------|--------------------------------------|
| OSinParticipantswith CPS ≥10  | 239/323             | 0.73 (0.55, 0.95) | 0.0113             |    0.0093 | Met                                  |
| OS inParticipants with CPS ≥1 | 513/636             | 0.86 (0.72, 1.04) | 0.0172             |    0.0563 | Not met                              |
| OSinAllParticipants           | 698/847             | 0.89 (0.76,1.05)  | N/A                |    0.0797 | Not tested                           |

Abbreviations:CPS=combined positive score;FA=final analysis;HR=hazard ratio; OS = overall survival.

DatabaseCutoffDate:15JUN2021.

Table: participant disposition - subjects with PS- L1 CPS≥10 (data cut - off 15 Jun 2021)

<div style=\"page-break-after: always\"></div>

|                                                                | Pembrolizumab + Chemotherapy                                   | Pembrolizumab + Chemotherapy                                   | Placebo + Chemotherapy                                         | Placebo + Chemotherapy                                         | Total                                                          | Total                                                          |
|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|
|                                                                | n                                                              | (%)                                                            | n                                                              | (%)                                                            | 1n                                                             | (%)                                                            |
| Subjects in population                                         | 220                                                            |                                                                | 103                                                            |                                                                | 323                                                            |                                                                |
| StatusforStudyMedicationinTrialSegment of FirstCourseTreatment | StatusforStudyMedicationinTrialSegment of FirstCourseTreatment | StatusforStudyMedicationinTrialSegment of FirstCourseTreatment | StatusforStudyMedicationinTrialSegment of FirstCourseTreatment | StatusforStudyMedicationinTrialSegment of FirstCourseTreatment | StatusforStudyMedicationinTrialSegment of FirstCourseTreatment | StatusforStudyMedicationinTrialSegment of FirstCourseTreatment |
| Started                                                        | 219                                                            |                                                                | 103                                                            |                                                                | 322                                                            |                                                                |
| Completed                                                      | 27                                                             | (12.3)                                                         | 5                                                              | (4.9)                                                          | 32                                                             | (9.9)                                                          |
| Discontinued                                                   | 189                                                            | (86.3)                                                         | 95                                                             | (92.2)                                                         | 284                                                            | (88.2)                                                         |
| Adverse Event                                                  | 21                                                             | (9.6)                                                          | 5                                                              | (4.9)                                                          | 26                                                             | (8.1)                                                          |
| Clinical Progression                                           | 17                                                             | (7.8)                                                          |                                                                | (10.7)                                                         | 28                                                             | (8.7)                                                          |
| Complete Response                                              | 3                                                              | (1.4)                                                          | 1                                                              | (1.0)                                                          | 4                                                              | (1.2)                                                          |
| Physician Decision                                             | 7                                                              | (3.2)                                                          | 3                                                              | (2.9)                                                          | 10                                                             | (3.1)                                                          |
| Progressive Disease                                            | 127                                                            | (58.0)                                                         | 71                                                             | (68.9)                                                         | 198                                                            | (61.5)                                                         |
| Withdrawal BySubject                                           | 14                                                             | (6.4)                                                          | 4                                                              | (3.9)                                                          | 18                                                             | (5.6)                                                          |
| Status Not Recorded                                            | 3                                                              | (1.4)                                                          | 3                                                              | (2.9)                                                          | 6                                                              | (6: 1)                                                         |
| Status forTrial                                                | Status forTrial                                                | Status forTrial                                                | Status forTrial                                                | Status forTrial                                                | Status forTrial                                                | Status forTrial                                                |
| Discontinued                                                   | 160                                                            | (72.7)                                                         | 84                                                             | (81.6)                                                         | 244                                                            | (75.5)                                                         |
| Death                                                          | 151                                                            | (68.6)                                                         | 82                                                             | (79.6)                                                         | 233                                                            | (72.1)                                                         |
| Withdrawal By Subject                                          | 9                                                              | (4.1)                                                          | 2                                                              | (1.9)                                                          | 11                                                             | (3.4)                                                          |
| Status Not Recorded                                            | 60                                                             | (27.3)                                                         | 19                                                             | (18.4)                                                         | 79                                                             | (24.5)                                                         |

Clinical Progression and Progressive Disease are based on Investigator's assessment and may be different from the data used in the primary analysis.

Progressive Disease refers to disease progression based on RECIST 1.1 and does not include Clinical Progression. Studymedicationdiscontinuationreferstodiscontinuationof allstudymedications.

Status Not Recorded: Subjects without a completed study medication discontinuation form or without a completed study dispositionform.

DatabaseCutoffDate:15JUN2021

## Overall survival (final analysis)

Pembrolizumab + chemotherapy was statistically superior to chemotherapy alone with respect to OS in participants with PDL1 positive tumors (CPS ≥10). The observed p -value of p=0.0093 successfully crossed the prespecified efficacy boundary at the FA (the multiplicity adjusted, one-sided nominal alpha level was 0.0113); the OS HR was 0.73 (95% CI: 0.55, 0.95), with longer median OS in the pembrolizumab + chemotherapy group compared with the placebo + chemotherapy group (23.0 vs 16.1 months), and OS rates by KM estimation at month 18 and 24 favouring the experimental arm.

Table: Analysis of Overall Survival (Part 2 Subjects with PDL1 CPS ≥10) (data cut -off 15 Jun 2021)

<div style=\"page-break-after: always\"></div>

|                                  | Pembrolizumab + Chemotherapy (N=220)   | Placebo + Chemotherapy (N=103)   |
|----------------------------------|----------------------------------------|----------------------------------|
| Number of Events (%)             | 155 (70.5)                             | 84 (81.6)                        |
| Kaplan-Meier Estimates (Months)t |                                        |                                  |
| Median (95% CI) [Q1, Q3]         | 23.0 (19.0, 26.3) [10.3, NR]           | 16.1 (12.6, 18.8) [8.6, 30.3]    |
| Person-Months                    | 5430.4                                 | 2091.1                           |
| Event Rate/100Person-Months      | 2.9                                    | 4.0                              |
| vs Placebo + Chemotherapy        |                                        |                                  |
| Hazard Ratio (95% CI)t           | 0.73 (0.55, 0.95)                      |                                  |
| OS Rate at Month 6 (%) (95% CI)  | 88.6 (83.5, 92.1)                      | 88.3 (80.4, 93.2)                |
| OS Rate at Month 12 (%) (95% CI) | 70.7 (64.1, 76.2)                      | 64.1 (54.0, 72.5)                |
| OS Rate at Month 18 (%) (95% CI) | 58.3 (51.4, 64.5)                      | 44.7 (34.9, 53.9)                |
| OS Rate at Month 24 (%) (95% CI) | 48.2 (41.4, 54.6)                      | 34.0 (25.0, 43.1)                |

t From product-limit (Kaplan-Meier) method for censored data.

+ Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by chemotherapy on study (taxane vs gemcitabine/carboplatin) and prior treatment with same class of chemotherapy in the (neo)adjuvant setting (yes vs no).

One-sided p-value based on log-rank test stratified by chemotherapy on study (taxane vs gemcitabine/carboplatin) and prior treatment with same class of chemotherapy in the (neo)adjuvant setting (yes vs no).

NR = Not reached.

Database Cutoff Date: 15JUN2021

Figure: Kaplan-Meier Estimates of Overall Survival (PDL1 CPS ≥10) (data c utoff 15 Jun 2021)

Overall Survival(%)

<!-- image -->

## Numberofsubjectsatrisk

Pembrolizumab + 2 0 Chemotherapy Placebo + 1039891776655463935302522221712862 0 Chemotherapy DatabseCutoffDate:15JUN2021

## Figure: Forest Plot of Overall Survival Hazard Ratio by Subgroup Factors (PDL1 CPS ≥10) (data cutoff 15 Jun 2021)

Time in Months

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                                                                                                                                                                                                                            | #Event/N                                         |                         | Median Overall Survival(mo)   |                     | HR (95% CI)                      | HR                  | 95%CI                                  | 95%CI                                  |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------|-------------------------|-------------------------------|---------------------|----------------------------------|---------------------|----------------------------------------|----------------------------------------|
|                                                                                                                                                                                                                            | 239/323                                          |                         | Pembro+Chemo 23.0             | Pbo+Chemo 16.1      |                                  | 0.73                |                                        |                                        |
| Overall Age (years)                                                                                                                                                                                                        | 193/257                                          | 21.8                    |                               | 16.8                |                                  |                     | (0.58,1.05)                            | (0.58,1.05)                            |
| <65yeers 265years                                                                                                                                                                                                          | 46/66                                            |                         | 28.3                          | 12.6                |                                  | 0.78 0.51           | (0.28,0.92)                            | (0.28,0.92)                            |
| Ethniaity Hispanic or Latino                                                                                                                                                                                               | 50/58                                            |                         | 14.7                          | 22.0                |                                  | 1.20                | (0.67, 2.15)                           | (0.67, 2.15)                           |
| Not Hispanic or Latino                                                                                                                                                                                                     | 178/250                                          | 25.7                    |                               | 15.2                |                                  | 0.60                | (0.44,0.81)                            | (0.44,0.81)                            |
| Geographic region Europe/NorthAmerica/Australia                                                                                                                                                                            | 154/212                                          |                         | 23.5                          | 15.2                |                                  | 0.72                | (0.52, 1.00)                           | (0.52, 1.00)                           |
| Asia                                                                                                                                                                                                                       | 40/56                                            |                         | 26.7                          | 17.4                |                                  | 0.44                | (0.23,0.84)                            | (0.23,0.84)                            |
| Rest of the World                                                                                                                                                                                                          | 45/55                                            |                         | 18.0                          | 22.0                |                                  | 1.07                | (0.57, 1.98)                           | (0.57, 1.98)                           |
| Chemotherapy on study(IVRS)                                                                                                                                                                                                |                                                  |                         |                               |                     |                                  |                     |                                        |                                        |
| Nab-Paditaxel Paditaxe                                                                                                                                                                                                     | 68/99 32/44                                      |                         | 29.8 28.6                     | 18.4 8.5            |                                  | 0.63 0.34           | (0.39,1.03) (0.16, 0.72)               | (0.39,1.03) (0.16, 0.72)               |
| Gemcitabine/Carboplatin                                                                                                                                                                                                    | 139/180                                          |                         | 19.1                          | 16.2                |                                  | 0.88                | (0.61, 1.25)                           | (0.61, 1.25)                           |
| Chemotherapyon study(Actual) Nab-Paditaxel                                                                                                                                                                                 | 66/97                                            |                         | 29.8                          | 18.4                |                                  | 0.63                | (0.39, 1.04)                           | (0.39, 1.04)                           |
| Paditaxe                                                                                                                                                                                                                   | 32/44                                            |                         |                               | 8.5 16.2            |                                  | 0.34                | (0.16, 0.72)                           | (0.16, 0.72)                           |
| Gemcitabine/Carboplatin Chemotherapyonstudy(taxanevs. gemaitabine/carboplatin)(IVRS)                                                                                                                                       | 140/181                                          |                         | 28.6 19.2                     |                     |                                  | 0.88                | (0.61, 1.25)                           | (0.61, 1.25)                           |
| Taxane Gemcitabine/Carboplatin                                                                                                                                                                                             | 100/143 139/180                                  |                         | 29.7 19.1                     | 16.1 16.2           |                                  | 0.54 0.88           | (0.36,0.82) (0.61, 1.25)               | (0.36,0.82) (0.61, 1.25)               |
|                                                                                                                                                                                                                            | 98/141                                           |                         |                               |                     |                                  |                     |                                        |                                        |
| gemdtabine/carboplatin)(Actual) Taxane                                                                                                                                                                                     |                                                  |                         | 29.7                          | 16.1 16.2           |                                  | 0.54 0.88           | (0.36,0.81)                            | (0.36,0.81)                            |
| Gemcitabine/Carboplatin                                                                                                                                                                                                    |                                                  |                         | 19.2                          |                     |                                  |                     | (0.61, 1.25)                           | (0.61, 1.25)                           |
|                                                                                                                                                                                                                            | 140/181                                          |                         |                               |                     |                                  |                     |                                        |                                        |
|                                                                                                                                                                                                                            |                                                  |                         |                               |                     | 1 10                             |                     |                                        |                                        |
| Prior treatmentwithsamedassofchemotherapy in the (neo)adjuvant setting (IVRS)                                                                                                                                              | Yes No Yes No                                    | 192/258 43/61 195/261   | 22.8 20.3 28.3                | 14.9 16.9 14.8 16.9 | 0.1 Pembro+ChemoFavorPbo+Chemo T | 0.60 0.74 0.65 0.73 | (0.61, 1.22) (0.34, 0.80) (0.60, 1.27) | (0.61, 1.22) (0.34, 0.80) (0.60, 1.27) |
| Prior treatment with samedass of chemotherapy in the (neo)adjuvant setting (Actual) Prior adjuvant or neoadjuvant chemotherapy Prior adjuvant or neoadjuvant taxane treatment Prioradjuvantorneoadjuvantplatinum treatment | Yes No Yes No                                    | 144/193 123/157 116/166 | 17.7 29.0                     | 17.1 13.0 15.8 16.1 | TH                               | 0.86 0.53 0.87      | (0.41, 0.87)                           | (0.41, 0.87)                           |
|                                                                                                                                                                                                                            |                                                  |                         |                               |                     |                                  | 0.59                |                                        |                                        |
|                                                                                                                                                                                                                            | No                                               | 225/304                 | 23.0                          | 16.4                |                                  | 0.69                | (0.52,0.91)                            | (0.52,0.91)                            |
|                                                                                                                                                                                                                            |                                                  | 78/108 161/215          | 23.3 22.8                     | 16.0 16.1           | T                                | 0.87 0.64           | (0.54, 1.41) (0.47,0.89)               | (0.54, 1.41) (0.47,0.89)               |
| Pre-menopausal Post-menopausal                                                                                                                                                                                             | Menopausal status ECOG                           |                         |                               |                     |                                  |                     |                                        |                                        |
|                                                                                                                                                                                                                            | 0 1                                              | 133/196 106/127 174/233 | 26.4 17.7                     | 19.8 10.6           | T                                | 0.70 0.70           | (0.49, 1.00) (0.47, 1.05)              | (0.49, 1.00) (0.47, 1.05)              |
|                                                                                                                                                                                                                            | HER2 status                                      | 65/90                   | 21.8 27.5                     |                     | T                                | 0.78 0.54           | (0.57, 1.07) (0.32,0.92)               | (0.57, 1.07) (0.32,0.92)               |
|                                                                                                                                                                                                                            |                                                  |                         |                               | 15.2                |                                  |                     |                                        |                                        |
|                                                                                                                                                                                                                            | 0-1+ by IHC 2+ by IHC Disease free interval(DFI) | 76/104                  | 26.4                          | 18.6                |                                  | 0.54                |                                        |                                        |
| <12months ≥12months                                                                                                                                                                                                        | denovometastasis                                 |                         |                               | 12.5                | + 0.1 1 10                       |                     | (0.34,0.86)                            | (0.34,0.86)                            |
|                                                                                                                                                                                                                            | 50/65                                            | 17.1 24.9               |                               | 19.7 17.1 18.8      |                                  | 1.44 0.65           | (0.45, 0.96) (0.43, 0.91)              | (0.45, 0.96) (0.43, 0.91)              |
| > ≥3 Visoeral disease Yes                                                                                                                                                                                                  | 112/153 117/184                                  |                         | 32.1 13.2                     | 10.5                | T1 T                             | 0.75                | (0.51, 1.10)                           | (0.51, 1.10)                           |
|                                                                                                                                                                                                                            | 121/138 227/300                                  |                         |                               | 15.0                | 王I                               | 0.63                | (0.48, 0.83)                           | (0.48, 0.83)                           |
| Basellne lactate dehydrogenase (L DH) <2× ULN ≥2 × ULN                                                                                                                                                                     | 196/276                                          |                         |                               |                     |                                  | 1.22                | (0.50,0.91) (0.59, 2.53)               | (0.50,0.91) (0.59, 2.53)               |
|                                                                                                                                                                                                                            |                                                  |                         | 22.8                          |                     |                                  |                     |                                        |                                        |
|                                                                                                                                                                                                                            | 34/37                                            |                         | 25.9                          | 17.6                |                                  | 0.68                |                                        |                                        |
|                                                                                                                                                                                                                            |                                                  |                         | 8.3                           | 10.3                |                                  |                     |                                        |                                        |
|                                                                                                                                                                                                                            |                                                  |                         |                               |                     | 1                                |                     |                                        |                                        |
|                                                                                                                                                                                                                            |                                                  |                         |                               |                     | Pembro+ChemoFavorPbo +Chemo      |                     |                                        |                                        |
|                                                                                                                                                                                                                            |                                                  |                         |                               | 0.1                 |                                  |                     |                                        |                                        |
|                                                                                                                                                                                                                            |                                                  |                         |                               |                     | 10                               |                     |                                        |                                        |
|                                                                                                                                                                                                                            |                                                  | 95/130                  | 23.5                          |                     |                                  |                     |                                        |                                        |
|                                                                                                                                                                                                                            |                                                  | 47/65                   |                               |                     |                                  |                     |                                        |                                        |
|                                                                                                                                                                                                                            |                                                  |                         |                               |                     |                                  | 0.63                |                                        |                                        |
|                                                                                                                                                                                                                            |                                                  |                         | 22.8 23.5                     |                     |                                  |                     |                                        |                                        |
| No.of metastatic organ sites                                                                                                                                                                                               |                                                  |                         |                               |                     |                                  |                     |                                        |                                        |

Analysis (HR and 95% CI) in the overall population is based on the stratified Cox regression model with Efron's method of tie handling stratified by chemotherapy on study (taxane vs gemcitabine/carboplatin) and prior treatment with same class of chemotherapy in the (neo)adjuvant setting (yes vs no); analysis in the subgroups is based on the unstratified Cox model. If any level of a subgroup variable has fewer than 30 subjects, subgroup analysis is not performed in that level of the subgroup variable. Database Cutoff Date: 15JUN2021.

<div style=\"page-break-after: always\"></div>

There was a directional improvement in the OS HR that favored the pembrolizumab + chemotherapy group in participants with PDL1 CPS≥1; however, the observed p -value of p=0.0563 did not cross the prespecified efficacy boundary at FA (the multiplicity adjusted, one-sided nominal alpha level was 0.0172). OS HR was 0.86 (95% CI: 0.72, 1.04) in CPS≥1.

Figure: Kaplan-Meier Estimates of Overall Survival (PDL1 CPS ≥1) (data cutoff 15 Jun 2021)

<!-- image -->

The primary hypothesis pertaining to OS in All Participants was not formally tested as per multiplicity strategy because the success criterion for the primary hypothesis of OS in participants CPS ≥1 was not met. The OS HR in all participants was 0.89 (95% CI: 0.76, 1.05).

Figure: Kaplan-Meier Estimates of Overall Survival (All Subjects) (data cutoff 15 Jun 2021)

<div style=\"page-break-after: always\"></div>

<!-- image -->

## Progression free survival (final analysis)

The analyses performed at IA2 were the final prespecified analyses for PFS. Updated data for PFS at the FA, with nominal p-values, are provided herein.

## Table: Analysis of Progression-Free Survival Based on BICR Assessment per RECIST 1.1 (CPS ≥10) (data cut -off 15 Jun 2021)

|                                   | Pembrolizumab + Chemotherapy (N=220)   | Placebo + Chemotherapy (N=103)   |
|-----------------------------------|----------------------------------------|----------------------------------|
| Number of Events (%)              | 144 (65.5)                             | 81 (78.6)                        |
| Kaplan-Meier Estimates (Months)t  |                                        |                                  |
| Median (95% CI)                   | 9.7 (7.6, 11.3)                        | 5.6 (5.3, 7.5)                   |
| [Q1, Q3]                          | [3.9,27.8]                             | [3.6, 11.8]                      |
| Person-Months                     | 2714.5                                 | 940.6                            |
| Event Rate/100 Person-Months      | 5.3                                    | 8.6                              |
| vs Placebo + Chemotherapy         |                                        |                                  |
| Hazard Ratio (95% CI)t p-values   | 0.66 (0.50, 0.88) 0.0018               |                                  |
| PFS Rate at Month 3 (%) (95% CI)  | 81.8 (76.0, 86.4)                      | 80.2 (71.0, 86.8)                |
| PFS Rate at Month 6 (%) (95% CI)  | 65.0 (58.1, 71.2)                      | 46.9 (36.5, 56.6)                |
| PFS Rate at Month 9 (%) (95% CI)  | 52.5 (45.2,59.2)                       | 36.6 (26.9, 46.4)                |
| PFS Rate at Month 12 (%) (95% CI) | 39.1 (32.0, 46.1)                      | 23.0 (14.7, 32.3)                |

From product-limit (Kaplan-Meier)method for censored data.

Based on Coxregression model with Efron's method oftie handlingwith treatment as a covariate stratified by chemotherapy on study (taxane vs gemcitabine/carboplatin) and prior treatment with same class of chemotherapy in the (neo)adjuvant setting (yes vs no).

One-sided p-value based on log-rank test stratified by chemotherapy on study (taxane vs gemcitabine/carboplatin) and prior treatment with same class of chemotherapy in the (neo)adjuvant setting (yes vs no).

BICR=Blinded Independent Central Review.

DatabaseCutoffDate:15JUN2021

Figure:  Kaplan-Meier  Estimates  of  Progression-Free  Survival  Based on  BICR  Assessment  per RECIST 1.1 (CPS ≥10) (data cut -off 15 Jun 2021)

<div style=\"page-break-after: always\"></div>

<!-- image -->

## Objective response rate (final analysis)

The endpoints of ORR were only tested at IA1 and not formally tested at the FA. Updated data for ORR at the FA, with nominal p-values, are provided herein.

Table: Analysis of Objective Response Based on BICR Assessment per RECIST 1.1 (CPS ≥ 10) (data cutoff 15 Jun 2021)

|                            |     |                              |                                 | Difference in%vs.Control   | Difference in%vs.Control   |
|----------------------------|-----|------------------------------|---------------------------------|----------------------------|----------------------------|
| Treatment                  | N   | Number of ObjectiveResponses | ObjectiveResponseRate(%)(95%Cl) | Estimate (95%C1)t          | p-Valuet                   |
| Pembrolizumab+Chemotherapy | 220 | 116                          | 52.7 (45.9, 59.5)               | 12.1 (0.4, 23.4)           | 0.0213                     |
| Placebo+Chemotherapy       | 103 | 42                           | 40.8 (31.2, 50.9)               |                            |                            |

BasedonMiettinen&amp;Nurminenmethodstratifiedbychemotherapyonstudy(taxanevsgemcitabine/carboplatin)andpriortreatmentwithsameclassofchemotherapyinthe (neo)adjuvantsetting(yesvsno).

t One-sided p-value for testing. HO: difference in % = 0 versus Hl: difference in % &gt; 0.

Confirmed responses are included.

BICR=BlindedIndependentCentralReview.

DatabaseCutoffDate:15JUN2021

The median DOR for responders with PD-L1 positive tumor s (CPS ≥10) was 12.1 months (range: 1.6+ to 45.9+ months) in the pembrolizumab + chemotherapy group and 7.3 months (range: 1.5 to 46.6+ months) in the placebo + chemotherapy group.

## Summary of main study

The  following  tables  summarise  the  efficacy  results  from  the  main  studies  supporting  the  present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 1. Summary of Efficacy for trial KEYNOTE-355

| Title: A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) plus Chemotherapy vs Placebo plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer - (KEYNOTE-355)   | Title: A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) plus Chemotherapy vs Placebo plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer - (KEYNOTE-355)   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                 | EudraCT: 2016-001432- 35; IND: 124,442; NCT: 02819518                                                                                                                                                                                            |
| Design                                                                                                                                                                                                                                           | Phase 3 (with safety run-in), two-arm, multicenter, international, randomized 2:1, double blind                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

|                                                                     | Duration of main phase:                                                                                   | Duration of main phase:                                                              | 01-AUG-2016 (first patient, first visit) 15-JUN-2021 (last patient, last visit) Study is ongoing. NA                                                                                           | 01-AUG-2016 (first patient, first visit) 15-JUN-2021 (last patient, last visit) Study is ongoing. NA                                                                                           | 01-AUG-2016 (first patient, first visit) 15-JUN-2021 (last patient, last visit) Study is ongoing. NA                                                                                           |
|---------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Hypothesis                                                          | Duration of Extension phase: NA Superiority                                                               | Duration of Extension phase: NA Superiority                                          | Duration of Extension phase: NA Superiority                                                                                                                                                    | Duration of Extension phase: NA Superiority                                                                                                                                                    | Duration of Extension phase: NA Superiority                                                                                                                                                    |
| Treatments groups                                                   | Pembrolizumab + chemotherapy (paclitaxel, nab- paclitaxel, carboplatin/ gemcitabine)                      | Pembrolizumab + chemotherapy (paclitaxel, nab- paclitaxel, carboplatin/ gemcitabine) | Pembrolizumab 200 mg IV Q3W, IV infusion Nab-paclitaxel 100 mg/m 2 Days 1,8, and 15, every 28 days Paclitaxel 90 mg/m 2 Days 1,8,and 15, every 28 days Gemcitabine/Carboplatin 1000 mg/m 2 and | Pembrolizumab 200 mg IV Q3W, IV infusion Nab-paclitaxel 100 mg/m 2 Days 1,8, and 15, every 28 days Paclitaxel 90 mg/m 2 Days 1,8,and 15, every 28 days Gemcitabine/Carboplatin 1000 mg/m 2 and | Pembrolizumab 200 mg IV Q3W, IV infusion Nab-paclitaxel 100 mg/m 2 Days 1,8, and 15, every 28 days Paclitaxel 90 mg/m 2 Days 1,8,and 15, every 28 days Gemcitabine/Carboplatin 1000 mg/m 2 and |
| Treatments groups                                                   | Placebo + chemotherapy (paclitaxel, nab-paclitaxel, carboplatin/ gemcitabine)                             | Placebo + chemotherapy (paclitaxel, nab-paclitaxel, carboplatin/ gemcitabine)        | Placebo (normal saline) Q3W Nab-paclitaxel 100 mg/m 2 Days 1,8, and 15, every 28 days Paclitaxel 90 mg/m 2 Days 1,8,and 15, every 28 days Gemcitabine/Carboplatin 1000 mg/m 2 and              | Placebo (normal saline) Q3W Nab-paclitaxel 100 mg/m 2 Days 1,8, and 15, every 28 days Paclitaxel 90 mg/m 2 Days 1,8,and 15, every 28 days Gemcitabine/Carboplatin 1000 mg/m 2 and              | Placebo (normal saline) Q3W Nab-paclitaxel 100 mg/m 2 Days 1,8, and 15, every 28 days Paclitaxel 90 mg/m 2 Days 1,8,and 15, every 28 days Gemcitabine/Carboplatin 1000 mg/m 2 and              |
| Endpoints and definitions                                           | Dual Primary endpoint                                                                                     | PFS (per RECIST 1.1 by CIV) In the ITT, CPS≥1 and in the CPS≥10 populations          | AUC 2, respectively, Days 1,8 every 21 days Time from randomization to the first documented disease progression or death due to any cause, whichever occurs first                              | AUC 2, respectively, Days 1,8 every 21 days Time from randomization to the first documented disease progression or death due to any cause, whichever occurs first                              | AUC 2, respectively, Days 1,8 every 21 days Time from randomization to the first documented disease progression or death due to any cause, whichever occurs first                              |
| Endpoints and definitions                                           | Dual primary endpoint                                                                                     | OS In the ITT, CPS≥1 and in the CPS≥10 populations                                   | Time from randomization to death due to any cause.                                                                                                                                             | Time from randomization to death due to any cause.                                                                                                                                             | Time from randomization to death due to any cause.                                                                                                                                             |
| Endpoints and definitions                                           | Secondary endpoint                                                                                        | ORR (per RECIST 1.1 by CIV) In the ITT, CPS≥1 and in the CPS≥10 populations          | Proportion of the participants in the analysis population who have a complete response (CR) or partial response (PR)                                                                           | Proportion of the participants in the analysis population who have a complete response (CR) or partial response (PR)                                                                           | Proportion of the participants in the analysis population who have a complete response (CR) or partial response (PR)                                                                           |
| Endpoints and definitions                                           | Secondary endpoint                                                                                        | DOR, AEs, PRO                                                                        |                                                                                                                                                                                                |                                                                                                                                                                                                |                                                                                                                                                                                                |
| Data cut-off                                                        | 11 Dec 2019 (IA2) 15 Jun 2021 (FA)                                                                        | 11 Dec 2019 (IA2) 15 Jun 2021 (FA)                                                   | 11 Dec 2019 (IA2) 15 Jun 2021 (FA)                                                                                                                                                             | 11 Dec 2019 (IA2) 15 Jun 2021 (FA)                                                                                                                                                             | 11 Dec 2019 (IA2) 15 Jun 2021 (FA)                                                                                                                                                             |
| Results and Analysis                                                | Results and Analysis                                                                                      | Results and Analysis                                                                 | Results and Analysis                                                                                                                                                                           | Results and Analysis                                                                                                                                                                           | Results and Analysis                                                                                                                                                                           |
| Analysis description Analysis population and time point description | Interim analysis 2 (i.e. final analysis for PFS, interim analysis for OS) Intent to treat, below, as this | CPS≥1, is the sought                                                                 | CPS≥10 (only the indication)                                                                                                                                                                   | CPS≥10                                                                                                                                                                                         | subpopulation is shown                                                                                                                                                                         |
| Descriptive statistics and estimate variability                     | Treatment group                                                                                           | Treatment group                                                                      | Pembrolizumab chemotherapy                                                                                                                                                                     | +                                                                                                                                                                                              | Placebo + chemotherapy                                                                                                                                                                         |
| Descriptive statistics and estimate variability                     | CPS≥10                                                                                                    | CPS≥10                                                                               |                                                                                                                                                                                                |                                                                                                                                                                                                |                                                                                                                                                                                                |
| Descriptive statistics and estimate variability                     | Number of subject                                                                                         | Number of subject                                                                    | 220 (ITT: 566)                                                                                                                                                                                 |                                                                                                                                                                                                | 103 (ITT: 281)                                                                                                                                                                                 |
| Descriptive statistics and estimate variability                     | PFS (median in months)                                                                                    | PFS (median in months)                                                               | 9.7                                                                                                                                                                                            |                                                                                                                                                                                                | 5.6                                                                                                                                                                                            |
| Descriptive statistics and estimate variability                     | OS (median in                                                                                             | OS (median in                                                                        | 23                                                                                                                                                                                             |                                                                                                                                                                                                | 16.1                                                                                                                                                                                           |
| Descriptive statistics and estimate variability                     | months) 95%CI ORR                                                                                         | months) 95%CI ORR                                                                    | (18.8, 27.5) 53.2%                                                                                                                                                                             |                                                                                                                                                                                                | (12.6, 18.8) 39.8%                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

|                                                 | 95%CI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | (46.4, 59.9)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | (30.3, 49.9)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|-------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                 | DOR (median in months)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 19.3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 7.3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|                                                 | range                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | (1.6+                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | (1.5 - 32.5+)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Effect estimate per comparison                  | Dual Primary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | - 29.8) Pembrolizumab + chemo vs placebo + chemo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | PFS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Effect estimate per comparison                  | Dual Primary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | HR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 0.65                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Effect estimate per comparison                  | Dual Primary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 95%CI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | (0.49, 0.86)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Effect estimate per comparison                  | Dual Primary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | P-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 0.0012                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Effect estimate per comparison                  | Dual Primary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Pembrolizumab+ chemo vs placebo + chemo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | OS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Effect estimate per comparison                  | Dual Primary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | HR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 0.69                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Effect estimate per comparison                  | Dual Primary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 95%CI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | (0.51, 0.93)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Effect estimate per comparison                  | Dual Primary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | P-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 0.0066                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Effect estimate per comparison                  | Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Pembrolizumab+ chemo vs placebo + chemo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | ORR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Effect estimate per comparison                  | Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Difference in%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 13.6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Effect estimate per comparison                  | Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 95%CI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | (1.9, 24.8)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Notes                                           | P-value 0.0115 (nominal) Only hypothesis H3 (PFS in the CPS≥10) can be rejected under the type -I-error control. This hypothesis was added to the type-I-error control with amendment 5 after interim analysis 1. P-values were one sided based on log-rank test. Hazard ratios based on Cox regression model with Efron's method of tie handling with treatment as covariate. Log-rank test and Cox-regression was stratified by chemotherapy on study (taxane vs. gemcitabine/carboplatin), tumor PD-L1 status ( CPS≥1 vs CPS <1 for ITT), and prior treatment with same class of chemotherapy in the (neo)adjuvant setting (yes vs no). | P-value 0.0115 (nominal) Only hypothesis H3 (PFS in the CPS≥10) can be rejected under the type -I-error control. This hypothesis was added to the type-I-error control with amendment 5 after interim analysis 1. P-values were one sided based on log-rank test. Hazard ratios based on Cox regression model with Efron's method of tie handling with treatment as covariate. Log-rank test and Cox-regression was stratified by chemotherapy on study (taxane vs. gemcitabine/carboplatin), tumor PD-L1 status ( CPS≥1 vs CPS <1 for ITT), and prior treatment with same class of chemotherapy in the (neo)adjuvant setting (yes vs no). | P-value 0.0115 (nominal) Only hypothesis H3 (PFS in the CPS≥10) can be rejected under the type -I-error control. This hypothesis was added to the type-I-error control with amendment 5 after interim analysis 1. P-values were one sided based on log-rank test. Hazard ratios based on Cox regression model with Efron's method of tie handling with treatment as covariate. Log-rank test and Cox-regression was stratified by chemotherapy on study (taxane vs. gemcitabine/carboplatin), tumor PD-L1 status ( CPS≥1 vs CPS <1 for ITT), and prior treatment with same class of chemotherapy in the (neo)adjuvant setting (yes vs no). |
| Analysis description Analysis population        | Final Analysis (i.e. final analysis for OS)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Final Analysis (i.e. final analysis for OS)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Final Analysis (i.e. final analysis for OS)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| and time point description                      | Intent to treat, CPS ≥ 1, CPS ≥ 10 (only the CPS ≥ 10 subpopulation is shown below, as this is the sought indication)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Intent to treat, CPS ≥ 1, CPS ≥ 10 (only the CPS ≥ 10 subpopulation is shown below, as this is the sought indication)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Intent to treat, CPS ≥ 1, CPS ≥ 10 (only the CPS ≥ 10 subpopulation is shown below, as this is the sought indication)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Descriptive statistics and estimate variability | Treatment group                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Pembrolizumab + chemotherapy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Placebo + chemotherapy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Descriptive statistics and estimate variability | CPS ≥ 10                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Descriptive statistics and estimate variability | Number of subject                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 220 (ITT: 566)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 103 (ITT: 281)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Descriptive statistics and estimate variability | PFS (median in months)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 9.7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 5.6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Descriptive statistics and estimate variability | 95%CI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | (7.6, 11.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (5.3, 7.5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Descriptive statistics and estimate variability | OS (median in months)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 23                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 16.1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Descriptive statistics and estimate variability | 95%CI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | (19, 26.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | (12.6, 18.8)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Descriptive statistics and estimate variability | ORR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 52.7%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 40.8%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Descriptive statistics and estimate variability | 95%CI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | (45.9, 59.5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | (31.2, 50.9)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Descriptive statistics and estimate variability | DOR (median in months)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 12.8                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 7.3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Effect estimate per comparison                  | range Dual Primary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (1.6+ - 45.9) Pembrolizumab + chemo vs placebo + chemo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | (1.5 - 46.6+) PFS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Effect estimate per comparison                  | range Dual Primary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | HR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 0.66                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Effect estimate per comparison                  | range Dual Primary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 95%CI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | (0.50, 0.88)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Effect estimate per comparison                  | range Dual Primary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | P-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 0.0018 (nominal)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Effect estimate per comparison                  | Dual Primary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Pembrolizumab+ chemo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | OS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Effect estimate per comparison                  | Dual Primary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | HR 95%CI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 0.73 (0.55, 0.95)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Effect estimate per comparison                  | Dual Primary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | P-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 0.0093                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Effect estimate per comparison                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Pembrolizumab+                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Effect estimate per comparison                  | Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | chemo vs placebo + chemo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | ORR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

|       |                                                     | Difference in%                                      | 12.1                                                |
|-------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|
|       |                                                     | 95%CI                                               | (0.4, 23.4)                                         |
|       |                                                     | P-value                                             | 0.0213 (nominal)                                    |
| Notes | Updated PFS and ORR data with nominal p-values only | Updated PFS and ORR data with nominal p-values only | Updated PFS and ORR data with nominal p-values only |

## Clinical studies in special populations

No data in special populations have been provided. Efficacy data of KN355 by age in the subgroup of patients with PD-L1 CPS ≥ 10 are summarized in the following table.

Approximately 20% of patients in KEYNOTE355 were aged ≥65 years, of those 16% were ≥65 -&lt;75 years and about 5% were ≥75 -&lt;85 years. There was only one 85 years old patient in the pembrolizumab + chemotherapy arm. No patients aged over 77 years of age was enrolled in the control arm. Efficacy results in patients &lt;65 and ≥65 years were overall consistent.

Table: Efficacy by age, Subjects with PD-L1 CPS ≥ 10 ( table prepared by the assessment team)

|                    | Age < 65 years    | Age < 65 years    | 65 ≤ Age < 75 years   | 65 ≤ Age < 75 years   | 75 ≤ Age < 85 years   | 75 ≤ Age < 85 years   |
|--------------------|-------------------|-------------------|-----------------------|-----------------------|-----------------------|-----------------------|
| Endpoint           | Pembro+C (N=178)  | Placebo+C (N=79)  | Pembro+C (N=35)       | Placebo+C (N=21)      | Pembro+C (N=7)        | Placebo+C (N=3)       |
| PFS                |                   |                   |                       |                       |                       |                       |
| Median PFS, months | 9.5               | 5.5               | 10.7                  | 7.6                   | 9.6                   | 3.5                   |
| HR (95% CI)        | 0.63 (0.46, 0.87) | 0.63 (0.46, 0.87) | 0.70 (0.37, 1.36)     | 0.70 (0.37, 1.36)     | 0.14 (0.01, 1.62)     | 0.14 (0.01, 1.62)     |
| OS                 |                   |                   |                       |                       |                       |                       |
| Median OS, months  | 21.8              | 16.8              | 28.3                  | 13.0                  | NR (7.5, NR)          | 5.0                   |
| HR (95% CI)        | 0.78 (0.56, 1.08) | 0.78 (0.56, 1.08) | 0.59 (0.29, 1.18)     | 0.59 (0.29, 1.18)     | 0.00                  | 0.00                  |
| Objective Response |                   |                   |                       |                       |                       |                       |
| ORR%               | 51.1              | 38                | 60                    | 47.6                  | 71.4                  | 33.3                  |
| ORR Difference%    | 13.1              | 13.1              | 12.4                  | 12.4                  | 38.1                  | 38.1                  |

## Supportive studies

Note: The MAH did not present any studies as supportive for the sought indication, although the clinical study reports of KEYNOTE-119, KEYNOTE-086 and KEYNOTE-012 in metastatic TNBC were included in the dossier. Brief summaries of these studies are presented below.

## KEYNOTE119

KEYNOTE-119 is a Phase 3 randomized, multicenter, open-label study of pembrolizumab versus single agent chemotherapy per physician's choice [TPC] (capecitabine, eribulin, vinorelbin, gemcitabine) for participants receiving 2L or 3L treatment for mTNBC.

Figure: Study Design Schematic KEYNOTE119

<div style=\"page-break-after: always\"></div>

<!-- image -->

Primary objectives were OS in subjects with PD-L1 positive tumors CPS ≥ 10, CPS ≥ 1 and in all subjects. PFS, ORR and DOR were secondary endpoints. 622 participants were enrolled (312 in the pembrolizumab arm, 310 in the TPC arm). First participant first visit was on 27 Oct 2015; the CSR included results as of the 11-APR-2019 data cutoff. Approximately 65% of patients had CPS ≥ 1 and 30% had CPS ≥ 10 tumors. Pembrolizumab monotherapy as 2/3L treatment for metastatic TNBC did not demonstrate a statistically significant improvement in OS compared to TPC in all participants or in participants with PD-L1 positive tumors (CPS ≥ 1 or CPS ≥ 10). Main results are summarized below:

OS HRs: ITT 0.97; CPS≥1 0.86; CPS≥

10 0.78.

PFS HRs: ITT 1.60; CPS≥1 1.35; CPS≥

10 1.14.

ORR: ITT 9.6% vs 10.6%; CPS≥1 12.3% vs 9.4%; CPS≥ 10 17.7% vs 9.2%.

DOR: ITT 12.2 vs 8.3 months; CPS≥ 1 12.2 vs 6.5 months; CPS≥ 10 NR vs 7.1 months.

Figure: KM Estimates of PFS and Overall Survival (Subjects with PD-L1 CPS ≥ 10) KM of OS ( CPS ≥10 ) KM of PFS ( CPS ≥10 )

<!-- image -->

KEYNOTE-119 study failed to demonstrate superiority of pembrolizumab monotherapy over chemotherapy

<div style=\"page-break-after: always\"></div>

as 2L or 3L treatment of patients with mTNBC in its primary endpoint OS; a short overview is presented since KN119 results might support an association between PD-L1 expression status and efficacy outcomes (with the largest treatment effect in the not prespecified subgroup of patients whose tumors express PDL1 CPS ≥20). Data further provide indirect evidence that monotherapy with pembrolizumab in the 1L TNBC setting would not be considered appropriate.

## KEYNOTE086

KEYNOTE-086 was planned as an open-label, nonrandomized, single-arm, multicenter, multicohort, Phase 2 study conducted in participants with centrally confirmed mTNBC, evaluating the efficacy and safety of pembrolizumab monotherapy as second line or above (2L+) in mTNBC with PDL1 expression CPS≥1 and independent of PD-L1 expression (Cohort A), and as first line (1L) in mTNBC with PDL1 expression CPS≥1 (Cohort B). ORR was the primary endpoint. Overall, 170 participants and 84 participants were allocated to treatment in Cohort A and Cohort B, respectively.

Cohort A (2L+): in the total population, ORR was 5.3% (95%CI 2.7%, 10%), Median DOR was not reached (range 1.2+ - 21.5+). Median PFS was 2.0 months, and median OS was 9.0 months. Results were similar regardless of PD-L1 status.

Cohort B (1L): ORR of 21.4% (95%CI 13.9%, 31.4%). Median DOR was 10.4 months (range: 4.2 - 19.2+ months). Median PFS was 2.1 months and median OS was 18.0 months.

## KEYNOTE0 12

KEYNOTE-012  is  a  Phase  Ib  Multi-Cohort  Study  of  pembrolizumab  (10  mg/kg  Q2W)  in  subjects  with advanced solid tumors. The CSR presented the results of 32 subjetcs from Cohort A, where patients with TNBC were enrolled. Safety and tolerability was the primary objective of this study. Of the 32 TNBC Cohort subjects in the ASaT population, 15.6% (5/32) had either a CR or PR as measured by RECIST 1.1 by BICR. Of the 5 responders, 3 had 5 or more prior lines of therapy for metastatic breast cancer, 1 had 3 prior lines, and 1 had 1 prior line. Median DOR was not reached as of the data cutoff.

## 2.4.3. Discussion on clinical efficacy

This is an extension of indication for Keytruda in combination with chemotherapy for patients with locally recurrent unresectable or metastatic triple negative breast cancer (TNBC) with PD-L1 CPS ≥ 10 and who have not received prior chemotherapy for metastatic disease, based on the IA2 (final analysis for PFS and IA2 for OS) results of Part 2 of the pivotal study KEYNOTE-355, with data cut-off date 11-Dec-2019 (approximately 18 months after the last participant was randomized). Median follow-up duration was 16.8 months in the ITT population and 19.2 months in the CPS≥10 population. During the procedure, the MAH submitted also the final analysis for overall survival, with data cut-off date 15-Jun-2021 (3 years after last participant randomised), with median follow-up of 16.7 months. Part 1 of the study was an unblinded, open-label, safety run-in with 35 participants.

## Design and conduct of clinical studies

Study KEYNOTE-355 is a randomized 2:1, double-blind, phase III study in previously untreated locally recurrent inoperable or metastatic TNBC comparing pembrolizumab (200 mg q3w) plus chemotherapy

<div style=\"page-break-after: always\"></div>

(paclitaxel, nab-paclitaxel or carboplatin/gemcitabine) vs placebo plus chemotherapy. The double-blind, placebo-controlled, add-on design of KEYNOTE-355 is endorsed.

Adult patients with PS 0-1 and measurable disease by RECIST 1.1 were eligible. The diagnosis of TNBC was centrally confirmed in line with most recent ASCO/CAP guidelines. If previously treated with curative intent, such treatment should have been completed ≥6 months earlier (12 months if retreated with the same class of chemotherapy within the study), and if treated with (neo)adjuvant systemic treatment, anthracycline should have been given unless not indicated. The study allowed re-treatment with same class of chemotherapy (taxane or gemcitabine/carboplatin), if ≥ 12 months had elapsed between the completion of treatment with curative intent and first documented local or distant disease recurrence. If chemotherapy options included more than one regimen, choice of study chemotherapy was at physician's discretion. Patients with early recurrences (i.e. between 6 and 12 months following completion of definitive treatment for early disease) were allowed. Other key eligibility criteria accounted for the known safety profile of pembrolizumab. Overall inclusion/exclusion criteria are considered acceptable and reflect the intended target population. The diagnosis of TNBC was centrally confirmed in line with most recent ASCO/CAP guidelines.

The comparator, and backbone chemotherapy administered with pembrolizumab, was an investigator's choice between 3 different chemotherapy options (paclitaxel, nab-paclitaxel or carboplatin plus gemcitabine). The dosing regimens proposed of the chemotherapy drugs can be considered acceptable. Chemotherapy on study (taxane vs gemcitabine/carboplatin) was one of the stratification factors as was prior treatment with same class of chemotherapy in the (neo)adjuvant setting and PD-L1 status (CPS cut off 1). Overall, stratification factors are considered appropriate, however the randomization was not stratified according to PD-L1 positive tumors CPS ≥ 10 (see below).

Patients received treatment until confirmed disease progression, unacceptable toxicity, withdrawal of consent, or physician's decision, with up to 35 cycles (2 years) for pembrolizumab/placebo.

The MAH justified the inclusion of two different taxane options based on differential availability and clinical use worldwide and similar efficacies in terms of OS in mBC. Nab-paclitaxel is however not formally approved in EU as 1L treatment for metastatic breast cancer, although it was recently authorized in combination with atezolizumab in the same setting.

Overall, 55% of KN355 study patients received gemcitabine/carboplatin and 45% received taxane as chemotherapy regimen. ESMO and NCCN guidelines recommend use of combination chemotherapy only for patients with 'high tumor burden, rapidly progressing disease, and visceral crisis' and 'taxane-based therapy would usually be considered as treatment of choice' for taxane-naïve and anthracycline noneligible patients according to ESMO guidance. Since nearly half of the study population were taxane-naïve (47%) and only 21% of patients had an early disease recurrence &lt;12 months, the low proportion of patients treated with taxane (and the high proportion of patients treated with combination chemotherapy) does not appear in line with current guidelines. It was noted, however, that it was the sole responsibility of the physicians to choose between the different chemotherapy options.

The choice of OS and PFS as primary objectives can be considered appropriate. Assessments of PFS, ORR and DOR were measured independently by BICR per RECIST 1.1 which is endorsed.

The primary objectives/endpoints of KEYNOTE-355 were modified while the study was ongoing. Patients were enrolled regardless of PD-L1 biomarker status but were required to provide tumor tissue sample (unless contraindicated) for central testing and stratified according to PD-L1 tumor status (CPS ≥ 1 vs. CPS &lt;1) in line with the biomarker plan of the original protocol that determined PD-L1 positive vs PD-L1 negative subpopulation by a PD-L1 CPS cutoff of 1. The addition of a higher PD-L1 CPS cut-off of ≥10 and the inclusion of subjects with PD-L1 CPS ≥ 10 in the primary analysis plan was introduced with amendment 5 (Oct 2019); it needs to be noted that Amendment No. 5 was finalised one year after the

<div style=\"page-break-after: always\"></div>

first interim analysis had occurred (18 Oct 2018). Although KEYNOTE-355 is a double-blind trial, the late changes in an ongoing study raise concern over the risk of a data driven approach, taking also into account that this study would have been negative based on the initial hypotheses. The MAH provided a justification that the selection of the CPS cut-off of 10 was not driven by any knowledge of IA1 results (IA conducted by independent DMC while the sponsor remained blinded to study results per protocol, including individual treatment assignment and CPS scores; the statistical criterion for success at IA1 was not met and the DMC recommended study continuation). The MAH documented that they did not have access to the IA1 DMC at the time point where the primary hypotheses testing was modified (Amendment 5), and that the choice of the additional cutoff of CPS≥10 was based on external results from studies KEYNOTE-119 and IMpassion130, showing improved benefit with enrichment of tumor PD-L1 expression levels in TNBC. Meeting minutes of the eDMC from 3 Dec 2018 and the DMC recommendation form of IA1 show that there was no content-related communication with the MAH. The DMC charter provides information about the DMC members and unblinded study statistician, and their confidential agreement about the obligation to keep all information related to the eDMC confidential and not to discuss information to anyone other than DMC members. The results of IA2 using the SAP specified in Amendment 4 versus that specified in Amendment 5 confirmed that without the inclusion of OS and PFS hypotheses for the PD-L1 positive CPS ≥ 10 population with amendment 5 none of the primary endpoints would have been met under amendment 4. Regarding KEYNOTE-119, a trend toward numerically better results for pembrolizumab was seen in a PD-L1 enriched population of recurrent locally advanced or metastatic TNBC tumors in (2L+), not reaching statistical significance though. IMpassion130 study demonstrated that atezolizumab + nab-paclitaxel significantly prolonged PFS in participants with PD-L1 positive tumors, defined as PD-L1 stained tumor-infiltrating immune cells of any intensity covering ≥ 1% of the tumor area by the VENTANA PD-L1 (SP142) assay. It is acknowledged that the timing the external results were publicly available is compatible with the date of Amendment 5 (IMpassion130 data were first publicly presented in Oct 2018 23 , KEYNOTE-119 data cut-off was 11 Apr 2019). It is also acknowledged that published studies indicated that the VENTANA PD-L1 SP142 assay (used for atezolizumab) detects lower PD-L1 expression compared to the PD-L1 IHC 22C3 pharmDx assay (used in pembrolizumab studies), although there is no exact correspondence between score and cut-offs. In particular, literature suggests that there is greater variability in immune-cell staining between the two assays. The prevalence of participants identified as PD-L1 positive (IC ≥ 1%) in IMpassion130 by the VENTANA PD-L1 (SP142) assay and the prevalence of participants with tumors that express PD-L1 with CPS ≥ 10 by the PD-L1 IHC 22C3 pharmDx assay in KEYNOTE-355 was similar between the two studies (41% and 38%, respectively). In addition to the consideration regarding the choice of the PD-L1 cut-off, it is noted that the target magnitude of PFS and OS improvements was reduced in Amendment 5 compared to the original protocol success criteria (e.g. success criteria for PFS in the ITT population was 0.70 in the latest amendment, compared to 0.64 in prior protocol version).

The explanation for adding the CPS ≥ 10 population as a confirmatory hypothesis seems reasonably justified by external studies and biological rationale. The results of PFS and OS with CPS as a continuous score show that CPS is a strong predictive factor for the pembrolizumab + chemotherapy group, but not for the placebo + chemotherapy group. Therefore, the treatment effect increases with increasing CPS values. Beneficial treatment effect for subgroups with CPS values lower than 10 is currently not proven and the treatment effect does not improve meaningfully for patients with CPS values higher than 10. With the given results it is comprehensible to set the cutoff at CPS = 10.

23  Abstract LBA1\\_PR ESMO Congress 2018 'IMpassion130: Results from a global, randomised, double-blind, phase 3 study of atezolizumab (atezo) + nab-paclitaxel (nab-P) vs placebo + nab-P in treatment-naive, locally advanced or metastatic triplenegative breast cancer (mTNBC)' Annals of Oncology, Volume 29 Supplement 8 October 2018

<div style=\"page-break-after: always\"></div>

The assumptions for median PFS of 5.5 months and OS of 17.5 months in the control arm were appropriately based on literature data available at the time of study initiation  24   25 .

The change in the multiplicity approach after interim analysis 1 was considered in the power calculation. For OS only the power calculation for the final analysis was described, not for the interim analyses. However, the provided power calculations are acceptable. Statistical methods were well reported in the protocol section and in the SAP, and considered appropriate.

## Efficacy data and additional analyses

Part 1 of KEYNOTE-355 was open-label safety run-in, where a total of 34 subjects received pembrolizumab + one of the three chemotherapy options (paclitaxel, nab-paclitaxel, carboplatin/gemcitabine). Safety was the primary objective of this part: no new safety concerns were identified in part 1. Overall, the data can be considered in line with what observed in part 2, however efficacy results of part 1 are descriptive in nature and based on a limited number of subjects.

Part 2 was the phase 3 study, on which efficacy data are based. At the data cut-off for IA2, more than 90% of patients in both arms have discontinued treatment, mostly due to PD. In the ITT population, a higher number of patients discontinued pembrolizumab combination due to AE compared to chemotherapy alone, as well as due to patient or physician decision, while in the control arm more patients stopped study medication due to radiological and clinical progression. Similar trends are observed in the CPS ≥ 10 population.

Patients in the ITT population (566 vs 281 in the pembro+chemo vs placebo+chemo arm) were well balanced with regard to baseline characteristics in the two arms. All patients were female with median age of 53 (about 20% &gt;65 years), approximately 70% were post-menopausal. About 60% had ECOG 0 and 40% ECOG 1. Overall, 30% had de-novo metastatic disease. Of the remaining patients who received prior treatment for early disease, 20% had disease free interval between 6 and 12 months (i.e. early progressors), and about 20% received treatment with the same class chemotherapy used in the study in the (neo)adjuvant setting. Only few patients (3%) had history of brain metastases, therefore it is not possible to make any conclusion on efficacy/safety data in this subgroup.

Study KEYNOTE-355 enrolled patients with previously untreated metastatic TNBC or locally recurrent inoperable breast cancer who could not be treated with curative intent. A low proportion of only 3% of study participants (n=25) were recruited with locally recurrent inoperable breast cancer. The MAH did not provide efficacy data for this subgroup of patients. Considering the limitations of the small patient numbers with locally recurrent disease it is acknowledged that no reliable conclusions could be drawn from these analyses. In view of the MoA and the disease characteristics of TNBC, extrapolation of efficacy data from metastatic to locally recurrent disease is considered possible.

In the CPS≥10 sub set, representing about 38% of the ITT population (220 vs 103 patients), baseline characteristics were overall similar to the ITT population. Although stratified by CPS with cut-off of 1 (and not 10), no pronounced unbalances in baseline characteristics are seen between the two arms clearly favouring the experimental arm. Few differences are however noted, such as age, number of patients receiving nab-paclitaxel or paclitaxel, patients with metastatic de novo/recurrence and DFI &lt;12 months or history of brain metastases. Only 12% of enrolled subjects had mutational status assessed locally, of those 17% were positive, and most of the BRCA mutant patients have PD-L1 positive tumors. Due to the

24  O'Shaughnessy J, et al. Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triplenegative breast cancer. J Clin Oncol. 2014 Dec 1;32(34):3840 -7.

25  Miles DW, et al. First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analy ses of data from 2447 patients. Ann Oncol. 2013 Nov;24(11):2773 -80.

<div style=\"page-break-after: always\"></div>

limited data, no conclusion can be drawn at this stage, and the CHMP recommended that BRCA analyses could be provided as part of exploratory biomarker research in the future.

Baseline characteristics were generally representative of a patient population with advanced TNBC, the majority of patients were &lt;65 years of age, postmenopausal, had recurrent disease and visceral metastasis. However, only 3.4% of patients had a history of brain metastasis. Only 4% of patients were enrolled with locally recurrent inoperable disease.

To summarize IA2 results (i.e. final analysis for PFS, interim for OS), PFS in the CPS≥10 population was the only endpoint reaching statistical significance. OS in CPS≥10, as well as PFS and OS in CPS≥1 did not cross the prespecified efficacy boundary at IA2. PFS and OS in the ITT population were not statistically tested at the IA2 per the prespecified multiplicity strategy. For the secondary endpoint ORR, ORR in all participants and in the CPS ≥ 1 population were only tested at IA1 and the success criterion were not met. ORR was not formally tested at IA2 per the prespecified multiplicity strategy in all the three populations.

In the CPS≥10 population , with approximately 62% vs 77% of PFS events, a PFS advantage for pembrolizumab combo over chemotherapy was shown (HR=0.65, 95%CI 0.49, 0.86, p=0.0012), corresponding to gain in median PFS of about 4 months (9.7 vs 5.6 months). PFS curves were overlapping up to month 3, then diverged with a 15% improvement in PFS rate in favour of the pembrolizumab arm, which is maintained in the long term. A high number of censored events observed in the PFS curves in the two arms up to month 6 was similar in both arms and mainly due to subjects starting a new anticancer treatment before radiological disease progression. An updated PFS analysis performed at the time of the final analysis for OS, with nominal p-values only, was consistent with the primary PFS analysis.

With more than half of the population experiencing an OS event, a numerical OS advantage was observed at IA2 in the PDL1 CPS≥10 population, with a gain in median survival of about 7 months: HR 0.69 (95%CI 0.51, 0.93), median OS 23 months (95%CI 18.8, 27.5) vs 16.1 (95%CI 12.6, 18.8). However, the observed p-value of p=0.0066 did not cross the prespecified efficacy boundary at IA2 (the multiplicity adjusted, one-sided nominal alpha level was 0.00472). The KM curves for OS separated since month 6 in favour of pembrolizumab + chemotherapy and remained separated over time; although curves tend to come closer toward the end, curves are no more interpretable after 18 months due to censoring. During the procedure, the MAH submitted the final analysis (FA) for OS . In the CPS≥10 population, OS result reached statistical significance. With 70.5% vs 81.6% of patients experiencing an OS event in the pembrolizumab + chemotherapy vs placebo + chemotherapy arm, the OS HR was 0.73 (95% CI: 0.55, 0.95), with the observed p-value of p=0.0093 successfully crossing the prespecified efficacy boundary at the FA (the multiplicity adjusted, one-sided nominal alpha level was 0.0113). Longer median OS in the pembrolizumab + chemotherapy group compared with the placebo + chemotherapy group was seen (23.0 vs 16.1 months), and OS rates by KM estimation at month 18 and 24 favoured the experimental arm. The KM OS separate starting at approximately 6 months in favor of pembrolizumab + chemotherapy in participants with PDL1 positive tumors (CPS ≥10) and r emained clearly separated over time (censoring observed after month 36). At the final analysis, OS did not reach statistical significance in the CPS≥1 population, and was not formally tested in the overall population.

In the CPS ≥ 10 population, a numerical advantage in the secondary endpoint ORR was observed (53.2% vs 40%) for the experimental arm, including some more CRs (16.8% vs 12.6%). Durable (SD ≥ 6 months) stable disease rate was similar in both arms, although more SD were recorded in the comparator arm (28% vs 44%).

As expected, median DOR for responders was longer for the pembrolizumab containing arm compared to placebo+chemotherapy. In the pembrolizumab combination arm, median DOR was longer in the CPS ≥ 10 (19.3 months) than in the ITT population (10.1 months).

<div style=\"page-break-after: always\"></div>

With regard to PRO assessment, the completion and compliance rate of PRO questionnaires in this doubleblind study was high and similar in both arms. Overall, in the CPS≥10 , no relevant differences were observed between treatment arms in the various PRO scores and parameters examined. These results do not provide supportive evidence for the clinical relevance of the combination therapy in the claimed indication. However, they also do not raise concerns about intolerable toxicities that would interfere with patients' quality of life.

PFS2 analysis by investigator showed a numerical advantage for the experimental treatment over the control arm, which was more pronounced in the CPS ≥ 10 population and can be considered supportive of the benefit of pembrolizumab + chemotherapy over placebo + chemotherapy in higher PD-L1 expressors: HR 0.69 (95%CI 0.49, 0.87), median PFS2 16.9 months (95%CI 13.8, 19.9) vs 10.9 (95%CI 9.1, 13.2).

Various PFS sensitivity analyses were presented. Firstly, an analysis taking into account the few discrepancies between the stratification factors data entered in the IVRS and the actual data had almost the same results of the primary analyses, thus not raising concern. PFS assessed by investigator showed (unexpectedly) worse results compared to BICR assessment. Worse HR was noted in the most conservative sensitivity analysis 2 as a higher number of subjects in the experimental combination arm than in the chemotherapy arm started a new anticancer treatment before radiological progression (considered as events in this analysis). It is acknowledged that the PFS primary analysis censoring by BICR was prespecified in the protocol. The results of the provided sensitivity analyses overall, however, do not fully support the primary analysis, which is not very reassuring.

The mostly used chemotherapy backbone was carboplatin/gemcitabine (about 55% of patients), followed by nab-paclitaxel (about 30%) and paclitaxel (15%). It is of concern that patients randomized to carboplatin/gemcitabine, representing more than half of the population, obtained limited or no benefit at all in all efficacy endpoints (PFS, OS and ORR) from the addition of pembrolizumab to backbone chemotherapy, differently from what observed in patients receiving taxanes. In particular, it seems that patients who received carboplatin/gemcitabine in the control arm performed better than patients treated with taxanes. Some differences in baseline characteristics between chemotherapy backbones were notable, as well as some differences between the pembrolizumab + chemotherapy arm and the placebo + chemotherapy as to be expected. Cox regressions showed however that the difference between treatment effects of patients treated with Gemcitabine/Carboplatin and Taxane cannot be explained by baseline characteristics, even by adjusting for disease free interval. Based on an inter-trial comparison, the outcome in the placebo + carboplatin/gemcitabine or pemetrexed arms in KEYNOTE-355 was not necessarily very consistent with external data. However, due to the small number of patients in the placebo + chemotherapy arms (especially paclitaxel, n=11) and the limitations of indirect study comparisons, conclusions are hampered, and results are prone to random variations. The question whether gemcitabine/carboplatin would be less effective than pembrolizumab + taxanes when administered to patients with tumors that express PD-L1 (CPS ≥ 10) is clinically relevant. However, it is acknowledged that there are many uncertainties around this question and maybe available data are not sufficient to draw reliable conclusions. In conclusion, the criteria used to choose one of the chemotherapy regimens remain not fully clear. Differences in baseline and prognostic criteria are notable, though measured characteristics do not seem to have an impact on the results. The performance of the different chemotherapy backbones in the control arm is variable. Numbers are small in subgroups and differences cannot be explained. Given the experience with pembrolizumab as add-on to platinum compounds in other disease settings, it would not be biologically plausible to assume a lack of treatment effect with carboplatin/gemcitabine as backbone. When considering the relevance to add information in the SmPC about the different treatment effects per chemotherapy regimen, it was agreed that, based on the available evidence, such information might not be appropriate.

The benefit of the addition of pembrolizumab to paclitaxel vs paclitaxel alone seems more pronounced than for pembrolizumab + nab-paclitaxel vs nab-paclitaxel. This is in contrast with what observed in

<div style=\"page-break-after: always\"></div>

studies IMpassion-130 26   27 and IMpassion-131 28   29  (atezolizumab + nab-paclitaxel or paclitaxel, respectively). While no concern is raised by KEYNOTE-355 results over the use of pembrolizumab combined with paclitaxel in this setting, limitations of subgroup analyses are acknowledged, especially for the limited number of patients receiving paclitaxel (33 vs 11 in the experimental and control arm, respectively, of the CPS≥10 population).

Patients with early recurrences (i.e. between 6 and 12 months following completion of definitive treatment for early disease) were enrolled in KEYNOTE-355 and represented about 20% of the total population, while not included instead in similar trials in the same setting (e.g. IMpassion-130 and -131). According to subgroup analyses, pembrolizumab on top of chemotherapy appears not to give survival or response advantage compared to chemotherapy alone in this subgroup. However, it is acknowledged the limited number of subjects who had early recurrence, especially in the CPS≥10 population and in the control arm (n=17), and the lack of support from other trials, limiting the possibility to draw conclusions in this population.

Regarding age , efficacy results were overall consistent in patients &lt;65 and ≥65 years. No conclusions can be drawn regarding efficacy in patients ≥75 years (n=10).

Heterogeneous treatment effects were further observed taking prior (neo)adjuvant chemotherapy treatments into consideration. Patients with prior chemotherapy (n=193) had a smaller additional benefit by adding pembrolizumab compared with patients without prior (neo)adjuvant therapy (n=130): PFS HR 0.78 vs. 0.47, OS HR 0.90 vs. 0.46, and ORR difference 3.8% vs. 27.7% for patients with and without prior treatment, respectively. The same was observed in the analogous IMpower130 study. Assessment of baseline characteristics and prognostic factors for patients with and without prior (neo)adjuvant chemotherapy and sensitivity analyses to account for possible differences in baseline factors did not identify a single factor that could explain the observed differences in efficacy outcomes between both subgroups. Only 'number of metastatic organ sites at baseline' changed the HR estimates in participants with prior (neo)adjuvant chemotherapy (PFS 0.78 to 0.66; OS 0.90 to 0.76), likely due to baseline imbalances, as a higher proportion of participants in the pembrolizumab arm had ≥ 3 metastatic organ sites as compared to the placebo arm in this subgroup.

In addition, no clear benefit was observed for the European population based on a post-hoc analysis (PFS HR 1.02; OS HR 1.41; ORR difference - 5.8% for the comparison of pembrolizumab + chemotherapy arm compared to the plac ebo + chemotherapy arm in the CPS ≥10 subgroup), within the limit of small number of EU patients (64 vs 28 in the CPS≥10 population). Compared to the ITT population, an outperformance of the control arm and more modest results in the experimental group were noted. Such negative trend was however not observed in the pre-specified subgroup Europe + North America + Australia (which includes EU patients). Some differences were observed in baseline characteristics between the two arms for participants enrolled in EU, as expected due to small number, but no single baseline factor seems to explain the observed results in the EU subgroup. Overall, within each region, intervention groups were generally well-balanced for all baseline characteristics and prognostic factors. Considering that the larger subgroup 'Europe/ North America / Australia' with CPS ≥10 (n=212) derived a benefit, and that there is no biological plausible rationale that the European TNBC patients would derive an inferior benefit, the results in the European CPS ≥ 10 population could theoretically be a chance finding due to random variation.

26  Schmid P, et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018 Nov 29;379(22):2108 -2121.

27   EPAR Tecentriq Var II/X/17 EMA/CHMP/425313/2019

28  Milles D. Primary results from IMpassion131, a double-blind placebo-controlled randomised phse 3 trial of first-line paclitaxel (PAC) +/- atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC). In: ESMO 2020 Proffered paper - breast cancer, metastatic 1, 2020 29  https://www.ema.europa.eu/en/news/ema-reminds-physicians-use-tecentriq-nab-paclitaxel-treating-breast-cancer

<div style=\"page-break-after: always\"></div>

## 2.4.4. Conclusions on the clinical efficacy

The pivotal double-blind KEYNOTE-355 study, at the IA2 (final analysis for PFS), showed a statistically significant improvement in PFS for pembrolizumab+chemotherapy compared to placebo+chemotherapy as 1L treatment of locally recurrent unresectable/metastatic TNBC patients only in the subset whose tumor has high PDL1 expression (CPS≥10) (HR=0.65, gain in median PFS of 4 months). This result is supported by a statistically significant OS advantage at the final analysis for OS. ORR, DOR and PFS2 were also in favour of the combination. The main concern derived from the late addition of the hypotheses in CPS≥10 population one year af ter conducting IA1, in an otherwise negative trial. The claim that the rational of the additional CPS≥10 cut off was based only on external results (KEYNOTE -119 and IMpassion-130) and no data from KEYNOTE-355 study itself was used is accepted. The biological rationale for an enriched pembrolizumab efficacy with higher PD-L1 expression is considered supported by the above external data, whose timing is also compatible with the amendment released, and by pembrolizumab data in various diseases. Additional data provided reassured that the MAH was blinded to data and that was comprehensible to set the cutoff at CPS 10. It is acknowledged that there are many uncertainties around the observed lower benefit of pembrolizumab in combination with carboplatin/gemcitabine and available data are not sufficient to draw reliable conclusions on this aspect.

## 2.5. Clinical safety

## Introduction

The safety data of pembrolizumab (KEYTRUDA, MK-3475) in combination with chemotherapy (nab-paclitaxel, paclitaxel, or gemcitabine/carboplatin) in the context of its intended use for the treatment of patients with locally recurrent inoperable or metastatic TNBC, derive from the pooled data from Part 1 and Part 2 of study KEYNOTE-355.

Part 1 - safety run-in : unblinded, open-label, safety run-in that monitored participants (N=35) for unacceptable toxicities to study treatment (pembrolizumab + chemotherapy). Participants were assigned by forced randomization to ensure at least 10 participants were included in each treatment group (pembrolizumab + gemcitabine/carboplatin or pembrolizumab + taxane [paclitaxel or nab-paclitaxel]).

Part 2 - phase 3 study : double-blind, placebo-controlled study on a background of chemotherapy, with 847 eligible participants randomly assigned in a 2:1 ratio to receive pembrolizumab + chemotherapy or placebo + chemotherapy, respectively.

The following table provides an overview of safety datasets used in the current application:

## Safety Datasets and Treatment Group Nomenclature

| Dataset                                   | Population                                                                                                                                                                                                                         | Study Treatment                                                                       | Nomenclature in Tables                        | Nomenclature in Text               |
|-------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|-----------------------------------------------|------------------------------------|
| KEYNOTE- 355 pembrolizumab + chemotherapy | N=596: Safety data from participants with locally recurrent inoperable or metastatic TNBC who received pembrolizumab in combination with chemotherapy in KEYNOTE-355. Includes safety data from Part 1 and Part 2 pooled together. | Pembrolizumab + chemotherapy (nab-paclitaxel, paclitaxel, or gemcitabine/carboplatin) | KN355 Data for Pembrolizumab + Chemotherapy a | Pembrolizumab + chemotherapy group |

<div style=\"page-break-after: always\"></div>

| KEYNOTE- 355 placebo + chemotherapy        | N=281: Safety data from participants with locally recurrent inoperable or metastatic TNBC who received placebo in combination with chemotherapy in KEYNOTE-355.                                                                                                                                                                                                                                                                                                                                                               | Placebo + chemotherapy (nab-paclitaxel, paclitaxel, or gemcitabine/carboplatin)   | KN355 Data for Placebo + Chemotherapy b                  | Placebo + chemotherapy group      |
|--------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|----------------------------------------------------------|-----------------------------------|
| TNBC pembrolizumab monotherapy             | N=595: Pooled safety data from participants with metastatic TNBC treated with pembrolizumab monotherapy in Cohort A of KEYNOTE-012, KEYNOTE-086, and KEYNOTE- 119.                                                                                                                                                                                                                                                                                                                                                            | Pembrolizumab Monotherapy                                                         | mTNBC Safety Dataset for Pembrolizumab Monotherapy c     | metastatic TNBC monotherapy group |
| Pembrolizumab monotherapy reference safety | N=5884: Pooled safety data from participants treated with pembrolizumab monotherapy, including 2076 participants with advanced melanoma from KEYNOTE-001, KEYNOTE- 002, KEYNOTE-006, and KEYNOTE-054; 2022 participants with NSCLC from KEYNOTE-001, KEYNOTE- 010, KEYNOTE-024, and KEYNOTE-042; 909 participants with HNSCC from KEYNOTE 012, KEYNOTE-040, KEYNOTE-048, and KEYNOTE- 055; 241 participants from HL in KEYNOTE-013 and KEYNOTE- 087, and 636 participants from bladder cancer in KEYNOTE-045 and KEYNOTE-052. | Pembrolizumab Monotherapy                                                         | Reference Safety Dataset for Pembrolizumab Monotherapy d | Pembrolizumab monotherapy RSD     |

Abbreviations: HL=Hodgkin lymphoma; HNSCC=head and neck squamous cell carcinoma; ISS = Integrated Summary of Safety; mTNBC = metastatic triple negative breast cancer; N = number; NSCLC = non-small cell lung cancer; RSD = reference safety dataset; TNBC = triple negative breast cancer.

- a. Includes all participants who received at least 1 dose of pembrolizumab or chemotherapy in KEYNOTE-355.
- b. Includes all participants who received at least 1 dose of placebo or chemotherapy in KEYNOTE-355.
- c. Includes all participants who received at least 1 dose of pembrolizumab in KEYNOTE-012 Cohort A, KEYNOTE-086, or KEYNOTE-119.
- d. The studies that comprise the Pembrolizumab Monotherapy RSD are listed in the footnotes of the data tables in this document and in the ISS.
- Safety results of KEYNOTE-012 (data cutoff 26-APR-2016): pembrolizumab (10 mg/kg Q2W) in participants with PDL1 positive advanced solid tumors. The study included 4 cohorts (Cohort A to D); Cohort A enrolled participants with metastatic TNBC (N=32).

- Safety results of KEYNOTE-086 (data cutoff 10-NOV-2017): pembrolizumab (200 mg Q3W) as 2L+ monotherapy in participants with metastatic TNBC independent of PDL1 status (Cohort A; N=170) or as 1L monotherapy in participants with PD-L1 positive (defined as CPS ≥ 1) metastatic TNBC (Cohort B; N=84).

- Safety results of KEYNOTE-119 (data cutoff 11-APR2019): pembrolizumab (200 mg Q3W; N=312) versus single-agent chemotherapy per physician's choice (ie, capecitabine, eribulin, gemcitabine, or vinorelbine; N=310) for participants receiving 2L or 3L treatment for metastatic TNBC.

<div style=\"page-break-after: always\"></div>

## Patient exposure

## Summary of Drug Exposure (ASaT Population)

|                                | KN355 Data for Pembrolizumab + Chemotherapy †† (N=596)   | KN355 Data for Placebo + Chemotherapy ¶¶ (N=281)   | mTNBC Safety Dataset for Pembrolizumab Monotherapy ‡‡ (N=595)   | Reference Safety Dataset for Pembrolizumab Monotherapy §§ (N=5884)   |
|--------------------------------|----------------------------------------------------------|----------------------------------------------------|-----------------------------------------------------------------|----------------------------------------------------------------------|
| Study Days On-Therapy (Months) | Study Days On-Therapy (Months)                           | Study Days On-Therapy (Months)                     | Study Days On-Therapy (Months)                                  | Study Days On-Therapy (Months)                                       |
| Mean                           | 8.6                                                      | 7.4                                                | 4.0                                                             | 7.1                                                                  |
| Median                         | 6.2                                                      | 5.3                                                | 2.1                                                             | 4.9                                                                  |
| SD                             | 7.15                                                     | 6.57                                               | 5.27                                                            | 6.55                                                                 |
| Range                          | 0.0 to 38.3                                              | 0.0 to 33.6                                        | 0.0 to 27.1                                                     | 0.0 to 32.5                                                          |

Each subject is counted once on each applicable duration category row.

Duration of Exposure is calculated as last dose date - first dose date + 1.

††  Includes all subjects who received at least one dose of treatment in the pembrolizumab + chemotherapy arm of KN355.

¶¶  Includes all subjects who received at least one dose of treatment in the placebo + chemotherapy arm of KN355.

‡‡  Includes all subjects who received at least one dose of pembrolizumab in KN012-Cohort A, KN086 and KN119.

§§  Includes all subjects who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 Cohorts B and B2 (Head and Neck Cancer), KN013 Cohort 3 (Hodgkin Lymphoma), KN024, KN040, KN042, KN045, KN048, KN052, KN054, KN055 and KN087.

Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015, KN006: 03MAR2015, KN054: 02OCT2017)

Database cutoff date for Lung (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015, KN024: 10JUL2017, KN042: 04SEP2018)

Database cutoff date for HNSCC (KN012-HNSCC: 26APR2016, KN040: 15MAY2017, KN048: 25FEB2019, KN055: 22APR2016)

Database cutoff date for cHL (KN013-Cohort 3: 28SEP2018, KN087: 25SEP2016)

Database cutoff date for Bladder (KN045: 26OCT2017, KN052: 26SEP2018)

Database cutoff date for TNBC (KN355: 11DEC2019, KN012: 26APR2016, KN086: 10NOV2017, KN119: 11APR2019)

KN021 + KN048 + KN189 + KN407

Pembrolizumab Combo Data ¶¶

(N=1067)

## Study Days On-Therapy (Months)

Mean

Median

SD

Range

9.7

6.9

8.37

0.0 to 48.0

Each subject is counted once on each applicable duration category row.

Duration of Exposure is calculated as last dose date - first dose date + 1.

††  Includes all subjects who received at least one dose of treatment in the pembrolizumab + chemotherapy arm of KN355.

§§  Includes all subjects who received at least one dose of treatment in the placebo + chemotherapy arm of KN355.

¶¶  Includes all subjects who received at least one dose of pembrolizumab combo therapy in KN021-A/C/G, KN048, KN189, and KN407.

MK-3475 Database Cutoff Date for Lung (KN021: 19AUG2019, KN189: 20MAY2019, KN407: 09MAY2019)

MK-3475 Database Cutoff Date for HNSCC (KN048: 25FEB2019)

MK-3475 Database Cutoff Date for mTNBC (KN355: 11DEC2019)

MedDRA version used is 23.0.

## Drug exposure by duration (ASaT Population)

<!-- image -->

|                   |      | KN355 Data for Pembrolizumab + Chemotherapy †† (N=596)   | KN355 Data for Pembrolizumab + Chemotherapy †† (N=596)   | KN355 Data for Pembrolizumab + Chemotherapy †† (N=596)   | KN355 Data for Placebo + Chemotherapy ¶¶ (N=281)   | KN355 Data for Placebo + Chemotherapy ¶¶ (N=281)   | KN355 Data for Placebo + Chemotherapy ¶¶ (N=281)   | mTNBC Safety Dataset for Pembrolizumab Monotherapy ‡‡ (N=595)   | mTNBC Safety Dataset for Pembrolizumab Monotherapy ‡‡ (N=595)   | mTNBC Safety Dataset for Pembrolizumab Monotherapy ‡‡ (N=595)   | Reference Safety Dataset for Pembrolizumab Monotherapy §§ (N=5884)   | Reference Safety Dataset for Pembrolizumab Monotherapy §§ (N=5884)   | Reference Safety Dataset for Pembrolizumab Monotherapy §§ (N=5884)   |
|-------------------|------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|
|                   |      | n                                                        | (%)                                                      | Person- years                                            | n                                                  | (%)                                                | Person- years                                      | n                                                               | (%)                                                             | Person- years                                                   | n                                                                    | (%)                                                                  | Person- years                                                        |
| Duration exposure | of   | of                                                       | of                                                       | of                                                       | of                                                 | of                                                 | of                                                 | of                                                              | of                                                              | of                                                              | of                                                                   | of                                                                   | of                                                                   |
| >0 m              | >0 m | 596                                                      | (100)                                                    | (426.0)                                                  | 281                                                | (100.0)                                            | (173.6)                                            | 595                                                             | (100.0)                                                         | (198.9)                                                         | 5,884                                                                | (100.0)                                                              | (3,465.2)                                                            |

7.1

4.9

6.55

0.0 to 32.5

<div style=\"page-break-after: always\"></div>

| >=1 m   |   568 | (95.3)   | (425.1)   |   266 | (94.7)   | (173.0)   |   459 | (77.1)   | (193.7)   | 5,033   | (85.5)   | (3,437.0)   |
|---------|-------|----------|-----------|-------|----------|-----------|-------|----------|-----------|---------|----------|-------------|
| >=3 m   |   469 | (78.7)   | (408.6)   |   214 | (76.2)   | (164.0)   |   222 | (37.3)   | (157.0)   | 3,620   | (61.5)   | (3,201.8)   |
| >=6 m   |   302 | (50.7)   | (348.1)   |   125 | (44.5)   | (131.5)   |   105 | (17.6)   | (117.0)   | 2,610   | (44.4)   | (2,835.0)   |
| >=12 m  |   151 | (25.3)   | (240.3)   |    47 | (16.7)   | (77.4)    |    48 | (8.1)    | (77.6)    | 1,196   | (20.3)   | (1,760.2)   |

Each subject is counted once on each applicable duration category row.

Duration of Exposure is calculated as last dose date - first dose date + 1.

††  Includes all subjects who received at least one dose of treatment in the pembrolizumab + chemotherapy arm of KN355.

¶¶  Includes all subjects who received at least one dose of treatment in the placebo + chemotherapy arm of KN355.

‡‡  Includes all subjects who received at least one dose of pembrolizumab in KN012-Cohort A, KN086 and KN119.

§§  Includes all subjects who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 Cohorts B and B2 (Head and Neck Cancer), KN013 Cohort 3 (Hodgkin Lymphoma), KN024, KN040, KN042, KN045, KN048, KN052, KN054, KN055 and KN087.

Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015, KN006: 03MAR2015, KN054: 02OCT2017)

Database cutoff date for Lung (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015, KN024: 10JUL2017, KN042: 04SEP2018)

Database cutoff date for HNSCC (KN012-HNSCC: 26APR2016, KN040: 15MAY2017, KN048: 25FEB2019, KN055: 22APR2016)

Database cutoff date for cHL (KN013-Cohort 3: 28SEP2018, KN087: 25SEP2016)

Database cutoff date for Bladder (KN045: 26OCT2017, KN052: 26SEP2018)

Database cutoff date for TNBC (KN355: 11DEC2019, KN012: 26APR2016, KN086: 10NOV2017, KN119: 11APR2019)

## Subject characteristics (ASaT population)

|                                            | KN355 Data for Pembrolizumab + Chemotherapy ††   | KN355 Data for Pembrolizumab + Chemotherapy ††   | KN355 Data for Placebo + Chemotherapy ¶¶   | KN355 Data for Placebo + Chemotherapy ¶¶   | mTNBC Safety Dataset for Pembrolizumab Monotherapy ‡‡   | mTNBC Safety Dataset for Pembrolizumab Monotherapy ‡‡   | Reference Safety Dataset for Pembrolizumab Monotherapy §§   | Reference Safety Dataset for Pembrolizumab Monotherapy §§   |
|--------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------|--------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|
|                                            | n                                                | (%)                                              | n                                          | (%)                                        | n                                                       | (%)                                                     | n                                                           | (%)                                                         |
| Subjects in population                     | 596                                              |                                                  | 281                                        |                                            | 595                                                     |                                                         | 5,884                                                       |                                                             |
| Gender                                     |                                                  |                                                  |                                            |                                            |                                                         |                                                         |                                                             |                                                             |
| Male                                       | 0                                                | (0.0)                                            | 0                                          | (0.0)                                      | 0                                                       | (0.0)                                                   | 3,887                                                       | (66.1)                                                      |
| Female                                     | 596                                              | (100.0)                                          | 281                                        | (100.0)                                    | 595                                                     | (100.0)                                                 | 1,997                                                       | (33.9)                                                      |
| Age (Years)                                |                                                  |                                                  |                                            |                                            |                                                         |                                                         |                                                             |                                                             |
| <65                                        | 459                                              | (77.0)                                           | 224                                        | (79.7)                                     | 474                                                     | (79.7)                                                  | 3,385                                                       | (57.5)                                                      |
| >=65                                       | 137                                              | (23.0)                                           | 57                                         | (20.3)                                     | 121                                                     | (20.3)                                                  | 2,499                                                       | (42.5)                                                      |
| Mean                                       | 53.9                                             |                                                  | 53.0                                       |                                            | 52.8                                                    |                                                         | 60.6                                                        |                                                             |
| SD                                         | 12.8                                             |                                                  | 12.7                                       |                                            | 12.3                                                    |                                                         | 13.2                                                        |                                                             |
| Median                                     | 54.0                                             |                                                  | 53.0                                       |                                            | 52.0                                                    |                                                         | 62.0                                                        |                                                             |
| Range                                      | 25 to 85                                         |                                                  | 22 to 77                                   |                                            | 26 to 91                                                |                                                         | 15 to 94                                                    |                                                             |
| Race                                       |                                                  |                                                  |                                            |                                            |                                                         |                                                         |                                                             |                                                             |
| American Indian Or Alaska Native           | 10                                               | (1.7)                                            | 1                                          | (0.4)                                      | 5                                                       | (0.8)                                                   | 29                                                          | (0.5)                                                       |
| Asian                                      | 138                                              | (23.2)                                           | 52                                         | (18.5)                                     | 125                                                     | (21.0)                                                  | 658                                                         | (11.2)                                                      |
| Black Or African American                  | 21                                               | (3.5)                                            | 17                                         | (6.0)                                      | 45                                                      | (7.6)                                                   | 108                                                         | (1.8)                                                       |
| Multiracial                                | 11                                               | (1.8)                                            | 8                                          | (2.8)                                      | 15                                                      | (2.5)                                                   | 66                                                          | (1.1)                                                       |
| Native Hawaiian Or Other Pacific Islander  | 0                                                | (0.0)                                            | 0                                          | (0.0)                                      | 0                                                       | (0.0)                                                   | 4                                                           | (0.1)                                                       |
| White                                      | 399                                              | (66.9)                                           | 195                                        | (69.4)                                     | 390                                                     | (65.5)                                                  | 4,444                                                       | (75.5)                                                      |
| Missing                                    | 17                                               | (2.9)                                            | 8                                          | (2.8)                                      | 15                                                      | (2.5)                                                   | 575                                                         | (9.8)                                                       |
| Ethnicity                                  |                                                  |                                                  |                                            |                                            |                                                         |                                                         |                                                             |                                                             |
| Hispanic Or Latino                         | 115                                              | (19.3)                                           | 48                                         | (17.1)                                     | 59                                                      | (9.9)                                                   | 388                                                         | (6.6)                                                       |
| Not Hispanic Or Latino                     | 453                                              | (76.0)                                           | 218                                        | (77.6)                                     | 500                                                     | (84.0)                                                  | 4,697                                                       | (79.8)                                                      |
| Not Reported                               | 18                                               | (3.0)                                            | 10                                         | (3.6)                                      | 14                                                      | (2.4)                                                   | 174                                                         | (3.0)                                                       |
| Unknown                                    | 9                                                | (1.5)                                            | 5                                          | (1.8)                                      | 21                                                      | (3.5)                                                   | 111                                                         | (1.9)                                                       |
| Missing                                    | 1                                                | (0.2)                                            | 0                                          | (0.0)                                      | 1                                                       | (0.2)                                                   | 514                                                         | (8.7)                                                       |
| Age Class (Years)                          |                                                  |                                                  |                                            |                                            |                                                         |                                                         |                                                             |                                                             |
| <65                                        | 459                                              | (77.0)                                           | 224                                        | (79.7)                                     | 474                                                     | (79.7)                                                  | 3,385                                                       | (57.5)                                                      |
| 65-74                                      | 103                                              | (17.3)                                           | 48                                         | (17.1)                                     | 91                                                      | (15.3)                                                  | 1,737                                                       | (29.5)                                                      |
| 75-84                                      | 33                                               | (5.5)                                            | 9                                          | (3.2)                                      | 27                                                      | (4.5)                                                   | 663                                                         | (11.3)                                                      |
| >=85                                       | 1                                                | (0.2)                                            | 0                                          | (0.0)                                      | 3                                                       | (0.5)                                                   | 99                                                          | (1.7)                                                       |
| ECOG Performance Scale                     |                                                  |                                                  |                                            |                                            |                                                         |                                                         |                                                             |                                                             |
| [0] Normal Activity                        | 357                                              | (59.9)                                           | 173                                        | (61.6)                                     | 160                                                     | (26.9)                                                  | 2,761                                                       | (46.9)                                                      |
| [1] Symptoms, but ambulatory               | 238                                              | (39.9)                                           | 108                                        | (38.4)                                     | 293                                                     | (49.2)                                                  | 2,931                                                       | (49.8)                                                      |
| Other/Missing                              | 1                                                | (0.2)                                            | 0                                          | (0.0)                                      | 142                                                     | (23.9)                                                  | 192                                                         | (3.3)                                                       |
| KN355 Data for KN355 Data for mTNBC Safety | KN355 Data for KN355 Data for mTNBC Safety       | KN355 Data for KN355 Data for mTNBC Safety       | KN355 Data for KN355 Data for mTNBC Safety | KN355 Data for KN355 Data for mTNBC Safety | KN355 Data for KN355 Data for mTNBC Safety              | KN355 Data for KN355 Data for mTNBC Safety              | Reference                                                   | Reference                                                   |

5,884

1,997

3,385

2,499

15 to 94

(0.5)

658

(1.8)

(1.1)

(0.1)

4,444

(9.8)

(6.6)

4,697

(3.0)

(1.9)

(8.7)

3,385

1,737

(1.7)

2,761

2,931

192

(3.3)

<div style=\"page-break-after: always\"></div>

(35.5)

(64.5)

|                   | Pembrolizumab + Chemotherapy † †   | Pembrolizumab + Chemotherapy † †   | Placebo + Chemotherapy ¶ ¶   | Placebo + Chemotherapy ¶ ¶   | Dataset for Pembrolizumab Monotherapy ‡‡   | Dataset for Pembrolizumab Monotherapy ‡‡   | Safety Dataset for Pembrolizumab Monotherapy §§   | Safety Dataset for Pembrolizumab Monotherapy §§   |
|-------------------|------------------------------------|------------------------------------|------------------------------|------------------------------|--------------------------------------------|--------------------------------------------|---------------------------------------------------|---------------------------------------------------|
|                   | n                                  | (%)                                | n                            | (%)                          | n                                          | (%)                                        | n                                                 | (%)                                               |
| Geographic Region |                                    |                                    |                              |                              |                                            |                                            |                                                   |                                                   |
| EU                | 177                                | (29.7)                             | 94                           | (33.5)                       | 195                                        | (32.8)                                     | 2,091                                             | (35.5)                                            |
| Ex-EU             | 419                                | (70.3)                             | 187                          | (66.5)                       | 400                                        | (67.2)                                     | 3,793                                             | (64.5)                                            |

††  Includes all subjects who received at least one dose of treatment in the pembrolizumab + chemotherapy arm of KN355.

¶¶  Includes all subjects who received at least one dose of treatment in the placebo + chemotherapy arm of KN355.

‡‡  Includes all subjects who received at least one dose of pembrolizumab in KN012-Cohort A, KN086 and KN119.

§§  Includes all subjects who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 Cohorts B and B2 (Head and Neck Cancer), KN013 Cohort 3 (Hodgkin Lymphoma), KN024, KN040, KN042, KN045, KN048, KN052, KN054, KN055 and KN087.

Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015, KN006: 03MAR2015, KN054: 02OCT2017)

Database cutoff date for Lung (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015, KN024: 10JUL2017, KN042: 04SEP2018)

Database cutoff date for HNSCC (KN012-HNSCC: 26APR2016, KN040: 15MAY2017, KN048: 25FEB2019, KN055: 22APR2016)

Database cutoff date for cHL (KN013-Cohort 3: 28SEP2018, KN087: 25SEP2016)

Database cutoff date for Bladder (KN045: 26OCT2017, KN052: 26SEP2018)

Database cutoff date for TNBC (KN355: 11DEC2019, KN012: 26APR2016, KN086: 10NOV2017, KN119: 11APR2019)

## Adverse events

## Overall AEs

## Summary of Adverse Events (ASaT population)

|                                                      | KN355 Data for Pembrolizumab + Chemotherapy † †   | KN355 Data for Pembrolizumab + Chemotherapy † †   | KN355 Data for Placebo + Chemotherapy ¶ ¶   | KN355 Data for Placebo + Chemotherapy ¶ ¶   | mTNBC Safety Dataset for Pembrolizumab Monotherapy ‡‡   | mTNBC Safety Dataset for Pembrolizumab Monotherapy ‡‡   | Reference Safety Dataset for Pembrolizumab Monotherapy §§   | Reference Safety Dataset for Pembrolizumab Monotherapy §§   |
|------------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|
|                                                      | n                                                 | (%)                                               | n                                           | (%)                                         | n                                                       | (%)                                                     | n                                                           | (%)                                                         |
| Subjects in population                               | 596                                               |                                                   | 281                                         |                                             | 595                                                     |                                                         | 5,884                                                       |                                                             |
| with one or more adverse events                      | 588                                               | (98.7)                                            | 276                                         | (98.2)                                      | 559                                                     | (93.9)                                                  | 5,687                                                       | (96.7)                                                      |
| with no adverse event                                | 8                                                 | (1.3)                                             | 5                                           | (1.8)                                       | 36                                                      | (6.1)                                                   | 197                                                         | (3.3)                                                       |
| with drug-related † adverse events                   | 574                                               | (96.3)                                            | 267                                         | (95.0)                                      | 368                                                     | (61.8)                                                  | 4,123                                                       | (70.1)                                                      |
| with toxicity grade 3-5 adverse events               | 465                                               | (78.0)                                            | 207                                         | (73.7)                                      | 218                                                     | (36.6)                                                  | 2,813                                                       | (47.8)                                                      |
| with toxicity grade 3-5 drug- related adverse events | 407                                               | (68.3)                                            | 188                                         | (66.9)                                      | 79                                                      | (13.3)                                                  | 909                                                         | (15.4)                                                      |
| with serious adverse events                          | 181                                               | (30.4)                                            | 67                                          | (23.8)                                      | 140                                                     | (23.5)                                                  | 2,252                                                       | (38.3)                                                      |
| with serious drug-related adverse events             | 105                                               | (17.6)                                            | 34                                          | (12.1)                                      | 46                                                      | (7.7)                                                   | 650                                                         | (11.0)                                                      |
| with any dose modification ‡ due to an adverse event | 456                                               | (76.5)                                            | 209                                         | (74.4)                                      | 129                                                     | (21.7)                                                  | 2,028                                                       | (34.5)                                                      |
| pembrolizumab dose modification                      | 18                                                | (3.0)                                             | 0                                           | (0.0)                                       | 129                                                     | (21.7)                                                  | 2,028                                                       | (34.5)                                                      |
| pembrolizumab/placebo dose modification              | 314                                               | (52.7)                                            | 134                                         | (47.7)                                      | 129                                                     | (21.7)                                                  | 2,028                                                       | (34.5)                                                      |
| nab-paclitaxel dose                                  | 106                                               | (17.8)                                            | 45                                          | (16.0)                                      | 0                                                       | (0.0)                                                   | 0                                                           | (0.0)                                                       |

(96.7)

197

(3.3)

(70.1)

(47.8)

909

(15.4)

(38.3)

650

(11.0)

(34.5)

(34.5)

(34.5)

0

(0.0)

<div style=\"page-break-after: always\"></div>

0

(0.0)

0

(0.0)

0

(0.0)

311

(5.3)

39

(0.7)

783

(13.3)

783

(13.3)

783

(13.3)

0

(0.0)

0

(0.0)

0

(0.0)

0

(0.0)

405

(6.9)

405

(6.9)

405

(6.9)

0

(0.0)

0

(0.0)

0

(0.0)

0

(0.0)

570

(9.7)

570

(9.7)

570

(9.7)

0

(0.0)

0

(0.0)

0

(0.0)

0

(0.0)

244

(4.1)

244

(4.1)

244

(4.1)

0

(0.0)

0

(0.0)

0

(0.0)

0

(0.0)

| modification                                                      | 60                                            |                                               | 21                                        |                                           |                                                       | (0.0)                                                 | 0                                                         | (0.0)                                                     |
|-------------------------------------------------------------------|-----------------------------------------------|-----------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|
| paclitaxel dose modification gemcitabine dose modification        | 275                                           | (10.1) (46.1)                                 | 138                                       | (7.5) (49.1)                              | 0 0                                                   | (0.0)                                                 | 0                                                         | (0.0)                                                     |
| carboplatin dose modification                                     | 272                                           | (45.6)                                        | 140                                       | (49.8)                                    | 0                                                     | (0.0)                                                 | 0                                                         | (0.0)                                                     |
| who died                                                          | 15                                            | (2.5)                                         | 5                                         | (1.8)                                     | 11                                                    | (1.8)                                                 | 311                                                       | (5.3)                                                     |
| who died due to a drug-related adverse event                      | 2                                             | (0.3)                                         | 0                                         | (0.0)                                     | 2                                                     | (0.3)                                                 | 39                                                        | (0.7)                                                     |
| discontinued any drug due to                                      | 128                                           | (21.5)                                        | 37                                        | (13.2)                                    | 30                                                    | (5.0)                                                 | 783                                                       | (13.3)                                                    |
| an adverse event discontinued pembrolizumab                       | 7                                             | (1.2)                                         | 0                                         | (0.0)                                     | 30                                                    | (5.0)                                                 | 783                                                       | (13.3)                                                    |
| discontinued                                                      | 60                                            | (10.1)                                        | 15                                        | (5.3)                                     | 30                                                    | (5.0)                                                 | 783                                                       | (13.3)                                                    |
| pembrolizumab/placebo                                             |                                               |                                               |                                           |                                           |                                                       |                                                       |                                                           |                                                           |
| discontinued nab-paclitaxel                                       | 26                                            | (4.4)                                         | 4                                         | (1.4)                                     | 0                                                     | (0.0)                                                 | 0                                                         | (0.0)                                                     |
| discontinued paclitaxel                                           | 19                                            | (3.2)                                         | 6                                         | (2.1)                                     | 0                                                     | (0.0)                                                 | 0                                                         | (0.0)                                                     |
| discontinued gemcitabine                                          | 39                                            | (6.5)                                         | 16                                        | (5.7)                                     | 0                                                     | (0.0)                                                 | 0                                                         | (0.0)                                                     |
| discontinued carboplatin                                          | 44                                            | (7.4)                                         | 17                                        | (6.0)                                     | 0                                                     | (0.0)                                                 | 0                                                         | (0.0)                                                     |
| discontinued any drug due to a                                    | 111                                           | (18.6)                                        | 31                                        | (11.0)                                    | 20                                                    | (3.4)                                                 | 405                                                       | (6.9)                                                     |
| drug-related adverse event discontinued pembrolizumab             | 3                                             | (0.5)                                         | 0                                         | (0.0)                                     | 20                                                    | (3.4)                                                 | 405                                                       | (6.9)                                                     |
| discontinued                                                      | 51                                            | (8.6)                                         | 10                                        | (3.6)                                     | 20                                                    | (3.4)                                                 | 405                                                       | (6.9)                                                     |
| pembrolizumab/placebo discontinued nab-paclitaxel                 | 22                                            | (3.7)                                         | 3                                         | (1.1)                                     | 0                                                     | (0.0)                                                 | 0                                                         | (0.0)                                                     |
| discontinued paclitaxel                                           | 17                                            | (2.9)                                         | 3                                         | (1.1)                                     | 0                                                     | (0.0)                                                 | 0                                                         | (0.0)                                                     |
| discontinued gemcitabine                                          | 34                                            | (5.7)                                         | 15                                        | (5.3)                                     | 0                                                     | (0.0)                                                 | 0                                                         | (0.0)                                                     |
| discontinued carboplatin                                          | 38                                            | (6.4)                                         | 16                                        | (5.7)                                     | 0                                                     | (0.0)                                                 | 0                                                         | (0.0)                                                     |
| discontinued any drug due to a serious adverse event              | 51                                            | (8.6)                                         | 9                                         | (3.2)                                     | 17                                                    | (2.9)                                                 | 570                                                       | (9.7)                                                     |
| discontinued pembrolizumab                                        | 6                                             | (1.0)                                         | 0                                         | (0.0)                                     | 17                                                    | (2.9)                                                 | 570                                                       | (9.7)                                                     |
| discontinued                                                      | 39                                            | (6.5)                                         | 8                                         | (2.8)                                     | 17                                                    | (2.9)                                                 | 570                                                       | (9.7)                                                     |
| discontinued nab-paclitaxel                                       | 10                                            | (1.7)                                         | 1                                         | (0.4)                                     | 0                                                     | (0.0)                                                 | 0                                                         | (0.0)                                                     |
| †                                                                 | KN355 Data for Pembrolizumab + Chemotherapy † | KN355 Data for Pembrolizumab + Chemotherapy † | KN355 Data for Placebo + Chemotherapy ¶ ¶ | KN355 Data for Placebo + Chemotherapy ¶ ¶ | mTNBC Safety Dataset for Pembrolizumab Monotherapy ‡‡ | mTNBC Safety Dataset for Pembrolizumab Monotherapy ‡‡ | Reference Safety Dataset for Pembrolizumab Monotherapy §§ | Reference Safety Dataset for Pembrolizumab Monotherapy §§ |
|                                                                   | n                                             | (%)                                           | n                                         | (%)                                       | n                                                     | (%)                                                   | n                                                         | (%)                                                       |
| discontinued paclitaxel                                           | 5                                             | (0.8)                                         | 4                                         | (1.4)                                     | 0                                                     | (0.0)                                                 | 0                                                         | (0.0)                                                     |
| discontinued gemcitabine                                          | 10                                            | (1.7)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 0                                                         | (0.0)                                                     |
| discontinued carboplatin                                          | 9                                             | (1.5)                                         | 1                                         | (0.4)                                     | 0                                                     | (0.0)                                                 | 0                                                         | (0.0)                                                     |
| discontinued any drug due to a serious drug-related adverse event | 40                                            | (6.7)                                         | 4                                         | (1.4)                                     | 10                                                    | (1.7)                                                 | 244                                                       | (4.1)                                                     |
| discontinued pembrolizumab                                        | 3                                             | (0.5)                                         | 0                                         | (0.0)                                     | 10                                                    | (1.7)                                                 | 244                                                       | (4.1)                                                     |
| discontinued                                                      | 32                                            | (5.4)                                         | 3                                         | (1.1)                                     | 10                                                    | (1.7)                                                 | 244                                                       | (4.1)                                                     |
| pembrolizumab/placebo discontinued nab-paclitaxel                 | 6                                             | (1.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 0                                                         | (0.0)                                                     |
| discontinued paclitaxel                                           | 4                                             | (0.7)                                         | 1                                         | (0.4)                                     | 0                                                     | (0.0)                                                 | 0                                                         | (0.0)                                                     |
| discontinued gemcitabine                                          | 7                                             | (1.2)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 0                                                         | (0.0)                                                     |
| discontinued carboplatin                                          | 6                                             | (1.0)                                         | 1                                         | (0.4)                                     | 0                                                     | (0.0)                                                 | 0                                                         | (0.0)                                                     |

†  Determined by the investigator to be related to the drug.

‡  Defined as an action taken of dose reduced, drug interrupted or drug withdrawn.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

MedDRA preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.

††  Includes all subjects who received at least one dose of treatment in the pembrolizumab + chemotherapy arm of KN355.

¶¶  Includes all subjects who received at least one dose of treatment in the placebo + chemotherapy arm of KN355.

‡‡  Includes all subjects who received at least one dose of pembrolizumab in KN012-Cohort A, KN086 and KN119.

<div style=\"page-break-after: always\"></div>

§§  Includes all subjects who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 Cohorts B and B2 (Head and Neck Cancer), KN013 Cohort 3 (Hodgkin Lymphoma), KN024, KN040, KN042, KN045, KN048, KN052, KN054, KN055 and KN087.

Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015, KN006: 03MAR2015, KN054: 02OCT2017)

Database cutoff date for Lung (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015, KN024: 10JUL2017, KN042: 04SEP2018)

Database cutoff date for HNSCC (KN012-HNSCC: 26APR2016, KN040: 15MAY2017, KN048: 25FEB2019, KN055: 22APR2016)

Database cutoff date for cHL (KN013-Cohort 3: 28SEP2018, KN087: 25SEP2016)

Database cutoff date for Bladder (KN045: 26OCT2017, KN052: 26SEP2018)

Database cutoff date for TNBC (KN355: 11DEC2019, KN012: 26APR2016, KN086: 10NOV2017, KN119: 11APR2019)

## Exposure-Adjusted Adverse Events summary

## (Including multiple occurrences of events) ASaT population

Table 5.3.5.3.3-tnbc2: 2 Exposure-AdjustedAdverseEventSummary (IncludingMultiple Occurrences ofEvents) (ASaT Population)

|                                                               | Event Count and Rate(Events/100 person-years)   | Event Count and Rate(Events/100 person-years)           | Event Count and Rate(Events/100 person-years)         | Event Count and Rate(Events/100 person-years)        |
|---------------------------------------------------------------|-------------------------------------------------|---------------------------------------------------------|-------------------------------------------------------|------------------------------------------------------|
|                                                               | KN355 Data for Pembrolizumab+ Chemotherapylt    | KN355 Data for Placebo + Chemotherapyf                  | mTNBC SafetyDatasetfor Pembrolizumab Monotherapytt    | ReferenceSafetyDatasetfor Pembrolizumab Monotherapy5 |
| Number of subjects exposed                                    | 596                                             | 281                                                     | 595                                                   | 5884                                                 |
| Total exposure in person-years                                | 473.14                                          | 195.89                                                  | 246.83                                                | 3894.24                                              |
| Total events (rate)                                           |                                                 |                                                         |                                                       |                                                      |
| adverse events                                                | 13089 (2766.39) 8696 (1837.92) 2313 (488.86)    | 5283 (2696.88) 3421 (1746.36) 956 (488.02) 810 (413.49) | 4210 (1705.61) 1383 (560.30) 424 (171.78) 106 (42.94) | 60969 (1565.62) 19170 (492.27) 6130 (157.41)         |
| drug-related adverse events                                   |                                                 |                                                         |                                                       |                                                      |
| toxicitygrade3-5 adverse events                               |                                                 |                                                         |                                                       |                                                      |
| toxicity grade 3-5 drug-related adverse events                | 1929 (407.70)                                   |                                                         |                                                       | 1371 (35.21)                                         |
| serious adverse events                                        | 327 (69.11)                                     | 119 (60.75)                                             | 225 (91.16)                                           | 4072 (104.56)                                        |
| serious drug-relatedadverseevents                             | 173 (36.56)                                     | 56 (28.59)                                              | 56 (22.69)                                            | 911 (23.39)                                          |
| adverse eventsleadingtodeath                                  | 15 (3.17)                                       | 5 (2.55)                                                | 11 (4.46)                                             | 318 (8.17)                                           |
| drug-related adverse events leading to death                  | 2 (0.42)                                        | 0 (0.00)                                                | 2 (0.81)                                              | 39 (1.00)                                            |
| adverse eventsresultingindrugdiscontinuation                  | 159 (33.61)                                     | 40 (20.42)                                              | 35 (14.18)                                            | 855 (21.96)                                          |
| drug-related adverse events resulting in drug discontinuation | 141 (29.80)                                     | 34 (17.36)                                              | 24 (9.72)                                             | 442 (11.35)                                          |
| serious adverseeventsresultingindrugdiscontinuation           | 56 (11.84)                                      | 9 (4.59)                                                | 18 (7.29)                                             | 606 (15.56)                                          |

|                                                                       | Event Count and Rate (Events/100 person-years)t   | Event Count and Rate (Events/100 person-years)t   | Event Count and Rate (Events/100 person-years)t   | Event Count and Rate (Events/100 person-years)t       |
|-----------------------------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|-------------------------------------------------------|
|                                                                       | KN355 Data for Pembrolizumab + Chemotherapytt     | KN355Data forPlacebo + Chemotherapyll             | mTNBC Safety Dataset for PembrolizumabMonotherapy | Reference SafetyDatasetfor Pembrolizumab Monotherapys |
| serious drug-related adverse events resulting in drug discontinuation | 44 (9.30)                                         | 4 (2.04)                                          | 11 (4.46)                                         | 257 (6.60)                                            |

+Drug exposure is defined as the time between the first dose date + 1 day and the earlier of the last dose date + 30 or the database cutoff date.

Event rate per 100 person-years of exposure=event count *100/person-years of exposure.

Determined by the investigator to be related to the drug.

For subjects who received second course treatment,adverse events which occurredin second course phase are excluded.

Non-serious adverse events up to30 days of last dose and serious adverse events up to 90days of last dose are included.

MedDRA preferred terms *Neoplasm progression\", \"Malignant neoplasm progression” and *Disease progression” not related to the drug are excluded.

Includes all subjects who received at least one dose of treatment in the placebo + chemotherapy arm of KN355.

fi Includes all subjects who received at least one dose of treatment in the pembrolizumab+ chemotherapy arm of KN355.

# Includes allsubjects who received at least one dose of pembrolizumab in KN012-Cohort A, KNO86 and KN119.

5 Includes all subjects who received at east one dose of pmbrolizumab in KN01 Part 1 B2, B3, D,C,F1, F2,F3, KNO02 (original phase),KNO06, KN10, KN012 CohortsB and B2 Head and

Database cutoff date for Melanoma (KN001-Melanoma:18APR2014,KN002: 28FEB2015,KN006:03MAR2015,KN054:02OCT2017)

Database cutoff date forLung (KN001-NSCLC: 23JAN2015,KN010:30SEP2015,KN024:10JUL2017,KN042:04SEP2018)

Databasecutoff dateforcHL(KN013-Cohort3:28SEP2018,KN087:25SEP2016)

Database cutoff date forBladder(KN045:26OCT2017,KN052:26SEP2018)

Database cutoff date forTNBC (KN355:11DEC2019,KN012: 26APR2016,KN086:10NOV2017,KN119:11APR2019)

Source:[ISS:adam-adsl; adae]

<div style=\"page-break-after: always\"></div>

## Subjects with Adverse events (Incidence ≥ 10% in One or More Treatment Groups) By Decreasing Frequency of Preferred Term (ASaT population)

(96.7)

197

(3.3)

834

(14.2)

(20.4)

49

(0.8)

85

(1.4)

(31.9)

(20.3)

992

(16.9)

726

(12.3)

388

(6.6)

380

(6.5)

37

(0.6)

(19.2)

(19.3)

90

(1.5)

663

(11.3)

706

(12.0)

896

(15.2)

45

(0.8)

56

(1.0)

734

(12.5)

846

(14.4)

647

(11.0)

(17.9)

73

(1.2)

654

(11.1)

984

(16.7)

371

(6.3)

114

(1.9)

510

(8.7)

428

(7.3)

389

(6.6)

| †                                               | KN355 Data for Pembrolizumab + Chemotherapy †   | KN355 Data for Pembrolizumab + Chemotherapy †   | KN355 Data for Placebo + Chemotherapy ¶ ¶   | KN355 Data for Placebo + Chemotherapy ¶ ¶   | mTNBC Safety Dataset for Pembrolizumab Monotherapy ‡‡   | mTNBC Safety Dataset for Pembrolizumab Monotherapy ‡‡   | Reference Safety Dataset for Pembrolizumab Monotherapy §§   | Reference Safety Dataset for Pembrolizumab Monotherapy §§   |
|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|
|                                                 | n                                               | (%)                                             | n                                           | (%)                                         | n                                                       | (%)                                                     | n                                                           | (%)                                                         |
| Subjects in population with one or more adverse | 596                                             |                                                 | 281                                         |                                             | 595                                                     |                                                         | 5,884                                                       |                                                             |
| events                                          | 588                                             | (98.7)                                          | 276                                         | (98.2)                                      | 559                                                     | (93.9)                                                  | 5,687                                                       | (96.7)                                                      |
| with no adverse events                          | 8                                               | (1.3)                                           | 5                                           | (1.8)                                       | 36                                                      | (6.1)                                                   | 197                                                         | (3.3)                                                       |
| Anaemia                                         | 318                                             | (53.4)                                          | 143                                         | (50.9)                                      | 62                                                      | (10.4)                                                  | 834                                                         | (14.2)                                                      |
| Nausea                                          | 262                                             | (44.0)                                          | 132                                         | (47.0)                                      | 113                                                     | (19.0)                                                  | 1,203                                                       | (20.4)                                                      |
| Neutropenia                                     | 243                                             | (40.8)                                          | 109                                         | (38.8)                                      | 6                                                       | (1.0)                                                   | 49                                                          | (0.8)                                                       |
| Alopecia                                        | 201                                             | (33.7)                                          | 97                                          | (34.5)                                      | 8                                                       | (1.3)                                                   | 85                                                          | (1.4)                                                       |
| Fatigue                                         | 182                                             | (30.5)                                          | 97                                          | (34.5)                                      | 152                                                     | (25.5)                                                  | 1,878                                                       | (31.9)                                                      |
| Diarrhoea                                       | 168                                             | (28.2)                                          | 66                                          | (23.5)                                      | 75                                                      | (12.6)                                                  | 1,193                                                       | (20.3)                                                      |
| Constipation                                    | 166                                             | (27.9)                                          | 77                                          | (27.4)                                      | 98                                                      | (16.5)                                                  | 992                                                         | (16.9)                                                      |
| Vomiting                                        | 155                                             | (26.0)                                          | 63                                          | (22.4)                                      | 57                                                      | (9.6)                                                   | 726                                                         | (12.3)                                                      |
| Alanine aminotransferase increased              | 146                                             | (24.5)                                          | 55                                          | (19.6)                                      | 39                                                      | (6.6)                                                   | 388                                                         | (6.6)                                                       |
| Aspartate aminotransferase increased            | 137                                             | (23.0)                                          | 47                                          | (16.7)                                      | 60                                                      | (10.1)                                                  | 380                                                         | (6.5)                                                       |
| Neutrophil count decreased                      | 134                                             | (22.5)                                          | 75                                          | (26.7)                                      | 3                                                       | (0.5)                                                   | 37                                                          | (0.6)                                                       |
| Decreased appetite                              | 128                                             | (21.5)                                          | 39                                          | (13.9)                                      | 72                                                      | (12.1)                                                  | 1,132                                                       | (19.2)                                                      |
| Cough                                           | 126                                             | (21.1)                                          | 49                                          | (17.4)                                      | 115                                                     | (19.3)                                                  | 1,138                                                       | (19.3)                                                      |
| Thrombocytopenia                                | 122                                             | (20.5)                                          | 57                                          | (20.3)                                      | 10                                                      | (1.7)                                                   | 90                                                          | (1.5)                                                       |
| Asthenia                                        | 119                                             | (20.0)                                          | 48                                          | (17.1)                                      | 61                                                      | (10.3)                                                  | 663                                                         | (11.3)                                                      |
| Headache                                        | 119                                             | (20.0)                                          | 66                                          | (23.5)                                      | 74                                                      | (12.4)                                                  | 706                                                         | (12.0)                                                      |
| Rash                                            | 117                                             | (19.6)                                          | 33                                          | (11.7)                                      | 52                                                      | (8.7)                                                   | 896                                                         | (15.2)                                                      |
| Leukopenia                                      | 116                                             | (19.5)                                          | 50                                          | (17.8)                                      | 6                                                       | (1.0)                                                   | 45                                                          | (0.8)                                                       |
| White blood cell count decreased                | 111                                             | (18.6)                                          | 54                                          | (19.2)                                      | 6                                                       | (1.0)                                                   | 56                                                          | (1.0)                                                       |
| Pyrexia                                         | 109                                             | (18.3)                                          | 56                                          | (19.9)                                      | 70                                                      | (11.8)                                                  | 734                                                         | (12.5)                                                      |
| Arthralgia                                      | 99                                              | (16.6)                                          | 39                                          | (13.9)                                      | 82                                                      | (13.8)                                                  | 846                                                         | (14.4)                                                      |
| Hypothyroidism                                  | 95                                              | (15.9)                                          | 9                                           | (3.2)                                       | 53                                                      | (8.9)                                                   | 647                                                         | (11.0)                                                      |
| Pruritus                                        | 93                                              | (15.6)                                          | 32                                          | (11.4)                                      | 66                                                      | (11.1)                                                  | 1,053                                                       | (17.9)                                                      |
| Platelet count decreased                        | 90                                              | (15.1)                                          | 44                                          | (15.7)                                      | 7                                                       | (1.2)                                                   | 73                                                          | (1.2)                                                       |
| Back pain                                       | 75                                              | (12.6)                                          | 41                                          | (14.6)                                      | 60                                                      | (10.1)                                                  | 654                                                         | (11.1)                                                      |
| Dyspnoea                                        | 69                                              | (11.6)                                          | 37                                          | (13.2)                                      | 91                                                      | (15.3)                                                  | 984                                                         | (16.7)                                                      |
| Upper respiratory tract infection               | 68                                              | (11.4)                                          | 25                                          | (8.9)                                       | 23                                                      | (3.9)                                                   | 371                                                         | (6.3)                                                       |
| Neuropathy peripheral                           | 67                                              | (11.2)                                          | 35                                          | (12.5)                                      | 14                                                      | (2.4)                                                   | 114                                                         | (1.9)                                                       |
| Oedema peripheral                               | 65                                              | (10.9)                                          | 28                                          | (10.0)                                      | 40                                                      | (6.7)                                                   | 510                                                         | (8.7)                                                       |
| Myalgia                                         | 62                                              | (10.4)                                          | 34                                          | (12.1)                                      | 42                                                      | (7.1)                                                   | 428                                                         | (7.3)                                                       |
| Chemotherapy †                                  | KN355 Data for Pembrolizumab +                  | KN355 Data for Pembrolizumab +                  | KN355 Data for Placebo + ¶                  | KN355 Data for Placebo + ¶                  | mTNBC Safety Dataset for                                | mTNBC Safety Dataset for                                | Reference Safety Dataset for                                | Reference Safety Dataset for                                |
|                                                 |                                                 |                                                 | Chemotherapy ¶                              | Chemotherapy ¶                              | Pembrolizumab Monotherapy ‡‡                            | Pembrolizumab Monotherapy ‡‡                            | Pembrolizumab                                               | Pembrolizumab                                               |
| n                                               | (%)                                             | (%)                                             | n (%)                                       | n (%)                                       | (%)                                                     | (%)                                                     | Monotherapy n (%)                                           | Monotherapy n (%)                                           |
| Pain in extremity                               | 59                                              | (9.9)                                           | 41                                          | (14.6)                                      | n 42                                                    | (7.1)                                                   | 389                                                         | (6.6)                                                       |

Every subject is counted a single time for each applicable row and column.

A system organ class or specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

MedDRA preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.

††  Includes all subjects who received at least one dose of treatment in the pembrolizumab + chemotherapy arm of KN355.

¶¶  Includes all subjects who received at least one dose of treatment in the placebo + chemotherapy arm of KN355.

<div style=\"page-break-after: always\"></div>

‡‡  Includes all subjects who received at least one dose of pembrolizumab in KN012-Cohort A, KN086 and KN119.

- §§  Includes all subjects who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 Cohorts B and B2 (Head and Neck Cancer), KN013 Cohort 3 (Hodgkin Lymphoma), KN024, KN040, KN042, KN045, KN048, KN052, KN054, KN055 and KN087.

Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015, KN006: 03MAR2015, KN054: 02OCT2017)

Database cutoff date for Lung (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015, KN024: 10JUL2017, KN042: 04SEP2018)

Database cutoff date for HNSCC (KN012-HNSCC: 26APR2016, KN040: 15MAY2017, KN048: 25FEB2019, KN055: 22APR2016)

Database cutoff date for cHL (KN013-Cohort 3: 28SEP2018, KN087: 25SEP2016)

Database cutoff date for Bladder (KN045: 26OCT2017, KN052: 26SEP2018)

Database cutoff date for TNBC (KN355: 11DEC2019, KN012: 26APR2016, KN086: 10NOV2017, KN119: 11APR2019)

Between-Treatment Comparisons in Adverse Events (Incidence ≥ 10% in One or More Treatment Groups)

Sorted by Risk Difference (Part 2 All Subjects) (ASaT Population)

<!-- image -->

Database Cutoff Date: 11DEC2019

Source:[P355V01MK3475: adam-adsl; adae]

## Drug-related Adverse Events

## Subjects With Drug-Related Adverse Events

(Incidence ≥ 5% in One or More Treatment Groups) By Decreasing Frequency of Preferred Term (ASaT Population)

<div style=\"page-break-after: always\"></div>

(70.1)

(29.9)

202

(3.4)

30

(0.5)

532

(9.0)

44

(0.7)

(19.8)

26

(0.4)

232

(3.9)

628

(10.7)

41

(0.7)

29

(0.5)

217

(3.7)

196

(3.3)

28

(0.5)

461

(7.8)

669

(11.4)

32

(0.5)

363

(6.2)

156

(2.7)

561

(9.5)

831

(14.1)

40

(0.7)

256

(4.4)

28

(0.5)

434

(7.4)

60

(1.0)

71

(1.2)

231

(3.9)

190

(3.2)

84

(1.4)

138

(2.3)

47

(0.8)

83

(1.4)

| †                                       | KN355 Data for Pembrolizumab + Chemotherapy †   | KN355 Data for Pembrolizumab + Chemotherapy †   | KN355 Data for Placebo + Chemotherapy ¶ ¶   | KN355 Data for Placebo + Chemotherapy ¶ ¶   | mTNBC Safety Dataset for Pembrolizumab Monotherapy ‡‡   | mTNBC Safety Dataset for Pembrolizumab Monotherapy ‡‡   | Reference Safety Dataset for Pembrolizumab Monotherapy §§   | Reference Safety Dataset for Pembrolizumab Monotherapy §§   |
|-----------------------------------------|-------------------------------------------------|-------------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|
|                                         | n                                               | (%)                                             | n                                           | (%)                                         | n                                                       | (%)                                                     | n                                                           | (%)                                                         |
| Subjects in population with one or more | 596                                             |                                                 | 281                                         |                                             | 595                                                     |                                                         | 5,884                                                       |                                                             |
| adverse events                          | 574                                             | (96.3)                                          | 267                                         | (95.0)                                      | 368                                                     | (61.8)                                                  | 4,123                                                       | (70.1)                                                      |
| with no adverse events                  | 22                                              | (3.7)                                           | 14                                          | (5.0)                                       | 227                                                     | (38.2)                                                  | 1,761                                                       | (29.9)                                                      |
| Anaemia                                 | 291                                             | (48.8)                                          | 129                                         | (45.9)                                      | 25                                                      | (4.2)                                                   | 202                                                         | (3.4)                                                       |
| Neutropenia                             | 241                                             | (40.4)                                          | 107                                         | (38.1)                                      | 3                                                       | (0.5)                                                   | 30                                                          | (0.5)                                                       |
| Nausea                                  | 229                                             | (38.4)                                          | 115                                         | (40.9)                                      | 67                                                      | (11.3)                                                  | 532                                                         | (9.0)                                                       |
| Alopecia                                | 197                                             | (33.1)                                          | 94                                          | (33.5)                                      | 3                                                       | (0.5)                                                   | 44                                                          | (0.7)                                                       |
| Fatigue                                 | 164                                             | (27.5)                                          | 83                                          | (29.5)                                      | 100                                                     | (16.8)                                                  | 1,166                                                       | (19.8)                                                      |
| Neutrophil count decreased              | 132                                             | (22.1)                                          | 74                                          | (26.3)                                      | 2                                                       | (0.3)                                                   | 26                                                          | (0.4)                                                       |
| Alanine aminotransferase increased      | 118                                             | (19.8)                                          | 46                                          | (16.4)                                      | 25                                                      | (4.2)                                                   | 232                                                         | (3.9)                                                       |
| Diarrhoea                               | 115                                             | (19.3)                                          | 45                                          | (16.0)                                      | 43                                                      | (7.2)                                                   | 628                                                         | (10.7)                                                      |
| Thrombocytopenia                        | 114                                             | (19.1)                                          | 54                                          | (19.2)                                      | 2                                                       | (0.3)                                                   | 41                                                          | (0.7)                                                       |
| Leukopenia                              | 113                                             | (19.0)                                          | 49                                          | (17.4)                                      | 3                                                       | (0.5)                                                   | 29                                                          | (0.5)                                                       |
| Aspartate aminotransferase increased    | 111                                             | (18.6)                                          | 42                                          | (14.9)                                      | 32                                                      | (5.4)                                                   | 217                                                         | (3.7)                                                       |
| Vomiting                                | 111                                             | (18.6)                                          | 42                                          | (14.9)                                      | 20                                                      | (3.4)                                                   | 196                                                         | (3.3)                                                       |
| White blood cell count decreased        | 108                                             | (18.1)                                          | 54                                          | (19.2)                                      | 3                                                       | (0.5)                                                   | 28                                                          | (0.5)                                                       |
| Decreased appetite                      | 97                                              | (16.3)                                          | 25                                          | (8.9)                                       | 33                                                      | (5.5)                                                   | 461                                                         | (7.8)                                                       |
| Rash                                    | 92                                              | (15.4)                                          | 26                                          | (9.3)                                       | 29                                                      | (4.9)                                                   | 669                                                         | (11.4)                                                      |
| Platelet count decreased                | 90                                              | (15.1)                                          | 43                                          | (15.3)                                      | 5                                                       | (0.8)                                                   | 32                                                          | (0.5)                                                       |
| Asthenia                                | 89                                              | (14.9)                                          | 37                                          | (13.2)                                      | 32                                                      | (5.4)                                                   | 363                                                         | (6.2)                                                       |
| Constipation                            | 80                                              | (13.4)                                          | 37                                          | (13.2)                                      | 19                                                      | (3.2)                                                   | 156                                                         | (2.7)                                                       |
| Hypothyroidism                          | 80                                              | (13.4)                                          | 8                                           | (2.8)                                       | 45                                                      | (7.6)                                                   | 561                                                         | (9.5)                                                       |
| Pruritus                                | 64                                              | (10.7)                                          | 26                                          | (9.3)                                       | 43                                                      | (7.2)                                                   | 831                                                         | (14.1)                                                      |
| Neuropathy peripheral                   | 61                                              | (10.2)                                          | 32                                          | (11.4)                                      | 5                                                       | (0.8)                                                   | 40                                                          | (0.7)                                                       |
| Pyrexia                                 | 58                                              | (9.7)                                           | 23                                          | (8.2)                                       | 29                                                      | (4.9)                                                   | 256                                                         | (4.4)                                                       |
| Peripheral sensory neuropathy           | 55                                              | (9.2)                                           | 20                                          | (7.1)                                       | 5                                                       | (0.8)                                                   | 28                                                          | (0.5)                                                       |
| Arthralgia                              | 48                                              | (8.1)                                           | 23                                          | (8.2)                                       | 36                                                      | (6.1)                                                   | 434                                                         | (7.4)                                                       |
| Dysgeusia                               | 47                                              | (7.9)                                           | 12                                          | (4.3)                                       | 8                                                       | (1.3)                                                   | 60                                                          | (1.0)                                                       |
| Stomatitis                              | 47                                              | (7.9)                                           | 17                                          | (6.0)                                       | 6                                                       | (1.0)                                                   | 71                                                          | (1.2)                                                       |
| Myalgia                                 | 46                                              | (7.7)                                           | 21                                          | (7.5)                                       | 22                                                      | (3.7)                                                   | 231                                                         | (3.9)                                                       |
| Headache                                | 39                                              | (6.5)                                           | 23                                          | (8.2)                                       | 20                                                      | (3.4)                                                   | 190                                                         | (3.2)                                                       |
| Blood alkaline phosphatase increased    | 35                                              | (5.9)                                           | 12                                          | (4.3)                                       | 12                                                      | (2.0)                                                   | 84                                                          | (1.4)                                                       |
| Weight decreased                        | 34                                              | (5.7)                                           | 7                                           | (2.5)                                       | 4                                                       | (0.7)                                                   | 138                                                         | (2.3)                                                       |
| Lymphocyte count decreased              | 30                                              | (5.0)                                           | 9                                           | (3.2)                                       | 2                                                       | (0.3)                                                   | 47                                                          | (0.8)                                                       |
| Chemotherapy                            | KN355 +                                         | Data for Pembrolizumab                          | KN355 Data for Placebo + ¶                  | KN355 Data for Placebo + ¶                  | mTNBC Dataset                                           | mTNBC Dataset                                           | Reference Safety Dataset for                                | Reference Safety Dataset for                                |
|                                         |                                                 |                                                 | Chemotherapy                                | Chemotherapy                                | Safety for Pembrolizumab                                | Safety for Pembrolizumab                                |                                                             |                                                             |
|                                         |                                                 |                                                 |                                             |                                             | Monotherapy ‡‡                                          | Monotherapy ‡‡                                          | Pembrolizumab Monotherapy §§                                | Pembrolizumab Monotherapy §§                                |
|                                         | n (%)                                           | n (%)                                           | n (%)                                       | n (%)                                       | n (%)                                                   | n (%)                                                   | n (%)                                                       | n (%)                                                       |
| Dizziness                               | 14                                              | (2.3)                                           | 15                                          | (5.3)                                       | 11                                                      | (1.8)                                                   | 83                                                          | (1.4)                                                       |

Every subject is counted a single time for each applicable row and column.

A system organ class or specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

††  Includes all subjects who received at least one dose of treatment in the pembrolizumab + chemotherapy arm of KN355.

¶¶  Includes all subjects who received at least one dose of treatment in the placebo + chemotherapy arm of KN355.

‡‡  Includes all subjects who received at least one dose of pembrolizumab in KN012-Cohort A, KN086 and KN119.

§§  Includes all subjects who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 Cohorts B and B2 (Head and Neck Cancer), KN013 Cohort 3 (Hodgkin Lymphoma), KN024, KN040, KN042, KN045, KN048, KN052, KN054, KN055 and KN087.

Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015, KN006: 03MAR2015, KN054: 02OCT2017) Database cutoff date for Lung (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015, KN024: 10JUL2017, KN042: 04SEP2018)

<div style=\"page-break-after: always\"></div>

Database cutoff date for HNSCC (KN012-HNSCC: 26APR2016, KN040: 15MAY2017, KN048: 25FEB2019, KN055: 22APR2016)

Database cutoff date for cHL (KN013-Cohort 3: 28SEP2018, KN087: 25SEP2016)

Database cutoff date for Bladder (KN045: 26OCT2017, KN052: 26SEP2018)

Database cutoff date for TNBC (KN355: 11DEC2019, KN012: 26APR2016, KN086: 10NOV2017, KN119: 11APR2019)

## All Grade 3 to 5 Adverse Events

## Subjects With Grade 3-5 Adverse Events (Incidence ≥ 5% in One or More Treatment Groups) By Decreasing Frequency of Preferred Term (ASaT Population)

(47.8)

(52.2)

15

(0.3)

234

(4.0)

8

(0.1)

17

(0.3)

4

(0.1)

7

(0.1)

60

(1.0)

8

(0.1)

65

(1.1)

|                                      | KN355 Data for Pembrolizumab + Chemotherapy † † ¶   | KN355 Data for Pembrolizumab + Chemotherapy † † ¶   | KN355 Data for Placebo + Chemotherapy ¶   | KN355 Data for Placebo + Chemotherapy ¶   | mTNBC Safety Dataset for Pembrolizumab Monotherapy ‡‡   | mTNBC Safety Dataset for Pembrolizumab Monotherapy ‡‡   | Reference Safety Dataset for Pembrolizumab Monotherapy §§   | Reference Safety Dataset for Pembrolizumab Monotherapy §§   |
|--------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-------------------------------------------|-------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|
|                                      | n                                                   | (%)                                                 | n                                         | (%)                                       | n                                                       | (%)                                                     | n                                                           | (%)                                                         |
| Subjects in population               | 596                                                 |                                                     | 281                                       |                                           | 595                                                     |                                                         | 5,884                                                       |                                                             |
| with one or more adverse events      | 465                                                 | (78.0)                                              | 207                                       | (73.7)                                    | 218                                                     | (36.6)                                                  | 2,813                                                       | (47.8)                                                      |
| with no adverse events               | 131                                                 | (22.0)                                              | 74                                        | (26.3)                                    | 377                                                     | (63.4)                                                  | 3,071                                                       | (52.2)                                                      |
| Neutropenia                          | 176                                                 | (29.5)                                              | 85                                        | (30.2)                                    | 2                                                       | (0.3)                                                   | 15                                                          | (0.3)                                                       |
| Anaemia                              | 107                                                 | (18.0)                                              | 46                                        | (16.4)                                    | 18                                                      | (3.0)                                                   | 234                                                         | (4.0)                                                       |
| Neutrophil count decreased           | 106                                                 | (17.8)                                              | 57                                        | (20.3)                                    | 2                                                       | (0.3)                                                   | 8                                                           | (0.1)                                                       |
| Thrombocytopenia                     | 65                                                  | (10.9)                                              | 33                                        | (11.7)                                    | 5                                                       | (0.8)                                                   | 17                                                          | (0.3)                                                       |
| White blood cell count decreased     | 63                                                  | (10.6)                                              | 29                                        | (10.3)                                    | 2                                                       | (0.3)                                                   | 4                                                           | (0.1)                                                       |
| Leukopenia                           | 59                                                  | (9.9)                                               | 31                                        | (11.0)                                    | 0                                                       | (0.0)                                                   | 7                                                           | (0.1)                                                       |
| Alanine aminotransferase increased   | 46                                                  | (7.7)                                               | 16                                        | (5.7)                                     | 7                                                       | (1.2)                                                   | 60                                                          | (1.0)                                                       |
| Platelet count decreased             | 36                                                  | (6.0)                                               | 20                                        | (7.1)                                     | 0                                                       | (0.0)                                                   | 8                                                           | (0.1)                                                       |
| Aspartate aminotransferase increased | 32                                                  | (5.4)                                               | 10                                        | (3.6)                                     | 19                                                      | (3.2)                                                   | 65                                                          | (1.1)                                                       |

Every subject is counted a single time for each applicable row and column.

A system organ class or specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

MedDRA preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.

††  Includes all subjects who received at least one dose of treatment in the pembrolizumab + chemotherapy arm of KN355.

¶¶  Includes all subjects who received at least one dose of treatment in the placebo + chemotherapy arm of KN355.

‡‡  Includes all subjects who received at least one dose of pembrolizumab in KN012-Cohort A, KN086 and KN119.

§§  Includes all subjects who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 Cohorts B and B2 (Head and Neck Cancer), KN013 Cohort 3 (Hodgkin Lymphoma), KN024, KN040, KN042, KN045, KN048, KN052, KN054, KN055 and KN087.

Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015, KN006: 03MAR2015, KN054: 02OCT2017)

Database cutoff date for Lung (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015, KN024: 10JUL2017, KN042: 04SEP2018)

Database cutoff date for HNSCC (KN012-HNSCC: 26APR2016, KN040: 15MAY2017, KN048: 25FEB2019, KN055: 22APR2016)

Database cutoff date for cHL (KN013-Cohort 3: 28SEP2018, KN087: 25SEP2016)

Database cutoff date for Bladder (KN045: 26OCT2017, KN052: 26SEP2018)

Database cutoff date for TNBC (KN355: 11DEC2019, KN012: 26APR2016, KN086: 10NOV2017, KN119: 11APR2019)

## Subjects  With  Grade  3-5  DrugRelated  Adverse  Events  (Incidence  ≥  5%  in  One  or  More Treatment Groups) By Decreasing Frequency of Preferred Term  (ASaT Population)

|                        |   KN355 Data for Pembrolizumab + Chemotherapy † † |   KN355 Data for Placebo + Chemotherapy ¶ ¶ |   mTNBC Safety Dataset for Pembrolizumab Monotherapy ‡‡ | Reference Safety Dataset for Pembrolizumab Monotherapy §§   |
|------------------------|---------------------------------------------------|---------------------------------------------|---------------------------------------------------------|-------------------------------------------------------------|
| Subjects in population |                                               596 |                                         281 |                                                     595 | 5,884                                                       |

<div style=\"page-break-after: always\"></div>

909

(15.4)

(84.6)

9

(0.2)

4

(0.1)

29

(0.5)

1

(0.0)

6

(0.1)

3

(0.1)

2

(0.0)

34

(0.6)

| with one or more adverse events    |   407 | (68.3)   |   188 | (66.9)   |   79 | (13.3)   | 909   | (15.4)   |
|------------------------------------|-------|----------|-------|----------|------|----------|-------|----------|
| with no adverse events             |   189 | (31.7)   |    93 | (33.1)   |  516 | (86.7)   | 4,975 | (84.6)   |
| Neutropenia                        |   174 | (29.2)   |    84 | (29.9)   |    1 | (0.2)    | 9     | (0.2)    |
| Neutrophil count decreased         |   103 | (17.3)   |    57 | (20.3)   |    1 | (0.2)    | 4     | (0.1)    |
| Anaemia                            |    98 | (16.4)   |    41 | (14.6)   |    5 | (0.8)    | 29    | (0.5)    |
| White blood cell count decreased   |    61 | (10.2)   |    29 | (10.3)   |    1 | (0.2)    | 1     | (0.0)    |
| Thrombocytopenia                   |    59 | (9.9)    |    31 | (11.0)   |    1 | (0.2)    | 6     | (0.1)    |
| Leukopenia                         |    58 | (9.7)    |    30 | (10.7)   |    0 | (0.0)    | 3     | (0.1)    |
| Platelet count decreased           |    36 | (6.0)    |    20 | (7.1)    |    0 | (0.0)    | 2     | (0.0)    |
| Alanine aminotransferase increased |    34 | (5.7)    |    13 | (4.6)    |    4 | (0.7)    | 34    | (0.6)    |

Every subject is counted a single time for each applicable row and column.

A system organ class or specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

††  Includes all subjects who received at least one dose of treatment in the pembrolizumab + chemotherapy arm of KN355.

¶¶  Includes all subjects who received at least one dose of treatment in the placebo + chemotherapy arm of KN355.

‡‡  Includes all subjects who received at least one dose of pembrolizumab in KN012-Cohort A, KN086 and KN119.

§§  Includes all subjects who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 Cohorts B and B2 (Head and Neck Cancer), KN013 Cohort 3 (Hodgkin Lymphoma), KN024, KN040, KN042, KN045, KN048, KN052, KN054, KN055 and KN087.

Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015, KN006: 03MAR2015, KN054: 02OCT2017)

Database cutoff date for Lung (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015, KN024: 10JUL2017, KN042: 04SEP2018)

Database cutoff date for HNSCC (KN012-HNSCC: 26APR2016, KN040: 15MAY2017, KN048: 25FEB2019, KN055: 22APR2016)

Database cutoff date for cHL (KN013-Cohort 3: 28SEP2018, KN087: 25SEP2016)

Database cutoff date for Bladder (KN045: 26OCT2017, KN052: 26SEP2018)

Database cutoff date for TNBC (KN355: 11DEC2019, KN012: 26APR2016, KN086: 10NOV2017, KN119: 11APR2019)

## Serious adverse event/deaths/other significant events

## Serious AEs

## Subjects With Serious Adverse Events Up to 90 Days of Last Dose (Incidence ≥ 1% in One or More Treatment Groups) By Decreasing Frequency of Preferred Term (ASaT Population)

(38.3)

(61.7)

59

(1.0)

243

(4.1)

7

(0.1)

28

(0.5)

4

(0.1)

116

(2.0)

71

(1.2)

66

(1.1)

42

(0.7)

3

(0.1)

83

(1.4)

58

(1.0)

28

(0.5)

|                                                        | KN355 Data for Pembrolizumab + Chemotherapy † †   | KN355 Data for Pembrolizumab + Chemotherapy † †   | KN355 Data for Placebo + Chemotherapy ¶ ¶   | KN355 Data for Placebo + Chemotherapy ¶ ¶   | mTNBC Safety Dataset for Pembrolizumab Monotherapy ‡‡   | mTNBC Safety Dataset for Pembrolizumab Monotherapy ‡‡   | Reference Safety Dataset for Pembrolizumab Monotherapy §§   | Reference Safety Dataset for Pembrolizumab Monotherapy §§   |
|--------------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|
|                                                        | n                                                 | (%)                                               | n                                           | (%)                                         | n                                                       | (%)                                                     | n                                                           | (%)                                                         |
| Subjects in population with one or more adverse events | 596 181                                           | (30.4)                                            | 281 67                                      | (23.8)                                      | 595 140                                                 | (23.5)                                                  | 5,884 2,252                                                 | (38.3)                                                      |
| with no adverse events                                 | 415                                               | (69.6)                                            | 214                                         | (76.2)                                      | 455                                                     | (76.5)                                                  | 3,632                                                       | (61.7)                                                      |
| Anaemia                                                | 13                                                | (2.2)                                             | 6                                           | (2.1)                                       | 4                                                       | (0.7)                                                   | 59                                                          | (1.0)                                                       |
| Pneumonia                                              | 12                                                | (2.0)                                             | 7                                           | (2.5)                                       | 11                                                      | (1.8)                                                   | 243                                                         | (4.1)                                                       |
| Thrombocytopenia                                       | 12                                                | (2.0)                                             | 4                                           | (1.4)                                       | 0                                                       | (0.0)                                                   | 7                                                           | (0.1)                                                       |
| Vomiting                                               | 10                                                | (1.7)                                             | 6                                           | (2.1)                                       | 0                                                       | (0.0)                                                   | 28                                                          | (0.5)                                                       |
| Febrile neutropenia                                    | 9                                                 | (1.5)                                             | 3                                           | (1.1)                                       | 2                                                       | (0.3)                                                   | 4                                                           | (0.1)                                                       |
| Pneumonitis                                            | 7                                                 | (1.2)                                             | 0                                           | (0.0)                                       | 4                                                       | (0.7)                                                   | 116                                                         | (2.0)                                                       |
| Pulmonary embolism                                     | 7                                                 | (1.2)                                             | 3                                           | (1.1)                                       | 5                                                       | (0.8)                                                   | 71                                                          | (1.2)                                                       |
| Pyrexia                                                | 7                                                 | (1.2)                                             | 4                                           | (1.4)                                       | 7                                                       | (1.2)                                                   | 66                                                          | (1.1)                                                       |
| Sepsis                                                 | 6                                                 | (1.0)                                             | 3                                           | (1.1)                                       | 3                                                       | (0.5)                                                   | 42                                                          | (0.7)                                                       |
| Neutropenia                                            | 5                                                 | (0.8)                                             | 4                                           | (1.4)                                       | 1                                                       | (0.2)                                                   | 3                                                           | (0.1)                                                       |
| Pleural effusion                                       | 5                                                 | (0.8)                                             | 3                                           | (1.1)                                       | 19                                                      | (3.2)                                                   | 83                                                          | (1.4)                                                       |
| Diarrhoea                                              | 4                                                 | (0.7)                                             | 0                                           | (0.0)                                       | 2                                                       | (0.3)                                                   | 58                                                          | (1.0)                                                       |
| Nausea                                                 | 3                                                 | (0.5)                                             | 3                                           | (1.1)                                       | 1                                                       | (0.2)                                                   | 28                                                          | (0.5)                                                       |

<div style=\"page-break-after: always\"></div>

Every subject is counted a single time for each applicable row and column.

| Dyspnoea Urinary tract infection   | 2 (0.3) 2 (0.3)                                 | 1 (0.4) 1 (0.4)                           | 7 (1.2) 2 (0.3)                                       | 83 (1.4) 59 (1.0)                                         |
|------------------------------------|-------------------------------------------------|-------------------------------------------|-------------------------------------------------------|-----------------------------------------------------------|
|                                    | KN355 Data for Pembrolizumab + Chemotherapy † † | KN355 Data for Placebo + Chemotherapy ¶ ¶ | mTNBC Safety Dataset for Pembrolizumab Monotherapy ‡‡ | Reference Safety Dataset for Pembrolizumab Monotherapy §§ |
|                                    | n (%)                                           | n (%)                                     | n (%)                                                 | n (%)                                                     |
| Colitis                            | 1 (0.2)                                         | 0 (0.0)                                   | 2 (0.3)                                               | 59 (1.0)                                                  |

Every subject is counted a single time for each applicable row and column.

A system organ class or specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

MedDRA preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.

††  Includes all subjects who received at least one dose of treatment in the pembrolizumab + chemotherapy arm of KN355.

¶¶  Includes all subjects who received at least one dose of treatment in the placebo + chemotherapy arm of KN355.

‡‡  Includes all subjects who received at least one dose of pembrolizumab in KN012-Cohort A, KN086 and KN119.

§§  Includes all subjects who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 Cohorts B and B2 (Head and Neck Cancer), KN013 Cohort 3 (Hodgkin Lymphoma), KN024, KN040, KN042, KN045, KN048, KN052, KN054, KN055 and KN087.

Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015, KN006: 03MAR2015, KN054: 02OCT2017)

Database cutoff date for Lung (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015, KN024: 10JUL2017, KN042: 04SEP2018)

Database cutoff date for HNSCC (KN012-HNSCC: 26APR2016, KN040: 15MAY2017, KN048: 25FEB2019, KN055: 22APR2016)

Database cutoff date for cHL (KN013-Cohort 3: 28SEP2018, KN087: 25SEP2016)

Database cutoff date for Bladder (KN045: 26OCT2017, KN052: 26SEP2018)

Database cutoff date for TNBC (KN355: 11DEC2019, KN012: 26APR2016, KN086: 10NOV2017, KN119: 11APR2019)

## Drug related SAEs

## Subjects With Drugrelated Serious Adverse Events Up to 90 Days of Last Dose (Incidence ≥ 1% in One or More Treatment Groups) By Decreasing Frequency of Preferred Term (ASaT Population)

650

(11.0)

(89.0)

5

(0.1)

3

(0.1)

0

(0.0)

9

(0.2)

110

(1.9)

17

(0.3)

1

(0.0)

|                                                        | KN355 Data for Pembrolizumab + Chemotherapy † † ¶   | KN355 Data for Pembrolizumab + Chemotherapy † † ¶   | KN355 Data for Placebo + Chemotherapy ¶   | KN355 Data for Placebo + Chemotherapy ¶   | mTNBC Safety Dataset for Pembrolizumab Monotherapy ‡‡   | mTNBC Safety Dataset for Pembrolizumab Monotherapy ‡‡   | Reference Safety Dataset for Pembrolizumab Monotherapy §§   | Reference Safety Dataset for Pembrolizumab Monotherapy §§   |
|--------------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-------------------------------------------|-------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|
|                                                        | n                                                   | (%)                                                 | n                                         | (%)                                       | n                                                       | (%)                                                     | n                                                           | (%)                                                         |
| Subjects in population with one or more adverse events | 596 105                                             | (17.6)                                              | 281 34                                    | (12.1)                                    | 595 46                                                  | (7.7)                                                   | 5,884 650                                                   | (11.0)                                                      |
| with no adverse events                                 | 491                                                 | (82.4)                                              | 247                                       | (87.9)                                    | 549                                                     | (92.3)                                                  | 5,234                                                       | (89.0)                                                      |
| Anaemia                                                | 13                                                  | (2.2)                                               | 4                                         | (1.4)                                     | 2                                                       | (0.3)                                                   | 5                                                           | (0.1)                                                       |
| Thrombocytopenia                                       | 10                                                  | (1.7)                                               | 3                                         | (1.1)                                     | 0                                                       | (0.0)                                                   | 3                                                           | (0.1)                                                       |
| Febrile neutropenia                                    | 8                                                   | (1.3)                                               | 3                                         | (1.1)                                     | 0                                                       | (0.0)                                                   | 0                                                           | (0.0)                                                       |
| Vomiting                                               | 8                                                   | (1.3)                                               | 3                                         | (1.1)                                     | 0                                                       | (0.0)                                                   | 9                                                           | (0.2)                                                       |
| Pneumonitis                                            | 7                                                   | (1.2)                                               | 0                                         | (0.0)                                     | 4                                                       | (0.7)                                                   | 110                                                         | (1.9)                                                       |
| Pyrexia                                                | 6                                                   | (1.0)                                               | 3                                         | (1.1)                                     | 2                                                       | (0.3)                                                   | 17                                                          | (0.3)                                                       |
| Neutropenia                                            | 5                                                   | (0.8)                                               | 4                                         | (1.4)                                     | 0                                                       | (0.0)                                                   | 1                                                           | (0.0)                                                       |

A system organ class or specific adverse event appears on this report only if its incidence in one or

83

(1.4)

59

(1.0)

59

(1.0)

<div style=\"page-break-after: always\"></div>

more of the columns meets the incidence criterion in the report title, after rounding.

- ††  Includes all subjects who received at least one dose of treatment in the pembrolizumab + chemotherapy arm of KN355.
- ¶¶  Includes all subjects who received at least one dose of treatment in the placebo + chemotherapy arm of KN355.
- ‡‡  Includes all subjects who received at least one dose of pembrolizumab in KN012-Cohort A, KN086 and KN119.
- §§  Includes all subjects who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 Cohorts B and B2 (Head and Neck Cancer), KN013 Cohort 3 (Hodgkin Lymphoma), KN024, KN040, KN042, KN045, KN048, KN052, KN054, KN055 and KN087.
- Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015, KN006: 03MAR2015, KN054: 02OCT2017)
- Database cutoff date for Lung (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015, KN024: 10JUL2017, KN042: 04SEP2018)
- Database cutoff date for HNSCC (KN012-HNSCC: 26APR2016, KN040: 15MAY2017, KN048: 25FEB2019, KN055: 22APR2016)

Database cutoff date for cHL (KN013-Cohort 3: 28SEP2018, KN087: 25SEP2016)

Database cutoff date for Bladder (KN045: 26OCT2017, KN052: 26SEP2018)

- Database cutoff date for TNBC (KN355: 11DEC2019, KN012: 26APR2016, KN086: 10NOV2017, KN119: 11APR2019)

## Subjects With Adverse Events Resulting in Death Up to 90 Days of Last Dose (Incidence &gt; 0% in One or More Treatment Groups) By Decreasing Frequency of Preferred Term (ASaT Population)

311

(5.3)

(94.7)

4

(0.1)

10

(0.2)

3

(0.1)

1

(0.0)

0

(0.0)

9

(0.2)

1

(0.0)

42

(0.7)

0

(0.0)

5

(0.1)

36

(0.6)

10

(0.2)

0

(0.0)

1

(0.0)

1

(0.0)

0

(0.0)

5

(0.1)

1

(0.0)

1

(0.0)

| †                                              | KN355 Data for Pembrolizumab + Chemotherapy † ¶   | KN355 Data for Pembrolizumab + Chemotherapy † ¶   | KN355 Data for Placebo + Chemotherapy ¶   | KN355 Data for Placebo + Chemotherapy ¶   | mTNBC Safety Dataset for Pembrolizumab Monotherapy ‡‡   | mTNBC Safety Dataset for Pembrolizumab Monotherapy ‡‡   | Reference Safety Dataset for Pembrolizumab Monotherapy §§   | Reference Safety Dataset for Pembrolizumab Monotherapy §§   |
|------------------------------------------------|---------------------------------------------------|---------------------------------------------------|-------------------------------------------|-------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|
|                                                | n                                                 | (%)                                               | n                                         | (%)                                       | n                                                       | (%)                                                     | n                                                           | (%)                                                         |
| Subjects in population with one or more events | 596                                               |                                                   | 281                                       |                                           | 595                                                     |                                                         | 5,884                                                       |                                                             |
| adverse                                        | 15                                                | (2.5)                                             | 5                                         | (1.8)                                     | 11                                                      | (1.8)                                                   | 311                                                         | (5.3)                                                       |
| with no adverse events                         | 581                                               | (97.5)                                            | 276                                       | (98.2)                                    | 584                                                     | (98.2)                                                  | 5,573                                                       | (94.7)                                                      |
| Cardio-respiratory arrest                      | 2                                                 | (0.3)                                             | 0                                         | (0.0)                                     | 2                                                       | (0.3)                                                   | 4                                                           | (0.1)                                                       |
| Septic shock                                   | 2                                                 | (0.3)                                             | 0                                         | (0.0)                                     | 0                                                       | (0.0)                                                   | 10                                                          | (0.2)                                                       |
| Acute kidney injury                            | 1                                                 | (0.2)                                             | 0                                         | (0.0)                                     | 0                                                       | (0.0)                                                   | 3                                                           | (0.1)                                                       |
| Acute myocardial infarction                    | 1                                                 | (0.2)                                             | 0                                         | (0.0)                                     | 0                                                       | (0.0)                                                   | 1                                                           | (0.0)                                                       |
| Arrhythmia                                     | 1                                                 | (0.2)                                             | 0                                         | (0.0)                                     | 0                                                       | (0.0)                                                   | 0                                                           | (0.0)                                                       |
| Cardiac arrest                                 | 1                                                 | (0.2)                                             | 0                                         | (0.0)                                     | 1                                                       | (0.2)                                                   | 9                                                           | (0.2)                                                       |
| Cardiopulmonary failure                        | 1                                                 | (0.2)                                             | 0                                         | (0.0)                                     | 0                                                       | (0.0)                                                   | 1                                                           | (0.0)                                                       |
| Death                                          | 1                                                 | (0.2)                                             | 0                                         | (0.0)                                     | 0                                                       | (0.0)                                                   | 42                                                          | (0.7)                                                       |
| Hepatic encephalopathy                         | 1                                                 | (0.2)                                             | 0                                         | (0.0)                                     | 0                                                       | (0.0)                                                   | 0                                                           | (0.0)                                                       |
| Multiple organ dysfunction syndrome            | 1                                                 | (0.2)                                             | 0                                         | (0.0)                                     | 0                                                       | (0.0)                                                   | 5                                                           | (0.1)                                                       |
| Pneumonia                                      | 1                                                 | (0.2)                                             | 1                                         | (0.4)                                     | 0                                                       | (0.0)                                                   | 36                                                          | (0.6)                                                       |
| Pulmonary embolism                             | 1                                                 | (0.2)                                             | 0                                         | (0.0)                                     | 1                                                       | (0.2)                                                   | 10                                                          | (0.2)                                                       |
| Shock haemorrhagic                             | 1                                                 | (0.2)                                             | 0                                         | (0.0)                                     | 0                                                       | (0.0)                                                   | 0                                                           | (0.0)                                                       |
| Accidental death                               | 0                                                 | (0.0)                                             | 0                                         | (0.0)                                     | 0                                                       | (0.0)                                                   | 1                                                           | (0.0)                                                       |
| Acute coronary syndrome                        | 0                                                 | (0.0)                                             | 0                                         | (0.0)                                     | 0                                                       | (0.0)                                                   | 1                                                           | (0.0)                                                       |
| Acute respiratory distress syndrome            | 0                                                 | (0.0)                                             | 0                                         | (0.0)                                     | 1                                                       | (0.2)                                                   | 0                                                           | (0.0)                                                       |
| Acute respiratory failure                      | 0                                                 | (0.0)                                             | 0                                         | (0.0)                                     | 0                                                       | (0.0)                                                   | 5                                                           | (0.1)                                                       |
| Adenocarcinoma gastric                         | 0                                                 | (0.0)                                             | 0                                         | (0.0)                                     | 0                                                       | (0.0)                                                   | 1                                                           | (0.0)                                                       |
| Alcohol poisoning                              | 0                                                 | (0.0)                                             | 0                                         | (0.0)                                     | 0                                                       | (0.0)                                                   | 1                                                           | (0.0)                                                       |

<div style=\"page-break-after: always\"></div>

1

(0.0)

1

(0.0)

1

(0.0)

3

(0.1)

1

(0.0)

1

(0.0)

1

(0.0)

3

(0.1)

1

(0.0)

2

(0.0)

2

(0.0)

2

(0.0)

1

(0.0)

1

(0.0)

1

(0.0)

5

(0.1)

1

(0.0)

1

(0.0)

0

(0.0)

1

(0.0)

1

(0.0)

3

(0.1)

1

(0.0)

1

(0.0)

1

(0.0)

1

(0.0)

1

(0.0)

5

(0.1)

5

(0.1)

1

(0.0)

1

(0.0)

1

(0.0)

1

(0.0)

2

(0.0)

2

(0.0)

8

(0.1)

1

(0.0)

1

(0.0)

1

(0.0)

1

(0.0)

1

(0.0)

2

(0.0)

1

(0.0)

3

(0.1)

1

(0.0)

1

(0.0)

1

(0.0)

1

(0.0)

1

(0.0)

1

(0.0)

1

(0.0)

1

(0.0)

| Anaemia                                               | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 1                                                         | (0.0)                                                     |
|-------------------------------------------------------|-----------------------------------------------|-----------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|
| Anaphylactic shock                                    | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 1                                                         | (0.0)                                                     |
| Arterial injury                                       | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 1                                                         | (0.0)                                                     |
| Aspiration                                            | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 3                                                         | (0.1)                                                     |
| Atypical pneumonia                                    | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 1                                                         | (0.0)                                                     |
| Autoinflammatory disease                              | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 1                                                         | (0.0)                                                     |
| Brain oedema                                          | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 1                                                         | (0.0)                                                     |
| Cachexia                                              | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 1                                                     | (0.2)                                                 | 3                                                         | (0.1)                                                     |
| Cardiac complication associated with device           | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 1                                                         | (0.0)                                                     |
| Cardiac failure                                       | 0                                             | (0.0)                                         | 1                                         | (0.4)                                     | 0                                                     | (0.0)                                                 | 2                                                         | (0.0)                                                     |
| Cardiac failure acute                                 | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 2                                                         | (0.0)                                                     |
| Cardiac failure congestive                            | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 2                                                         | (0.0)                                                     |
| Cardiac tamponade                                     | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 1                                                         | (0.0)                                                     |
| Cellulitis                                            | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 1                                                         | (0.0)                                                     |
| Cerebral                                              | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 1                                                         | (0.0)                                                     |
| haemorrhage Cerebrovascular accident                  | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 5                                                         | (0.1)                                                     |
| †                                                     | KN355 Data for Pembrolizumab + Chemotherapy † | KN355 Data for Pembrolizumab + Chemotherapy † | KN355 Data for Placebo + Chemotherapy ¶ ¶ | KN355 Data for Placebo + Chemotherapy ¶ ¶ | mTNBC Safety Dataset for Pembrolizumab Monotherapy ‡‡ | mTNBC Safety Dataset for Pembrolizumab Monotherapy ‡‡ | Reference Safety Dataset for Pembrolizumab Monotherapy §§ | Reference Safety Dataset for Pembrolizumab Monotherapy §§ |
|                                                       | n                                             | (%)                                           | n                                         | (%)                                       | n                                                     | (%)                                                   | n                                                         | (%)                                                       |
| Chronic kidney disease                                | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 1                                                         | (0.0)                                                     |
| Chronic obstructive pulmonary                         | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 1                                                         | (0.0)                                                     |
| disease                                               |                                               |                                               |                                           |                                           |                                                       |                                                       |                                                           |                                                           |
| Circulatory collapse                                  | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 1                                                     | (0.2)                                                 | 0                                                         | (0.0)                                                     |
| Clostridium difficile infection                       | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 1                                                         | (0.0)                                                     |
| Coma                                                  | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 1                                                         | (0.0)                                                     |
| Completed suicide                                     | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 1                                                     | (0.2)                                                 | 3                                                         | (0.1)                                                     |
| Diffuse alveolar damage                               | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 1                                                         | (0.0)                                                     |
| Disseminated intravascular                            | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 1                                                     | (0.2)                                                 | 1                                                         | (0.0)                                                     |
| coagulation Diverticulitis                            | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 1                                                         | (0.0)                                                     |
| Drug reaction with eosinophilia and systemic symptoms | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 1                                                         | (0.0)                                                     |
| Duodenal obstruction                                  | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 1                                                         | (0.0)                                                     |
| Dyspnoea                                              | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 5                                                         | (0.1)                                                     |
| Embolism                                              | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 5                                                         | (0.1)                                                     |
| Encephalopathy                                        | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 1                                                         | (0.0)                                                     |
| Fall                                                  | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 1                                                         | (0.0)                                                     |
| Febrile neutropenia                                   | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 1 1                                                       | (0.0)                                                     |
| Gastric haemorrhage                                   | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 |                                                           | (0.0)                                                     |
| Gastric ulcer haemorrhage                             | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 2                                                         | (0.0)                                                     |
| Gastrointestinal perforation health                   | 0                                             | (0.0) (0.0)                                   | 0 0                                       | (0.0) (0.0)                               | 0                                                     | (0.0)                                                 | 2 8                                                       | (0.0) (0.1)                                               |
| General physical                                      | 0                                             |                                               |                                           |                                           | 0                                                     | (0.0)                                                 |                                                           |                                                           |
| deterioration Generalised oedema                      | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 1                                                         | (0.0)                                                     |
| Graft versus host disease                             | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 1                                                         | (0.0)                                                     |
| Haemoptysis                                           | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 1                                                         | (0.0)                                                     |
| Haemorrhage intracranial                              | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 1                                                         | (0.0)                                                     |
| Haemorrhagic infarction                               | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 1                                                         | (0.0)                                                     |
| Haemorrhagic stroke                                   | 0                                             | (0.0)                                         | 1                                         | (0.4)                                     | 0                                                     | (0.0)                                                 | 2                                                         | (0.0)                                                     |
| Haemothorax                                           | 0 0                                           | (0.0)                                         | 0 0                                       | (0.0)                                     | 0                                                     | (0.0)                                                 | 1                                                         | (0.0)                                                     |
| Hepatic failure                                       |                                               | (0.0)                                         | 0                                         | (0.0) (0.0)                               | 0 0                                                   | (0.0) (0.0)                                           | 3 1                                                       | (0.1) (0.0)                                               |
| Hyperglycaemia Hypoxia                                | 0 0                                           | (0.0) (0.0)                                   | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 1                                                         | (0.0)                                                     |
|                                                       | 0                                             |                                               | 0                                         | (0.0)                                     | 0                                                     |                                                       | 1                                                         | (0.0)                                                     |
| Ileus paralytic                                       | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     |                                                       | (0.0)                                                 |                                                           | (0.0)                                                     |
| Infectious pleural effusion                           | 0                                             | (0.0) (0.0)                                   | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 1                                                         | (0.0)                                                     |
| Interstitial lung disease                             |                                               |                                               |                                           |                                           |                                                       | (0.0)                                                 |                                                           |                                                           |
| Intestinal ischaemia                                  |                                               |                                               |                                           |                                           | 0                                                     |                                                       | 1                                                         | (0.0)                                                     |
|                                                       | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 1                                                         | (0.0)                                                     |
| Intestinal obstruction Intestinal perforation         | 0 0                                           | (0.0) (0.0)                                   | 0 0                                       | (0.0) (0.0)                               | 0 0                                                   | (0.0) (0.0)                                           | 1 1                                                       | (0.0)                                                     |

<div style=\"page-break-after: always\"></div>

Every subject is counted a single time for each applicable row and column.

| Ischaemic cardiomyopathy Ischaemic stroke Large intestine perforation   | 0 0 0                          | (0.0) (0.0) (0.0)              | 0 0 0                                   | (0.0) (0.0) (0.0)                       | 0 0 0                                                 | (0.0) (0.0) (0.0)                                     | 1 1 2                                      | (0.0) (0.0) (0.0)                          |
|-------------------------------------------------------------------------|--------------------------------|--------------------------------|-----------------------------------------|-----------------------------------------|-------------------------------------------------------|-------------------------------------------------------|--------------------------------------------|--------------------------------------------|
|                                                                         | KN355 Data for Pembrolizumab + | KN355 Data for Pembrolizumab + | KN355 Data for Placebo + Chemotherapy ¶ | KN355 Data for Placebo + Chemotherapy ¶ | mTNBC Safety Dataset for Pembrolizumab Monotherapy ‡‡ | mTNBC Safety Dataset for Pembrolizumab Monotherapy ‡‡ | Reference Safety Dataset for Pembrolizumab | Reference Safety Dataset for Pembrolizumab |
|                                                                         | n                              | (%)                            | n                                       | (%)                                     | n                                                     | (%)                                                   | n                                          | Monotherapy (%)                            |
| Lung neoplasm malignant                                                 | 0                              | (0.0)                          | 0                                       | (0.0)                                   | 0                                                     | (0.0)                                                 | 1                                          | (0.0)                                      |
| Lymphangiosis carcinomatosa                                             | 0                              | (0.0)                          | 0                                       | (0.0)                                   | 0                                                     | (0.0)                                                 | 1                                          | (0.0)                                      |
| Malignant neoplasm progression                                          | 0                              | (0.0)                          | 0                                       | (0.0)                                   | 0                                                     | (0.0)                                                 | 4                                          | (0.1)                                      |
| Mental status changes                                                   | 0                              | (0.0)                          | 0                                       | (0.0)                                   | 0                                                     | (0.0)                                                 | 1                                          | (0.0)                                      |
| Metastatic malignant melanoma                                           | 0                              | (0.0)                          | 0                                       | (0.0)                                   | 0                                                     | (0.0)                                                 | 1                                          | (0.0)                                      |
| Myocardial infarction                                                   | 0                              | (0.0)                          | 0                                       | (0.0)                                   | 0                                                     | (0.0)                                                 | 6                                          | (0.1)                                      |
| Myositis                                                                | 0                              | (0.0)                          | 0                                       | (0.0)                                   | 0                                                     | (0.0)                                                 | 1                                          | (0.0)                                      |
| Neutropenic sepsis                                                      | 0                              | (0.0)                          | 0                                       | (0.0)                                   | 0                                                     | (0.0)                                                 | 1                                          | (0.0)                                      |
| Pelvic neoplasm                                                         | 0                              | (0.0)                          | 0                                       | (0.0)                                   | 1                                                     | (0.2)                                                 | 0                                          | (0.0)                                      |
| Peripheral artery occlusion                                             | 0                              | (0.0)                          | 0                                       | (0.0)                                   | 0                                                     | (0.0)                                                 | 1                                          | (0.0)                                      |
| Pleural effusion                                                        | 0                              | (0.0)                          | 0                                       | (0.0)                                   | 0                                                     | (0.0)                                                 | 1                                          | (0.0)                                      |
| Pneumocystis jirovecii pneumonia                                        | 0                              | (0.0)                          | 0                                       | (0.0)                                   | 0                                                     | (0.0)                                                 | 1                                          | (0.0)                                      |
| Pneumonia aspiration                                                    | 0                              | (0.0)                          | 0                                       | (0.0)                                   | 0                                                     | (0.0)                                                 | 8                                          | (0.1)                                      |
| Pneumonia klebsiella                                                    | 0                              | (0.0)                          | 0                                       | (0.0)                                   | 0                                                     | (0.0)                                                 | 1                                          | (0.0)                                      |
| Pneumonia staphylococcal                                                | 0                              | (0.0)                          | 0                                       | (0.0)                                   | 0                                                     | (0.0)                                                 | 1                                          | (0.0)                                      |
| Pneumonia streptococcal                                                 | 0                              | (0.0)                          | 0                                       | (0.0)                                   | 0                                                     | (0.0)                                                 | 1                                          | (0.0)                                      |
| Pneumonitis                                                             | 0                              | (0.0)                          | 0                                       | (0.0)                                   | 0                                                     | (0.0)                                                 | 8                                          | (0.1)                                      |
| Pneumothorax                                                            | 0                              | (0.0)                          | 0                                       | (0.0)                                   | 0                                                     | (0.0)                                                 | 1                                          | (0.0)                                      |
| Post procedural haemorrhage                                             | 0                              | (0.0)                          | 0                                       | (0.0)                                   | 0                                                     | (0.0)                                                 | 1                                          | (0.0)                                      |
| Pseudomonal sepsis                                                      | 0                              | (0.0)                          | 0                                       | (0.0)                                   | 0                                                     | (0.0)                                                 | 1                                          | (0.0)                                      |
| Pulmonary artery thrombosis                                             | 0                              | (0.0)                          | 0                                       | (0.0)                                   | 0                                                     | (0.0)                                                 | 1                                          | (0.0)                                      |
| Pulmonary haemorrhage                                                   | 0                              | (0.0)                          | 0                                       | (0.0)                                   | 0                                                     | (0.0)                                                 | 5                                          | (0.1)                                      |
| Pulmonary oedema                                                        | 0                              | (0.0)                          | 0                                       | (0.0)                                   | 0                                                     | (0.0)                                                 | 1                                          | (0.0)                                      |
| Pulmonary sepsis                                                        | 0                              | (0.0)                          | 0                                       | (0.0)                                   | 0                                                     | (0.0)                                                 | 2                                          | (0.0)                                      |
| Renal failure                                                           | 0                              | (0.0)                          | 0                                       | (0.0)                                   | 0                                                     | (0.0)                                                 | 1                                          | (0.0)                                      |
| Respiratory distress failure                                            | 0 0                            | (0.0) (0.0)                    | 0 1                                     | (0.0)                                   | 0 1                                                   | (0.0)                                                 | 2                                          | (0.0) (0.3)                                |
| Respiratory                                                             | 0                              |                                |                                         | (0.4)                                   | 0                                                     | (0.2)                                                 | 17                                         | (0.2)                                      |
| Sepsis                                                                  |                                | (0.0)                          | 0                                       | (0.0)                                   |                                                       | (0.0)                                                 | 9                                          |                                            |
| Soft tissue infection Spinal cord compression                           | 0                              | (0.0)                          | 0 0                                     | (0.0)                                   | 0                                                     | (0.0) (0.0)                                           | 2 1                                        | (0.0) (0.0)                                |
|                                                                         | 0                              | (0.0)                          |                                         | (0.0)                                   | 0                                                     |                                                       |                                            |                                            |
| Stevens-Johnson syndrome                                                | 0                              | (0.0)                          | 0 0                                     | (0.0)                                   | 0 0                                                   | (0.0) (0.0)                                           | 1 2                                        | (0.0) (0.0)                                |
| Sudden death                                                            | 0                              | (0.0)                          |                                         | (0.0)                                   |                                                       |                                                       |                                            |                                            |
| Superior vena cava syndrome                                             | 0                              | (0.0)                          | 0                                       | (0.0)                                   | 0                                                     | (0.0)                                                 | 1                                          | (0.0)                                      |
| Traumatic intracranial haemorrhage                                      | 0                              | (0.0)                          | 0                                       | (0.0)                                   | 0                                                     | (0.0)                                                 | 1                                          | (0.0)                                      |
| Tumour haemorrhage                                                      | 0                              | (0.0)                          | 0                                       | (0.0)                                   | 0                                                     | (0.0)                                                 | 5                                          | (0.1)                                      |
| Type 2 diabetes mellitus                                                | 0                              | (0.0)                          | 0                                       | (0.0)                                   | 0                                                     | (0.0)                                                 | 1                                          | (0.0)                                      |
| Upper gastrointestinal haemorrhage                                      | 0                              | (0.0)                          | 0                                       | (0.0) (0.0)                             | 0 0                                                   | (0.0) (0.0)                                           | 1 1                                        | (0.0) (0.0) (0.1)                          |
| Urinary tract obstruction Urosepsis                                     | 0 0                            | (0.0)                          | 0                                       | (0.0)                                   | 0                                                     | (0.0)                                                 | 5                                          |                                            |
|                                                                         |                                | (0.0)                          | 0                                       |                                         |                                                       |                                                       |                                            |                                            |
|                                                                         | KN355                          |                                |                                         |                                         |                                                       |                                                       |                                            |                                            |
| Chemotherapy                                                            | Data for Pembrolizumab +       | Data for Pembrolizumab +       | KN355 Data for Placebo + Chemotherapy ¶ | KN355 Data for Placebo + Chemotherapy ¶ | mTNBC Safety Dataset for Pembrolizumab                | mTNBC Safety Dataset for Pembrolizumab                | Reference Safety Dataset for Pembrolizumab | Reference Safety Dataset for Pembrolizumab |
|                                                                         |                                |                                |                                         |                                         | Monotherapy ‡‡                                        | Monotherapy ‡‡                                        | Monotherapy §§                             | Monotherapy §§                             |
|                                                                         | n (%)                          | n (%)                          | n (%)                                   | n (%)                                   |                                                       |                                                       |                                            |                                            |
| Vascular device infection                                               | 0 (0.0)                        | 0 (0.0)                        | 1 (0.4)                                 | 1 (0.4)                                 | n (%) 0 (0.0)                                         | n (%) 0 (0.0)                                         | n (%)                                      | n (%)                                      |
|                                                                         |                                |                                |                                         |                                         |                                                       |                                                       | 0                                          | (0.0)                                      |

A system organ class or specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

††  Includes all subjects who received at least one dose of treatment in the pembrolizumab +

1

(0.0)

1

(0.0)

2

(0.0)

1

(0.0)

1

(0.0)

4

(0.1)

1

(0.0)

1

(0.0)

6

(0.1)

1

(0.0)

1

(0.0)

0

(0.0)

1

(0.0)

1

(0.0)

1

(0.0)

8

(0.1)

1

(0.0)

1

(0.0)

1

(0.0)

8

(0.1)

1

(0.0)

1

(0.0)

1

(0.0)

1

(0.0)

5

(0.1)

1

(0.0)

2

(0.0)

1

(0.0)

2

(0.0)

17

(0.3)

9

(0.2)

2

(0.0)

1

(0.0)

1

(0.0)

2

(0.0)

1

(0.0)

1

(0.0)

5

(0.1)

1

(0.0)

1

(0.0)

1

(0.0)

5

(0.1)

0

(0.0)

<div style=\"page-break-after: always\"></div>

chemotherapy arm of KN355.

- ¶¶  Includes all subjects who received at least one dose of treatment in the placebo + chemotherapy arm of KN355.
- ‡‡  Includes all subjects who received at least one dose of pembrolizumab in KN012-Cohort A, KN086 and KN119.
- §§  Includes all subjects who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 Cohorts B and B2 (Head and Neck Cancer), KN013 Cohort 3 (Hodgkin Lymphoma), KN024, KN040, KN042, KN045, KN048, KN052, KN054, KN055 and KN087.
- Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015, KN006: 03MAR2015, KN054: 02OCT2017)
- Database cutoff date for Lung (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015, KN024: 10JUL2017, KN042: 04SEP2018)
- Database cutoff date for HNSCC (KN012-HNSCC: 26APR2016, KN040: 15MAY2017, KN048: 25FEB2019, KN055: 22APR2016)

Database cutoff date for cHL (KN013-Cohort 3: 28SEP2018, KN087: 25SEP2016)

Database cutoff date for Bladder (KN045: 26OCT2017, KN052: 26SEP2018)

Database cutoff date for TNBC (KN355: 11DEC2019, KN012: 26APR2016, KN086: 10NOV2017, KN119: 11APR2019)

## Adverse events of Special Interest (AEOSIs)

## Adverse Event Summary AEOSI (ASaT Population)

| †                                                    | KN355 Data for Pembrolizumab + Chemotherapy † ¶   | KN355 Data for Pembrolizumab + Chemotherapy † ¶   | KN355 Data for Placebo + Chemotherapy ¶   | KN355 Data for Placebo + Chemotherapy ¶   | mTNBC Safety Dataset for Pembrolizumab Monotherapy ‡‡   | mTNBC Safety Dataset for Pembrolizumab Monotherapy ‡‡   | Reference Safety Dataset for Pembrolizumab Monotherapy §§   | Reference Safety Dataset for Pembrolizumab Monotherapy §§   |
|------------------------------------------------------|---------------------------------------------------|---------------------------------------------------|-------------------------------------------|-------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|
|                                                      | n                                                 | (%)                                               | n                                         | (%)                                       | n                                                       | (%)                                                     | n                                                           | (%)                                                         |
| Subjects in population                               | 596                                               | 596                                               | 281                                       | 281                                       | 595                                                     | 595                                                     | 5,884                                                       | 5,884                                                       |
| with one or more adverse events                      | 168                                               | (28.2)                                            | 30                                        | (10.7)                                    | 99                                                      | (16.6)                                                  | 1,464                                                       | (24.9)                                                      |
| with no adverse event                                | 428                                               | (71.8)                                            | 251                                       | (89.3)                                    | 496                                                     | (83.4)                                                  | 4,420                                                       | (75.1)                                                      |
| with drug-related † adverse events                   | 152                                               | (25.5)                                            | 25                                        | (8.9)                                     | 86                                                      | (14.5)                                                  | 1,272                                                       | (21.6)                                                      |
| with toxicity grade 3-5 adverse events               | 34                                                | (5.7)                                             | 0                                         | (0.0)                                     | 15                                                      | (2.5)                                                   | 377                                                         | (6.4)                                                       |
| with toxicity grade 3-5 drug- related adverse events | 32                                                | (5.4)                                             | 0                                         | (0.0)                                     | 12                                                      | (2.0)                                                   | 329                                                         | (5.6)                                                       |
| with serious adverse events                          | 20                                                | (3.4)                                             | 0                                         | (0.0)                                     | 16                                                      | (2.7)                                                   | 378                                                         | (6.4)                                                       |
| with serious drug-related adverse events             | 18                                                | (3.0)                                             | 0                                         | (0.0)                                     | 16                                                      | (2.7)                                                   | 335                                                         | (5.7)                                                       |
| with any dose modification ‡ due                     | 61                                                | (10.2)                                            | 12                                        | (4.3)                                     | 23                                                      | (3.9)                                                   | 525                                                         | (8.9)                                                       |
| to an adverse event pembrolizumab dose modification  | 3                                                 | (0.5)                                             | 0                                         | (0.0)                                     | 23                                                      | (3.9)                                                   | 525                                                         | (8.9)                                                       |
| pembrolizumab/placebo dose modification              | 44                                                | (7.4)                                             | 2                                         | (0.7)                                     | 23                                                      | (3.9)                                                   | 525                                                         | (8.9)                                                       |
| nab-paclitaxel dose modification                     | 15                                                | (2.5)                                             | 0                                         | (0.0)                                     | 0                                                       | (0.0)                                                   | 0                                                           | (0.0)                                                       |
| paclitaxel dose modification                         | 10                                                | (1.7)                                             | 1                                         | (0.4)                                     | 0                                                       | (0.0)                                                   | 0                                                           | (0.0)                                                       |
| gemcitabine dose modification                        | 19                                                | (3.2)                                             | 6                                         | (2.1)                                     | 0                                                       | (0.0)                                                   | 0                                                           | (0.0)                                                       |
| carboplatin dose modification                        | 20                                                | (3.4)                                             | 10                                        | (3.6)                                     | 0                                                       | (0.0)                                                   | 0                                                           | (0.0)                                                       |
| who died                                             | 0                                                 | (0.0)                                             | 0                                         | (0.0)                                     | 0                                                       | (0.0)                                                   | 11                                                          | (0.2)                                                       |
| who died due to a drug-related adverse event         | 0                                                 | (0.0)                                             | 0                                         | (0.0)                                     | 0                                                       | (0.0)                                                   | 11                                                          | (0.2)                                                       |
| discontinued any drug due to an adverse event        | 24                                                | (4.0)                                             | 3                                         | (1.1)                                     | 7                                                       | (1.2)                                                   | 227                                                         | (3.9)                                                       |
| discontinued pembrolizumab                           | 2                                                 | (0.3)                                             | 0                                         | (0.0)                                     | 7                                                       | (1.2)                                                   | 227                                                         | (3.9)                                                       |
| discontinued pembrolizumab/placebo                   | 14                                                | (2.3)                                             | 0                                         | (0.0)                                     | 7                                                       | (1.2)                                                   | 227                                                         | (3.9)                                                       |

(24.9)

(75.1)

(21.6)

377

(6.4)

329

(5.6)

378

(6.4)

335

(5.7)

525

(8.9)

525

(8.9)

525

(8.9)

0

(0.0)

0

(0.0)

0

(0.0)

0

(0.0)

11

(0.2)

11

(0.2)

227

(3.9)

227

(3.9)

227

(3.9)

<div style=\"page-break-after: always\"></div>

0

(0.0)

0

(0.0)

0

(0.0)

0

(0.0)

224

(3.8)

224

(3.8)

224

(3.8)

0

(0.0)

0

(0.0)

0

(0.0)

0

(0.0)

155

(2.6)

155

(2.6)

155

(2.6)

0

(0.0)

0

(0.0)

0

(0.0)

0

(0.0)

153

(2.6)

153

(2.6)

153

(2.6)

0

(0.0)

0

(0.0)

0

(0.0)

0

(0.0)

| discontinued nab-paclitaxel                                       | 3                                             | (0.5)                                         | 0                                       | (0.0)                                   | 0                                                     | (0.0)                                                 | 0                                                         | (0.0)                                                     |
|-------------------------------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------|-----------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|
| discontinued paclitaxel                                           | 1                                             | (0.2)                                         | 0                                       | (0.0)                                   | 0                                                     | (0.0)                                                 | 0                                                         | (0.0)                                                     |
| discontinued gemcitabine                                          | 6                                             | (1.0)                                         | 0                                       | (0.0)                                   | 0                                                     | (0.0)                                                 | 0                                                         | (0.0)                                                     |
| discontinued carboplatin                                          | 6                                             | (1.0)                                         | 3                                       | (1.1)                                   | 0                                                     | (0.0)                                                 | 0                                                         | (0.0)                                                     |
| discontinued any drug due to a                                    | 24                                            | (4.0)                                         | 3                                       | (1.1)                                   | 7                                                     | (1.2)                                                 | 224                                                       | (3.8)                                                     |
| drug-related adverse event discontinued pembrolizumab             | 2                                             | (0.3)                                         | 0                                       | (0.0)                                   | 7                                                     | (1.2)                                                 | 224                                                       | (3.8)                                                     |
| discontinued                                                      | 14                                            | (2.3)                                         | 0                                       | (0.0)                                   | 7                                                     | (1.2)                                                 | 224                                                       | (3.8)                                                     |
| pembrolizumab/placebo                                             |                                               |                                               |                                         |                                         |                                                       |                                                       |                                                           |                                                           |
| discontinued nab-paclitaxel                                       | 3                                             | (0.5)                                         | 0                                       | (0.0)                                   | 0                                                     | (0.0)                                                 | 0                                                         | (0.0)                                                     |
| discontinued paclitaxel                                           | 1                                             | (0.2)                                         | 0                                       | (0.0)                                   | 0                                                     | (0.0)                                                 | 0                                                         | (0.0)                                                     |
| discontinued gemcitabine                                          | 6                                             | (1.0)                                         | 0                                       | (0.0)                                   | 0                                                     | (0.0)                                                 | 0                                                         | (0.0)                                                     |
| discontinued carboplatin                                          | 6                                             | (1.0)                                         | 3                                       | (1.1)                                   | 0                                                     | (0.0)                                                 | 0                                                         | (0.0)                                                     |
| discontinued any drug due to a serious adverse event              | 15                                            | (2.5)                                         | 0                                       | (0.0)                                   | 4                                                     | (0.7)                                                 | 155                                                       | (2.6)                                                     |
| discontinued pembrolizumab                                        | 2                                             | (0.3)                                         | 0                                       | (0.0)                                   | 4                                                     | (0.7)                                                 | 155                                                       | (2.6)                                                     |
| discontinued pembrolizumab/placebo                                | 12                                            | (2.0)                                         | 0                                       | (0.0)                                   | 4                                                     | (0.7)                                                 | 155                                                       | (2.6)                                                     |
| †                                                                 | KN355 Data for Pembrolizumab + Chemotherapy † | KN355 Data for Pembrolizumab + Chemotherapy † | KN355 Data for Placebo + Chemotherapy ¶ | KN355 Data for Placebo + Chemotherapy ¶ | mTNBC Safety Dataset for Pembrolizumab Monotherapy ‡‡ | mTNBC Safety Dataset for Pembrolizumab Monotherapy ‡‡ | Reference Safety Dataset for Pembrolizumab Monotherapy §§ | Reference Safety Dataset for Pembrolizumab Monotherapy §§ |
|                                                                   | n                                             | (%)                                           | n                                       | (%)                                     | n                                                     | (%)                                                   | n                                                         | (%)                                                       |
| discontinued nab-paclitaxel                                       | 2                                             | (0.3)                                         | 0                                       | (0.0)                                   | 0                                                     | (0.0)                                                 | 0                                                         | (0.0)                                                     |
| discontinued paclitaxel                                           | 1                                             | (0.2)                                         | 0                                       | (0.0)                                   | 0                                                     | (0.0)                                                 | 0                                                         | (0.0)                                                     |
| discontinued gemcitabine                                          | 1                                             | (0.2)                                         | 0                                       | (0.0)                                   | 0                                                     | (0.0)                                                 | 0                                                         | (0.0)                                                     |
| discontinued carboplatin                                          | 1                                             | (0.2)                                         | 0                                       | (0.0)                                   | 0                                                     | (0.0)                                                 | 0                                                         | (0.0)                                                     |
| discontinued any drug due to a serious drug-related adverse event | 15                                            | (2.5)                                         | 0                                       | (0.0)                                   | 4                                                     | (0.7)                                                 | 153                                                       | (2.6)                                                     |
| discontinued pembrolizumab                                        | 2                                             | (0.3)                                         | 0                                       | (0.0)                                   | 4                                                     | (0.7)                                                 | 153                                                       | (2.6)                                                     |
| discontinued                                                      | 12                                            | (2.0)                                         | 0                                       | (0.0)                                   | 4                                                     | (0.7)                                                 | 153                                                       | (2.6)                                                     |
| pembrolizumab/placebo                                             |                                               |                                               |                                         |                                         |                                                       |                                                       |                                                           |                                                           |
| discontinued nab-paclitaxel                                       | 2                                             | (0.3)                                         | 0                                       | (0.0)                                   | 0                                                     | (0.0)                                                 | 0                                                         | (0.0)                                                     |
| discontinued paclitaxel                                           | 1                                             | (0.2)                                         | 0                                       | (0.0)                                   | 0                                                     | (0.0)                                                 | 0                                                         | (0.0)                                                     |
| discontinued gemcitabine                                          | 1                                             | (0.2)                                         | 0                                       | (0.0)                                   | 0                                                     | (0.0)                                                 | 0                                                         | (0.0)                                                     |
| discontinued carboplatin                                          | 1                                             | (0.2)                                         | 0                                       | (0.0)                                   | 0                                                     | (0.0)                                                 | 0                                                         | (0.0)                                                     |

†  Determined by the investigator to be related to the drug.

‡  Defined as an action taken of dose reduced, drug interrupted or drug withdrawn.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

MedDRA preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.

††  Includes all subjects who received at least one dose of treatment in the pembrolizumab + chemotherapy arm of KN355.

¶¶  Includes all subjects who received at least one dose of treatment in the placebo + chemotherapy arm of KN355.

‡‡  Includes all subjects who received at least one dose of pembrolizumab in KN012-Cohort A, KN086 and KN119.

§§  Includes all subjects who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 Cohorts B and B2 (Head and Neck Cancer), KN013 Cohort 3 (Hodgkin Lymphoma), KN024, KN040, KN042, KN045, KN048, KN052, KN054, KN055 and KN087.

Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015, KN006: 03MAR2015, KN054: 02OCT2017)

Database cutoff date for Lung (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015, KN024: 10JUL2017, KN042: 04SEP2018)

Database cutoff date for HNSCC (KN012-HNSCC: 26APR2016, KN040: 15MAY2017, KN048: 25FEB2019, KN055: 22APR2016)

Database cutoff date for cHL (KN013-Cohort 3: 28SEP2018, KN087: 25SEP2016)

Database cutoff date for Bladder (KN045: 26OCT2017, KN052: 26SEP2018)

Database cutoff date for TNBC (KN355: 11DEC2019, KN012: 26APR2016, KN086: 10NOV2017, KN119:

<div style=\"page-break-after: always\"></div>

## Subjects With Adverse Events of Special Interest (Incidence &gt; 0% in One or More Treatment Groups) By AEOSI Category and Preferred Term (ASaT Population)

(24.9)

(75.1)

2

(0.0)

42

(0.7)

2

(0.0)

1

(0.0)

3

(0.1)

95

(1.6)

4

(0.1)

8

(0.1)

3

(0.1)

2

(0.0)

1

(0.0)

1

(0.0)

2

(0.0)

24

(0.4)

6

(0.1)

24

(0.4)

1

(0.0)

1

(0.0)

245

(4.2)

22

(0.4)

14

(0.2)

647

(11.0)

1

(0.0)

|                                                | KN355 Data for Pembrolizumab + Chemotherapy †   | KN355 Data for Pembrolizumab + Chemotherapy †   | KN355 Data for Placebo + Chemotherapy ¶ ¶   | KN355 Data for Placebo + Chemotherapy ¶ ¶   | mTNBC Safety Dataset for Pembrolizumab Monotherapy ‡‡   | mTNBC Safety Dataset for Pembrolizumab Monotherapy ‡‡   | Reference Safety Dataset for Pembrolizumab Monotherapy §§   | Reference Safety Dataset for Pembrolizumab Monotherapy §§   |
|------------------------------------------------|-------------------------------------------------|-------------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|
|                                                | n                                               | (%)                                             | n                                           | (%)                                         | n                                                       | (%)                                                     | n                                                           | (%)                                                         |
| Subjects in population with one or more        | 596                                             |                                                 | 281                                         |                                             | 595                                                     |                                                         | 5,884                                                       |                                                             |
| adverse                                        | 168                                             | (28.2)                                          | 30                                          | (10.7)                                      | 99                                                      | (16.6)                                                  | 1,464                                                       | (24.9)                                                      |
| events with no adverse events                  | 428                                             | (71.8)                                          | 251                                         | (89.3)                                      | 496                                                     | (83.4)                                                  | 4,420                                                       | (75.1)                                                      |
| Adrenal Insufficiency                          | 7                                               | (1.2)                                           | 0                                           | (0.0)                                       | 4                                                       | (0.7)                                                   | 47                                                          | (0.8)                                                       |
| Addison's disease                              | 0                                               | (0.0)                                           | 0                                           | (0.0)                                       | 0                                                       | (0.0)                                                   | 2                                                           | (0.0)                                                       |
| Adrenal insufficiency                          | 7                                               | (1.2)                                           | 0                                           | (0.0)                                       | 2                                                       | (0.3)                                                   | 42                                                          | (0.7)                                                       |
| Adrenocortical insufficiency acute             | 0                                               | (0.0)                                           | 0                                           | (0.0)                                       | 0                                                       | (0.0)                                                   | 2                                                           | (0.0)                                                       |
| Secondary adrenocortical insufficiency         | 0                                               | (0.0)                                           | 0                                           | (0.0)                                       | 2                                                       | (0.3)                                                   | 1                                                           | (0.0)                                                       |
| Colitis                                        | 11                                              | (1.8)                                           | 4                                           | (1.4)                                       | 5                                                       | (0.8)                                                   | 110                                                         | (1.9)                                                       |
| Autoimmune colitis                             | 0                                               | (0.0)                                           | 0                                           | (0.0)                                       | 0                                                       | (0.0)                                                   | 3                                                           | (0.1)                                                       |
| Colitis                                        | 10                                              | (1.7)                                           | 3                                           | (1.1)                                       | 4                                                       | (0.7)                                                   | 95                                                          | (1.6)                                                       |
| Colitis microscopic                            | 0                                               | (0.0)                                           | 0                                           | (0.0)                                       | 0                                                       | (0.0)                                                   | 4                                                           | (0.1)                                                       |
| Enterocolitis                                  | 1                                               | (0.2)                                           | 1                                           | (0.4)                                       | 1                                                       | (0.2)                                                   | 8                                                           | (0.1)                                                       |
| Immune-mediated enterocolitis                  | 0                                               | (0.0)                                           | 0                                           | (0.0)                                       | 0                                                       | (0.0)                                                   | 3                                                           | (0.1)                                                       |
| Encephalitis                                   | 0                                               | (0.0)                                           | 0                                           | (0.0)                                       | 0                                                       | (0.0)                                                   | 2                                                           | (0.0)                                                       |
| Encephalitis                                   |                                                 | (0.0)                                           |                                             |                                             | 0                                                       | (0.0)                                                   | 2                                                           | (0.0)                                                       |
|                                                | 0                                               |                                                 | 0 0                                         | (0.0) (0.0)                                 |                                                         | (0.0)                                                   | 4                                                           | (0.1)                                                       |
| Guillain-Barre Syndrome                        | 1 0                                             | (0.2) (0.0)                                     | 0                                           |                                             | 0 0                                                     |                                                         | 1                                                           | (0.0)                                                       |
| Axonal neuropathy Demyelinating polyneuropathy | 0                                               | (0.0)                                           | 0                                           | (0.0) (0.0)                                 | 0                                                       | (0.0) (0.0)                                             | 1                                                           | (0.0)                                                       |
| Guillain-Barre syndrome                        | 1                                               | (0.2)                                           | 0                                           | (0.0)                                       | 0                                                       | (0.0)                                                   | 2                                                           | (0.0)                                                       |
| Hepatitis                                      | 5                                               | (0.8)                                           | 2                                           | (0.7)                                       | 1                                                       | (0.2)                                                   | 55                                                          | (0.9)                                                       |
| Autoimmune hepatitis                           | 1                                               | (0.2)                                           | 0                                           | (0.0)                                       | 0 0                                                     | (0.0) (0.0)                                             | 24                                                          | (0.4) (0.1)                                                 |
| Drug-induced liver injury                      | 0                                               | (0.0)                                           | 0                                           | (0.0)                                       |                                                         |                                                         | 6                                                           |                                                             |
| Hepatitis                                      | 3                                               | (0.5)                                           | 2                                           | (0.7)                                       | 1                                                       | (0.2)                                                   | 24                                                          | (0.4)                                                       |
| Hepatitis acute                                | 0                                               | (0.0)                                           | 0                                           | (0.0)                                       | 0                                                       | (0.0)                                                   | 1                                                           | (0.0)                                                       |
| Immune-mediated hepatitis                      | 1                                               | (0.2)                                           | 0                                           | (0.0)                                       | 0                                                       | (0.0)                                                   | 1                                                           | (0.0)                                                       |
| Hyperthyroidism                                | 31                                              | (5.2)                                           | 3                                           | (1.1)                                       | 24                                                      | (4.0)                                                   | 245                                                         | (4.2)                                                       |
| Hyperthyroidism                                | 31                                              | (5.2)                                           | 3                                           | (1.1)                                       | 24                                                      | (4.0)                                                   | 245                                                         | (4.2)                                                       |
| Hypophysitis                                   | 1                                               | (0.2)                                           | 0                                           | (0.0)                                       | 0                                                       | (0.0)                                                   | 36                                                          | (0.6)                                                       |
| Hypophysitis                                   | 1                                               | (0.2)                                           | 0                                           | (0.0)                                       | 0                                                       | (0.0)                                                   | 22                                                          | (0.4)                                                       |
| Hypopituitarism                                | 0                                               | (0.0)                                           | 0                                           | (0.0)                                       | 0                                                       | (0.0)                                                   | 14                                                          | (0.2)                                                       |
| Hypothyroidism                                 | 95                                              | (15.9)                                          | 9                                           | (3.2)                                       | 53                                                      | (8.9)                                                   | 648                                                         | (1 1.0)                                                     |
|                                                | KN355 + Chemotherapy †                          | Data for Pembrolizumab †                        | KN355 Placebo Chemotherapy ¶                | Data for + ¶                                |                                                         | Safety for ‡‡                                           | Reference Safety Dataset for Pembrolizumab §§               | Reference Safety Dataset for Pembrolizumab §§               |
| Hypothyroidism                                 | n                                               | (%)                                             |                                             |                                             | mTNBC Dataset Pembrolizumab Monotherapy                 | mTNBC Dataset Pembrolizumab Monotherapy                 | Monotherapy                                                 | Monotherapy                                                 |
|                                                |                                                 |                                                 | n                                           | (%)                                         | n                                                       | (%)                                                     | n                                                           | (%)                                                         |
|                                                | 95                                              | (15.9)                                          | 9                                           | (3.2)                                       | 53                                                      | (8.9)                                                   | 648                                                         | (11.0)                                                      |
| Hypothyroidism Myxoedema                       | 95 0                                            | (15.9) (0.0)                                    | 9 0                                         | (3.2) (0.0)                                 | 53                                                      | (8.9)                                                   | 647 1                                                       | (11.0)                                                      |
|                                                |                                                 |                                                 |                                             |                                             | 0                                                       | (0.0)                                                   |                                                             | (0.0)                                                       |

<div style=\"page-break-after: always\"></div>

1

(0.0)

10

(0.2)

1

(0.0)

8

(0.1)

18

(0.3)

45

(0.8)

55

(0.9)

1

(0.0)

2

(0.0)

1

(0.0)

1

(0.0)

5

(0.1)

0

(0.0)

4

(0.1)

14

(0.2)

1

(0.0)

2

(0.0)

3

(0.1)

1

(0.0)

3

(0.1)

1

(0.0)

2

(0.0)

11

(0.2)

1

(0.0)

14

(0.2)

4

(0.1)

22

(0.4)

2

(0.0)

238

(4.0)

10

(0.2)

8

(0.1)

5

(0.1)

2

(0.0)

5

(0.1)

2

(0.0)

4

(0.1)

1

(0.0)

3

(0.1)

2

(0.0)

| Primary hypothyroidism           | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 1                                                         | (0.0)                                                     |
|----------------------------------|-----------------------------------------------|-----------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|
| Infusion Reactions               | 22                                            | (3.7)                                         | 14                                        | (5.0)                                     | 5                                                     | (0.8)                                                 | 135                                                       | (2.3)                                                     |
| Anaphylactic reaction            | 1                                             | (0.2)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 10                                                        | (0.2)                                                     |
| Anaphylactoid reaction           | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 1                                                         | (0.0)                                                     |
| Cytokine release syndrome        | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 8                                                         | (0.1)                                                     |
| Drug hypersensitivity            | 3                                             | (0.5)                                         | 1                                         | (0.4)                                     | 1                                                     | (0.2)                                                 | 18                                                        | (0.3)                                                     |
| Hypersensitivity                 | 10                                            | (1.7)                                         | 8                                         | (2.8)                                     | 1                                                     | (0.2)                                                 | 45                                                        | (0.8)                                                     |
| Infusion related reaction        | 8                                             | (1.3)                                         | 6                                         | (2.1)                                     | 3                                                     | (0.5)                                                 | 55                                                        | (0.9)                                                     |
| Myasthenic Syndrome              | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 1                                                     | (0.2)                                                 | 3                                                         | (0.1)                                                     |
| Myasthenia gravis                | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 1                                                     | (0.2)                                                 | 1                                                         | (0.0)                                                     |
| Myasthenic syndrome              | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 2                                                         | (0.0)                                                     |
| Myelitis                         | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 2                                                         | ( 0.0)                                                    |
| Myelitis                         | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 1                                                         | (0.0)                                                     |
| Myelitis transverse              | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 1                                                         | (0.0)                                                     |
| Myocarditis                      | 1                                             | (0.2)                                         | 0                                         | (0.0)                                     | 1                                                     | (0.2)                                                 | 5                                                         | (0.1)                                                     |
| Myocarditis                      | 1                                             | (0.2)                                         | 0                                         | (0.0)                                     | 1                                                     | (0.2)                                                 | 5                                                         | (0.1)                                                     |
| Myositis                         | 3                                             | (0.5)                                         | 0                                         | (0.0)                                     | 2                                                     | (0.3)                                                 | 19                                                        | (0.3)                                                     |
| Dermatomyositis                  | 1                                             | (0.2)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 0                                                         | (0.0)                                                     |
| Myopathy                         | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 4                                                         | (0.1)                                                     |
| Myositis                         | 2                                             | (0.3)                                         | 0                                         | (0.0)                                     | 2                                                     | (0.3)                                                 | 14                                                        | (0.2)                                                     |
| Rhabdomyolysis                   | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 1                                                     | (0.2)                                                 | 1                                                         | (0.0)                                                     |
| Nephritis                        | 4                                             | (0.7)                                         | 0                                         | (0.0)                                     | 1                                                     | (0.2)                                                 | 23                                                        | (0.4)                                                     |
| Acute kidney injury              | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 2                                                         | (0.0)                                                     |
| Autoimmune nephritis             | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 3                                                         | (0.1)                                                     |
| Glomerulonephritis               | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 1                                                         | (0.0)                                                     |
| membranous Nephritis             | 4                                             | (0.7)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 3                                                         | (0.1)                                                     |
| Nephrotic syndrome               | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 1                                                         | (0.0)                                                     |
| Renal failure                    | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 2                                                         | (0.0)                                                     |
| Tubulointerstitial nephritis     | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 1                                                     | (0.2)                                                 | 11                                                        | (0.2)                                                     |
| Pancreatitis                     |                                               |                                               |                                           | (0.0)                                     | 0                                                     | (0.0)                                                 | 18                                                        |                                                           |
|                                  | 1                                             | (0.2)                                         | 0                                         |                                           |                                                       |                                                       |                                                           | (0.3)                                                     |
|                                  | KN355 Data for Pembrolizumab + Chemotherapy † | KN355 Data for Pembrolizumab + Chemotherapy † | KN355 Data for Placebo + Chemotherapy ¶ ¶ | KN355 Data for Placebo + Chemotherapy ¶ ¶ | mTNBC Safety Dataset for Pembrolizumab Monotherapy ‡‡ | mTNBC Safety Dataset for Pembrolizumab Monotherapy ‡‡ | Reference Safety Dataset for Pembrolizumab Monotherapy §§ | Reference Safety Dataset for Pembrolizumab Monotherapy §§ |
|                                  | n                                             | (%)                                           | n                                         | (%)                                       | n                                                     | (%)                                                   | n                                                         | (%)                                                       |
| Pancreatitis                     | 1                                             | (0.2)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 18                                                        | (0.3)                                                     |
| Autoimmune pancreatitis          | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 1                                                         | (0.0)                                                     |
| Pancreatitis                     | 1                                             | (0.2)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 14                                                        | (0.2)                                                     |
| Pancreatitis acute               | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 4                                                         | (0.1)                                                     |
| Pneumonitis                      | 15                                            | (2.5)                                         | 0                                         | (0.0)                                     | 16                                                    | (2.7)                                                 | 259                                                       | (4.4)                                                     |
| Interstitial lung disease        | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 2                                                     | (0.3)                                                 | 22                                                        | (0.4)                                                     |
| Organising pneumonia             | 1                                             | (0.2)                                         | 0                                         | (0.0)                                     | 1                                                     | (0.2)                                                 | 2                                                         | (0.0)                                                     |
| Pneumonitis                      | 14                                            | (2.3)                                         | 0                                         | (0.0)                                     | 13                                                    | (2.2)                                                 | 238                                                       | (4.0)                                                     |
| Sarcoidosis                      | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 10                                                        | (0.2)                                                     |
| Sarcoidosis                      | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 10                                                        | (0.2)                                                     |
| Severe Skin Reactions            | 12                                            | (2.0)                                         | 1                                         | (0.4)                                     | 6                                                     | (1.0)                                                 | 95                                                        | (1.6)                                                     |
| Dermatitis bullous               | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 1                                                     | (0.2)                                                 | 8                                                         | (0.1)                                                     |
| Dermatitis exfoliative           | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 5                                                         | (0.1)                                                     |
| Dermatitis exfoliative           | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 1                                                     | (0.2)                                                 | 2                                                         |                                                           |
| generalised                      |                                               |                                               |                                           |                                           |                                                       |                                                       |                                                           | (0.0)                                                     |
| Erythema multiforme              | 0                                             | (0.0)                                         | 1                                         | (0.4)                                     | 1                                                     | (0.2)                                                 | 5                                                         | (0.1)                                                     |
| Exfoliative rash                 | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 2                                                         | (0.0) (0.1)                                               |
| Lichen planus Oral lichen planus | 0 0                                           | (0.0) (0.0)                                   | 0 0                                       | (0.0) (0.0)                               | 0 0                                                   | (0.0) (0.0)                                           | 4 1                                                       | (0.0)                                                     |
| Pemphigoid                       | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 3                                                         | (0.1)                                                     |
| Pemphigus                        | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 2                                                         | (0.0)                                                     |

<div style=\"page-break-after: always\"></div>

11

(0.2)

1

(0.0)

30

(0.5)

1

(0.0)

16

(0.3)

2

(0.0)

1

(0.0)

2

(0.0)

3

(0.1)

2

(0.0)

13

(0.2)

5

(0.1)

41

(0.7)

0

(0.0)

9

(0.2)

16

(0.3)

4

(0.1)

3

(0.1)

13

(0.2)

| Pruritus                 | 1                                             | (0.2)                                         | 0                                         | (0.0)                                     | 1                                                     | (0.2)                                                 | 11                                                        | (0.2)                                                     |
|--------------------------|-----------------------------------------------|-----------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|
| Pruritus genital         | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 1                                                         | (0.0)                                                     |
| Rash                     | 5                                             | (0.8)                                         | 0                                         | (0.0)                                     | 1                                                     | (0.2)                                                 | 30                                                        | (0.5)                                                     |
| Rash erythematous        | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 1                                                         | (0.0)                                                     |
| Rash maculo-papular      | 7                                             | (1.2)                                         | 0                                         | (0.0)                                     | 1                                                     | (0.2)                                                 | 16                                                        | (0.3)                                                     |
| Rash pruritic            | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 2                                                         | (0.0)                                                     |
| Rash pustular            | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 1                                                         | (0.0)                                                     |
| Skin necrosis            | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 2                                                         | (0.0)                                                     |
| Stevens-Johnson syndrome | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 3                                                         | (0.1)                                                     |
| Toxic skin eruption      | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 2                                                         | (0.0)                                                     |
| Thyroiditis              | 8                                             | (1.3)                                         | 0                                         | (0.0)                                     | 1                                                     | (0.2)                                                 | 57                                                        | (1.0)                                                     |
| Autoimmune thyroiditis   | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 13                                                        | (0.2)                                                     |
| Thyroid disorder         | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 5                                                         | (0.1)                                                     |
| Thyroiditis              | 7                                             | (1.2)                                         | 0                                         | (0.0)                                     | 1                                                     | (0.2)                                                 | 41                                                        | (0.7)                                                     |
| Thyroiditis acute        | 1                                             | (0.2)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 0                                                         | (0.0)                                                     |
|                          | KN355 Data for Pembrolizumab + Chemotherapy † | KN355 Data for Pembrolizumab + Chemotherapy † | KN355 Data for Placebo + Chemotherapy ¶ ¶ | KN355 Data for Placebo + Chemotherapy ¶ ¶ | mTNBC Safety Dataset for Pembrolizumab Monotherapy ‡‡ | mTNBC Safety Dataset for Pembrolizumab Monotherapy ‡‡ | Reference Safety Dataset for Pembrolizumab Monotherapy §§ | Reference Safety Dataset for Pembrolizumab Monotherapy §§ |
|                          | n                                             | (%)                                           | n                                         | (%)                                       | n                                                     | (%)                                                   | n                                                         | (%)                                                       |
| Type 1 Diabetes Mellitus | 2                                             | (0.3)                                         | 0                                         | (0.0)                                     | 2                                                     | (0.3)                                                 | 20                                                        | (0.3)                                                     |
| Diabetic ketoacidosis    | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 1                                                     | (0.2)                                                 | 9                                                         | (0.2)                                                     |
| Type 1 diabetes mellitus | 2                                             | (0.3)                                         | 0                                         | (0.0)                                     | 1                                                     | (0.2)                                                 | 16                                                        | (0.3)                                                     |
| Uveitis                  | 1                                             | (0.2)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 20                                                        | ( 0.3)                                                    |
| Iridocyclitis            | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 4                                                         | (0.1)                                                     |
| Iritis                   | 0                                             | (0.0)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 3                                                         | (0.1)                                                     |
| Uveitis                  | 1                                             | (0.2)                                         | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 13                                                        | (0.2)                                                     |

Every subject is counted a single time for each applicable row and column.

A bolded term or specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

††  Includes all subjects who received at least one dose of treatment in the pembrolizumab + chemotherapy arm of KN355.

¶¶  Includes all subjects who received at least one dose of treatment in the placebo + chemotherapy arm of KN355.

‡‡  Includes all subjects who received at least one dose of pembrolizumab in KN012-Cohort A, KN086 and KN119.

§§  Includes all subjects who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 Cohorts B and B2 (Head and Neck Cancer), KN013 Cohort 3 (Hodgkin Lymphoma), KN024, KN040, KN042, KN045, KN048, KN052, KN054, KN055 and KN087.

Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015, KN006: 03MAR2015, KN054: 02OCT2017)

Database cutoff date for Lung (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015, KN024: 10JUL2017, KN042: 04SEP2018)

Database cutoff date for HNSCC (KN012-HNSCC: 26APR2016, KN040: 15MAY2017, KN048: 25FEB2019, KN055: 22APR2016)

Database cutoff date for cHL (KN013-Cohort 3: 28SEP2018, KN087: 25SEP2016)

Database cutoff date for Bladder (KN045: 26OCT2017, KN052: 26SEP2018)

Database cutoff date for TNBC (KN355: 11DEC2019, KN012: 26APR2016, KN086: 10NOV2017, KN119: 11APR2019)

<div style=\"page-break-after: always\"></div>

## Time to Onset and Duration of AEOSI (ASaT Population)

|                                                          | KN355Datafor Pembrolizumab +  Chemotherapyit 11 (%)   | KN355 Data for Placebo + Chemotherapyl 11 (%)   | mTNBC Safety Dataset for Pembrolizumab Monotherapytt 1 (%)   | Reference Safety Dataset for Pembrolizumab Monotherapy's (%)   |
|----------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------|--------------------------------------------------------------|----------------------------------------------------------------|
| Subjects in population                                   | 596 168 (28.2)                                        | 281 30 (10.7)                                   | 595 99 (16.6)                                                | 5884 1464 (24.9)                                               |
| Subjects with AEOSI Time to Onset of First AEOSI (days)↑ | 122.3 (122.5)                                         | 135.5 (148.1) 77.5 4 to 531                     | 75.0 (82.4) 60.0 1 to 473                                    | 116.2 (118.7)                                                  |
| Mean (Std) Median Range                                  | 84.0 1to 707                                          |                                                 |                                                              | 78.0 1 to 775                                                  |
| Total episodes of AEOSI                                  | 257                                                   | 45                                              | 129                                                          | 2077                                                           |
| Average Episodes per patient                             | 1.53                                                  | 1.50                                            | 1.30                                                         | 1.42                                                           |
| Episode duration (days)t Median                          | 85.0                                                  | 2.0                                             | 424.0                                                        | 86.0                                                           |
| Range                                                    | 1 to1112+                                             | 1 to 745+                                       | 1 to 1044+                                                   | 1 to 1640+                                                     |

(%)= Number of subjects with AEOSI / Number of subjects in population.

↑TimetoonsetstatisticsarebasedonnumberofsubjectswithAEOSI.

- ↑ From product-limit (Kaplan-Meier) method for censored data.If an adverse event is not resolved at the time of analysis or the subjectdiedwithoutadverseeventresolved,thedurationiscensoredateitherdatacutoffdateordateofdeath,whichever occurred first.

+ indicates the AE episode is not recovered/resolved by the time of the cutoff date or date of death.

Std = Standard Deviation.

GradesarebasedonNCICTCAE4.0.

- tt Includes all subjects who received at least one dose of treatment in the pembrolizumab + chemotherapy arm of KN355.
- # Includes all subjects who received at least one dose of pembrolizumab in KN012-Cohort A, KN086 and KN119.

Includes all subjects who received at least one dose of treatment in the placebo + chemotherapy arm of KN355.

- $ Includes all subjects who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 Cohorts B and B2 (Head and Neck Cancer), KN013 Cohort 3 (Hodgkin Lymphoma), KN024,KN040,KN042,KN045,KN048,KN052,KN054,KN055andKN087.

Databasecutoff dateforMelanoma(KN001-Melanoma:18APR2014,KN002:28FEB2015,KN006:03MAR2015,KN054: 020CT2017)

Databasecutoff dateforLung(KN001-NSCLC:23JAN2015,KN010:30SEP2015,KN024:10JUL2017,KN042:04SEP2018) Database cutoff dateforHNSCC(KN012-HNSCC:26APR2016,KN040:15MAY2017,KN048:25FEB2019,KN055:

22APR2016)

Databasecutoff datefor cHL(KN013-Cohort3:28SEP2018,KN087:25SEP2016)

Databasecutoff dateforBladder(KN045:26OCT2017,KN052:26SEP2018)

Databasecutoff dateforTNBC(KN355:11DEC2019,KN012:26APR2016,KN086:10NOV2017,KN119:11APR2019)

## Summary of ConcomitantCorticosteroid UseforAEOSI (ASaT Population)

|                                       | KN355 Data for Pembrolizumab+ Chemotherapyit (96S=N)   | KN355 Data for Pembrolizumab+ Chemotherapyit (96S=N)   | KN355 Data for Placebo+ Chemotherapyl (N=281)   | KN355 Data for Placebo+ Chemotherapyl (N=281)   | mTNBC Safety Dataset for Pembrolizumab Monotherapyit (S6S=N)   | mTNBC Safety Dataset for Pembrolizumab Monotherapyit (S6S=N)   | Reference Safety Dataset for Pembrolizumab Monotherapyss (N=5884)   | Reference Safety Dataset for Pembrolizumab Monotherapyss (N=5884)   |
|---------------------------------------|--------------------------------------------------------|--------------------------------------------------------|-------------------------------------------------|-------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|
|                                       | n                                                      | %                                                      | n                                               | %                                               | n                                                              | %                                                              | n                                                                   | %                                                                   |
| Patientswith one or moreAEOSI         | 168                                                    |                                                        | 30                                              |                                                 | 99                                                             |                                                                | 1464                                                                |                                                                     |
| Treatedwithsystemiccorticosteroid     | 61                                                     | 36.3                                                   | 9                                               | 30.0                                            | 29                                                             | 29.3                                                           | 450                                                                 | 30.7                                                                |
| Not treatedwithsystemiccorticosteroid | 107                                                    | 63.7                                                   | 21                                              | 70.0                                            | 70                                                             | 70.7                                                           | 1014                                                                | 69.3                                                                |

Thenumber ofPatientswithoneormoreAEOSIisusedas the denominatorforthepercentagecalculation.

Includes all subjects who received at least one dose of treatment in the placebo + chemotherapy arm of KN355.

Includes all subjects who received at least one dose of treatment in the pembrolizumab + chemotherapy arm of KN355.

Includes allsubjects who received at least one dose of pembrolizumab in KN012-Cohort A, KN086 and KN119.

Includes allsubjects who received at least one dose of pembrolizumab inKNo01 Part B1, B2,B3,D, C,F1,F2,F3,KN002 (original phase),KN006,KN010,KN012 Cohorts B and B2(Head and Neck Cancer),KN013Cohort 3(Hodgkin Lymphoma), KN024, KN040, KN042, KN045, KN048, KN052, KN054, KN055 and KN087.

Database cutoff date for Melanoma (KN001-Melanoma:18APR2014,KN002: 28FEB2015,KN006:03MAR2015, KN054: 020CT2017)

Database cutoff date forLung (KN001-NSCLC: 23JAN2015,KN010:30SEP2015,KN024:10JUL2017,KN042:04SEP2018)

Database cutoff date forHNSCC(KN012-HNSCC:26APR2016,KN040:15MAY2017,KN048:25FEB2019,KN055:22APR2016)

Database cutoff dateforcHL(KN013-Cohort3:28SEP2018,KN087:25SEP2016)

Database cutoff dateforBladder(KN045:26OCT2017,KN052:26SEP2018)

Database cutoff dateforTNBC(KN355:11DEC2019,KN012:26APR2016,KN086:10NOV2017,KN119:11APR2019)

<div style=\"page-break-after: always\"></div>

## Laboratory findings

Summary of Subjects with Increases from Baseline in Laboratory Test Toxicity Grade Based on Highest Post-baseline Toxicity Grade

(Overall Incidence &gt; O% in One or More Treatment Groups) (Subjects with Baseline and Post-baseline Measurements) (ASaT Population)

|                                                                                           | KN355 Data for Pembrolizumab+ Chemotherapytt (N=596)                                      | KN355 Data for Pembrolizumab+ Chemotherapytt (N=596)                                      | KN355 Data for Placebo + Chemotherapy (N=281)                                             | KN355 Data for Placebo + Chemotherapy (N=281)                                             | mTNBC Safety Dataset for Pembrolizumab Monotherapyit (S6S=N)                              | mTNBC Safety Dataset for Pembrolizumab Monotherapyit (S6S=N)                              | Reference Safety Dataset for Pembrolizumab Monotherapy's (N=5884) n                       | Reference Safety Dataset for Pembrolizumab Monotherapy's (N=5884) n                       |
|-------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|
| LaboratoryTest                                                                            | n                                                                                         | (%)                                                                                       |                                                                                           | (%)                                                                                       |                                                                                           | (%)                                                                                       |                                                                                           | (%)                                                                                       |
| ActivatedPartialThromboplastinTineIncreased(Activatedpartialthroimboplastintineprolonged) | ActivatedPartialThromboplastinTineIncreased(Activatedpartialthroimboplastintineprolonged) | ActivatedPartialThromboplastinTineIncreased(Activatedpartialthroimboplastintineprolonged) | ActivatedPartialThromboplastinTineIncreased(Activatedpartialthroimboplastintineprolonged) | ActivatedPartialThromboplastinTineIncreased(Activatedpartialthroimboplastintineprolonged) | ActivatedPartialThromboplastinTineIncreased(Activatedpartialthroimboplastintineprolonged) | ActivatedPartialThromboplastinTineIncreased(Activatedpartialthroimboplastintineprolonged) | ActivatedPartialThromboplastinTineIncreased(Activatedpartialthroimboplastintineprolonged) | ActivatedPartialThromboplastinTineIncreased(Activatedpartialthroimboplastintineprolonged) |
| SubjectswithBaseline and Post-baseline Measurements                                       | 182                                                                                       |                                                                                           | 85                                                                                        |                                                                                           | 171                                                                                       |                                                                                           | 1444                                                                                      |                                                                                           |
| Grade 1                                                                                   | 21                                                                                        | (11.5)                                                                                    | 9                                                                                         | (10.6)                                                                                    | 23                                                                                        | (13.5)                                                                                    | 143                                                                                       | (9.9)                                                                                     |
| Grade 2                                                                                   | 9                                                                                         | (4.9)                                                                                     | 2                                                                                         | (2.4)                                                                                     | 9                                                                                         | (5.3)                                                                                     | 27                                                                                        | (6:1)                                                                                     |
| Grade 3                                                                                   | 6                                                                                         | (3.3)                                                                                     | 1                                                                                         | (1.2)                                                                                     | 5                                                                                         | (2.9)                                                                                     | 25                                                                                        | (1.7)                                                                                     |
| Grade 4                                                                                   | 0                                                                                         | (0.0)                                                                                     | 0                                                                                         | (0.0)                                                                                     | 0                                                                                         | (0.0)                                                                                     | 0                                                                                         | (0.0)                                                                                     |
| Grade 3-4                                                                                 | 6                                                                                         | (3.3)                                                                                     | 1                                                                                         | (1.2)                                                                                     | 5                                                                                         | (2.9)                                                                                     | 25                                                                                        | (1.7)                                                                                     |
| All Grades                                                                                | 36                                                                                        | (19.8)                                                                                    | 12                                                                                        | (14.1)                                                                                    | 37                                                                                        | (21.6)                                                                                    | 195                                                                                       | (13.5)                                                                                    |
| AlanineAminotransferaseIncreased(Alanine aininotransferase increased)                     | AlanineAminotransferaseIncreased(Alanine aininotransferase increased)                     | AlanineAminotransferaseIncreased(Alanine aininotransferase increased)                     | AlanineAminotransferaseIncreased(Alanine aininotransferase increased)                     | AlanineAminotransferaseIncreased(Alanine aininotransferase increased)                     | AlanineAminotransferaseIncreased(Alanine aininotransferase increased)                     | AlanineAminotransferaseIncreased(Alanine aininotransferase increased)                     | AlanineAminotransferaseIncreased(Alanine aininotransferase increased)                     | AlanineAminotransferaseIncreased(Alanine aininotransferase increased)                     |
| SubjectswithBaseline andPost-baseline Measurements                                        | 590                                                                                       |                                                                                           | 279                                                                                       |                                                                                           | 557                                                                                       |                                                                                           | 5133                                                                                      |                                                                                           |
| Grade 1                                                                                   | 216                                                                                       | (36.6)                                                                                    | 108                                                                                       | (38.7)                                                                                    | 112                                                                                       | (20.1)                                                                                    | 989                                                                                       | (E61)                                                                                     |
| Grade 2                                                                                   | 71                                                                                        | (12.0)                                                                                    | 33                                                                                        | (11.8)                                                                                    | 22                                                                                        | (3.9)                                                                                     | 139                                                                                       | (2.7)                                                                                     |
| Grade 3                                                                                   | 55                                                                                        | (9.3)                                                                                     | 21                                                                                        | (7.5)                                                                                     | 15                                                                                        | (2.7)                                                                                     | 120                                                                                       | (2.3)                                                                                     |
| Grade 4                                                                                   | 11                                                                                        | (6:1)                                                                                     | 1                                                                                         | (0.4)                                                                                     | 1                                                                                         | (0.2)                                                                                     | 22                                                                                        | (0.4)                                                                                     |
| Grade 3-4                                                                                 | 66                                                                                        | (11.2)                                                                                    | 22                                                                                        | (7.9)                                                                                     | 16                                                                                        | (2.9)                                                                                     | 142                                                                                       | (2.8)                                                                                     |
| All Grades                                                                                | 353                                                                                       | (59.8)                                                                                    | 163                                                                                       | (58.4)                                                                                    | 150                                                                                       | (26.9)                                                                                    | 1270                                                                                      | (24.7)                                                                                    |
| AlbuminDecreased (Hypoalbuminemia)                                                        | AlbuminDecreased (Hypoalbuminemia)                                                        | AlbuminDecreased (Hypoalbuminemia)                                                        | AlbuminDecreased (Hypoalbuminemia)                                                        | AlbuminDecreased (Hypoalbuminemia)                                                        | AlbuminDecreased (Hypoalbuminemia)                                                        | AlbuminDecreased (Hypoalbuminemia)                                                        | AlbuminDecreased (Hypoalbuminemia)                                                        | AlbuminDecreased (Hypoalbuminemia)                                                        |
| SubjectswithBaseline andPost-baseline                                                     | 587                                                                                       |                                                                                           | 278                                                                                       |                                                                                           | 548                                                                                       |                                                                                           | 5066                                                                                      |                                                                                           |
| Measurements Grade 1                                                                      | 142                                                                                       | (24.2)                                                                                    | 64                                                                                        | (23.0)                                                                                    | 125                                                                                       | (22.8)                                                                                    | 1012                                                                                      | (20.0)                                                                                    |
| Grade 2                                                                                   | 60                                                                                        | (10.2)                                                                                    | 20                                                                                        | (7.2)                                                                                     | 87                                                                                        | (15.9)                                                                                    | 741                                                                                       | (14.6)                                                                                    |
| Grade 3                                                                                   | 13                                                                                        | (2.2)                                                                                     | 6                                                                                         | (2.2)                                                                                     | 13                                                                                        | (2.4)                                                                                     | 84                                                                                        | (1.7)                                                                                     |
| Grade 4                                                                                   | 0                                                                                         | (0.0)                                                                                     | 0                                                                                         | (0.0)                                                                                     | 0                                                                                         | (0.0)                                                                                     | 0                                                                                         | (0.0)                                                                                     |
| Grade 3-4                                                                                 | 13                                                                                        | (2.2)                                                                                     | 6                                                                                         | (2.2)                                                                                     | 13                                                                                        | (2.4)                                                                                     | 84                                                                                        | (1.7)                                                                                     |
| All Grades                                                                                | 215                                                                                       | (36.6)                                                                                    | 90                                                                                        | (32.4)                                                                                    | 225                                                                                       | (41.1)                                                                                    | 1837                                                                                      | (36.3)                                                                                    |
| AlkalinePhosphataseIncreased (Alkalinephosphataseincreased)                               | AlkalinePhosphataseIncreased (Alkalinephosphataseincreased)                               | AlkalinePhosphataseIncreased (Alkalinephosphataseincreased)                               | AlkalinePhosphataseIncreased (Alkalinephosphataseincreased)                               | AlkalinePhosphataseIncreased (Alkalinephosphataseincreased)                               | AlkalinePhosphataseIncreased (Alkalinephosphataseincreased)                               | AlkalinePhosphataseIncreased (Alkalinephosphataseincreased)                               | AlkalinePhosphataseIncreased (Alkalinephosphataseincreased)                               | AlkalinePhosphataseIncreased (Alkalinephosphataseincreased)                               |
| Subjects withBaseline and Post-baseline Measurements                                      | 590                                                                                       |                                                                                           | 279                                                                                       |                                                                                           | 553                                                                                       |                                                                                           | 5112                                                                                      |                                                                                           |
| Grade 1                                                                                   | 154                                                                                       | (26.1)                                                                                    | 88                                                                                        | (31.5)                                                                                    | 103                                                                                       | (18.6)                                                                                    | 975                                                                                       | (19.1)                                                                                    |
| Grade 2                                                                                   | 29 23                                                                                     | (4.9)                                                                                     | 14                                                                                        | (5.0)                                                                                     | 35 24                                                                                     | (6.3)                                                                                     | 267 134                                                                                   | (5.2)                                                                                     |
| Grade 4                                                                                   | 0                                                                                         | (0.0)                                                                                     | 0                                                                                         | (0.0)                                                                                     | 1                                                                                         | (0.2)                                                                                     | 3                                                                                         | (2.6) (0.1)                                                                               |

<div style=\"page-break-after: always\"></div>

|                                                                            | KN355 Data for Pembrolizumab + Chemotherapytt (N=596)                      | KN355 Data for Pembrolizumab + Chemotherapytt (N=596)                      | KN355 Data for Placebo+ Chemotherapyfl (N=281)                             | KN355 Data for Placebo+ Chemotherapyfl (N=281)                             | mTNBC Safety Dataset for Pembrolizumab Monotherapyit (N=595)               | mTNBC Safety Dataset for Pembrolizumab Monotherapyit (N=595)               | Reference Safety Dataset for Pembrolizumab Monotherapy's (N=5884) n        | Reference Safety Dataset for Pembrolizumab Monotherapy's (N=5884) n        |
|----------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|
| Laboratory Test                                                            | n1                                                                         | (%)                                                                        |                                                                            | (%)                                                                        |                                                                            | (%)                                                                        |                                                                            | (%)                                                                        |
| Alkaline Phosphatase Increased (Alkaline phosphatase increased)            | Alkaline Phosphatase Increased (Alkaline phosphatase increased)            | Alkaline Phosphatase Increased (Alkaline phosphatase increased)            | Alkaline Phosphatase Increased (Alkaline phosphatase increased)            | Alkaline Phosphatase Increased (Alkaline phosphatase increased)            | Alkaline Phosphatase Increased (Alkaline phosphatase increased)            | Alkaline Phosphatase Increased (Alkaline phosphatase increased)            | Alkaline Phosphatase Increased (Alkaline phosphatase increased)            | Alkaline Phosphatase Increased (Alkaline phosphatase increased)            |
| Grade 3-4                                                                  | 23                                                                         | (3.9)                                                                      | 6                                                                          | (2.2)                                                                      | 25                                                                         | (4.5)                                                                      | 137                                                                        | (2.7)                                                                      |
| All Grades                                                                 | 206                                                                        | (34.9)                                                                     | 108                                                                        | (38.7)                                                                     | 163                                                                        | (29.5)                                                                     | 1379                                                                       | (27.0)                                                                     |
| Aspartate AminotransferaseIncreased (Aspartate aminotransferase increased) | Aspartate AminotransferaseIncreased (Aspartate aminotransferase increased) | Aspartate AminotransferaseIncreased (Aspartate aminotransferase increased) | Aspartate AminotransferaseIncreased (Aspartate aminotransferase increased) | Aspartate AminotransferaseIncreased (Aspartate aminotransferase increased) | Aspartate AminotransferaseIncreased (Aspartate aminotransferase increased) | Aspartate AminotransferaseIncreased (Aspartate aminotransferase increased) | Aspartate AminotransferaseIncreased (Aspartate aminotransferase increased) | Aspartate AminotransferaseIncreased (Aspartate aminotransferase increased) |
| Subjects withBaseline andPost-baseline                                     | 587                                                                        |                                                                            | 277                                                                        |                                                                            | 556                                                                        |                                                                            | 5129                                                                       |                                                                            |
| Measurements                                                               |                                                                            |                                                                            |                                                                            |                                                                            |                                                                            |                                                                            |                                                                            |                                                                            |
| Grade 1                                                                    | 227                                                                        | (38.7)                                                                     | 113                                                                        | (40.8)                                                                     | 132                                                                        | (23.7)                                                                     | 1110                                                                       | (21.6)                                                                     |
| Grade 2                                                                    | 54                                                                         | (9.2)                                                                      | 23                                                                         | (8.3)                                                                      | 25                                                                         | (4.5)                                                                      | 178                                                                        | (3.5)                                                                      |
| Grade 3                                                                    | 44                                                                         | (7.5)                                                                      | 17                                                                         | (6.1)                                                                      | 32                                                                         | (5.8)                                                                      | 118                                                                        | (2.3)                                                                      |
| Grade 4                                                                    | 9                                                                          | (S:1)                                                                      | 0                                                                          | (0.0)                                                                      | 3                                                                          | (0.5)                                                                      | 29                                                                         | (0.6)                                                                      |
| Grade 3-4                                                                  | 53                                                                         | (9.0)                                                                      | 17                                                                         | (6.1)                                                                      | 35                                                                         | (6.3)                                                                      | 147                                                                        | (2.9)                                                                      |
| All Grades                                                                 | 334                                                                        | (56.9)                                                                     | 153                                                                        | (55.2)                                                                     | 192                                                                        | (34.5)                                                                     | 1435                                                                       | (28.0)                                                                     |
| BilirubinIncreased(Blood bilirubinincreased)                               | BilirubinIncreased(Blood bilirubinincreased)                               | BilirubinIncreased(Blood bilirubinincreased)                               | BilirubinIncreased(Blood bilirubinincreased)                               | BilirubinIncreased(Blood bilirubinincreased)                               | BilirubinIncreased(Blood bilirubinincreased)                               | BilirubinIncreased(Blood bilirubinincreased)                               | BilirubinIncreased(Blood bilirubinincreased)                               | BilirubinIncreased(Blood bilirubinincreased)                               |
| Subjects with Baseline and Post-baseline                                   | 589                                                                        |                                                                            | 278                                                                        |                                                                            | 556                                                                        |                                                                            | 5133                                                                       |                                                                            |
| Measurements                                                               |                                                                            |                                                                            |                                                                            |                                                                            |                                                                            |                                                                            |                                                                            |                                                                            |
| Grade 1                                                                    | 25                                                                         | (4.2)                                                                      | 12                                                                         | (4.3)                                                                      | 19                                                                         | (3.4)                                                                      | 284                                                                        | (5.5)                                                                      |
| Grade 2                                                                    | 20                                                                         | (3.4)                                                                      | 7                                                                          | (2.5)                                                                      | 4                                                                          | (0.7)                                                                      | 138                                                                        | (2.7)                                                                      |
| Grade 3                                                                    | 18                                                                         | (3.1)                                                                      | 1                                                                          | (0.4)                                                                      | 13                                                                         | (2.3)                                                                      | 69                                                                         | (1.3)                                                                      |
| Grade 4                                                                    | 2                                                                          | (0.3)                                                                      | 1                                                                          | (0.4)                                                                      | 2                                                                          | (0.4)                                                                      | 20                                                                         | (0.4)                                                                      |
| Grade 3-4                                                                  | 20                                                                         | (3.4)                                                                      | 2                                                                          | (0.7)                                                                      | 15                                                                         | (2.7)                                                                      | 89                                                                         | (1.7)                                                                      |
| All Grades                                                                 | 65                                                                         | (11.0)                                                                     | 21                                                                         | (7.6)                                                                      | 38                                                                         | (6.8)                                                                      | 511                                                                        | (10.0)                                                                     |
| Calcium Decreased (Hypocalcemia)                                           | Calcium Decreased (Hypocalcemia)                                           | Calcium Decreased (Hypocalcemia)                                           | Calcium Decreased (Hypocalcemia)                                           | Calcium Decreased (Hypocalcemia)                                           | Calcium Decreased (Hypocalcemia)                                           | Calcium Decreased (Hypocalcemia)                                           | Calcium Decreased (Hypocalcemia)                                           | Calcium Decreased (Hypocalcemia)                                           |
| SubjectswithBaseline andPost-baseline Measurements                         | 584                                                                        |                                                                            | 275                                                                        |                                                                            | 548                                                                        |                                                                            | 5449                                                                       |                                                                            |
| Grade 1                                                                    | 126                                                                        | (21.6)                                                                     | 50                                                                         | (18.2)                                                                     | 93                                                                         | (17.0)                                                                     | 926                                                                        | (17.0)                                                                     |
| Grade 2                                                                    | 26                                                                         | (4.5)                                                                      | 18                                                                         | (6.5)                                                                      | 28                                                                         | (5.1)                                                                      | 227                                                                        | (4.2)                                                                      |
| Grade 3                                                                    | 8                                                                          | (1.4)                                                                      | 2                                                                          | (0.7)                                                                      | 2                                                                          | (0.4)                                                                      | 33                                                                         | (0.6)                                                                      |
| Grade 4                                                                    | 11                                                                         | (6'1)                                                                      | 3                                                                          | (1.1)                                                                      | 7                                                                          | (1.3)                                                                      | 47                                                                         | (0.9)                                                                      |
| Grade 3-4                                                                  | 19                                                                         | (3.3)                                                                      | 5                                                                          | (1.8)                                                                      | 9                                                                          | (1.6)                                                                      | 80                                                                         | (S:1)                                                                      |
| All Grades                                                                 | 171                                                                        | (29.3)                                                                     | 73                                                                         | (26.5)                                                                     | 130                                                                        | (23.7)                                                                     | 1233                                                                       | (22.6)                                                                     |

|                                                       | KN355Data for Pembrolizumab+ Chemotherapyit (96S=N)   | KN355Data for Pembrolizumab+ Chemotherapyit (96S=N)   | KN355Data for Placebo+ Chemotherapyll (N=281)        | KN355Data for Placebo+ Chemotherapyll (N=281)        | mTNBC Safety Dataset for Pembrolizumab Monotherapyit (S6S=N)   | mTNBC Safety Dataset for Pembrolizumab Monotherapyit (S6S=N)   | Reference Safety Dataset for Pembrolizumab Monotherapys (N=5884)   | Reference Safety Dataset for Pembrolizumab Monotherapys (N=5884)   |
|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|--------------------------------------------------------------------|--------------------------------------------------------------------|
| Laboratory Test                                       | n (%)                                                 | n (%)                                                 | n (%)                                                | n (%)                                                | n (%)                                                          | n (%)                                                          | n (%)                                                              | n (%)                                                              |
| Calcium Increased (Hypercalceinia)                    |                                                       |                                                       |                                                      |                                                      |                                                                |                                                                |                                                                    |                                                                    |
| Grade 1                                               | 70                                                    | (12.0)                                                | 26                                                   | (9.5)                                                | 18                                                             | (3.3)                                                          | 448                                                                | (8.2)                                                              |
| Grade 2                                               | 2                                                     | (0.3)                                                 | 0                                                    | (0.0)                                                | 4                                                              | (0.7)                                                          | 67                                                                 | (1.2)                                                              |
| Grade3                                                | 0                                                     | (0.0)                                                 | 0                                                    | (0.0)                                                | 0                                                              | (0.0)                                                          | 41                                                                 | (0.8)                                                              |
| Grade 4                                               | 4                                                     | (0.7)                                                 | 3                                                    | (1.1)                                                | 0                                                              | (0.0)                                                          | 63                                                                 | (1.2)                                                              |
| Grade 3-4                                             | 4                                                     | (0.7)                                                 | 3                                                    | (1.1)                                                | 0                                                              | (0.0)                                                          | 104                                                                | (61)                                                               |
| All Grades                                            | 76                                                    | (13.0)                                                | 29                                                   | (10.5)                                               | 22                                                             | (4.0)                                                          | 619                                                                | (11.4)                                                             |
| CholesterolIncreased(Cholesterolhigh)                 |                                                       |                                                       |                                                      |                                                      |                                                                |                                                                |                                                                    |                                                                    |
| Subjects withBaseline and Post-baseline               | 0                                                     |                                                       | 0                                                    |                                                      | 0                                                              |                                                                | 2401                                                               |                                                                    |
| Measurements                                          |                                                       |                                                       |                                                      |                                                      |                                                                |                                                                |                                                                    |                                                                    |
| Grade 1                                               | 0                                                     | (0.0)                                                 | 0                                                    | (0.0)                                                | 0                                                              | (0.0)                                                          | 427                                                                | (17.8)                                                             |
| Grade 2                                               | 0                                                     | (0.0)                                                 | 0                                                    | (0.0)                                                | 0                                                              | (0.0)                                                          | 75                                                                 | (3.1)                                                              |
| Grade 3                                               | 0                                                     | (0.0)                                                 | 0                                                    | (0.0)                                                | 0                                                              | (0.0)                                                          | 12                                                                 | (0.5)                                                              |
| Grade 4                                               | 0                                                     | (0.0)                                                 | 0                                                    | (0.0)                                                | 0                                                              | (0.0)                                                          | 12                                                                 | (0.5)                                                              |
| Grade 3-4                                             | 0                                                     | (0.0)                                                 | 0                                                    | (0.0)                                                | 0                                                              | (0.0)                                                          | 24                                                                 | (1.0)                                                              |
| All Grades                                            | 0                                                     | (0.0)                                                 | 0                                                    | (0.0)                                                | 0                                                              | (0.0)                                                          | 526                                                                | (21.9)                                                             |
| CreatinineIncreased(Creatinine increased)             | CreatinineIncreased(Creatinine increased)             |                                                       |                                                      |                                                      |                                                                |                                                                |                                                                    |                                                                    |
| Subjects with Baseline and Post-baseline Measurements | 590                                                   |                                                       | 278                                                  |                                                      | 558                                                            |                                                                | 5156                                                               |                                                                    |
| Grade 1                                               | 67                                                    | (11.4)                                                | 35                                                   | (12.6)                                               | 51                                                             | (9.1)                                                          | 630                                                                | (12.2)                                                             |
| Grade 2                                               | 24                                                    | (4.1)                                                 | 5                                                    | (1.8)                                                | 12                                                             | (2.2)                                                          | 262                                                                | (5.1)                                                              |
| Grade 3                                               | 7                                                     | (1.2)                                                 | 3                                                    | (1.1)                                                | 5                                                              | (0.9)                                                          | 51                                                                 | (1.0)                                                              |
| Grade 4                                               | 2                                                     | (0.3)                                                 | 0                                                    | (0.0)                                                | 2                                                              | (0.4)                                                          | 20                                                                 | (0.4)                                                              |
| Grade 3-4                                             | 9                                                     | (1.5)                                                 | 3                                                    | (1.1)                                                | 7                                                              | (1.3)                                                          | 71                                                                 | (1.4)                                                              |
| All Grades                                            | 100                                                   | (16.9)                                                | 43                                                   | (15.5)                                               | 70                                                             | (12.5)                                                         | 963                                                                | (18.7)                                                             |
| Gamma Glutamyl Transferase Increased (GGT increased)  | Gamma Glutamyl Transferase Increased (GGT increased)  | Gamma Glutamyl Transferase Increased (GGT increased)  | Gamma Glutamyl Transferase Increased (GGT increased) | Gamma Glutamyl Transferase Increased (GGT increased) | Gamma Glutamyl Transferase Increased (GGT increased)           | Gamma Glutamyl Transferase Increased (GGT increased)           | Gamma Glutamyl Transferase Increased (GGT increased)               | Gamma Glutamyl Transferase Increased (GGT increased)               |
| Subjects with Baseline andPost-baseline               | 0                                                     |                                                       | 0                                                    |                                                      | 0                                                              |                                                                | 7                                                                  |                                                                    |
| Measurements                                          |                                                       |                                                       |                                                      |                                                      |                                                                |                                                                |                                                                    |                                                                    |
| Grade 1                                               | 0                                                     | (0.0)                                                 | 0                                                    | (0.0)                                                | 0                                                              | (0.0)                                                          | 0                                                                  | (0.0)                                                              |
| Grade 2                                               | 0                                                     | (0.0)                                                 | 0                                                    | (0.0)                                                | 0                                                              | (0.0)                                                          | 0                                                                  | (0.0)                                                              |
| Grade 3                                               | 0                                                     | (0.0)                                                 | 0                                                    | (0.0)                                                | 0                                                              | (0.0)                                                          | 1                                                                  | (14.3)                                                             |
| Grade 4                                               | 0                                                     | (0.0)                                                 | 0                                                    | (0.0)                                                | 0                                                              | (0.0)                                                          | 0                                                                  | (0.0)                                                              |
| Grade 3-4                                             | 0                                                     | (0.0)                                                 | 0                                                    | (0.0)                                                | 0                                                              | (0.0)                                                          | 1                                                                  | (14.3)                                                             |
| All Grades                                            | 0                                                     | (0.0)                                                 | 0                                                    | (0.0)                                                | 0                                                              | (0.0)                                                          | 1                                                                  | (14.3)                                                             |

<div style=\"page-break-after: always\"></div>

|                                                       | KN355Data for Pembrolizumab+ Chemotherapyit (N=596)   | KN355Data for Pembrolizumab+ Chemotherapyit (N=596)   | KN355Data for Placebo+ Chemotherapyf (N=281)   | KN355Data for Placebo+ Chemotherapyf (N=281)   | mTNBC Safety Dataset for Pembrolizumab Monotherapyit (S6S=N)   | mTNBC Safety Dataset for Pembrolizumab Monotherapyit (S6S=N)   | Reference Safety Dataset for Pembrolizumab Monotherapyi (N=5884)   | Reference Safety Dataset for Pembrolizumab Monotherapyi (N=5884)   |
|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|------------------------------------------------|------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|--------------------------------------------------------------------|--------------------------------------------------------------------|
| Laboratory Test                                       | (%)                                                   | (%)                                                   | n (%)                                          | n (%)                                          | n (%)                                                          | n (%)                                                          | n (%)                                                              | n (%)                                                              |
| GlucoseDecreased (Hypoglycemia)                       |                                                       |                                                       |                                                |                                                |                                                                |                                                                |                                                                    |                                                                    |
| Subjects with Baseline and Post-baseline Measurements | 585                                                   |                                                       | 276                                            |                                                | 545                                                            |                                                                | 5025                                                               |                                                                    |
| Grade 1                                               | 38                                                    | (6.5)                                                 | 16                                             | (5.8)                                          | 25                                                             | (4.6)                                                          | 398                                                                | (6L)                                                               |
| Grade 2                                               | 8                                                     | (1.4)                                                 | 3                                              | (1.1)                                          | 5                                                              | (0.9)                                                          | 63                                                                 | (1.3)                                                              |
| Grade 3                                               | 3                                                     | (0.5)                                                 | 1                                              | (0.4)                                          | 0                                                              | (0.0)                                                          | 12                                                                 | (0.2)                                                              |
| Grade 4                                               | 6                                                     | (1.0)                                                 | 1                                              | (0.4)                                          | 1                                                              | (0.2)                                                          | 19                                                                 | (0.4)                                                              |
| Grade 3-4                                             | 9                                                     | (1.5)                                                 | 2                                              | (0.7)                                          | 1                                                              | (0.2)                                                          | 31                                                                 | (0.6)                                                              |
| All Grades                                            | 55                                                    | (9.4)                                                 | 21                                             | (7.6)                                          | 31                                                             | (5.7)                                                          | 492                                                                | (9.8)                                                              |
| Glucose Increased (Hyperglycemia)                     |                                                       |                                                       |                                                |                                                |                                                                |                                                                |                                                                    |                                                                    |
| Subjects with Baseline and Post-baseline Measurements | 585                                                   |                                                       | 276                                            |                                                | 545                                                            |                                                                | 5025                                                               |                                                                    |
| Grade 1                                               | 207                                                   | (35.4)                                                | 104                                            | (37.7)                                         | 176                                                            | (32.3)                                                         | 1624                                                               | (32.3)                                                             |
| Grade 2                                               | 71                                                    | (12.1)                                                | 32                                             | (11.6)                                         | 34                                                             | (6.2)                                                          | 629                                                                | (12.5)                                                             |
| Grade 3                                               | 22                                                    | (3.8)                                                 | 6                                              | (2.2)                                          | 17                                                             | (3.1)                                                          | 213                                                                | (4.2)                                                              |
| Grade 4                                               | 4                                                     | (0.7)                                                 | 0                                              | (0.0)                                          | 4                                                              | (0.7)                                                          | 34                                                                 | (0.7)                                                              |
| Grade 3-4                                             | 26                                                    | (4.4)                                                 | 6                                              | (2.2)                                          | 21                                                             | (3.9)                                                          | 247                                                                | (4.9)                                                              |
| All Grades                                            | 304                                                   | (52.0)                                                | 142                                            | (51.4)                                         | 231                                                            | (42.4)                                                         | 2500                                                               | (49.8)                                                             |
| Hemoglobin Decreased (Anemia)                         |                                                       |                                                       |                                                |                                                |                                                                |                                                                |                                                                    |                                                                    |
| Subjects with Baseline and Post-baseline              | 592                                                   |                                                       | 280                                            |                                                | 547                                                            |                                                                | 5152                                                               |                                                                    |
| Measurements Grade 1                                  | 174                                                   | (29.4)                                                | 72                                             | (25.7)                                         | 115                                                            | (21.0)                                                         | 1096                                                               | (21.3)                                                             |
| Grade 2                                               | 236                                                   | (39.9)                                                | 113                                            | (40.4)                                         | 75                                                             | (13.7)                                                         | 831                                                                | (16.1)                                                             |
| Grade 3                                               | 120                                                   | (20.3)                                                | 52                                             | (18.6)                                         | 35                                                             | (6.4)                                                          | 321                                                                | (6.2)                                                              |
| Grade 4                                               | 0                                                     | (0.0)                                                 | 0                                              | (0.0)                                          | 0                                                              | (0.0)                                                          | 9                                                                  | (0.2)                                                              |
| Grade 3-4                                             | 120                                                   | (20.3)                                                | 52                                             | (18.6)                                         | 35                                                             | (6.4)                                                          | 330                                                                | (6.4)                                                              |
| All Grades                                            | 530                                                   | (89.5)                                                | 237                                            | (84.6)                                         | 225                                                            | (41.1)                                                         | 2257                                                               | (43.8)                                                             |
| HemoglobinIncreased (Hemoglobin increased)            |                                                       |                                                       |                                                |                                                |                                                                |                                                                |                                                                    |                                                                    |
| Subjects with Baseline and Post-baseline Measurements | 592                                                   |                                                       | 280                                            |                                                | 547                                                            |                                                                | 5152                                                               |                                                                    |
| Grade 1                                               | 0                                                     | (0.0)                                                 | 0                                              | (0.0)                                          | 0                                                              | (0.0)                                                          | 0                                                                  | (0.0)                                                              |
| Grade 2 Grade 3                                       | 0 1                                                   | (0.0) (0.2)                                           | 0 0                                            | (0.0) (0.0)                                    | 0 0                                                            | (0.0) (0.0)                                                    | 1 0                                                                | (0.0)                                                              |
| Grade 4                                               | 0                                                     | (0.0)                                                 | 0                                              | (0.0)                                          | 0                                                              | (0.0)                                                          | 0                                                                  | (0.0) (0.0)                                                        |

|                                                      | KN355 Data for Pembrolizumab + Chemotherapyit (N=596)   | KN355 Data for Pembrolizumab + Chemotherapyit (N=596)   | KN355 Data for Placebo+ Chemotherapyf (N=281)      | KN355 Data for Placebo+ Chemotherapyf (N=281)      | mTNBC Safety Dataset for Pembrolizumab Monotherapyit (S6S=N)   | mTNBC Safety Dataset for Pembrolizumab Monotherapyit (S6S=N)   | Reference Safety Dataset for Pembrolizumab Monotherapyss (N=5884) n   | Reference Safety Dataset for Pembrolizumab Monotherapyss (N=5884) n   |
|------------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------------------------------------|
| Laboratory Test                                      | n                                                       | (%)                                                     | n                                                  | (%)                                                |                                                                | (%)                                                            |                                                                       | (%)                                                                   |
| Hemoglobin Increased (Hemoglobin increased)          | Hemoglobin Increased (Hemoglobin increased)             | Hemoglobin Increased (Hemoglobin increased)             | Hemoglobin Increased (Hemoglobin increased)        | Hemoglobin Increased (Hemoglobin increased)        | Hemoglobin Increased (Hemoglobin increased)                    | Hemoglobin Increased (Hemoglobin increased)                    | Hemoglobin Increased (Hemoglobin increased)                           | Hemoglobin Increased (Hemoglobin increased)                           |
| Grade 3-4                                            | 1                                                       | (0.2)                                                   | 0                                                  | (0.0)                                              | 0                                                              | (0.0)                                                          | 0                                                                     | (0.0)                                                                 |
| All Grades                                           | 1                                                       | (0.2)                                                   | 0                                                  | (0.0)                                              | 0                                                              | (0.0)                                                          | 1                                                                     | (0.0)                                                                 |
| LeukocytesDecreased (IVhite blood cell decreased)    | LeukocytesDecreased (IVhite blood cell decreased)       | LeukocytesDecreased (IVhite blood cell decreased)       | LeukocytesDecreased (IVhite blood cell decreased)  | LeukocytesDecreased (IVhite blood cell decreased)  | LeukocytesDecreased (IVhite blood cell decreased)              | LeukocytesDecreased (IVhite blood cell decreased)              | LeukocytesDecreased (IVhite blood cell decreased)                     | LeukocytesDecreased (IVhite blood cell decreased)                     |
| SubjectswithBaseline and Post-baseline Measurements  | 592                                                     |                                                         | 280                                                |                                                    | 550                                                            |                                                                | 5151                                                                  |                                                                       |
| Grade 1                                              | 87                                                      | (14.7)                                                  | 45                                                 | (16.1)                                             | 64                                                             | (11.6)                                                         | 433                                                                   | (8.4)                                                                 |
| Grade 2                                              | 182                                                     | (30.7)                                                  | 86                                                 | (30.7)                                             | 28                                                             | (5.1)                                                          | 149                                                                   | (2.9)                                                                 |
| Grade 3                                              | 206                                                     | (34.8)                                                  | 96                                                 | (34.3)                                             | 6                                                              | (1.1)                                                          | 17                                                                    | (0.3)                                                                 |
| Grade 4                                              | 27                                                      | (4.6)                                                   | 14                                                 | (5.0)                                              | 3                                                              | (0.5)                                                          | 24                                                                    | (0.5)                                                                 |
| Grade 3-4                                            | 233                                                     | (39.4)                                                  | 110                                                | (39.3)                                             | 9                                                              | (1.6)                                                          | 41                                                                    | (0.8)                                                                 |
| All Grades                                           | 502                                                     | (84.8)                                                  | 241                                                | (86.1)                                             | 101                                                            | (18.4)                                                         | 623                                                                   | (12.1)                                                                |
| Lymphocytes Decreased (Lymphocyte count decreased)   | Lymphocytes Decreased (Lymphocyte count decreased)      | Lymphocytes Decreased (Lymphocyte count decreased)      | Lymphocytes Decreased (Lymphocyte count decreased) | Lymphocytes Decreased (Lymphocyte count decreased) | Lymphocytes Decreased (Lymphocyte count decreased)             | Lymphocytes Decreased (Lymphocyte count decreased)             | Lymphocytes Decreased (Lymphocyte count decreased)                    | Lymphocytes Decreased (Lymphocyte count decreased)                    |
| Subjects withBaseline and Post-baseline Measurements | 591                                                     |                                                         | 280                                                |                                                    | 548                                                            |                                                                | 4787                                                                  |                                                                       |
| Grade 1                                              | 83                                                      | (14.0)                                                  | 49                                                 | (17.5)                                             | 73                                                             | (13.3)                                                         | 534                                                                   | (11.2)                                                                |
| Grade 2                                              | 176                                                     | (29.8)                                                  | 95                                                 | (33.9)                                             | 88                                                             | (16.1)                                                         | 743                                                                   | (15.5)                                                                |
| Grade 3                                              | 135                                                     | (22.8)                                                  | 42                                                 | (15.0)                                             | 56                                                             | (10.2)                                                         | 441                                                                   | (9.2)                                                                 |
| Grade 4                                              | 21                                                      | (3.6)                                                   | 10                                                 | (3.6)                                              | 11                                                             | (2.0)                                                          | 85                                                                    | (1.8)                                                                 |
| Grade 3-4                                            | 156                                                     | (26.4)                                                  | 52                                                 | (18.6)                                             | 67                                                             | (12.2)                                                         | 526                                                                   | (11.0)                                                                |
| All Grades                                           | 415                                                     | (70.2)                                                  | 196                                                | (70.0)                                             | 228                                                            | (41.6)                                                         | 1803                                                                  | (37.7)                                                                |
| Magnesium Decreased (Hypomagnesemia)                 | Magnesium Decreased (Hypomagnesemia)                    | Magnesium Decreased (Hypomagnesemia)                    | Magnesium Decreased (Hypomagnesemia)               | Magnesium Decreased (Hypomagnesemia)               | Magnesium Decreased (Hypomagnesemia)                           | Magnesium Decreased (Hypomagnesemia)                           | Magnesium Decreased (Hypomagnesemia)                                  | Magnesium Decreased (Hypomagnesemia)                                  |
| SubjectswithBaseline and Post-baseline Measurements  | 0                                                       |                                                         | 0                                                  |                                                    | 83                                                             |                                                                | 3953                                                                  |                                                                       |
| Grade 1                                              | 0                                                       | (0.0)                                                   | 0                                                  | (0.0)                                              | 11                                                             | (13.3)                                                         | 492                                                                   | (12.4)                                                                |
| Grade 2                                              | 0                                                       | (0.0)                                                   | 0                                                  | (0.0)                                              | 2                                                              | (2.4)                                                          | 107                                                                   | (2.7)                                                                 |
| Grade 3                                              | 0                                                       | (0.0)                                                   | 0                                                  | (0.0)                                              | 0                                                              | (0.0)                                                          | 0                                                                     | (0.0)                                                                 |
| Grade 4                                              | 0                                                       | (0.0)                                                   | 0                                                  | (0.0)                                              | 1                                                              | (1.2)                                                          | 9                                                                     | (0.2)                                                                 |
| Grade 3-4                                            | 0                                                       | (0.0)                                                   | 0                                                  | (0.0)                                              | 1                                                              | (1.2)                                                          | 9                                                                     | (0.2)                                                                 |
| All Grades                                           | 0                                                       | (0.0)                                                   | 0                                                  | (0.0)                                              | 14                                                             | (16.9)                                                         | 608                                                                   | (15.4)                                                                |
| Magnesium Increased (Hypermagnesemia)                | Magnesium Increased (Hypermagnesemia)                   | Magnesium Increased (Hypermagnesemia)                   | Magnesium Increased (Hypermagnesemia)              | Magnesium Increased (Hypermagnesemia)              | Magnesium Increased (Hypermagnesemia)                          | Magnesium Increased (Hypermagnesemia)                          | Magnesium Increased (Hypermagnesemia)                                 | Magnesium Increased (Hypermagnesemia)                                 |
| Subjects withBaseline and Post-baseline Measurements | 0                                                       |                                                         | 0                                                  |                                                    | 83                                                             |                                                                | 3953                                                                  |                                                                       |

<div style=\"page-break-after: always\"></div>

|                                                 | KN355 Data for Pembrolizumab+ Chemotherapyit (96S=N)   | KN355 Data for Pembrolizumab+ Chemotherapyit (96S=N)   | KN355 Data for Placebo+ Chemotherapyf (N=281)   | KN355 Data for Placebo+ Chemotherapyf (N=281)   | mTNBC Safety Dataset for Pembrolizumab Monotherapyit (S6S=N) n   | mTNBC Safety Dataset for Pembrolizumab Monotherapyit (S6S=N) n   | Reference Safety Dataset for Pembrolizumab Monotherapyss (N=5884) n   | Reference Safety Dataset for Pembrolizumab Monotherapyss (N=5884) n   |
|-------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|-------------------------------------------------|-------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------------------------------------|
| LaboratoryTest                                  | n                                                      | (%)                                                    | n                                               | (%)                                             |                                                                  | (%)                                                              |                                                                       | (%)                                                                   |
| MagnesiumIncreased(Hypermagnesemia)             |                                                        |                                                        |                                                 |                                                 |                                                                  |                                                                  |                                                                       |                                                                       |
| Grade 1                                         | 0                                                      | (0.0)                                                  | 0                                               | (0.0)                                           | 4                                                                | (4.8)                                                            | 235                                                                   | (5.9)                                                                 |
| Grade 2                                         | 0                                                      | (0.0)                                                  | 0                                               | (0.0)                                           | 0                                                                | (0.0)                                                            | 0                                                                     | (0.0)                                                                 |
| Grade 3                                         | 0                                                      | (0.0)                                                  | 0                                               | (0.0)                                           | 1                                                                | (1.2)                                                            | 17                                                                    | (0.4)                                                                 |
| Grade 4                                         | 0                                                      | (0.0)                                                  | 0                                               | (0.0)                                           | 0                                                                | (0.0)                                                            | 12                                                                    | (0.3)                                                                 |
| Grade 3-4                                       | 0                                                      | (0.0)                                                  | 0                                               | (0.0)                                           | 1                                                                | (1.2)                                                            | 29                                                                    | (0.7)                                                                 |
| All Grades                                      | 0                                                      | (0.0)                                                  | 0                                               | (0.0)                                           | 5                                                                | (6.0)                                                            | 264                                                                   | (6.7)                                                                 |
| NeutrophilsDecreased (Neutrophilcountdecreased) | NeutrophilsDecreased (Neutrophilcountdecreased)        |                                                        |                                                 |                                                 |                                                                  |                                                                  |                                                                       |                                                                       |
| SubjectswithBaseline andPost-baseline           | 592                                                    |                                                        | 280                                             |                                                 | 549                                                              |                                                                  | 4773                                                                  |                                                                       |
| Measurements                                    |                                                        |                                                        |                                                 |                                                 |                                                                  |                                                                  |                                                                       |                                                                       |
| Grade 1                                         | 46                                                     | (8L)                                                   | 21                                              | (7.5)                                           | 28                                                               | (5.1)                                                            | 162                                                                   | (3.4)                                                                 |
| Grade 2                                         | 112                                                    | (18.9)                                                 | 48                                              | (17.1)                                          | 17                                                               | (3.1)                                                            | 104                                                                   | (2.2)                                                                 |
| Grade 3                                         | 161                                                    | (27.2)                                                 | 82                                              | (29.3)                                          | 3                                                                | (0.5)                                                            | 34                                                                    | (0.7)                                                                 |
| Grade 4                                         | 129                                                    | (21.8)                                                 | 64                                              | (22.9)                                          | 8                                                                | (1.5)                                                            | 56                                                                    | (1.2)                                                                 |
| Grade 3-4                                       | 290                                                    | (49.0)                                                 | 146                                             | (52.1)                                          | 11                                                               | (2.0)                                                            | 90                                                                    | (61)                                                                  |
| All Grades                                      | 448                                                    | (75.7)                                                 | 215                                             | (76.8)                                          | 56                                                               | (10.2)                                                           | 356                                                                   | (7.5)                                                                 |
| Phosphate Decreased (Hypophosphatenia)          | Phosphate Decreased (Hypophosphatenia)                 |                                                        |                                                 |                                                 |                                                                  |                                                                  |                                                                       |                                                                       |
| SubjectswithBaseline andPost-baseline           | 566                                                    |                                                        | 269                                             |                                                 | 529                                                              |                                                                  | 4859                                                                  |                                                                       |
| Measurements                                    |                                                        |                                                        |                                                 |                                                 |                                                                  |                                                                  |                                                                       |                                                                       |
| Grade 1                                         | 15                                                     | (2.7)                                                  | 6                                               | (2.2)                                           | 7                                                                | (1.3)                                                            | 112                                                                   | (2.3)                                                                 |
| Grade 2                                         | 66                                                     | (11.7)                                                 | 30                                              | (11.2)                                          | 43                                                               | (8.1)                                                            | 675                                                                   | (13.9)                                                                |
| Grade 3                                         | 36                                                     | (6.4)                                                  | 12                                              | (4.5)                                           | 12                                                               | (2.3)                                                            | 247                                                                   | (5.1)                                                                 |
| Grade 4                                         | 3                                                      | (0.5)                                                  | 1                                               | (0.4)                                           | 1                                                                | (0.2)                                                            | 10                                                                    | (0.2)                                                                 |
| Grade 3-4                                       | 39                                                     | (6.9)                                                  | 13                                              | (4.8)                                           | 13                                                               | (2.5)                                                            | 257                                                                   | (5.3)                                                                 |
| All Grades                                      | 120                                                    | (21.2)                                                 | 49                                              | (18.2)                                          | 63                                                               | (11.9)                                                           | 1044                                                                  | (21.5)                                                                |
| PlateletsDecreased(Platelet count decreased)    |                                                        |                                                        |                                                 |                                                 |                                                                  |                                                                  |                                                                       |                                                                       |
| Subjects withBaseline and Post-baseline         | 591                                                    |                                                        | 278                                             |                                                 | 549                                                              |                                                                  | 5144                                                                  |                                                                       |
| Measurements                                    |                                                        |                                                        |                                                 |                                                 |                                                                  |                                                                  |                                                                       |                                                                       |
| Grade 1                                         | 146                                                    | (24.7)                                                 | 67                                              | (24.1)                                          | 46                                                               | (8.4)                                                            | 512                                                                   | (10.0)                                                                |
| Grade 2                                         | 58                                                     | (9.8)                                                  | 23                                              | (8.3)                                           | 9                                                                | (1.6)                                                            | 46                                                                    | (0.9)                                                                 |
| Grade 3                                         | 49                                                     | (8.3)                                                  | 34                                              | (12.2)                                          | 7                                                                | (1.3)                                                            | 32                                                                    | (0.6)                                                                 |
| Grade 4                                         | 66                                                     | (11.2)                                                 | 24                                              | (8.6)                                           | 7                                                                | (1.3)                                                            | 56                                                                    | (1.1)                                                                 |
| Grade 3-4                                       | 115                                                    | (19.5)                                                 | 58                                              | (20.9)                                          | 14                                                               | (2.6)                                                            | 88                                                                    | (1.7)                                                                 |
| All Grades                                      | 319                                                    | (54.0)                                                 | 148                                             | (53.2)                                          | 69                                                               | (12.6)                                                           | 646                                                                   | (12.6)                                                                |

|                                                              | KN355Data for Pembrolizumab+ Chemotherapytt (N=596)          | KN355Data for Pembrolizumab+ Chemotherapytt (N=596)          | KN355 Data for Placebo+ Chemotherapyfl                       | KN355 Data for Placebo+ Chemotherapyfl                       | mTNBC Safety Dataset for Pembrolizumab Monotherapyit (S6S=N)   | mTNBC Safety Dataset for Pembrolizumab Monotherapyit (S6S=N)   | Reference Safety Dataset for Pembrolizumab Monotherapyis (N=5884)   | Reference Safety Dataset for Pembrolizumab Monotherapyis (N=5884)   |
|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|
| Laboratory Test                                              | n (%)                                                        | n (%)                                                        | (N=281) n (%)                                                | (N=281) n (%)                                                | n (%)                                                          | n (%)                                                          | n (%)                                                               | n (%)                                                               |
| Potassium Decreased (Hypokalemia)                            | Potassium Decreased (Hypokalemia)                            | Potassium Decreased (Hypokalemia)                            | Potassium Decreased (Hypokalemia)                            | Potassium Decreased (Hypokalemia)                            | Potassium Decreased (Hypokalemia)                              | Potassium Decreased (Hypokalemia)                              | Potassium Decreased (Hypokalemia)                                   | Potassium Decreased (Hypokalemia)                                   |
| Subjects with Baseline and Post-baseline Measurements        | 590                                                          |                                                              | 278                                                          |                                                              | 551                                                            |                                                                | 5457                                                                |                                                                     |
| Grade 1                                                      | 94                                                           | (15.9)                                                       | 39                                                           | (14.0)                                                       | 59                                                             | (10.7)                                                         | 562                                                                 | (10.3)                                                              |
| Grade 2                                                      | 0                                                            | (0.0)                                                        | 0                                                            | (0.0)                                                        | 0                                                              | (0.0)                                                          | 0                                                                   | (0.0)                                                               |
| Grade 3                                                      | 20                                                           | (3.4)                                                        | 6                                                            | (2.2)                                                        | 3                                                              | (0.5)                                                          | 96                                                                  | (1.8)                                                               |
| Grade 4                                                      | 6                                                            | (1.0)                                                        | 5                                                            | (1.8)                                                        | 2                                                              | (0.4)                                                          | 26                                                                  | (0.5)                                                               |
| Grade 3-4                                                    | 26                                                           | (4.4)                                                        | 11                                                           | (4.0)                                                        | 5                                                              | (0.9)                                                          | 122                                                                 | (2.2)                                                               |
| All Grades                                                   | 120                                                          | (20.3)                                                       | 50                                                           | (18.0)                                                       | 64                                                             | (11.6)                                                         | 684                                                                 | (12.5)                                                              |
| Potassium Increased (Hyperkalemia)                           | Potassium Increased (Hyperkalemia)                           | Potassium Increased (Hyperkalemia)                           | Potassium Increased (Hyperkalemia)                           | Potassium Increased (Hyperkalemia)                           | Potassium Increased (Hyperkalemia)                             | Potassium Increased (Hyperkalemia)                             | Potassium Increased (Hyperkalemia)                                  | Potassium Increased (Hyperkalemia)                                  |
| Subjects with Baseline and Post-baseline Measurements        | 590                                                          |                                                              | 278                                                          |                                                              | 551                                                            |                                                                | 5457                                                                |                                                                     |
| Grade 1                                                      | 45                                                           | (7.6)                                                        | 31                                                           | (11.2)                                                       | 33                                                             | (6.0)                                                          | 657                                                                 | (12.0)                                                              |
| Grade 2                                                      | 32                                                           | (5.4)                                                        | 5                                                            | (1.8)                                                        | 12                                                             | (2.2)                                                          | 215                                                                 | (3.9)                                                               |
| Grade 3                                                      | 9                                                            | (1.5)                                                        | 3                                                            | (1.1)                                                        | 2                                                              | (0.4)                                                          | 62                                                                  | (1.1)                                                               |
| Grade 4                                                      | 5                                                            | (0.8)                                                        | 0                                                            | (0.0)                                                        | 5                                                              | (0.9)                                                          | 36                                                                  | (0.7)                                                               |
| Grade 3-4                                                    | 14                                                           | (2.4)                                                        | 3                                                            | (1.1)                                                        | 7                                                              | (1.3)                                                          | 98                                                                  | (1.8)                                                               |
| All Grades                                                   | 91                                                           | (15.4)                                                       | 39                                                           | (14.0)                                                       | 52                                                             | (9.4)                                                          | 970                                                                 | (17.8)                                                              |
| Prothrombin Intl. Normalized Ratio Increased (INR increased) | Prothrombin Intl. Normalized Ratio Increased (INR increased) | Prothrombin Intl. Normalized Ratio Increased (INR increased) | Prothrombin Intl. Normalized Ratio Increased (INR increased) | Prothrombin Intl. Normalized Ratio Increased (INR increased) | Prothrombin Intl. Normalized Ratio Increased (INR increased)   | Prothrombin Intl. Normalized Ratio Increased (INR increased)   | Prothrombin Intl. Normalized Ratio Increased (INR increased)        | Prothrombin Intl. Normalized Ratio Increased (INR increased)        |
| Subjects with Baseline and Post-baseline                     | 179                                                          |                                                              | 93                                                           |                                                              | 173                                                            |                                                                | 1417                                                                |                                                                     |
| Measurements Grade 1                                         | 18                                                           | (10.1)                                                       | 10                                                           | (10.8)                                                       | 19                                                             | (11.0)                                                         | 163                                                                 | (11.5)                                                              |
| Grade 2                                                      | 0                                                            | (0.0)                                                        | 4                                                            | (4.3)                                                        | 2                                                              | (1.2)                                                          | 18                                                                  | (1.3)                                                               |
| Grade 3                                                      | 3                                                            | (1.7)                                                        | 1                                                            | (1.1)                                                        | 2                                                              | (1.2)                                                          | 43                                                                  | (3.0)                                                               |
| Grade 4                                                      | 0                                                            | (0.0)                                                        | 0                                                            | (0.0)                                                        | 0                                                              | (0.0)                                                          | 0                                                                   | (0.0)                                                               |
| Grade 3-4                                                    | 3                                                            | (1.7)                                                        | 1                                                            | (1.1)                                                        | 2                                                              | (1.2)                                                          | 43                                                                  | (3.0)                                                               |
| All Grades                                                   | 21                                                           | (11.7)                                                       | 15                                                           | (16.1)                                                       | 23                                                             | (13.3)                                                         | 224                                                                 | (15.8)                                                              |
| SodiumDecreased (Hyponatremia)                               |                                                              |                                                              |                                                              |                                                              |                                                                |                                                                |                                                                     |                                                                     |
| Subjects with Baseline and Post-baseline Measurements        | 590                                                          |                                                              | 279                                                          |                                                              | 552                                                            |                                                                | 5471                                                                |                                                                     |
| Grade 1                                                      | 136                                                          | (23.1)                                                       | 55                                                           | (19.7)                                                       | 139                                                            | (25.2)                                                         | 1485                                                                | (27.1)                                                              |
| Grade 2                                                      | 0                                                            | (0.0)                                                        | 0                                                            | (0.0)                                                        | 0                                                              | (0.0)                                                          | 0                                                                   | (0.0)                                                               |
| Grade 3 Grade 4                                              | 16                                                           | (2.7) (2.4)                                                  | 13                                                           | (4.7)                                                        | 24                                                             | (4.3)                                                          | 376                                                                 | (6.9) (1.4)                                                         |
|                                                              | 14                                                           |                                                              | 5                                                            | (1.8)                                                        | 10                                                             | (1.8)                                                          | 79                                                                  |                                                                     |

<div style=\"page-break-after: always\"></div>

| Laboratory Test                                    | KN355Data for Pembrolizumab + Chemotherapytt (N=596) n (%)   | KN355Data for Pembrolizumab + Chemotherapytt (N=596) n (%)   | KN355Data for Placebo + Chemotherapyfl (N=281) 1 (%)   | KN355Data for Placebo + Chemotherapyfl (N=281) 1 (%)   | mTNBC Safety Dataset for Pembrolizumab Monotherapyit (S6S=N) n (%)   | mTNBC Safety Dataset for Pembrolizumab Monotherapyit (S6S=N) n (%)   | Reference Safety Datasetfor Pembrolizumab Monotherapy's (N=5884) 1n (%)   | Reference Safety Datasetfor Pembrolizumab Monotherapy's (N=5884) 1n (%)   |
|----------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|
| SodiumDecreased (Hyponatremia)                     |                                                              |                                                              |                                                        |                                                        |                                                                      |                                                                      |                                                                           |                                                                           |
| Grade 3-4 All Grades                               | 30 166                                                       | (5.1) (28.1)                                                 | 18 73                                                  | (6.5) (26.2)                                           | 34 173                                                               | (6.2) (31.3)                                                         | 455 1940                                                                  | (8.3) (35.5)                                                              |
| SodiunIncreased (Hypernatremia)                    |                                                              |                                                              |                                                        |                                                        |                                                                      |                                                                      |                                                                           |                                                                           |
| SubjectswithBaselineandPost-baseline Measurements  | 590                                                          |                                                              | 279                                                    |                                                        | 552                                                                  |                                                                      | 5471                                                                      |                                                                           |
| Grade 1                                            | 58                                                           | (9.8)                                                        | 26                                                     | (9.3)                                                  | 14                                                                   | (2.5)                                                                | 260                                                                       | (4.8)                                                                     |
| Grade 2                                            | 6                                                            | (1.0)                                                        | 3                                                      | (1.1)                                                  | 2                                                                    | (0.4)                                                                | 17                                                                        | (0.3)                                                                     |
| Grade 3                                            | 2                                                            | (0.3)                                                        | 1                                                      | (0.4)                                                  | 0                                                                    | (0.0)                                                                | 5                                                                         | (0.1)                                                                     |
| Grade 4                                            | 4                                                            | (0.7)                                                        | 0                                                      | (0.0)                                                  | 1                                                                    | (0.2)                                                                | 7                                                                         | (0.1)                                                                     |
| Grade 3-4                                          | 6                                                            | (1.0)                                                        | 1                                                      | (0.4)                                                  | 1                                                                    | (0.2)                                                                | 12                                                                        | (0.2)                                                                     |
| All Grades                                         | 70                                                           | (11.9)                                                       | 30                                                     | (10.8)                                                 | 17                                                                   | (3.1)                                                                | 289                                                                       | (5.3)                                                                     |
| Triglycerides Increased (Hypertriglyceridemia)     |                                                              |                                                              |                                                        |                                                        |                                                                      |                                                                      |                                                                           |                                                                           |
| SubjectswithBaseline andPost-baseline Measurements | 0                                                            |                                                              | 0                                                      |                                                        | 0                                                                    |                                                                      | 2309                                                                      |                                                                           |
| Grade 1                                            | 0                                                            | (0.0)                                                        | 0                                                      | (0.0)                                                  | 0                                                                    | (0.0)                                                                | 646                                                                       | (28.0)                                                                    |
| Grade 2                                            | 0                                                            | (0.0)                                                        | 0                                                      | (0.0)                                                  | 0                                                                    | (0.0)                                                                | 133                                                                       | (5.8)                                                                     |
| Grade 3                                            | 0                                                            | (0.0)                                                        | 0                                                      | (0.0)                                                  | 0                                                                    | (0.0)                                                                | 24                                                                        | (1.0)                                                                     |
| Grade 4                                            | 0                                                            | (0.0)                                                        | 0                                                      | (0.0)                                                  | 0                                                                    | (0.0)                                                                | 5                                                                         | (0.2)                                                                     |
| Grade 3-4                                          | 0                                                            | (0.0)                                                        | 0                                                      | (0.0)                                                  | 0                                                                    | (0.0)                                                                | 29                                                                        | (1.3)                                                                     |

| Laboratory Test                              | KN355Datafor Pembrolizumab +  Chemotherapyit (N=596) n (%)   | KN355 Data for Placebo + Chemotherapyfl (N=281) 1n (%)   | mTNBC Safety Dataset for Pembrolizumab Monotherapytt (S6S=N) n (%)   | Reference Safety Dataset for Pembrolizumab Monotherapy?s (N=5884) 1n (%)   |
|----------------------------------------------|--------------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------------|
| TriglyceridesIncreased(Hypertriglyceridemia) | TriglyceridesIncreased(Hypertriglyceridemia)                 | TriglyceridesIncreased(Hypertriglyceridemia)             | TriglyceridesIncreased(Hypertriglyceridemia)                         | TriglyceridesIncreased(Hypertriglyceridemia)                               |
| All Grades                                   | 0 (0.0)                                                      | 0 (0.0)                                                  | 0 (0.0)                                                              | 808 (35.0)                                                                 |

If a subject had more than one toxicity grade for a laboratory test, only the highest grade is counted.

Numberof subjectswith atleastonebaseline andpost-baselinelaboratorymeasurementisusedasthedenominatorinpercentage calculation.

Grades are based on NCI CTCAEversion 4.03.

ft Includes all subjects who received at least one dose of treatment in the pembrolizumab + chemotherapy arm of KN355.

MIncludes all subjects who received at least one dose of treatment in the placebo + chemotherapy arm of KN355.

tt Includes all subjects who received at least one dose of pembrolizumab in KN012-Cohort A, KN086 and KN119.

- (original phase), KN006,KN010,KN012 Cohorts B and B2 (Head and Neck Cancer),KN013 Cohort 3 (Hodgkin Lymphoma), KN024,KN040,KN042,KN045,KN048,KN052,KN054,KN055 and KN087.
- DatabasecutoffdateforMelanoma(KN001-Melanoma:18APR2014,KN002:28FEB2015,KN006:03MAR2015,KN054: 020CT2017)

Database cutoff date forLung(KN001-NSCLC:23JAN2015,KN010:30SEP2015,KN024:10JUL2017,KN042:04SEP2018)

Databasecutoff dateforHNSCC(KN012-HNSCC:26APR2016,KN040:15MAY2017,KN048:25FEB2019,KN055:22APR2016)

Database cutoff datefor cHL (KN013-Cohort3:28SEP2018,KN087:25SEP2016)

DatabasecutoffdateforBladder(KN045:26OCT2017,KN052:26SEP2018)

Databasecutoff dateforTNBC(KN355:11DEC2019,KN012:26APR2016,KN086:10NOV2017,KN119:11APR2019)

## Safety in special populations

AGE

<div style=\"page-break-after: always\"></div>

## Adverse Event Summary by Age (Part 2 All Subjects) (ASaT Population)

|                                                     | Pembrolizumab+Chemotherapy   | Pembrolizumab+Chemotherapy   | Pembrolizumab+Chemotherapy   | Pembrolizumab+Chemotherapy   | Placebo + Chemotherapy   | Placebo + Chemotherapy   | Placebo + Chemotherapy   | Placebo + Chemotherapy   |
|-----------------------------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
|                                                     | <65                          | <65                          | >=65                         | >=65                         | <65                      | <65                      | >=65                     | >=65                     |
|                                                     | n                            | (%)                          | n                            | (%)                          | n                        | (%)                      | n                        | (%)                      |
| Subjects in population                              | 439                          |                              | 123                          |                              | 224                      |                          | 57                       |                          |
| with one or more adverse events                     | 433                          | (98.6)                       | 121                          | (98.4)                       | 219                      | (97.8)                   | 57                       | (100.0)                  |
| with no adverse event                               | 6                            | (1.4)                        | 2                            | (1.6)                        | 5                        | (2.2)                    | 0                        | (0.0)                    |
| with drug-relatedf adverse events                   | 421                          | (95.9)                       | 120                          | (97.6)                       | 212                      | (94.6)                   | 55                       | (96.5)                   |
| with toxicity grade 3-5 adverse events              | 341                          | (77.7)                       | 97                           | (78.9)                       | 161                      | (71.9)                   | 46                       | (80.7)                   |
| with toxicity grade 3-5 drug-related adverse events | 298                          | (67.9)                       | 85                           | (69.1)                       | 146                      | (65.2)                   | 42                       | (73.7)                   |
| with serious adverse events                         | 122                          | (27.8)                       | 43                           | (35.0)                       | 47                       | (21.0)                   | 20                       | (35.1)                   |
| with serious drug-related adverse events            | 76                           | (17.3)                       | 22                           | (17.9)                       | 25                       | (11.2)                   | 9                        | (15.8)                   |
| with anydosemodificationduetoanadverseevent         | 325                          | (74.0)                       | 104                          | (84.6)                       | 163                      | (72.8)                   | 46                       | (80.7)                   |
| pembrolizumab/placebodosemodification               | 232                          | (52.8)                       | 82                           | (66.7)                       | 105                      | (46.9)                   | 29                       | (50.9)                   |
| nab-paclitaxel dose modification                    | 70                           | (15.9)                       | 29                           | (23.6)                       | 32                       | (14.3)                   | 13                       | (22.8)                   |
| paclitaxel dose modification                        | 30                           | (6.8)                        | 22                           | (17.9)                       | 13                       | (5.8)                    | 8                        | (14.0)                   |
| gemcitabine dose modification                       | 214                          | (48.7)                       | 50                           | (40.7)                       | 114                      | (50.9)                   | 24                       | (42.1)                   |
| carboplatin dose modification                       | 211                          | (48.1)                       | 50                           | (40.7)                       | 116                      | (51.8)                   | 24                       | (42.1)                   |
| who died                                            | 10                           | (2.3)                        | 4                            | (3.3)                        | 3                        | (1.3)                    | 2                        | (3.5)                    |
| who died due to a drug-related adverse event        | 2                            | (0.5)                        | 0                            | (0.0)                        | 0                        | (0.0)                    | 0                        | (0.0)                    |
| discontinued any drug due to an adverse event       | 82                           | (18.7)                       | 33                           | (26.8)                       | 27                       | (12.1)                   | 10                       | (17.5)                   |
| discontinuedpembrolizumab/placebo                   | 45                           | (10.3)                       | 15                           | (12.2)                       | 10                       | (4.5)                    | 5                        | (8.8)                    |
| discontinuednab-paclitaxel                          | 11                           | (2.5)                        | 11                           | (8.9)                        | 3                        | (1.3)                    | 1                        | (1.8)                    |

|                                                                   | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Placebo + Chemotherapy   | Placebo + Chemotherapy   | Placebo + Chemotherapy   |
|-------------------------------------------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------|--------------------------|--------------------------|
|                                                                   | <65                            | <65                            | >=65                           | >=65                           | <65                      | <65                      | >=65                     |
|                                                                   | n                              | (%)                            |                                | (%)                            | 1                        | (%)                      | n (%)                    |
| discontinuedpaclitaxel                                            | 7                              | (1.6)                          | 9                              | (7.3)                          | 2                        | (0.9)                    | 4 (7.0)                  |
| discontinued gemcitabine                                          | 32                             | (7.3)                          | 5                              | (4.1)                          | 12                       | (5.4)                    | 4 (7.0)                  |
| discontinued carboplatin                                          | 36                             | (8.2)                          | 6                              | (4.9)                          | 15                       | (6.7)                    | 2 (3.5)                  |
| discontinuedanydrugduetoadrug-relatedadverse event                | 73                             | (16.6)                         | 29                             | (23.6)                         | 24                       | (10.7)                   | 7 (12.3)                 |
| discontinuedpembrolizumab/placebo                                 | 39                             | (8.9)                          | 12                             | (9.8)                          | 7                        | (3.1)                    | 3 (5.3)                  |
| discontinued nab-paclitaxel                                       | 10                             | (2.3)                          | 8                              | (6.5)                          | 2                        | (0.9)                    | 1 (1.8)                  |
| discontinuedpaclitaxel                                            | 7                              | (1.6)                          | 9                              | (7.3)                          | 1                        | (0.4)                    | 2 (3.5)                  |
| discontinued gemcitabine                                          | 28                             | (6.4)                          | 5                              | (4.1)                          | 12                       | (5.4)                    | 3 (5.3)                  |
| discontinued carboplatin                                          | 31                             | (7.1)                          | 6                              | (4.9)                          | 15                       | (6.7)                    | 1 (1.8)                  |
| discontinued any drug due to a serious adverse event              | 31                             | (7.1)                          | 13                             | (10.6)                         | 5                        | (2.2)                    | 4 (7.0)                  |
| discontinuedpembrolizumab/placebo                                 | 28                             | (6.4)                          | 11                             | (8.9)                          | 5                        | (2.2)                    | 3 (5.3)                  |
| discontinuednab-paclitaxel                                        | 4                              | (0.9)                          | 5                              | (4.1)                          | 1                        | (0.4)                    | 0 (0.0)                  |
| discontinuedpaclitaxel                                            | 2                              | (0.5)                          | 2                              | (1.6)                          | 1                        | (0.4)                    | 3 (5.3)                  |
| discontinued gemcitabine                                          | 9                              | (2.1)                          | 0                              | (0.0)                          | 0                        | (0.0)                    | 0 (0.0)                  |
| discontinued carboplatin                                          | 8                              | (1.8)                          | 0                              | (0.0)                          | 1                        | (0.4)                    | 0 (0.0)                  |
| discontinued any drug due to a serious drug-related adverse event | 27                             | (6.2)                          | 9                              | (7.3)                          | 2                        | (0.9)                    | 2 (3.5)                  |
| discontinuedpembrolizumab/placebo                                 | 24                             | (5.5)                          | 8                              | (6.5)                          | 2                        | (0.9)                    | 1 (1.8)                  |
| discontinued nab-paclitaxel                                       | 3                              | (0.7)                          | 2                              | (1.6)                          | 0                        | (0.0)                    | 0 (0.0)                  |

|                          | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Placebo + Chemotherapy   | Placebo + Chemotherapy   |
|--------------------------|--------------------------------|--------------------------------|--------------------------|--------------------------|
|                          | <65                            | >=65                           | <65                      | >=65                     |
|                          | (%)                            | 1 (%)                          | n (%)                    | n (%)                    |
| discontinued paclitaxel  | 2 (0.5)                        | 2 (1.6)                        | 0 (0.0)                  | 1 (1.8)                  |
| discontinuedgemcitabine  | 7 (1.6)                        | 0 (0.0)                        | 0 (0.0)                  | 0 (0.0)                  |
| discontinued carboplatin | 6 (1.4)                        | 0 (0.0)                        | 1 (0.4)                  | 0 (0.0)                  |

IDetermined by the investigator to be related to the drug.

+Defined as an action taken of dose reduced, drug interrupted or drug withdrawn.

GradesarebasedonNCICTCAEversion4.0.

Non-serious adverse events up to 30 days after last dose and serious adverse events up to 90 days after last dose are included.

MedDRA preferred terms \"Neoplasm progression\", \"Malignant neoplasm progression\" and \"Disease progression\" not related to the drug are excluded. Database Cutoff Date:11DEC2019

<div style=\"page-break-after: always\"></div>

## Adverse Event Summary by Age Category (&lt;65, 65-74, 75-84, ≥85 Years) (ASaT Population)

|                                                     | KN355DataforPembrolizumab+ Chemotherapyit   | KN355DataforPembrolizumab+ Chemotherapyit   | KN355DataforPembrolizumab+ Chemotherapyit   | KN355DataforPembrolizumab+ Chemotherapyit   | KN355DataforPembrolizumab+ Chemotherapyit   | KN355DataforPembrolizumab+ Chemotherapyit   | KN355DataforPembrolizumab+ Chemotherapyit   | ReferenceSafetyDatasetforPembrolizumab Monotherapyss   | ReferenceSafetyDatasetforPembrolizumab Monotherapyss   | ReferenceSafetyDatasetforPembrolizumab Monotherapyss   | ReferenceSafetyDatasetforPembrolizumab Monotherapyss   | ReferenceSafetyDatasetforPembrolizumab Monotherapyss   | ReferenceSafetyDatasetforPembrolizumab Monotherapyss   | ReferenceSafetyDatasetforPembrolizumab Monotherapyss   | ReferenceSafetyDatasetforPembrolizumab Monotherapyss   |
|-----------------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|
|                                                     | <65                                         | <65                                         | 65-74                                       | 65-74                                       | 75-84                                       | 75-84                                       | >=85                                        | <65                                                    | <65                                                    | 65-74                                                  | 65-74                                                  | 75-84                                                  | 75-84                                                  | >=85                                                   | >=85                                                   |
|                                                     | 1n                                          | (%)                                         | n                                           | (%)                                         | n                                           | (%)                                         |                                             | n                                                      |                                                        | (%)                                                    | (%)                                                    | n                                                      | (%)                                                    | n                                                      | (%)                                                    |
| Subjects in population                              | 459                                         |                                             | 103                                         |                                             | 33                                          |                                             | 1                                           | (%)                                                    | 3,3 85                                                 | n                                                      | 1,7 37                                                 | 663                                                    |                                                        | 99                                                     |                                                        |
| withoneormoreadverse events                         | 453                                         | (98. 7)                                     | 101                                         | (98. 1)                                     | 33                                          | (10 0.0)                                    | 1                                           | (10 0.0)                                               | 3,2 (96. 66 5)                                         | 1,6 77                                                 | (96. 5)                                                | 646                                                    | (97. 4)                                                | 98                                                     | (99. 0)                                                |
| withno adverse event                                | 6                                           | (1.3                                        | 2                                           | (1.9 ）                                      | 0                                           | (0.0 ）                                      | 0                                           | (0.0 7                                                 | 119 ）                                                  | (3.5 60                                                | (3.5 ）                                                 | 17                                                     | (2.6 ）                                                 | 1                                                      | (1.0 ）                                                 |
| with drug-related adverse events                    | 441                                         | (96. 1)                                     | 100                                         | (97. 1)                                     | 32                                          | (97. 0)                                     | 1                                           | (10 0.0)                                               | 2,3 58                                                 | (69. 1,2 7) 23                                         | (70. 4)                                                | 467                                                    | (70. 4)                                                | 75                                                     | (75. 8)                                                |
| with toxicity grade 3-5 adverse events              | 356                                         | (77. 6)                                     | 81                                          | (78. 6)                                     | 27                                          | (81. 8)                                     | 1                                           | (10 0.0)                                               | 1,4 89                                                 | (44. 891 0                                             | (51. 3)                                                | 373                                                    | (56. 3)                                                | 60                                                     | (60. 6                                                 |
| with toxicity grade 3-5 drug-related adverse events | 312                                         | (68. 0                                      | 73                                          | (70. 9)                                     | 21                                          | (63. 6)                                     | 1                                           | (10 0.0)                                               | 452                                                    | (13. 311 4)                                            | (17. 9)                                                | 128                                                    | (19. 3)                                                | 18                                                     | (18. 2)                                                |
| withseriousadverseevents                            | 132                                         | (28. 8)                                     | 36                                          | (35. 0)                                     | 13                                          | (39. 4)                                     | 0                                           | (0.0 ）                                                 | 1,1 68                                                 | (34. 5)                                                | 719 (41. 4)                                            | 315                                                    | (47. 5)                                                | 50                                                     | (50. 5)                                                |
| with serious drug-related adverse events            | 81                                          | (17. 6)                                     | 17                                          | (16. 5)                                     | 7                                           | (21. 2)                                     | 0                                           | (0.0 ）                                                 | 339                                                    | (10. 0                                                 | 214 (12. 3)                                            | 85                                                     | (12. 8)                                                | 12                                                     | (12. 1)                                                |
| with dose modification* duetoan adverseevent        | 339                                         | (73. 9)                                     | 84                                          | (81. 6)                                     | 32                                          | (97. 0                                      | 1                                           | (10 0.0)                                               | 1,0 60                                                 | (31. 3)                                                | 649 (37. 4)                                            | 284                                                    | (42. 8)                                                | 35                                                     | (35. 4)                                                |
| who died                                            | 10                                          | (2.2                                        | 3                                           | (2.9 ）                                      | 2                                           | (6.1 ）                                      | 0                                           | (0.0 ）                                                 | 143                                                    | (4.2 ）                                                 | 103 (5.9 ）                                             | 54                                                     | (8.1 ）                                                 | 11                                                     | (11. 1)                                                |
| who died due to a drug- related adverse event       | 2                                           | (0.4                                        | 0                                           | (0.0 C                                      | 0                                           | (0.0 ）                                      | 0                                           | (0.0 ）                                                 | 21                                                     | (0.6 12 ）                                              | (0.7 ）                                                 | 5                                                      | (0.8 ）                                                 | 1                                                      | (1.0 ）                                                 |
| discontinued drug due to an adverseevent            | 89                                          | (19. 4)                                     | 28                                          | (27. 2)                                     | 11                                          | (33. 3)                                     | 0                                           | (0.0 ）                                                 | 392                                                    | (11. 246 6)                                            | (14. 2)                                                | 131                                                    | (19. 8)                                                | 14                                                     | (14. 1)                                                |
| discontinueddrugduetoa drug-related adverse event   | 78                                          | (17. 0)                                     | 25                                          | (24. 3)                                     | 8                                           | (24. 2)                                     | 0                                           | (0.0 C                                                 | 202 ）                                                  | (6.0 135                                               | (7.8 ）                                                 | 62                                                     | (9.4 ）                                                 | 6                                                      | (6.1 ）                                                 |
| discontinueddrugduetoa seriousadverseevent          | 36                                          | (7.8                                        | 10                                          | (9.7                                        | 5                                           | (15. 2)                                     | 0                                           | (0.0                                                   | 285 ）                                                  | (8.4 174                                               | (10. 0)                                                | 100                                                    | (15. 1)                                                | 11                                                     | (11. 1)                                                |

|                                                               | KN355DataforPembrolizumab+ Chemotherapyit   | KN355DataforPembrolizumab+ Chemotherapyit   | KN355DataforPembrolizumab+ Chemotherapyit   | KN355DataforPembrolizumab+ Chemotherapyit   | KN355DataforPembrolizumab+ Chemotherapyit   | ReferenceSafetyDatasetforPembrolizumab Monotherapy\"s   | ReferenceSafetyDatasetforPembrolizumab Monotherapy\"s   | ReferenceSafetyDatasetforPembrolizumab Monotherapy\"s   | ReferenceSafetyDatasetforPembrolizumab Monotherapy\"s   | ReferenceSafetyDatasetforPembrolizumab Monotherapy\"s   | ReferenceSafetyDatasetforPembrolizumab Monotherapy\"s   |
|---------------------------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|
|                                                               | <65                                         | 65-74                                       |                                             | 75-84                                       | >=85                                        | <65                                                    | <65                                                    | 65-74                                                  | 65-74                                                  | 75-84                                                  | >=85                                                   |
|                                                               | n                                           | (%)                                         | n (%)                                       | 1n (%)                                      | n (%)                                       | n                                                      | (%)                                                    | n                                                      | (%) n                                                  | (%)                                                    | (%)                                                    |
| discontinued drug due to a serious drug-related adverse event | 30                                          | (6.5 ）                                      | 7 (6.8 ）                                    | 3 (9.1 ）                                    | 0 (0.0 ）                                    | 122                                                    | (3.6                                                   | 81                                                     | (4.7 38 ）                                              | (5.7 ）                                                 | 3 (3.0 ）                                               |

I Determined by the investigator to be related to the drug.

+ Defined as an action taken of dose reduced, drug interrupted or drug withdrawn.

Non-serious adverse events upto 30 days of last dose and serious adverse events upto90 days of last dose are included. the drug are excluded.

ti Includes all subjects who received at least one dose of treatment in the pembrolizumab + chemotherapy arm of KN355.

$ Includes all subjects who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 Cohorts B and B2 (Head and Neck Cancer), KN013 Cohort 3 (Hodgkin Lymphoma), KN024,KN040,KN042,KN045,KN048,KN052,KN054,KN055andKN087.

DatabasecutoffdateforMelanoma(KN001-Melanoma:18APR2014,KN002:28FEB2015,KN006:03MAR2015,KN054: 020CT2017)

Database cutoff date for Lung (KN001-NSCLC: 23JAN2015,KN010: 30SEP2015,KN024:10JUL2017,KN042:04SEP2018) DatabasecutoffdateforHNSCC(KN012-HNSCC:26APR2016,KN040:15MAY2017,KN048:25FEB2019,KN055: 22APR2016)

Databasecutoffdatefor cHL(KN013-Cohort3:28SEP2018,KN087:25SEP2016)

DatabasecutoffdateforBladder(KN045:26OCT2017,KN052:26SEP2018)

Databasecutoff dateforTNBC(KN355:11DEC2019,KN012:26APR2016,KN086:10NOV2017,KN119:11APR2019)

<div style=\"page-break-after: always\"></div>

## Adverse Event Summary for Elderly Subjects by Age (Part 2 All Subjects) (ASaT Population)

|                                           | Age (Years)                 | Age (Years)                 | Age (Years)                 | Age (Years)                 | Age (Years)                 | Age (Years)                 | Age (Years)                 | Age (Years)           | Age (Years)           | Age (Years)           | Age (Years)           | Age (Years)           | Age (Years)           |
|-------------------------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|
|                                           | Pembrolizumab +Chemotherapy | Pembrolizumab +Chemotherapy | Pembrolizumab +Chemotherapy | Pembrolizumab +Chemotherapy | Pembrolizumab +Chemotherapy | Pembrolizumab +Chemotherapy | Pembrolizumab +Chemotherapy | Placebo +Chemotherapy | Placebo +Chemotherapy | Placebo +Chemotherapy | Placebo +Chemotherapy | Placebo +Chemotherapy | Placebo +Chemotherapy |
|                                           | <65                         | <65                         | ≥ 65 to < 75                | ≥ 65 to < 75                | ≥75 to <85                  | ≥75 to <85                  | ≥85                         | <65                   | <65                   | ≥65 to < 75           | ≥65 to < 75           | ≥75 to<85             | ≥85                   |
|                                           | n                           | (%)                         | n                           | (%)                         | n                           | (%)                         | n (%)                       | n                     | (%)                   | n                     | (%)                   | n (%)                 | n (%)                 |
| SubjectsinPopulation                      | 439                         |                             | 93                          |                             | 29                          |                             | 1                           | 224                   |                       | 48                    |                       | 9                     | 0                     |
| with one or more adverse events           | 433                         | (98.6)                      | 91                          | (97.8)                      | 29                          | (100.0)                     | 1 (100.0)                   | 219                   | (97.8)                | 48                    | (100.0)               | 9 (100.0)             | 0 (0.0)               |
| who died                                  | 10                          | (2.3)                       | 3                           | (3.2)                       | 1                           | (3.4)                       | 0 (0.0)                     | 3                     | (1.3)                 | 1                     | (2.1)                 | 1 (11.1)              | 0 (0.0)               |
| with serious adverse events               | 122                         | (27.8)                      | 33                          | (35.5)                      | 10                          | (34.5)                      | 0 (0.0)                     | 47                    | (21.0)                | 16                    | (33.3)                | 4 (44.4)              | 0 (0.0)               |
| discontinued drug due to an adverse event | 82                          | (18.7)                      | 25                          | (26.9)                      | 8                           | (27.6)                      | 0 (0.0)                     | 27                    | (12.1)                | 7                     | (14.6)                | 3 (33.3)              | 0 (0.0)               |
| CNS (confusion/extrapyramidal)            | 31                          | (7.1)                       | 15                          | (16.1)                      | 7                           | (24.1)                      | 1 (100.0)                   | 12                    | (5.4)                 | 5                     | (10.4)                | 0 (0.0)               | 0 (0.0)               |
| AE related to falling                     | 34                          | (7.7)                       | 9                           | (9.7)                       | 7                           | (24.1)                      | 0 (0.0)                     | 15                    | (6.7)                 | 5                     | (10.4)                | 0 (0.0)               | 0 (0.0)               |
| Cardiovascular events                     | 112                         | (25.5)                      | 24                          | (25.8)                      | 12                          | (41.4)                      | 0 (0.0)                     | 49                    | (21.9)                | 15                    | (31.3)                | 5 (55.6)              | 0 (0.0)               |
| Cerebrovascular events                    | 7                           | (1.6)                       | 4                           | (4.3)                       | 0                           | (0.0)                       | 0 (0.0)                     | 3                     | (1.3)                 | 0                     | (0.0)                 | 1 (11.1)              | 0 (0.0)               |
| Infections                                | 222                         | (50.6)                      | 45                          | (48.4)                      | 23                          | (79.3)                      | 1 (100.0)                   | 101                   | (45.1)                | 26                    | (54.2)                | 4 (44.4)              | 0 (0.0)               |

MedDRA preferred terms \"Neoplasm progression\", \"Malignant neoplasm progression\" and \"Disease progression\" not related to the drug are excluded.

Adverse Event Summary for Elderly Subjects by Age (Subjects in ASaT Population Treated with Pembrolizumab)

|                                       | KN355 Data for Pembrolizumab + Chemotheraphys   | KN355 Data for Pembrolizumab + Chemotheraphys   | KN355 Data for Pembrolizumab + Chemotheraphys   | KN355 Data for Pembrolizumab + Chemotheraphys   | KN355 Data for Pembrolizumab + Chemotheraphys   | KN355 Data for Pembrolizumab + Chemotheraphys   | KN355 Data for Pembrolizumab + Chemotheraphys   | Reference Safety Dataset for Pembrolizumab Monotherapyyift   | Reference Safety Dataset for Pembrolizumab Monotherapyyift   | Reference Safety Dataset for Pembrolizumab Monotherapyyift   | Reference Safety Dataset for Pembrolizumab Monotherapyyift   | Reference Safety Dataset for Pembrolizumab Monotherapyyift   | Reference Safety Dataset for Pembrolizumab Monotherapyyift   | Reference Safety Dataset for Pembrolizumab Monotherapyyift   | Reference Safety Dataset for Pembrolizumab Monotherapyyift   |
|---------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|
|                                       | <65                                             | <65                                             | 65-74                                           | 65-74                                           | 75-84                                           | 75-84                                           | >=85                                            | >=85                                                         | <65                                                          | <65                                                          | 65-74                                                        | 65-74                                                        | 75-84                                                        |                                                              | >= 85                                                        |
|                                       | n (%)                                           | n (%)                                           | n (%)                                           | n (%)                                           | n (%)                                           | n (%)                                           | n (%)                                           | n (%)                                                        | n (%)                                                        | n (%)                                                        | (%)                                                          | (%)                                                          | 1n (%) n                                                     | 1n (%) n                                                     | (%)                                                          |
| Subjects in population                | 459                                             | (100.0)                                         | 103                                             | (100.0)                                         | 33                                              | (100.0)                                         | 1                                               | (100.0)                                                      | 3385                                                         | (100.0) 1737                                                 | (100.0)                                                      | 663                                                          | (100.0)                                                      | 99                                                           | (100.0)                                                      |
| with one ormore adverse events        | 453                                             | (98.7)                                          | 101                                             | (98.1)                                          | 33                                              | (100.0)                                         | 1                                               | (100.0)                                                      | 3266                                                         | (96.5) 1677                                                  | (96.5)                                                       | 646                                                          | (97.4)                                                       | 98                                                           | (99.0)                                                       |
| who died                              | 10                                              | (2.2)                                           | 3                                               | (2.9)                                           | 2                                               | (6.1)                                           | 0                                               | (0.0)                                                        | 143                                                          | (4.2) 103                                                    | (5.9)                                                        | 54                                                           | (8.1)                                                        | 11                                                           | (11.1)                                                       |
| with serious adverse events           | 132                                             | (28.8)                                          | 36                                              | (35.0)                                          | 13                                              | (39.4)                                          | 0                                               | (0.0) 1168                                                   | (34.5)                                                       | 719                                                          | (41.4)                                                       | 315                                                          | (47.5)                                                       | 50                                                           | (50.5)                                                       |
| discontinuedf due to an adverse event | 89                                              | (19.4)                                          | 28                                              | (27.2)                                          | 11                                              | (33.3)                                          | 0                                               | (0.0)                                                        | 392                                                          | (11.6) 246                                                   | (14.2)                                                       | 131                                                          | (19.8)                                                       | 14                                                           | (14.1)                                                       |
| CNS (confusion/extrapyramidal)        | 31                                              | (6.8)                                           | 15                                              | (14.6)                                          | 6                                               | (18.2)                                          | 1                                               | (100.0)                                                      | 247                                                          | (7.3) 157                                                    | (9.0)                                                        | 46                                                           | (6.9)                                                        | 16                                                           | (16.2)                                                       |
| AErelated to falling                  | 36                                              | (7.8)                                           | 9                                               | (8.7)                                           | 7                                               | (21.2)                                          | 0                                               | (0.0)                                                        | 225                                                          | (6.6) 152                                                    | (8.8)                                                        | 70                                                           | (10.6)                                                       | 20                                                           | (20.2)                                                       |
| CV events                             | 117                                             | (25.5)                                          | 26                                              | (25.2)                                          | 14                                              | (42.4)                                          | 0                                               | (0.0)                                                        | 649                                                          | (19.2) 395                                                   | (22.7)                                                       | 160                                                          | (24.1)                                                       | 25                                                           | (25.3)                                                       |
| Cerebrovascular events                | 7                                               | (1.5)                                           | 4                                               | (3.9)                                           | 0                                               | (0.0)                                           | 0                                               | (0.0)                                                        | 61                                                           | (1.8) 40                                                     | (2.3)                                                        | 20                                                           | (3.0)                                                        | 3                                                            | (3.0)                                                        |
| Infections                            | 235                                             | (51.2)                                          | 52                                              | (50.5)                                          | 26                                              | (78.8)                                          | 1                                               | (100.0) 1434                                                 | (42.4)                                                       | 773                                                          | (44.5)                                                       | 308                                                          | (46.5)                                                       | 44                                                           | (44.4)                                                       |

MedDRA preferred terms \"Neoplasm progression\", \"Malignant neoplasm progression\" and \"Disease progression\" not related to the drug are excluded.

AEswerefollowed30days afterlastdoseof studytreatment;SAEswerefollowed90days afterlastdoseof studytreatment.

Includes all subjects who received at least one dose of pembrolizumab or chemotheraphy in KN355.

ft Includes all subjects who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 Cohorts

Database cutoff date forMelanoma (KN001-Melanoma:18APR2014,KN002:28FEB2015,KN006:03MAR2015,KN054:02OCT2017)

Database cutoff date for Lung (KN001-NSCLC:23JAN2015,KN010:30SEP2015,KN024:10JUL2017,KN042:04SEP2018)

Database cutoff date for HNSCC (KN012-HNSCC: 26APR2016, KN040: 15MAY2017, KN048: 25FEB2019,KN055: 22APR2016)

Databasecutoff datefor cHL(KN013-Cohort3:28SEP2018,KN087:21MAR2019)

Database cutoff dateforBladder(KN045:26OCT2017,KN052:26SEP2018)

Database cutoff datefor TNBC (KN355:15JUN2020)

Upon request, the MAH provided a pooled analysis of safety data by age categories (&lt;75 years and ≥ 75 years of age) comprising all pembrolizumab combination studies conducted across different indications. The sample size consisted of a total of 1871 patients aged &lt;75 years and 162 patients aged ≥ 75 years who were exposed to the combination pembrolizumab+chemotherapy, compared to 1359 patients aged &lt;75 years and 123 patients aged ≥ 75 years who were assigned to chemotherapy only. Data were pooled from individual studies conducted in lung, HNSCC, esophaegeal and TNBC tumours. The MAH also presented a pooled analysis related to pembrolizumab monotherapy across tumours.

Non-serious adverse events up to 30 days after last dose and serious adverse events up to 90 days after last dose are included.

DatabaseCutoffDate:11DEC2019

<div style=\"page-break-after: always\"></div>

Table Summary of Drug Exposure (ASaT Population)

|                                | Pooled Pembrolizumab + Chemotherapy †† , Age < 75 Years (N=1871)   | Pooled Pembrolizumab + Chemotherapy †† , Age >= 75 Years (N=162)   | Pooled Comparator Chemotherapy §§ , Age < 75 Years (N=1359)   | Pooled Comparator Chemotherapy §§ , Age >= 75 Years (N=123)   |
|--------------------------------|--------------------------------------------------------------------|--------------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
| Study Days On-Therapy (Months) |                                                                    |                                                                    |                                                               |                                                               |
| Mean                           | 9.1                                                                | 8.2                                                                | 6.5                                                           | 6.3                                                           |
| Median                         | 6.3                                                                | 5.7                                                                | 4.9                                                           | 4.7                                                           |
| SD                             | 7.81                                                               | 7.64                                                               | 6.29                                                          | 5.80                                                          |
| Range                          | 0.0 to 48.0                                                        | 0.0 to 28.7                                                        | 0.0 to 49.2                                                   | 0.0 to 26.2                                                   |

Each subject is counted once on each applicable duration category row.

Duration of Exposure is calculated as last dose date - first dose date + 1.

††  Includes all subjects who received at least one dose of pembrolizumab combo therapy in KN021-A/C/G, KN048, KN189, KN355, KN407 and KN590.

§§  Includes all subjects who received at least one dose of comparator chemotherapy in KN021-A/C/G, KN048, KN189, KN355, KN407 and KN590.

MK-3475 Database Cutoff Date for Lung (KN021: 19AUG2019, KN189: 20MAY2019, KN407: 09MAY2019)

MK-3475 Database Cutoff Date for HNSCC (KN048: 25FEB2019)

MK-3475 Database Cutoff Date for Esophageal (KN590: 02JUL2020)

MK-3475 Database Cutoff Date for mTNBC (KN355: 11DEC2019)

MedDRA version used is 23.0.

<div style=\"page-break-after: always\"></div>

Table 1 Summary of Drug Exposure (ASaT Population)

|                                | Pooled Pembrolizumab Monotherapy †† , Age < 75 Years (N=5384)   | Pooled Pembrolizumab Monotherapy †† , Age >= 75 Years (N=801)   |
|--------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|
| Study Days On-Therapy (Months) |                                                                 |                                                                 |
| Mean                           | 7.6                                                             | 6.8                                                             |
| Median                         | 5.0                                                             | 4.2                                                             |
| SD                             | 7.07                                                            | 6.75                                                            |
| Range                          | 0.0 to 32.5                                                     | 0.0 to 30.6                                                     |

Each subject is counted once on each applicable duration category row.

Duration of Exposure is calculated as last dose date - first dose date + 1.

††  Includes all participants who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 (HNSCC), KN013 Cohort 3 (Hodgkin Lymphoma), KN024, KN040, KN042, KN045, KN048, KN052, KN054, KN055, KN087, KN177, and KN204.

Database Cutoff Date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015, KN006: 03MAR2015, KN054: 02OCT2017)

Database Cutoff Date for Lung (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015, KN024: 10JUL2017, KN042: 04SEP2018)

Database cutoff date for HNSCC (KN012-HNSCC: 26APR2016, KN040: 15MAY2017, KN048: 25FEB2019, KN055: 22APR2016)

Database cutoff date for cHL (KN013-Cohort 3: 28SEP2018, KN087: 21MAR2019, KN204: 16JAN2020)

Database cutoff date for Bladder (KN045: 26OCT2017, KN052:26SEP2018)

Database cutoff date for CRC MSI-H or dMMMR (KN177:19FEB2020)

MedDRA version used is 23.0.

Determined by the investigator to be related to the drug.

Table 58 Adverse Event Summary (ASaT Population)

|                                                               | Pooled Pembrolizumab + Chemotherapyft, Age < 75 Years   | Pooled Pembrolizumab + Chemotherapyft, Age < 75 Years   | Pooled Pembrolizumab + Chemotherapyft, Age >= 75 Years   | Pooled Pembrolizumab + Chemotherapyft, Age >= 75 Years   | Pooled Comparator Chemotherapy, Age < 75 Years   | Pooled Comparator Chemotherapy, Age < 75 Years   | Pooled Comparator Chemotherapyss , Age >= 75 Years   | Pooled Comparator Chemotherapyss , Age >= 75 Years   |
|---------------------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|--------------------------------------------------|--------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
|                                                               | n                                                       | (%)                                                     | n                                                        | (%)                                                      | n                                                | (%)                                              | n                                                    | (%)                                                  |
| Subjects in population                                        | 1,871                                                   |                                                         | 162                                                      |                                                          | 1,359                                            |                                                  | 123                                                  |                                                      |
| with one or more adverse events                               | 1,854                                                   | (99.1)                                                  | 161                                                      | (99.4)                                                   | 1,345                                            | (99.0)                                           | 121                                                  | (98.4)                                               |
| with no adverse event                                         | 17                                                      | (0.9)                                                   | 1                                                        | (0.6)                                                    | 14                                               | (1.0)                                            | 2                                                    | (1.6)                                                |
| with drug-related adverse cvents                              | 1,794                                                   | (95.9)                                                  | 154                                                      | (95.1)                                                   | 1,282                                            | (94.3)                                           | 116                                                  | (94.3)                                               |
| with toxicity grade 3-5 adverse events                        | 1,446                                                   | (77.3)                                                  | 137                                                      | (84.6)                                                   | 1,017                                            | (74.8)                                           | 101                                                  | (82.1)                                               |
| with toxicity grade 3-5 drug-related adverse events           | 1,182                                                   | (63.2)                                                  | 103                                                      | (63.6)                                                   | 817                                              | (60.1)                                           | 79                                                   | (64.2)                                               |
| with serious adverse events                                   | 865                                                     | (46.2)                                                  | 97                                                       | (59.9)                                                   | 584                                              | (43.0)                                           | 65                                                   | (52.8)                                               |
| with serious drug-related adverse events                      | 494                                                     | (26.4)                                                  | 56                                                       | (34.6)                                                   | 280                                              | (20.6)                                           | 26                                                   | (21.1)                                               |
| who died                                                      | 107                                                     | (5.7)                                                   | 32                                                       | (19.8)                                                   | 91                                               | (6.7)                                            | 15                                                   | (12.2)                                               |
| who died due to a drug-related adverse event                  | 32                                                      | (1.7)                                                   |                                                          | (6.8)                                                    | 17                                               | (1.3)                                            | 5                                                    | (4.1)                                                |
| discontinued drug due to an advcrse event                     | 482                                                     | (25.8)                                                  | 67                                                       | (41.4)                                                   | 241                                              | (17.7)                                           | 31                                                   | (25.2)                                               |
| discontinued drug due to a drug-related adverse event         | 387                                                     | (20.7)                                                  | 45                                                       | (27.8)                                                   | 161                                              | (11.8)                                           | 21                                                   | (17.1)                                               |
| discontinued drug due to a serious adverse event              | 275                                                     | (14.7)                                                  | 51                                                       | (31.5)                                                   | 132                                              | (9.7)                                            | 23                                                   | (18.7)                                               |
| discontinued drug due to a serious drug-related adverse event | 188                                                     | (10.0)                                                  | 30                                                       | (18.5)                                                   | 59                                               | (4.3)                                            | 12                                                   | (9.8)                                                |

Non-serious adveise events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

MedDRA preferred terms\"Neoplasm Progression\",\"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.

$ Includes all subjects who received at least one dose of comparator chemotherapy in KN021-A/C/G, KN048, KN189, KN355, KN407 and KN590.

t Includes all subjects who received at least one dose of pembrolizumab combo therapy in KN021-A/C/G, KN048, KN189, KN355, KN407 and KN590.

MK-3475 Database Cutoff Date for Lung (KN021: 19AUG2019, KN189: 20MAY2019, KN407: 09MAY2019)

MK-3475 Database Cutoff Date for HNSCC (KN048:25FEB2019)

MK-3475 Database Cutoff Date for Esophagcal (KN590: 02JUL2020)

MK-3475 Database Cutof Date for mTNBC (KN355: 11DEC2019)

MedDRA version used is 23.0.

6.8

4.2

6.75

0.0 to 30.6

<div style=\"page-break-after: always\"></div>

Table 2 Adverse Event Summary (ASaT Population)

|                                                                | Pooled Pembrolizumab Monotherapy †† , Age < 75 Years   | Pooled Pembrolizumab Monotherapy †† , Age < 75 Years   | Pooled Pembrolizumab Monotherapy †† , Age >= 75 Years   | Pooled Pembrolizumab Monotherapy †† , Age >= 75 Years   |
|----------------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|
|                                                                | n                                                      | (%)                                                    | n                                                       | (%)                                                     |
| Subjects in population                                         | 5,384                                                  |                                                        | 801                                                     |                                                         |
| with one or more adverse events                                | 5,202                                                  | (96.6)                                                 | 782                                                     | (97.6)                                                  |
| with no adverse event                                          | 182                                                    | (3.4)                                                  | 19                                                      | (2.4)                                                   |
| with drug-related † adverse events                             | 3,791                                                  | (70.4)                                                 | 573                                                     | (71.5)                                                  |
| with toxicity grade 3-5 adverse events                         | 2,521                                                  | (46.8)                                                 | 459                                                     | (57.3)                                                  |
| with toxicity grade 3-5 drug-related adverse events            | 816                                                    | (15.2)                                                 | 159                                                     | (19.9)                                                  |
| with serious adverse events                                    | 1,987                                                  | (36.9)                                                 | 385                                                     | (48.1)                                                  |
| with serious drug-related adverse events                       | 598                                                    | (11.1)                                                 | 107                                                     | (13.4)                                                  |
| who died                                                       | 254                                                    | (4.7)                                                  | 67                                                      | (8.4)                                                   |
| who died due to a drug-related adverse event                   | 34                                                     | (0.6)                                                  | 6                                                       | (0.7)                                                   |
| discontinued drug due to an adverse event                      | 677                                                    | (12.6)                                                 | 154                                                     | (19.2)                                                  |
| discontinued drug due to a drug-related adverse event          | 370                                                    | (6.9)                                                  | 74                                                      | (9.2)                                                   |
| discontinued drug due to a serious adverse event               | 482                                                    | (9.0)                                                  | 116                                                     | (14.5)                                                  |
| discontinued drug due to a serious drug- related adverse event | 221                                                    | (4.1)                                                  | 44                                                      | (5.5)                                                   |

†  Determined by the investigator to be related to the drug.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

MedDRA preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.

††  Includes all participants who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 (HNSCC), KN013 Cohort 3 (Hodgkin Lymphoma), KN024, KN040, KN042, KN045, KN048, KN052, KN054, KN055, KN087, KN177, and KN204.

Database Cutoff Date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015, KN006: 03MAR2015, KN054: 02OCT2017)

Database Cutoff Date for Lung (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015, KN024: 10JUL2017, KN042: 04SEP2018)

Database cutoff date for HNSCC (KN012-HNSCC: 26APR2016, KN040: 15MAY2017, KN048: 25FEB2019, KN055: 22APR2016)

Database cutoff date for cHL (KN013-Cohort 3: 28SEP2018, KN087: 21MAR2019, KN204: 16JAN2020)

Database cutoff date for Bladder (KN045: 26OCT2017, KN052:26SEP2018)

Database cutoff date for CRC MSI-H or dMMMR (KN177:19FEB2020)

MedDRA version used is 23.0.

801

782

19

573

459

159

385

107

67

6

(0.7)

154

74

116

44

<div style=\"page-break-after: always\"></div>

## Table 3 Adverse Event Summary AEOSI (ASaT Population)

|                                                     | PooledPembrolizumab+ Chemotherapyltt, Age < 75 Years   | PooledPembrolizumab+ Chemotherapyltt, Age < 75 Years   | PooledPembrolizumab+ Chemotherapylt, Age >= 75 Years   | PooledPembrolizumab+ Chemotherapylt, Age >= 75 Years   | Pooled Comparator Chemotherapy, Age < 75 Years   | Pooled Comparator Chemotherapy, Age < 75 Years   | Pooled Comparator Chemotherapy , Age >= 75 Years   | Pooled Comparator Chemotherapy , Age >= 75 Years   |
|-----------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------|--------------------------------------------------|----------------------------------------------------|----------------------------------------------------|
|                                                     |                                                        | (%)                                                    |                                                        | (%)                                                    |                                                  | (%)                                              |                                                    | (%)                                                |
| Subjects in population                              | 1,871                                                  |                                                        | 162                                                    |                                                        | 1,359                                            |                                                  | 123                                                |                                                    |
| with one ormore advcrse events                      | 523                                                    | (28.0)                                                 | 54                                                     | (33.3)                                                 | 179                                              | (13.2)                                           | 20                                                 | (16.3)                                             |
| with no adverse event                               | 1,348                                                  | (72.0)                                                 | 108                                                    | (66.7)                                                 | 1,180                                            | (86.8)                                           | 103                                                | (83.7)                                             |
| with drug-rclatedt advcrse cvents                   | 456                                                    | (24.4)                                                 | 50                                                     | (30.9)                                                 | 135                                              | (9.9)                                            | 16                                                 | (13.0)                                             |
| with toxicity grade 3-5 adverse cvents              | 147                                                    | (7.9)                                                  | 20                                                     | (12.3)                                                 | 45                                               | (3.3)                                            | 11                                                 | (8.9)                                              |
| with toxicity grade 3-5 drug-related adverse events | 130                                                    | (6.9)                                                  | 19                                                     | (11.7)                                                 | 40                                               | (2.9)                                            | 7                                                  | (5.7)                                              |
| with serious adverse cvents                         | 124                                                    | (6.6)                                                  | 18                                                     | (11.1)                                                 | 26                                               | (61)                                             | 7                                                  | (5.7)                                              |
| with serious drug-related adverse cvents            | 111                                                    | (5.9)                                                  | 17                                                     | (10.5)                                                 | 21                                               | (1.5)                                            | 4                                                  | (3.3)                                              |
| who dicd                                            | 3                                                      | (0.2)                                                  | 3                                                      | (1.9)                                                  | 1                                                | (0.1)                                            | 1                                                  | (0.8)                                              |
| who died due to a drug-related advcrse cvent        | 3                                                      | (0.2)                                                  | 3                                                      | (1.9)                                                  | 1                                                | (0.1)                                            | 0                                                  | (0.0)                                              |
| discontinued drug due to an adverse cvent           | 98                                                     | (5.2)                                                  | 17                                                     | (10.5)                                                 | 29                                               | (2.1)                                            | 4                                                  | (3.3)                                              |
| discontinued drugdue toadrug-relatedadversecvent    | 95                                                     | (5.1)                                                  | 17                                                     | (10.5)                                                 | 29                                               | (2.1)                                            | 3                                                  | (2.4)                                              |
| discontinued drugduetoaserious adversecvent         | 70                                                     | (3.7)                                                  | 14                                                     | (8.6)                                                  | 15                                               | (1.1)                                            | 3                                                  | (2.4)                                              |

discontinued drugdue toa seriousdrug-related adverse event

Determined by theinvestigator to be rclated tothe drug.

Non serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

it Includes all subjccts who reccived at lcast one dose of pembrolizumab combo therapy in KN021-A/C/G, KN048, KN189, KN355, KN407 and KN590.

Includes all subjects who received at least one dose of comparator chemotherapy in KN021-A/C/G, KN048, KN189, KN355, KN407 and KN590.

MK-3475 Databasc Cutoff Datc forLumg (KN021: 19AUG2019,KN189: 20MAY2019,KN407: 09MAY2019)

MK-3475DatabaseCutoffDatc forHNSCC (KN048: 25FEB2019)

MK-3475DatabaseCutoff DateforEsophagcal(KN590:02JUL2020)

MK-3475 Databasc Cutoff Date for mTNBC (KN355: 11DEC2019)

MedDRA version used is 23.0.

67

(3.6)

14

(8.6)

15

(1.1)

2

(1.6)

Table 4 Adverse Event Summary AEOSI (ASaT Population)

|                                                       | Pooled Pembrolizumab Monothcrapyit, Age< 75 Ycars   | Pooled Pembrolizumab Monothcrapyit, Age< 75 Ycars   | Pooled Pembrolizumab Monothcrapyit, Age > 75 Ycars   | Pooled Pembrolizumab Monothcrapyit, Age > 75 Ycars   |
|-------------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
|                                                       |                                                     | (%)                                                 |                                                      | (%)                                                  |
| Subjects in population                                | 5,384                                               |                                                     | 801                                                  |                                                      |
| with one ormore advcrse cvents                        | 1,372                                               | (25.5)                                              | 202                                                  | (25.2)                                               |
| with no adverse cvent                                 | 4,012                                               | (74.5)                                              | 599                                                  | (74.8)                                               |
| with drug-rclated advcrse cvents                      | 1,187                                               | (22.0)                                              | 179                                                  | (22.3)                                               |
| with toxicitygrade 3-5 adverse events                 | 341                                                 | (6.3)                                               | 65                                                   | (8.1)                                                |
| with toxicity grade 3-5 drug-rclated advcrse cvents   | 290                                                 | (5.4)                                               | 62                                                   | (7.7)                                                |
| with serious adverse cvents                           | 352                                                 | (6.5)                                               | 58                                                   | (7.2)                                                |
| with serious drug-related adverse cvents              | 308                                                 | (5.7)                                               | 55                                                   | (6.9)                                                |
| who died                                              | 10                                                  | (0.2)                                               | 1                                                    | (0.1)                                                |
| who dieddue to a drug-rclatedadverse cvent            | 10                                                  | (0.2)                                               | 1                                                    | (0.1)                                                |
| discontinued drug due to an adverse cvcnt             | 216                                                 | (4.0)                                               | 39                                                   | (4.9)                                                |
| discontinued drug due to a drug-related advcrse cvent | 212                                                 | (3.9)                                               | 39                                                   | (4.9)                                                |
| discontinued drug due to a serious adverse cvcnt      | 145                                                 | (2.7)                                               | 27                                                   | (3.4)                                                |

discontinued drug due to a serious drug-related adveise cvent t Determined by the investigator to be rclated to the drug.

143

(2.7)

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

MedDRA preferred terms \"Ncoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.

f Includes allparticipants who reccived at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D. C, F1, F2, F3, KN002 (oniginal phase), KN006, KN010, KN012 (HNSCC), KN013 Cohort 3 (Hodgkin Lymphoma), KN024, KN040, KN042, KN045, KN048,KN052, KN054, KN055, KN087, KN177, and KN204.

Databasc CutoffDate forMclanoma (KN001-Mclanoma:18APR2014,KN002: 28FEB2015,KN006:03MAR2015,KN054:02OCT2017)

Databasc Cutoff Date for Lung (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015, KN024:10JUL2017, KN042: 04SEP2018)

Databasc cutoff dateforHNSCC(KN012-HNSCC: 26APR2016,KN040:15MAY2017,KN048:25FEB2019,KN055:22APR2016)

Databasc cutoff date for cHL (KN013-Cohort 3:28SEP2018,KN087:2IMAR2019,KN204:16JAN2020)

Databasc cutoff date forBladder (KN045: 26OCT2017,KN052:26SEP2018)

Databasc cutoff date forCRC MSI-H or dMMMR (KN177:19FEB2020)

MedDRA version usedis 23.0.

27

(3.4)

<div style=\"page-break-after: always\"></div>

Table 5 Adverse Event Summary by Age (ASaT Population)

|                                      | PooledPembrolizumab+Chemotherapyit   | PooledPembrolizumab+Chemotherapyit   | PooledPembrolizumab+Chemotherapyit   | PooledPembrolizumab+Chemotherapyit   | Pooled Comparator Chemotherapy$$   | Pooled Comparator Chemotherapy$$   | Pooled Comparator Chemotherapy$$   | Pooled Comparator Chemotherapy$$   |
|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|
|                                      | <75                                  | <75                                  | >75                                  | >75                                  | <75                                | <75                                | >=75                               | >=75                               |
|                                      |                                      | (%)                                  |                                      | (%)                                  |                                    | (%)                                | I1                                 | (%)                                |
| Subjccts in population               | 1871                                 | (100.0)                              | 162                                  | (100.0)                              | 1359                               | (100.0)                            | 123                                | (100.0)                            |
| with one ormore adverse cvents       | 1854                                 | (99.1)                               | 161                                  | (99.4)                               | 1345                               | (99.0)                             | 121                                | (98.4)                             |
| whodicd                              | 107                                  | (5.7)                                | 32                                   | (19.8)                               | 91                                 | (6.7)                              | 15                                 | (12.2)                             |
| with serious adverse cvents          | 865                                  | (46.2)                               | 97                                   | (59.9)                               | 584                                | (43.0)                             | 65                                 | (52.8)                             |
| discontinued due to an adverse event | 482                                  | (25.8)                               | 67                                   | (41.4)                               | 241                                | (17.7)                             | 31                                 | (25.2)                             |
| CNS (confusion/extrapyramidal)       | 185                                  | (9.9)                                | 27                                   | (16.7)                               | 117                                | (8.6)                              | 13                                 | (10.6)                             |
| AE rclated to falling                | 161                                  | (8.6)                                | 25                                   | (15.4)                               | 108                                | (7.9)                              | 11                                 | (8.9)                              |
| CV events                            | 512                                  | (27.4)                               | 55                                   | (34.0)                               | 336                                | (24.7)                             | 32                                 | (26.0)                             |
| Cercbrovascular cvents               | 50                                   | (2.7)                                | 9                                    | (5.6)                                | 41                                 | (3.0)                              | 6                                  | (4.9)                              |
| Infections                           | 1003                                 | (53.6)                               | 89                                   | (54.9)                               | 647                                | (47.6)                             | 69                                 | (56.1)                             |

MedDRA preferred terms \"Neoplasm progression\", \"Malignant neoplasm progression\" and \"Disease progression\" not related to the drug are excluded.

AEswcre followcd 30 days afier last dose of study treatment;SAEs wcre followcd 90 days afterlast dose of study treatment.

t Includes all subjccts who received at least one dose of pembrolizumab combo therapy in KN021-A/C/G, KN048, KN189, KN355, KN407 and KN590.

Includes all subjccts who reccived at least one dose of comparator chemotherapy in KN021-A/C/G, KN048, KN189, KN355, KN407 and KN590.

MK-3475 Databasc Cutoff Datc forLumg (KN021: 19AUG2019,KN189: 20MAY2019,KN407: 09MAY2019)

MK-3475 Databasc Cutoff Datc for HNSCC(KN048: 25FEB2019)

MK-3475DatabascCutoff Date for Esophagcal (KN590: 02JUL2020)

MK-3475Database Cutoff Date for mTNBC (KN355: 11DEC2019)

MedDRA version uscdis 23.0.

Table 6 Adverse Event Summary by Age (ASaT Population)

|                                      | Pooled PembrolizumabMonotherapyit   | Pooled PembrolizumabMonotherapyit   | Pooled PembrolizumabMonotherapyit   | Pooled PembrolizumabMonotherapyit   |
|--------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|
|                                      | <75                                 | <75                                 | >=75                                | >=75                                |
|                                      | 11                                  | (%)                                 |                                     | (%)                                 |
| Subjccts in population               | 5384                                | (100.0)                             | 801                                 | (100.0)                             |
| with one ormore advcrse cvents       | 5202                                | (96.6)                              | 782                                 | (97.6)                              |
| who died                             | 254                                 | (4.7)                               | 67                                  | (8.4)                               |
| with serious adverse events          | 1986                                | (36.9)                              | 385                                 | (48.1)                              |
| discontinued due to an adverse cvent | 677                                 | (12.6)                              | 154                                 | (19.2)                              |
| CNS (confusion/extrapyramidal)       | 495                                 | (9.2)                               | 88                                  | (0'1D)                              |
| AErclatcd to falling                 | 405                                 | (7.5)                               | 98                                  | (12.2)                              |
| CV events                            | 1601                                | (20.3)                              | 199                                 | (24.8)                              |
| Cercbrovascular events               | 104                                 | (1.9)                               | 24                                  | (3.0)                               |
| Infections                           | 2397                                | (44.5)                              | 373                                 | (46.6)                              |

MedDRA preferred terms \"Ncoplasm progression\", \"Malignant ncoplasm progression\" and \"Discase progression\" not related to the drug are excluded.

AEswcrefollowed30 days afierlast dose of study treatment;SAEs werefollowcd 90 days after last dose of study treatment.

fi Includes all participants who reccived at least one dose of pembrolizumab in KN001 Part B1,B2, B3, D, C, F1, F2,F3,KN002 (original phase), KN006,KN010, KN012 (HNSCC), KN013 Cohort 3 (Hodgkin Lymphoma), KN024, KN040, KN042, KN045, KN048, KN052, KN054, KN055, KN087, KN177, and KN204.

Databasc CutoffDate forMclanoma (KN001-Mclanoma:18APR2014,KN002:28FEB2015,KN006:03MAR2015,KN054:02OCT2017)

Database Cutoff Date for Lung (KN001-NSCLC: 23JAN2015,KN010: 30SEP2015,KN024: 10JUL2017,KN042: 04SEP2018)

Databasc cutoff datcforHNSCC(KN012-HNSCC:26APR2016,KN040:15MAY2017,KN048:25FEB2019,KN055:22APR2016)

Databasc cutoff date for cHL (KN013-Cohort 3:28SEP2018,KN087:21MAR2019,KN204:16JAN2020)

Databasc cutoff date for Bladdcr(KN045:26OCT2017,KN052:26SEP2018)

Databasc cutoff date forCRC MSI-H or dMMMR (KN177:19FEB2020)

MedDRA version usedis 23.0.

Exposure in patients aged ≥ 75 years is generally lower than those with age &lt;75 years, in both combination and monotherapy pooled datasets. This can be partly attributable to a higher rate of fatalities and drug discontinuation due to AEs, including SAEs, in older than younger participants.

In looking at the combined therapeutic scheme, it should be recognised that within the comparator arm (chemotherapy only) these events were generally more frequent in patients  older  than  75  years  with respect  to  their  younger  counterpart,  in  line  with  the  age-dependent  frailty  that  clearly  affects  drug tolerability. However, the rate of fatalities and drug discontinuation increases with the combined therapy vs chemotherapy in both age categories. When considering AEOSI only, ageing in itself seems to increase the rate of these events in the control group (chemotherapy only); however, pembrolizumab in addition to

<div style=\"page-break-after: always\"></div>

chemotherapy further amplifies the occurrence of events in both age categories, particularly in the oldest group.

The age-dependent increase in AEOSI that emerges in pembrolizumab+chemotherapy pooled dataset, is not observable in pembrolizumab monotherapy since an equal rate of events was reported in both age categories.

The analysis of specific AEs by age reveals that CNS, AE related to falling, CV and cerebrovascular events were all increased by pembrolizumab when added to chemotherapy in the group of patients ≥ 75 years, while  a  similar  frequency  of  these  events  is  recognisable  between  pembrolizymab+chemotherapy  and chemotherapy alone in patients &lt;75 years. Of note, within the comparator arm (chemotherapy only) there is  no  difference  in  the  incidence  of  these  events  between  age  categories.  In  the  monotherapy  pooled dataset, patients ≥ 75 years experienced more numerous CNS, AE related to falling, CV and cerebrovascular events than their younger counterpart. However, as these are events commonly associated with ageing, disantangling  the  effect  of  age  from  drug  is  challenging.  Taken  together,  these  data  suggest  that pembrolizumab as add-on to chemotherapeutic agents is less tolerated in patients ≥ 75 years of age than their younger counterpart. This pooled analysis corroborates the consistent trend observed across individual studies showing increased toxicity of pembrolizumab as add-on to chemotherapy by age. Amendments to the SmPC to appropriately reflect these data has been requested (please refer to the PI)

## CHEMOTHERAPY

## Adverse Event Summary by Chemotherapy (Part 2 All Subjects) (ASaT Population)

|                                                     | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Placebo+Chemotherapy   | Placebo+Chemotherapy   | Placebo+Chemotherapy   | Placebo+Chemotherapy   | Placebo+Chemotherapy     | Placebo+Chemotherapy     |
|-----------------------------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|------------------------|------------------------|------------------------|------------------------|--------------------------|--------------------------|
|                                                     | Nab-Paclitaxel                 | Nab-Paclitaxel                 | Paclitaxel                     | Paclitaxel                     | Gemcitabine/Carb oplatin       | Gemcitabine/Carb oplatin       | Nab-Paclitaxel         | Nab-Paclitaxel         | Paclitaxel             | Paclitaxel             | Gemcitabine/Carb oplatin | Gemcitabine/Carb oplatin |
|                                                     | n                              | (%)                            | n                              | (%)                            | 1n                             | (%)                            | n                      | (%)                    | n                      | (%)                    | n                        | (%)                      |
| Subjects in population                              | 172                            |                                | 81                             |                                | 309                            |                                | 95                     |                        | 32                     |                        | 154                      |                          |
| withone ormore adverseevents                        | 169                            | (98.3)                         | 79                             | (97.5)                         | 306                            | (99.0)                         | 93                     | (97.9)                 | 30                     | (93.8)                 | 153                      | (99.4)                   |
| with no adverse event                               | 3                              | (1.7)                          | 2                              | (2.5)                          | 3                              | (1.0)                          | 2                      | (2.1)                  | 2                      | (6.3)                  | 1                        | (0.6)                    |
| with drug-relatedf adverse events                   | 164                            | (95.3)                         | 78                             | (96.3)                         | 299                            | (96.8)                         | 87                     | (91.6)                 | 29                     | (90.6)                 | 151                      | (98.1)                   |
| with toxicity grade 3-5 adverse events              | 108                            | (62.8)                         | 51                             | (63.0)                         | 279                            | (90.3)                         | 47                     | (49.5)                 | 19                     | (59.4)                 | 141                      | (91.6)                   |
| with toxicity grade 3-5 drug-related adverse events | 83                             | (48.3)                         | 36                             | (44.4)                         | 264                            | (85.4)                         | 35                     | (36.8)                 | 15                     | (46.9)                 | 138                      | (89.6)                   |
| with serious adverse events                         | 52                             | (30.2)                         | 21                             | (25.9)                         | 92                             | (29.8)                         | 17                     | (17.9)                 | 7                      | (21.9)                 | 43                       | (27.9)                   |
| with serious drug-related adverse events            | 25                             | (14.5)                         | 14                             | (17.3)                         | 59                             | (19.1)                         | 7                      | (7.4)                  | 1                      | (3.1)                  | 26                       | (16.9)                   |
| with any dose modificationdue toan adverse event    | 107                            | (62.2)                         | 55                             | (67.9)                         | 267                            | (86.4)                         | 46                     | (48.4)                 | 23                     | (71.9)                 | 140                      | (90.9)                   |
| pembrolizumab/placebo dose modification             | 75                             | (43.6)                         | 38                             | (46.9)                         | 201                            | (65.0)                         | 20                     | (21.1)                 | 15                     | (46.9)                 | 99                       | (64.3)                   |
| nab-paclitaxel dose modification                    | 99                             | (57.6)                         | 0                              | (0.0)                          | 0                              | (0.0)                          | 45                     | (47.4)                 | 0                      | (0.0)                  | 0                        | (0.0)                    |
| paclitaxel dose modification                        | 0                              | (0.0)                          | 52                             | (64.2)                         | 0                              | (0.0)                          | 0                      | (0.0)                  | 21                     | (65.6)                 | 0                        | (0.0)                    |
| gemcitabine dose modification                       | 0                              | (0.0)                          | 0                              | (0.0)                          | 264                            | (85.4)                         | 0                      | (0.0)                  | 0                      | (0.0)                  | 138                      | (89.6)                   |
| carboplatin dosemodification                        | 0                              | (0.0)                          | 0                              | (0.0)                          | 261                            | (84.5)                         | 0                      | (0.0)                  | 0                      | (0.0)                  | 140                      | (90.9)                   |
| who died                                            | 7                              | (4.1)                          | 1                              | (1.2)                          | 6                              | (6'1)                          | 1                      | (1.1)                  | 2                      | (6.3)                  | 2                        | (1.3)                    |
| whodied due toa drug-related adverse event          | 1                              | (0.6)                          | 0                              | (0.0)                          | 1                              | (0.3)                          | 0                      | (0.0)                  | 0                      | (0.0)                  | 0                        | (0.0)                    |

<div style=\"page-break-after: always\"></div>

|                                                           | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Placebo + Chemotherapy   | Placebo + Chemotherapy   | Placebo + Chemotherapy   |
|-----------------------------------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------|--------------------------|--------------------------|
|                                                           | Nab-Paclitaxel                 | Nab-Paclitaxel                 | Paclitaxel                     | Gemcitabine/Carb oplatin       | Nab-Paclitaxel           | Paclitaxel               | Gemcitabine/Carb oplatin |
|                                                           |                                | (%)                            | n (%)                          | n (%)                          | n (%)                    | n (%)                    | n (%)                    |
| discontinuedanydrugduetoanadverseevent                    | 28                             | (16.3)                         | 26 (32.1)                      | 61 (19.7)                      | 5 (5.3)                  | 7 (21.9)                 | 25 (16.2)                |
| discontinuedpembrolizumab/placebo                         | 16                             | (9.3)                          | 15 (18.5)                      | 29 (9.4)                       | 2 (2.1)                  | 4 (12.5)                 | 9 (5.8)                  |
| discontinuednab-paclitaxel                                | 22                             | (12.8)                         | 0 (0.0)                        | 0 (0.0)                        | 4 (4.2)                  | 0 (0.0)                  | 0 (0.0)                  |
| discontinued paclitaxel                                   | 0                              | (0.0)                          | 16 (19.8)                      | 0 (0.0)                        | 0 (0.0)                  | 6 (18.8)                 | 0 (0.0)                  |
| discontinued gemcitabine                                  | 0                              | (0.0)                          | 0 (0.0)                        | 37 (12.0)                      | 0 (0.0)                  | 0 (0.0)                  | 16 (10.4)                |
| discontinued carboplatin                                  | 0                              | (0.0)                          | 0 (0.0)                        | 42 (13.6)                      | 0 (0.0)                  | 0 (0.0)                  | 17 (11.0)                |
| discontinued any drug due to a drug-related adverse event | 24                             | (14.0)                         | 24 (29.6)                      | 54 (17.5)                      | 4 (4.2)                  | 4 (12.5)                 | 23 (14.9)                |
| discontinuedpembrolizumab/placebo                         | 13                             | (7.6)                          | 13 (16.0)                      | 25 (8.1)                       | 1 (1.1)                  | 1 (3.1)                  | 8 (5.2)                  |
| discontinued nab-paclitaxel                               | 18                             | (10.5)                         | 0 (0.0)                        | 0 (0.0)                        | 3 (3.2)                  | 0 (0.0)                  | 0 (0.0)                  |
| discontinuedpaclitaxel                                    | 0                              | (0.0)                          | 16 (19.8)                      | 0 (0.0)                        | 0 (0.0)                  | 3 (9.4)                  | 0 (0.0)                  |
| discontinuedgemcitabine                                   | 0                              | (0.0)                          | 0 (0.0)                        | 33 (10.7)                      | 0 (0.0)                  | 0 (0.0)                  | 15 (9.7)                 |
| discontinued carboplatin                                  | 0                              | (0.0)                          | 0 (0.0)                        | 37 (12.0)                      | 0 (0.0)                  | 0 (0.0)                  | 16 (10.4)                |
| discontinued any drug due to a serious adverse event      | 14                             | (8.1)                          | 8 (9.9)                        | 22 (7.1)                       | 2 (2.1)                  | 4 (12.5)                 | 3 (1.9)                  |
| discontinuedpembrolizumab/placebo                         | 12                             | (7.0)                          | 7 (8.6)                        | 20 (6.5) 0                     | 2 (2.1)                  | 3 (9.4)                  | 3 (1.9)                  |
| discontinued nab-paclitaxel                               | 9                              | (5.2)                          | 0 (0.0)                        | (0.0)                          | 1 (1.1)                  | 0 (0.0)                  | 0 (0.0)                  |
| discontinued paclitaxel                                   | 0                              | (0.0)                          | 4 (4.9)                        | 0 (0.0)                        | 0 (0.0)                  | 4 (12.5)                 | 0 (0.0)                  |

|                                                                    | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Placebo + Chemotherapy   | Placebo + Chemotherapy   | Placebo + Chemotherapy   |
|--------------------------------------------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------|--------------------------|--------------------------|
|                                                                    | Nab-Paclitaxel                 | Paclitaxel                     | Gemcitabine/Carb oplatin       | Nab-Paclitaxel           | Paclitaxel               | Gemcitabine/Carb oplatin |
|                                                                    | n (%)                          | n (%)                          | n (%)                          | n (%)                    | n (%)                    | n (%)                    |
| discontinuedgemcitabine                                            | 0 (0.0)                        | 0 (0.0)                        | 9 (2.9)                        | 0 (0.0)                  | 0 (0.0)                  | 0 (0.0)                  |
| discontinuedcarboplatin                                            | 0 (0.0)                        | 0 (0.0)                        | 8 (2.6)                        | 0 (0.0)                  | 0 (0.0)                  | 1 (0.6)                  |
| discontinued any drug due to a serious drug- related adverse event | 10 (5.8)                       | 7 (8.6)                        | 19 (6.1)                       | 1 (1.1)                  | 1 (3.1)                  | 2 (1.3)                  |
| discontinuedpembrolizumab/placebo                                  | 9 (5.2)                        | 6 (7.4)                        | 17 (5.5)                       | 1 (1.1)                  | 0 (0.0)                  | 2 (1.3)                  |
| discontinued nab-paclitaxel                                        | 5 (2.9)                        | 0 (0.0)                        | 0 (0.0)                        | 0 (0.0)                  | 0 (0.0)                  | 0 (0.0)                  |
| discontinuedpaclitaxel                                             | 0 (0.0)                        | 4 (4.9)                        | 0 (0.0)                        | 0 (0.0)                  | 1 (3.1)                  | 0 (0.0)                  |
| discontinued gemcitabine                                           | 0 (0.0)                        | 0 (0.0)                        | 7 (2.3)                        | 0 (0.0)                  | 0 (0.0)                  | 0 (0.0)                  |
| discontinued carboplatin                                           | 0 (0.0)                        | 0 (0.0)                        | 6 (1.9)                        | 0 (0.0)                  | 0 (0.0)                  | 1 (0.6)                  |

Determinedbytheinvestigatortoberelated tothedrug.

+Defined as an action taken of dosereduced,drug interrupted or drugwithdrawn.

Grades are based on NCI CTCAE version 4.0.

Non-serious adverse events upto30 days afterlast dose and serious adverse events up to90 days afterlast dose are included.

MedDRA preferred terms\"Neoplasm progression\",\"Malignant neoplasm progression\"and\"Disease progression\"not related to the drug are excluded.

Database Cutoff Date:11DEC2019

## ECOG STATUS

## Adverse Event Summaryby ECOG Status (Part 2 All Subjects) (ASaT Population)

|                                                    |   Pembrolizumab + Chemotherapy | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Placebo+Chemotherapy   | Placebo+Chemotherapy   | Placebo+Chemotherapy   | Placebo+Chemotherapy   | Placebo+Chemotherapy   |
|----------------------------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|
|                                                    |                              0 | 0                              |                                | 1                              | 2                              | 2                              | 0                      | 0                      | 1                      | 1                      | 2                      |
|                                                    |                              1 | (%)                            | n                              | (%)                            | n                              | (%)                            | n                      | (%)                    | n                      | (%)                    | n (%)                  |
| Subjects in population                             |                            331 |                                | 230                            |                                | 1                              |                                | 173                    |                        | 108                    |                        | 0                      |
| with one or more adverse events                    |                            327 | (98.8)                         | 226                            | (98.3)                         | 1                              | (100.0)                        | 170                    | (98.3)                 | 106                    | (98.1)                 | 0 (0.0)                |
| with no adverse event                              |                              4 | (1.2)                          | 4                              | (1.7)                          | 0                              | (0.0)                          | 3                      | (1.7)                  | 2                      | (1.9)                  | 0 (0.0)                |
| with drug-related adverse events                   |                            320 | (96.7)                         | 220                            | (95.7)                         | 1                              | (100.0)                        | 164                    | (94.8)                 | 103                    | (95.4)                 | 0 (0.0)                |
| with toxicity grade 3-5 adverse events             |                            248 | (74.9)                         | 189                            | (82.2)                         | 1                              | (100.0)                        | 126                    | (72.8)                 | 81                     | (75.0)                 | 0 (0.0)                |
| with toxicity grade 3-5drug-related adverse events |                            222 | (67.1)                         | 161                            | (70.0)                         | 0                              | (0.0)                          | 113                    | (65.3)                 | 75                     | (69.4)                 | 0 (0.0)                |
| with serious adverse events                        |                             83 | (25.1)                         | 81                             | (35.2)                         | 1                              | (100.0)                        | 36                     | (20.8)                 | 31                     | (28.7)                 | 0 (0.0)                |
| with serious drug-related adverse events           |                             47 | (14.2)                         | 51                             | (22.2)                         | 0                              | (0.0)                          | 16                     | (9.2)                  | 18                     | (16.7)                 | 0 (0.0)                |
| with anydosemodificationduetoan adverse event      |                            249 | (75.2)                         | 180                            | (78.3)                         | 0                              | (0.0)                          | 130                    | (75.1)                 | 79                     | (73.1)                 | 0 (0.0)                |
| pembrolizumab/placebodosemodification              |                            182 | (55.0)                         | 132                            | (57.4)                         | 0                              | (0.0)                          | 87                     | (50.3)                 | 47                     | (43.5)                 | 0 (0.0)                |
| nab-paclitaxel dose modification                   |                             56 | (16.9)                         | 43                             | (18.7)                         | 0                              | (0.0)                          | 29                     | (16.8)                 | 16                     | (14.8)                 | 0 (0.0)                |
| paclitaxel dose modification                       |                             27 | (8.2)                          | 25                             | (10.9)                         | 0                              | (0.0)                          | 14                     | (8.1)                  | 7                      | (6.5)                  | 0 (0.0)                |
| gemcitabine dose modification                      |                            161 | (48.6)                         | 103                            | (44.8)                         | 0                              | (0.0)                          | 84                     | (48.6)                 | 54                     | (50.0)                 | 0 (0.0)                |
| carboplatin dose modification                      |                            157 | (47.4)                         | 104                            | (45.2)                         | 0                              | (0.0)                          | 8                      | (48.6)                 | 56                     | (51.9)                 | 0 (0.0)                |
| who died                                           |                              6 | (1.8)                          | 8                              | (3.5)                          | 0                              | (0.0)                          | 4                      | (2.3)                  | 1                      | (0.9)                  | 0 (0.0)                |
| who died due to a drug-related adverse event       |                              1 | (0.3)                          | 1                              | (0.4)                          | 0                              | (0.0)                          | 0                      | (0.0)                  | 0                      | (0.0)                  | 0 (0.0)                |
| discontinuedanydrugduetoan adverseevent            |                             69 | (20.8)                         | 46                             | (20.0)                         | 0                              | (0.0)                          | 25                     | (14.5)                 | 12                     | (11.1)                 | 0 (0.0)                |
| discontinuedpembrolizumab/placebo                  |                             31 | (9.4)                          | 29                             | (12.6)                         | 0                              | (0.0)                          | 12                     | (6.9)                  | 3                      | (2.8)                  | 0 (0.0)                |

<div style=\"page-break-after: always\"></div>

|                                                                    | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Placebo + Chemotherapy   | Placebo + Chemotherapy   | Placebo + Chemotherapy   |
|--------------------------------------------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------|--------------------------|--------------------------|
|                                                                    | 0                              | 0                              | 1 2                            | 1 2                            | 0                        | 1                        | 2                        |
|                                                                    | (%)                            | 1n                             |                                | (%) n (%)                      | n (%)                    | n (%)                    | n (%)                    |
| discontinuednab-paclitaxel                                         | 11 (3.3)                       | 11                             | (4.8)                          | 0 (0.0)                        | 4 (2.3)                  | 0 (0.0)                  | 0 (0.0)                  |
| discontinued paclitaxel                                            | 8 (2.4)                        | 8                              | (3.5)                          | 0 (0.0)                        | 4 (2.3)                  | 2 (1.9)                  | 0 (0.0)                  |
| discontinuedgemcitabine                                            | 23 (6.9)                       | 14                             | (6.1)                          | 0 (0.0)                        | 8 (4.6)                  | 8 (7.4)                  | 0 (0.0)                  |
| discontinued carboplatin                                           | 27                             | (8.2) 15                       | (6.5)                          | 0 (0.0)                        | 9 (5.2)                  | 8 (7.4)                  | 0 (0.0)                  |
| discontinued any drug due to a drug-related adverseevent           | 61                             | (18.4) 41                      | (17.8)                         | 0 (0.0)                        | 21 (12.1)                | 10 (9.3)                 | 0 (0.0)                  |
| discontinued pembrolizumab/placebo                                 | 26                             | (7.9) 25                       | (10.9)                         | 0 (0.0)                        | 8 (4.6)                  | 2 (6:1)                  | 0 (0.0)                  |
| discontinuednab-paclitaxel                                         | 9                              | (2.7) 9                        | (3.9)                          | 0 (0.0)                        | 3 (1.7)                  | 0 (0.0)                  | 0 (0.0)                  |
| discontinued paclitaxel                                            | 8                              | (2.4) 8                        | (3.5)                          | 0 (0.0)                        | 2 (1.2)                  | 1 (0.9)                  | 0 (0.0)                  |
| discontinued gemcitabine                                           | 21                             | (6.3) 12                       | (5.2)                          | 0 (0.0)                        | 8 (4.6)                  | 7 (6.5)                  | 0 (0.0)                  |
| discontinued carboplatin                                           | 24                             | (7.3) 13                       | (5.7)                          | 0 (0.0)                        | 9 (5.2)                  | 7 (6.5)                  | 0 (0.0)                  |
| discontinued any drug due to a serious adverse event               | 23                             | (6.9) 21                       | (9.1)                          | 0 (0.0)                        | 8 (4.6)                  | 1 (0.9)                  | 0 (0.0)                  |
| discontinued pembrolizumab/placebo                                 | 19                             | (5.7) 20                       | (8.7)                          | 0 (0.0)                        | 7 (4.0)                  | 1 (0.9)                  | 0 (0.0)                  |
| discontinued nab-paclitaxel                                        | 2                              | (0.6) 7                        | (3.0)                          | 0 (0.0)                        | 1 (0.6)                  | 0 (0.0)                  | 0 (0.0)                  |
| discontinued paclitaxel                                            | 2                              | (0.6) 2                        | (0.9)                          | 0 (0.0)                        | 3 (1.7)                  | 1 (0.9)                  | 0 (0.0)                  |
| discontinuedgemcitabine                                            | 5                              | (1.5) 4                        | (1.7)                          | 0 (0.0)                        | 0 (0.0)                  | 0 (0.0)                  | 0 (0.0)                  |
| discontinued carboplatin                                           | 4 (1.2)                        | 4                              | (1.7)                          | 0 (0.0)                        | 1 (0.6)                  | 0 (0.0)                  | 0 (0.0)                  |
| discontinued any drug due to a serious drug- related adverse event | 19 (5.7)                       | 17                             | (7.4)                          | 0 (0.0)                        | 4 (2.3)                  | 0 (0.0)                  | 0 (0.0)                  |

|                                   | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Placebo + Chemotherapy   | Placebo + Chemotherapy   | Placebo + Chemotherapy   |
|-----------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------|--------------------------|--------------------------|
|                                   | 0                              | 1                              | 2                              | 0                        | 1                        | 2                        |
|                                   | 1 (%)                          | n (%)                          | n (%)                          | n (%)                    | n (%)                    | n (%)                    |
| discontinuedpembrolizumab/placebo | 16 (4.8)                       | 16 (7.0)                       | 0 (0.0)                        | 3 (1.7)                  | 0 (0.0)                  | 0 (0.0)                  |
| discontinued nab-paclitaxel       | 0 (0.0)                        | 5 (2.2)                        | 0 (0.0)                        | 0 (0.0)                  | 0 (0.0)                  | 0 (0.0)                  |
| discontinued paclitaxel           | 2 (0.6)                        | 2 (0.9)                        | 0 (0.0)                        | 1 (0.6)                  | 0 (0.0)                  | 0 (0.0)                  |
| discontinuedgemcitabine           | 4 (1.2)                        | 3 (1.3)                        | 0 (0.0)                        | 0 (0.0)                  | 0 (0.0)                  | 0 (0.0)                  |
| discontinued carboplatin          | 3 (0.9)                        | 3 (1.3)                        | 0 (0.0)                        | 1 (0.6)                  | 0 (0.0)                  | 0 (0.0)                  |

Determined bytheinvestigator toberelated tothedrug.

+ Defined as an action taken of dose reduced, drug interrupted or drug withdrawn.

GradesarebasedonNCICTCAEversion4.0.

Non-serious adverse events up to 30 days after last dose and serious adverse events up to 90 days after last dose are included.

DatabaseCutoffDate:11DEC2019

## RACE

Adverse Event Summaryby Race (Part 2 All Subjects)

(ASaT Population)

|                                                     | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Placebo + Chemotherapy   | Placebo + Chemotherapy   | Placebo + Chemotherapy   | Placebo + Chemotherapy   |
|-----------------------------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
|                                                     | WHITE                          | WHITE                          | NON-WHITE                      | NON-WHITE                      | WHITE                    | WHITE                    | NON-WHITE                | NON-WHITE                |
|                                                     | n                              | (%)                            | n                              | (%)                            | n                        | (%)                      | n                        | (%)                      |
| Subjects in population                              | 381                            |                                | 164                            |                                | 195                      |                          | 78                       |                          |
| with one ormore adverseevents                       | 374                            | (98.2)                         | 163                            | (99.4)                         | 190                      | (97.4)                   | 78                       | (100.0)                  |
| with no adverse event                               | 7                              | (1.8)                          | 1                              | (0.6)                          | 5                        | (2.6)                    | 0                        | (0.0)                    |
| with drug-related adverse events                    | 365                            | (95.8)                         | 159                            | (97.0)                         | 183                      | (93.8)                   | 76                       | (97.4)                   |
| with toxicity grade 3-5 adverse events              | 293                            | (76.9)                         | 131                            | (79.9)                         | 138                      | (70.8)                   | 63                       | (80.8)                   |
| with toxicity grade 3-5 drug-related adverse events | 250                            | (65.6)                         | 121                            | (73.8)                         | 123                      | (63.1)                   | 59                       | (75.6)                   |
| withserious adverseevents                           | 117                            | (30.7)                         | 43                             | (26.2)                         | 42                       | (21.5)                   | 22                       | (28.2)                   |
| with serious drug-related adverse events            | 70                             | (18.4)                         | 25                             | (15.2)                         | 20                       | (10.3)                   | 12                       | (15.4)                   |
| with any dose modification+ due to an adverse event | 275                            | (72.2)                         | 140                            | (85.4)                         | 141                      | (72.3)                   | 62                       | (79.5)                   |
| pembrolizumab/placebodosemodification               | 204                            | (53.5)                         | 99                             | (60.4)                         | 86                       | (44.1)                   | 42                       | (53.8)                   |
| nab-paclitaxel dose modification                    | 67                             | (17.6)                         | 32                             | (S:61)                         | 31                       | (15.9)                   | 14                       | (17.9)                   |
| paclitaxel dose modification                        | 38                             | (10.0)                         | 8                              | (4.9)                          | 16                       | (8.2)                    | 3                        | (3.8)                    |
| gemcitabine dose modification                       | 162                            | (42.5)                         | 95                             | (57.9)                         | 90                       | (46.2)                   | 45                       | (57.7)                   |
| carboplatin dose modification                       | 159                            | (41.7)                         | 95                             | (57.9)                         | 92                       | (47.2)                   | 45                       | (57.7)                   |
| who died                                            | 10                             | (2.6)                          | 4                              | (2.4)                          | 5                        | (2.6)                    | 0                        | (0.0)                    |
| whodied due to adrug-related adverse event          | 2                              | (0.5)                          | 0                              | (0.0)                          | 0                        | (0.0)                    | 0                        | (0.0)                    |
| discontinued any drug due to an adverse event       | 74                             | (19.4)                         | 35                             | (21.3)                         | 28                       | (14.4)                   | 8                        | (10.3)                   |
| discontinuedpembrolizumab/placebo                   | 39                             | (10.2)                         | 18                             | (11.0)                         | 11                       | (5.6)                    | 3                        | (3.8)                    |
| discontinued nab-paclitaxel                         | 15                             | (3.9)                          | 7                              | (4.3)                          | 4                        | (2.1)                    | 0                        | (0.0)                    |

<div style=\"page-break-after: always\"></div>

|                                                                   | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Placebo + Chemotherapy   | Placebo + Chemotherapy   | Placebo + Chemotherapy   |
|-------------------------------------------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------|--------------------------|--------------------------|
|                                                                   | WHITE                          | WHITE                          | NON-WHITE                      | NON-WHITE                      | WHITE                    | WHITE                    | NON-WHITE                |
|                                                                   |                                | (%)                            | 1n                             | (%)                            | n                        | (%)                      | n (%)                    |
| discontinuedpaclitaxel                                            | 9                              | (2.4)                          | 4                              | (2.4)                          | 6                        | (3.1)                    | 0 (0.0)                  |
| discontinuedgemcitabine                                           | 27                             | (7.1)                          | 9                              | (5.5)                          | 12                       | (6.2)                    | 4 (5.1)                  |
| discontinued carboplatin                                          | 27                             | (7.1)                          | 14                             | (8.5)                          | 11                       | (5.6)                    | 6 (7.7)                  |
| discontinued any drug due to a drug-related adverse event         | 66                             | (17.3)                         | 31                             | (18.9)                         | 22                       | (11.3)                   | 8 (10.3)                 |
| discontinuedpembrolizumab/placebo                                 | 33                             | (8.7)                          | 16                             | (9.8)                          | 6                        | (3.1)                    | 3 (3.8)                  |
| discontinuednab-paclitaxel                                        | 12                             | (3.1)                          | 6                              | (3.7)                          | 3                        | (1.5)                    | 0 (0.0)                  |
| discontinuedpaclitaxel                                            | 9                              | (2.4)                          | 4                              | (2.4)                          | 3                        | (1.5)                    | 0 (0.0)                  |
| discontinuedgemcitabine                                           | 25                             | (6.6)                          | 7                              | (4.3)                          | 11                       | (5.6)                    | 4 (5.1)                  |
| discontinuedcarboplatin                                           | 25                             | (6.6)                          | 11                             | (6.7)                          | 10                       | (5.1)                    | 6 (7.7)                  |
| discontinued any drugdue toaserious adverse event                 | 29                             | (7.6)                          | 14                             | (8.5)                          | 7                        | (3.6)                    | 1 (1.3)                  |
| discontinued pembrolizumab/placebo                                | 27                             | (7.1)                          | 11                             | (6.7)                          | 6                        | (3.1)                    | 1 (1.3)                  |
| discontinuednab-paclitaxel                                        | 7                              | (1.8)                          | 2                              | (1.2)                          | 1                        | (0.5)                    | 0 (0.0)                  |
| discontinued paclitaxel                                           | 3                              | (0.8)                          | 1                              | (0.6)                          | 4                        | (2.1)                    | 0 (0.0)                  |
| discontinued gemcitabine                                          | 6                              | (1.6)                          | 3                              | (1.8)                          | 0                        | (0.0)                    | 0 (0.0)                  |
| discontinued carboplatin                                          | 6                              | (1.6)                          | 2                              | (1.2)                          | 0                        | (0.0)                    | 1 (1.3)                  |
| discontinued any drug due to a serious drug-related adverse event | 25                             | (6.6)                          | 11                             | (6.7)                          | 2                        | (1.0)                    | 1 (1.3)                  |
| discontinued pembrolizumab/placebo                                | 23                             | (6.0)                          | 9                              | (5.5)                          | 1                        | (0.5)                    | 1 (1.3)                  |
| discontinuednab-paclitaxel                                        | 4                              | (1.0)                          | 1                              | (0.6)                          | 0                        | (0.0)                    | 0 (0.0)                  |

|                          | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Placebo + Chemotherapy   | Placebo + Chemotherapy   |
|--------------------------|--------------------------------|--------------------------------|--------------------------|--------------------------|
|                          | WHITE                          | NON-WHITE                      | WHITE                    | NON-WHITE                |
|                          | n (%)                          | n (%)                          | n (%)                    | n (%)                    |
| discontinued paclitaxel  | 3 (0.8)                        | 1 (0.6)                        | 1 (0.5)                  | 0 (0.0)                  |
| discontinuedgemcitabine  | 6 (1.6)                        | 1 (0.6)                        | 0 (0.0)                  | 0 (0.0)                  |
| discontinued carboplatin | 6 (1.6)                        | 0 (0.0)                        | 0 (0.0)                  | 1 (1.3)                  |

Determinedbytheinvestigatortoberelated tothedrug.

+ Defined as an action taken of dose reduced, drug interrupted or drug withdrawn.

Grades are based on NCI CTCAE version 4.0.

Non-serious adverse events up to 30 days after last dose and serious adverse events up to 90 days after last dose are included.

MedDRA preferred terms \"Neoplasm progression\", \"Malignant neoplasm progression\" and \"Disease progression\" not related to the drug are excluded. DatabaseCutoffDate:11DEC2019

Source:[P355V01MK3475:adam-adsl;adae]

Table 14.3-47 Adverse Event Summary by Region (EU vs Non-EU) (Part 2 All Subjects) (ASaT Population)

|                                                    | Pembrolizumab+Chemotherapy   | Pembrolizumab+Chemotherapy   | Pembrolizumab+Chemotherapy   | Pembrolizumab+Chemotherapy   | Placebo + Chemotherapy   | Placebo + Chemotherapy   | Placebo + Chemotherapy   | Placebo + Chemotherapy   |
|----------------------------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
|                                                    | EU                           | EU                           | Non-EU                       | Non-EU                       | EU                       | EU                       | Non-EU                   | Non-EU                   |
|                                                    |                              | (%)                          | n                            | (%)                          | n                        | (%)                      | n                        | (%)                      |
| Subjects in population                             | 164                          |                              | 398                          |                              | 94                       |                          | 187                      |                          |
| with one ormore adverseevents                      | 161                          | (98.2)                       | 393                          | (98.7)                       | 94                       | (100.0)                  | 182                      | (97.3)                   |
| with no adverse event                              | 3                            | (1.8)                        | 5                            | (1.3)                        | 0                        | (0.0)                    | 5                        | (2.7)                    |
| with drug-related adverse events                   | 158                          | (96.3)                       | 383                          | (96.2)                       | 91                       | (96.8)                   | 176                      | (94.1)                   |
| with toxicity grade 3-5 adverse events             | 117                          | (71.3)                       | 321                          | (80.7)                       | 72                       | (76.6)                   | 135                      | (72.2)                   |
| with toxicity grade 3-5drug-related adverse events | 102                          | (62.2)                       | 281                          | (70.6)                       | 63                       | (67.0)                   | 125                      | (66.8)                   |
| with serious adverse events                        | 55                           | (33.5)                       | 110                          | (27.6)                       | 30                       | (31.9)                   | 37                       | (19.8)                   |
| with serious drug-related adverse events           | 35                           | (21.3)                       | 63                           | (15.8)                       | 14                       | (14.9)                   | 20                       | (10.7)                   |
| with any dosemodification+due to an adverseevent   | 117                          | (71.3)                       | 312                          | (78.4)                       | 70                       | (74.5)                   | 139                      | (74.3)                   |
| pembrolizumab/placebo dose modification            | 84                           | (51.2)                       | 230                          | (57.8)                       | 48                       | (51.1)                   | 86                       | (46.0)                   |
| nab-paclitaxeldosemodification                     | 37                           | (22.6)                       | 62                           | (15.6)                       | 19                       | (20.2)                   | 26                       | (13.9)                   |
| paclitaxel dose modification                       | 15                           | (9.1)                        | 37                           | (9.3)                        | 7                        | (7.4)                    | 14                       | (7.5)                    |
| gemcitabine dose modification                      | 63                           | (38.4)                       | 201                          | (50.5)                       | 42                       | (44.7)                   | 96                       | (51.3)                   |
| carboplatin dose modification                      | 61                           | (37.2)                       | 200                          | (50.3)                       | 42                       | (44.7)                   | 98                       | (52.4)                   |
| who died                                           | 6                            | (3.7)                        | 8                            | (2.0)                        | 3                        | (3.2)                    | 2                        | (1.1)                    |
| whodieddue toadrug-related adverse event           | 2                            | (1.2)                        | 0                            | (0.0)                        | 0                        | (0.0)                    | 0                        | (0.0)                    |
| discontinued any drugdue toan adverse event        | 38                           | (23.2)                       | 77                           | (19.3)                       | 13                       | (13.8)                   | 24                       | (12.8)                   |
| discontinuedpembrolizumab/placebo                  | 22                           | (13.4)                       | 38                           | (9.5)                        | 6                        | (6.4)                    | 9                        | (4.8)                    |
| discontinued nab-paclitaxel                        | 9                            | (5.5)                        | 13                           | (3.3)                        | 3                        | (3.2)                    | 1                        | (0.5)                    |

## REGION

<div style=\"page-break-after: always\"></div>

|                                                                   | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Placebo + Chemotherapy   | Placebo + Chemotherapy   | Placebo + Chemotherapy   | Placebo + Chemotherapy   |
|-------------------------------------------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
|                                                                   | EU                             | EU                             | Non-EU                         | Non-EU                         | EU                       | EU                       | Non-EU                   | Non-EU                   |
|                                                                   | n                              | (%)                            | n                              | (%)                            | n                        | (%)                      | n                        | (%)                      |
| discontinued paclitaxel                                           | 5                              | (3.0)                          | 11                             | (2.8)                          | 2                        | (2.1)                    | 4                        | (2.1)                    |
| discontinued gemcitabine                                          | 11                             | (6.7)                          | 26                             | (6.5)                          | 4                        | (4.3)                    | 12                       | (6.4)                    |
| discontinued carboplatin                                          | 11                             | (6.7)                          | 31                             | (7.8)                          | 5                        | (5.3)                    | 12                       | (6.4)                    |
| discontinued any drug due to a drug-related adverse event         | 33                             | (20.1)                         | 69                             | (17.3)                         | 11                       | (11.7)                   | 20                       | (10.7)                   |
| discontinuedpembrolizumab/placebo                                 | 17                             | (10.4)                         | 34                             | (8.5)                          | 4                        | (4.3)                    | 6                        | (3.2)                    |
| discontinued nab-paclitaxel                                       | 6                              | (3.7)                          | 12                             | (3.0)                          | 2                        | (2.1)                    | 1                        | (0.5)                    |
| discontinuedpaclitaxel                                            | 5                              | (3.0)                          | 11                             | (2.8)                          | 2                        | (2.1)                    | 1                        | (0.5)                    |
| discontinuedgemcitabine                                           | 11                             | (6.7)                          | 22                             | (5.5)                          | 4                        | (4.3)                    | 11                       | (5.9)                    |
| discontinued carboplatin                                          | 11                             | (6.7)                          | 26                             | (6.5)                          | 5                        | (5.3)                    | 11                       | (5.9)                    |
| discontinuedany drug due to a serious adverse event               | 17                             | (10.4)                         | 27                             | (6.8)                          | 4                        | (4.3)                    | 5                        | (2.7)                    |
| discontinued pembrolizumab/placebo                                | 17                             | (10.4)                         | 22                             | (5.5)                          | 3                        | (3.2)                    | 5                        | (2.7)                    |
| discontinued nab-paclitaxel                                       | 6                              | (3.7)                          | 3                              | (0.8)                          | 1                        | (1.1)                    | 0                        | (0.0)                    |
| discontinued paclitaxel                                           | 0                              | (0.0)                          | 4                              | (1.0)                          | 1                        | (1.1)                    | 3                        | (1.6)                    |
| discontinued gemcitabine                                          | 2                              | (1.2)                          | 7                              | (1.8)                          | 0                        | (0.0)                    | 0                        | (0.0)                    |
| discontinued carboplatin                                          | 2                              | (1.2)                          | 6                              | (1.5)                          | 0                        | (0.0)                    | 1                        | (0.5)                    |
| discontinued any drug due to a serious drug-related adverse event | 12                             | (7.3)                          | 24                             | (6.0)                          | 2                        | (2.1)                    | 2                        | (1.1)                    |
| discontinuedpembrolizumab/placebo                                 | 12                             | (7.3)                          | 20                             | (5.0)                          | 1                        | (1.1)                    | 2                        | (1.1)                    |
| discontinued nab-paclitaxel                                       | 3                              | (1.8)                          | 2                              | (0.5)                          | 0                        | (0.0)                    | 0                        | (0.0)                    |

|                          | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Placebo +Chemotherapy   | Placebo +Chemotherapy   |
|--------------------------|--------------------------------|--------------------------------|-------------------------|-------------------------|
|                          | EU                             | Non-EU                         | EU                      | Non-EU                  |
|                          | n (%)                          | n (%)                          | n (%)                   | n (%)                   |
| discontinuedpaclitaxel   | 0 (0.0)                        | 4 (1.0)                        | 1 (1.1)                 | 0 (0.0)                 |
| discontinuedgemcitabine  | 2 (1.2)                        | 5 (1.3)                        | 0 (0.0)                 | 0 (0.0)                 |
| discontinued carboplatin | 2 (1.2)                        | 4 (1.0)                        | 0 (0.0)                 | 1 (0.5)                 |

Defined as an action taken of dosereduced,drug interrupted or drugwithdrawn.

I Determined by the investigator to be related to the drug.

Grades arebased onNCICTCAEversion 4.0.

Non-serious adverse events up to30days after last dose and serious adverse events up to90 days afterlast dose are included.

MedDRA preferred terms \"Neoplasm progression\", \"Malignant neoplasm progression\" and \"Disease progression\" not related to the drug are excluded. DatabaseCutoffDate:11DEC2019

<div style=\"page-break-after: always\"></div>

Table 7 Subjects With Adverse Events by Decreasing Incidence (Incidence ≥ 10% in One or More Treatment Groups) (Part 2 All Subjects-Chemotherapy with Gemcitabine/Carboplatin) (ASaT Population)

(99.4)

(69.5)

(55.8)

(51.3)

(35.1)

(36.4)

(34.4)

(35.1)

(25.3)

(27.3)

(22.7)

(28.6)

(23.4)

(24.7)

(27.3)

(18.8)

(24.0)

(16.9)

(24.7)

(18.8)

(14.9)

(16.2)

(13.0)

(12.3)

(16.9)

(13.0)

(11.0)

|                                                | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Placebo + Chemotherapy   | Placebo + Chemotherapy   |
|------------------------------------------------|--------------------------------|--------------------------------|--------------------------|--------------------------|
|                                                | n                              | (%)                            | n                        | (%)                      |
| Subjects in population with one or more events | 309                            |                                | 154                      |                          |
| adverse                                        | 306                            | (99.0)                         | 153                      | (99.4)                   |
| with no adverse events                         | 3                              | (1.0)                          | 1                        | (0.6)                    |
| Anaemia                                        | 207                            | (67.0)                         | 107                      | (69.5)                   |
| Nausea                                         | 163                            | (52.8)                         | 86                       | (55.8)                   |
| Neutropenia                                    | 161                            | (52.1)                         | 79                       | (51.3)                   |
| Fatigue                                        | 111                            | (35.9)                         | 54                       | (35.1)                   |
| Thrombocytopenia                               | 107                            | (34.6)                         | 56                       | (36.4)                   |
| Constipation                                   | 102                            | (33.0)                         | 53                       | (34.4)                   |
| Neutrophil count decreased                     | 100                            | (32.4)                         | 54                       | (35.1)                   |
| Alanine aminotransferase increased             | 97                             | (31.4)                         | 39                       | (25.3)                   |
| Vomiting                                       | 92                             | (29.8)                         | 42                       | (27.3)                   |
| Aspartate aminotransferase increased           | 88                             | (28.5)                         | 35                       | (22.7)                   |
| Platelet count decreased                       | 88                             | (28.5)                         | 44                       | (28.6)                   |
| Leukopenia                                     | 81                             | (26.2)                         | 36                       | (23.4)                   |
| White blood cell count decreased               | 79                             | (25.6)                         | 38                       | (24.7)                   |
| Headache                                       | 68                             | (22.0)                         | 42                       | (27.3)                   |
| Cough                                          | 67                             | (21.7)                         | 29                       | (18.8)                   |
| Pyrexia                                        | 62                             | (20.1)                         | 37                       | (24.0)                   |
| Rash                                           | 62                             | (20.1)                         | 15                       | (9.7)                    |
| Decreased appetite                             | 61                             | (19.7)                         | 26                       | (16.9)                   |
| Diarrhoea                                      | 60                             | (19.4)                         | 38                       | (24.7)                   |
| Asthenia                                       | 50                             | (16.2)                         | 29                       | (18.8)                   |
| Alopecia                                       | 49                             | (15.9)                         | 23                       | (14.9)                   |
| Back pain                                      | 47                             | (15.2)                         | 25                       | (16.2)                   |
| Arthralgia                                     | 43                             | (13.9)                         | 20                       | (13.0)                   |
| Hypothyroidism                                 | 41                             | (13.3)                         | 7                        | (4.5)                    |
| Pruritus                                       | 41                             | (13.3)                         | 19                       | (12.3)                   |
| Dyspnoea                                       | 36                             | (11.7)                         | 26                       | (16.9)                   |
| Dizziness                                      | 32                             | (10.4)                         | 15                       | (9.7)                    |
| Stomatitis                                     | 32                             | (10.4)                         | 9                        | (5.8)                    |
| Pain in extremity                              | 26                             | (8.4)                          | 20                       | (13.0)                   |
| Myalgia                                        | 24                             | (7.8)                          | 17                       | (11.0)                   |

<div style=\"page-break-after: always\"></div>

Table 8 Subjects With Adverse Events by Decreasing Incidence (Incidence ≥ 10% in One or More Treatment Groups) (Part 2 All Subjects-Chemotherapy with Nab-Paclitaxel) (ASaT Population)

|                                                | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Placebo + Chemotherapy   | Placebo + Chemotherapy   |
|------------------------------------------------|--------------------------------|--------------------------------|--------------------------|--------------------------|
|                                                | n                              | (%)                            | n                        | (%)                      |
| Subjects in population with one or more events | 172                            |                                | 95                       |                          |
| adverse                                        | 169                            | (98.3)                         | 93                       | (97.9)                   |
| with no adverse events                         | 3                              | (1.7)                          | 2                        | (2.1)                    |
| Alopecia                                       | 90                             | (52.3)                         | 54                       | (56.8)                   |
| Diarrhoea                                      | 62                             | (36.0)                         | 23                       | (24.2)                   |
| Nausea                                         | 62                             | (36.0)                         | 39                       | (41.1)                   |
| Anaemia                                        | 58                             | (33.7)                         | 31                       | (32.6)                   |
| Neutropenia                                    | 50                             | (29.1)                         | 24                       | (25.3)                   |
| Fatigue                                        | 46                             | (26.7)                         | 32                       | (33.7)                   |
| Decreased appetite                             | 40                             | (23.3)                         | 9                        | (9.5)                    |
| Vomiting                                       | 40                             | (23.3)                         | 18                       | (18.9)                   |
| Asthenia                                       | 39                             | (22.7)                         | 17                       | (17.9)                   |
| Rash                                           | 37                             | (21.5)                         | 14                       | (14.7)                   |
| Cough                                          | 35                             | (20.3)                         | 18                       | (18.9)                   |
| Headache                                       | 33                             | (19.2)                         | 21                       | (22.1)                   |
| Hypothyroidism                                 | 33                             | (19.2)                         | 2                        | (2.1)                    |
| Pruritus                                       | 32                             | (18.6)                         | 11                       | (11.6)                   |
| Constipation                                   | 30                             | (17.4)                         | 21                       | (22.1)                   |
| Arthralgia                                     | 29                             | (16.9)                         | 16                       | (16.8)                   |
| Neuropathy peripheral                          | 27                             | (15.7)                         | 23                       | (24.2)                   |
| Pyrexia                                        | 27                             | (15.7)                         | 17                       | (17.9)                   |
| Alanine aminotransferase increased             | 26                             | (15.1)                         | 11                       | (11.6)                   |
| Aspartate aminotransferase increased           | 25                             | (14.5)                         | 9                        | (9.5)                    |
| Upper respiratory tract infection              | 25                             | (14.5)                         | 13                       | (13.7)                   |
| Oedema peripheral                              | 23                             | (13.4)                         | 14                       | (14.7)                   |
| Myalgia                                        | 22                             | (12.8)                         | 14                       | (14.7)                   |
| Pain in extremity                              | 20                             | (11.6)                         | 18                       | (18.9)                   |
| Neutrophil count decreased                     | 19                             | (11.0)                         | 13                       | (13.7)                   |
| Peripheral sensory neuropathy                  | 19                             | (11.0)                         | 8                        | (8.4)                    |
| Urinary tract infection                        | 19                             | (11.0)                         | 3                        | (3.2)                    |
| Back pain                                      | 18                             | (10.5)                         | 13                       | (13.7)                   |
| Insomnia                                       | 14                             | (8.1)                          | 14                       | (14.7)                   |
| Nasopharyngitis                                | 12                             | (7.0)                          | 10                       | (10.5)                   |

(97.9)

(56.8)

(24.2)

(41.1)

(32.6)

(25.3)

(33.7)

(18.9)

(17.9)

(14.7)

(18.9)

(22.1)

(11.6)

(22.1)

(16.8)

(24.2)

(17.9)

(11.6)

(13.7)

(14.7)

(14.7)

(18.9)

(13.7)

(13.7)

(14.7)

(10.5)

<div style=\"page-break-after: always\"></div>

Table 9 Subjects With Adverse Events by Decreasing Incidence (Incidence ≥ 10% in One or More Treatment Groups) (Part 2 All Subjects-Chemotherapy with Paclitaxel) (ASaT Population)

|                                      | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Placebo + Chemotherapy   | Placebo + Chemotherapy   |
|--------------------------------------|--------------------------------|--------------------------------|--------------------------|--------------------------|
|                                      | n                              | (%)                            | n                        | (%)                      |
| Subjects in population               | 81                             |                                | 32                       |                          |
| with one or more adverse events      | 79                             | (97.5)                         | 30                       | (93.8)                   |
| with no adverse events               | 2                              | (2.5)                          | 2                        | (6.3)                    |
| Alopecia                             | 51                             | (63.0)                         | 20                       | (62.5)                   |
| Anaemia                              | 34                             | (42.0)                         | 5                        | (15.6)                   |
| Diarrhoea                            | 33                             | (40.7)                         | 5                        | (15.6)                   |
| Nausea                               | 25                             | (30.9)                         | 7                        | (21.9)                   |
| Arthralgia                           | 22                             | (27.2)                         | 3                        | (9.4)                    |
| Constipation                         | 22                             | (27.2)                         | 3                        | (9.4)                    |
| Neutropenia                          | 22                             | (27.2)                         | 6                        | (18.8)                   |
| Fatigue                              | 21                             | (25.9)                         | 11                       | (34.4)                   |
| Neuropathy peripheral                | 21                             | (25.9)                         | 7                        | (21.9)                   |
| Aspartate aminotransferase increased | 20                             | (24.7)                         | 3                        | (9.4)                    |
| Alanine aminotransferase increased   | 19                             | (23.5)                         | 5                        | (15.6)                   |
| Asthenia                             | 18                             | (22.2)                         | 2                        | (6.3)                    |
| Leukopenia                           | 18                             | (22.2)                         | 6                        | (18.8)                   |
| Peripheral sensory neuropathy        | 17                             | (21.0)                         | 8                        | (25.0)                   |
| Cough                                | 16                             | (19.8)                         | 2                        | (6.3)                    |
| Decreased appetite                   | 15                             | (18.5)                         | 4                        | (12.5)                   |
| Oedema peripheral                    | 14                             | (17.3)                         | 5                        | (15.6)                   |
| Dysgeusia                            | 13                             | (16.0)                         | 1                        | (3.1)                    |
| Dyspnoea                             | 13                             | (16.0)                         | 3                        | (9.4)                    |
| Hypothyroidism                       | 13                             | (16.0)                         | 0                        | (0.0)                    |
| Pruritus                             | 13                             | (16.0)                         | 2                        | (6.3)                    |
| Pyrexia                              | 13                             | (16.0)                         | 2                        | (6.3)                    |
| White blood cell count decreased     | 13                             | (16.0)                         | 7                        | (21.9)                   |
| Vomiting                             | 12                             | (14.8)                         | 3                        | (9.4)                    |
| Weight decreased                     | 12                             | (14.8)                         | 1                        | (3.1)                    |
| Blood alkaline phosphatase increased | 11                             | (13.6)                         | 3                        | (9.4)                    |
| Myalgia                              | 11                             | (13.6)                         | 3                        | (9.4)                    |
| Rash                                 | 11                             | (13.6)                         | 4                        | (12.5)                   |
| Abdominal pain                       | 10                             | (12.3)                         | 2                        | (6.3)                    |
| Abdominal pain upper                 | 10                             | (12.3)                         | 0                        | (0.0)                    |
| Headache                             | 10                             | (12.3)                         | 3                        | (9.4)                    |
| Pain in extremity                    | 10                             | (12.3)                         | 3                        | (9.4)                    |
| Stomatitis                           | 10                             | (12.3)                         | 3                        | (9.4)                    |
| Nasopharyngitis                      | 9                              | (11.1)                         | 3                        | (9.4)                    |
| Neutrophil count decreased           | 8                              | (9.9)                          | 8                        | (25.0)                   |
| Nail discolouration                  | 3                              | (3.7)                          | 4                        | (12.5)                   |

(93.8)

(62.5)

(15.6)

(15.6)

(21.9)

(18.8)

(34.4)

(21.9)

(15.6)

(18.8)

(25.0)

(12.5)

(15.6)

(21.9)

(12.5)

(25.0)

(12.5)

<div style=\"page-break-after: always\"></div>

## Discontinuation due to adverse events

The overall incidence of drug-related AEs resulting in discontinuation of any study intervention was higher in the pembrolizumab + chemotherapy group (18.6%) compared with the placebo + chemotherapy group (11.0%). The higher incidence of drug-related AEs resulting in discontinuation of study intervention in the pembrolizumab + chemotherapy group were primarily driven by pneumonitis and events that occurred in &lt;1% of participants. Pneumonitis is a known AEOSI for pembrolizumab and the observed incidence of pneumonitis  leading  to  discontinuation  of  any  study  intervention  was  similar  to  the  pembrolizumab monotherapy RSD (1.2% vs 1.5%, respectively). There were no trends observed suggesting a new safety concern for pembrolizumab + chemotherapy.

The overall incidence of drug-related AEs leading to the discontinuation of any study treatment was higher in the pembrolizumab + chemotherapy group (18.6%) compared with the pembrolizumab monotherapy RSD (6.9%).  The  higher  incidence  was  primarily  driven  by  the  following:  neutropenia  (1.7%  vs  0%), increased ALT (2.0% vs 0.3%), increased AST (1.5% vs 0.3%), decreased neutrophil count (1.2% vs 0%), neuropathy peripheral (1.3% vs 0%), and peripheral sensory neuropathy (1.0% vs 0%). These differences were consistent with the established safety profiles of the chemotherapies administered.

## AE summary (Discontinuation due to AEs):

| †                                                                 | KN355 Data for Pembrolizumab + Chemotherapy †   | KN355 Data for Pembrolizumab + Chemotherapy †   | KN355 Data for Placebo + Chemotherapy ¶ ¶   | KN355 Data for Placebo + Chemotherapy ¶ ¶   | mTNBC Safety Dataset for Pembrolizumab Monotherapy ‡‡   | mTNBC Safety Dataset for Pembrolizumab Monotherapy ‡‡   | Reference Safety Dataset for Pembrolizumab Monotherapy §§   | Reference Safety Dataset for Pembrolizumab Monotherapy §§   |
|-------------------------------------------------------------------|-------------------------------------------------|-------------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|
|                                                                   | n                                               | (%)                                             | n                                           | (%)                                         | n                                                       | (%)                                                     | n                                                           | (%)                                                         |
| Subjects in population                                            | 596                                             | 596                                             | 281                                         | 281                                         | 595                                                     | 595                                                     | 5,884                                                       | 5,884                                                       |
| discontinued any drug due to an adverse event                     | 128                                             | (21.5)                                          | 37                                          | (13.2)                                      | 30                                                      | (5.0)                                                   | 783                                                         | (13.3)                                                      |
| discontinued pembrolizumab                                        | 7                                               | (1.2)                                           | 0                                           | (0.0)                                       | 30                                                      | (5.0)                                                   | 783                                                         | (13.3)                                                      |
| discontinued pembrolizumab/placebo                                | 60                                              | (10.1)                                          | 15                                          | (5.3)                                       | 30                                                      | (5.0)                                                   | 783                                                         | (13.3)                                                      |
| discontinued nab-paclitaxel                                       | 26                                              | (4.4)                                           | 4                                           | (1.4)                                       | 0                                                       | (0.0)                                                   | 0                                                           | (0.0)                                                       |
| discontinued paclitaxel                                           | 19                                              | (3.2)                                           | 6                                           | (2.1)                                       | 0                                                       | (0.0)                                                   | 0                                                           | (0.0)                                                       |
| discontinued gemcitabine                                          | 39                                              | (6.5)                                           | 16                                          | (5.7)                                       | 0                                                       | (0.0)                                                   | 0                                                           | (0.0)                                                       |
| discontinued carboplatin                                          | 44                                              | (7.4)                                           | 17                                          | (6.0)                                       | 0                                                       | (0.0)                                                   | 0                                                           | (0.0)                                                       |
| discontinued any drug due to a drug-related adverse event         | 111                                             | (18.6)                                          | 31                                          | (11.0)                                      | 20                                                      | (3.4)                                                   | 405                                                         | (6.9)                                                       |
| discontinued pembrolizumab                                        | 3                                               | (0.5)                                           | 0                                           | (0.0)                                       | 20                                                      | (3.4)                                                   | 405                                                         | (6.9)                                                       |
| discontinued                                                      | 51                                              | (8.6)                                           | 10                                          | (3.6)                                       | 20                                                      | (3.4)                                                   | 405                                                         | (6.9)                                                       |
| discontinued nab-paclitaxel                                       | 22                                              | (3.7)                                           | 3                                           | (1.1)                                       | 0                                                       | (0.0)                                                   | 0                                                           | (0.0)                                                       |
| discontinued paclitaxel                                           | 17                                              | (2.9)                                           | 3                                           | (1.1)                                       | 0                                                       | (0.0)                                                   | 0                                                           | (0.0)                                                       |
| discontinued gemcitabine                                          | 34                                              | (5.7)                                           | 15                                          | (5.3)                                       | 0                                                       | (0.0)                                                   | 0                                                           | (0.0)                                                       |
| discontinued carboplatin                                          | 38                                              | (6.4)                                           | 16                                          | (5.7)                                       | 0                                                       | (0.0)                                                   | 0                                                           | (0.0)                                                       |
| discontinued any drug due                                         | 51                                              | (8.6)                                           | 9                                           | (3.2)                                       | 17                                                      | (2.9)                                                   | 570                                                         | (9.7)                                                       |
| to a serious adverse event discontinued pembrolizumab             | 6                                               | (1.0)                                           | 0                                           | (0.0)                                       | 17                                                      | (2.9)                                                   | 570                                                         | (9.7)                                                       |
| discontinued pembrolizumab/placebo                                | 39                                              | (6.5)                                           | 8                                           | (2.8)                                       | 17                                                      | (2.9)                                                   | 570                                                         | (9.7)                                                       |
| discontinued nab-paclitaxel                                       | 10                                              | (1.7)                                           | 1                                           | (0.4)                                       | 0                                                       | (0.0)                                                   | 0                                                           | (0.0)                                                       |
| discontinued paclitaxel                                           | 5                                               | (0.8)                                           | 4                                           | (1.4)                                       | 0                                                       | (0.0)                                                   | 0                                                           | (0.0)                                                       |
| discontinued gemcitabine                                          | 10                                              | (1.7)                                           | 0                                           | (0.0)                                       | 0                                                       | (0.0)                                                   | 0                                                           | (0.0)                                                       |
| discontinued carboplatin                                          | 9                                               | (1.5)                                           | 1                                           | (0.4)                                       | 0                                                       | (0.0)                                                   | 0                                                           | (0.0)                                                       |
| discontinued any drug due to a serious drug-related adverse event | 40                                              | (6.7)                                           | 4                                           | (1.4)                                       | 10                                                      | (1.7)                                                   | 244                                                         | (4.1)                                                       |

783

(13.3)

783

(13.3)

783

(13.3)

0

(0.0)

0

(0.0)

0

(0.0)

0

(0.0)

(6.9)

405

(6.9)

405

(6.9)

0

(0.0)

0

(0.0)

0

(0.0)

0

(0.0)

570

(9.7)

570

(9.7)

570

(9.7)

0

(0.0)

0

(0.0)

0

(0.0)

0

(0.0)

244

(4.1)

<div style=\"page-break-after: always\"></div>

244

(4.1)

244

(4.1)

0

(0.0)

0

(0.0)

0

(0.0)

0

| discontinued pembrolizumab         | 3 (0.5)   | 0 (0.0)   | 10 (1.7)   | 244 (4.1)   |
|------------------------------------|-----------|-----------|------------|-------------|
| discontinued pembrolizumab/placebo | 32 (5.4)  | 3 (1.1)   | 10 (1.7)   | 244 (4.1)   |
| discontinued nab-paclitaxel        | 6 (1.0)   | 0 (0.0)   | 0 (0.0)    | 0 (0.0)     |
| discontinued paclitaxel            | 4 (0.7)   | 1 (0.4)   | 0 (0.0)    | 0 (0.0)     |
| discontinued gemcitabine           | 7 (1.2)   | 0 (0.0)   | 0 (0.0)    | 0 (0.0)     |
| discontinued carboplatin           | 6 (1.0)   | 1 (0.4)   | 0 (0.0)    | 0 (0.0)     |

(0.0)

## Table: Subjects With Drug-Related Adverse Events Resulting in Any Treatment Discontinuation (Incidence &gt; 0% in One or More Treatment Groups) By Body System or Organ Class and Preferred Term (ASaT Population)

|                                                                               | KN355 Data for Pembrolizmab + Chemotherapylt   | KN355 Data for Pembrolizmab + Chemotherapylt   | KN355 Data for Placebo + Chemotherapyll   | KN355 Data for Placebo + Chemotherapyll   | mINBC Safety Dataset for Pembrolizmab Monotherapytt   | mINBC Safety Dataset for Pembrolizmab Monotherapytt   | Reference Safety Dataset for Pembrolizmab Monotherapy\"   | Reference Safety Dataset for Pembrolizmab Monotherapy\"   |
|-------------------------------------------------------------------------------|------------------------------------------------|------------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|
|                                                                               | n                                              | (%)                                            | n                                         | (%)                                       | n                                                     | (%)                                                   | n                                                        | (%)                                                      |
| Subjects in population with one or more adverse events with no adverse events | 596 111 485                                    | (18.6) (81.4)                                  | 281 31 250                                | (11.0) (89.0)                             | 595 20 575                                            | (3.4) (96.6)                                          | 5,884 405 5,479                                          | (6.9) (93.1)                                             |
| Bloodandlymphaticsystem disorders                                             | 21                                             | (3.5)                                          | 6                                         | (2.1)                                     | 1                                                     | (0.2)                                                 | 7                                                        | (0.1)                                                    |
| Anaemia                                                                       | 4                                              | (0.7)                                          | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 0                                                        | (0.0)                                                    |
| Autoimmumehaemolyticanaemia                                                   | 0                                              | (0.0)                                          | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 1                                                        | (0.0)                                                    |
| Disseminated intravascular coagulation                                        | 0                                              | (0.0)                                          | 0                                         | (0.0)                                     | 1                                                     | (0.2)                                                 | 1                                                        | (0.0)                                                    |
| Haemolytic anaemia                                                            | 0                                              | (0.0)                                          | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 1                                                        | (0.0)                                                    |
| Immue thrombocytopenic puupura                                                | 0                                              | (0.0)                                          | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 1                                                        | (0.0)                                                    |
| Leukopenia                                                                    |                                                | (0.3)                                          | 1                                         | (0.4)                                     | 0                                                     | (0.0)                                                 | 0                                                        | (0.0)                                                    |
| Neutropenia                                                                   | 10                                             | (1.7)                                          | 1                                         | (0.4)                                     | 0                                                     | (0.0)                                                 | 1                                                        | (0.0)                                                    |
| Thrombocytopenia                                                              | 5                                              | (0.8)                                          | 4                                         | (1.4)                                     | 0                                                     | (0.0)                                                 |                                                          | (0.0)                                                    |
| Thrombotic microangiopathy                                                    | 1                                              | (0.2)                                          | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 0                                                        | (0.0)                                                    |
| Cardiac disorders                                                             | 1                                              | (0.2)                                          | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 11                                                       | (0.2)                                                    |
| Atial fibrillation                                                            | 0                                              | (0.0)                                          | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 1                                                        | (0.0)                                                    |
| Atioventricular block complete                                                | 0                                              | (0.0)                                          | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 1                                                        | (0.0)                                                    |
| Autoimmune pericarditis                                                       | 0                                              | (0.0)                                          | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 1                                                        | (0.0)                                                    |
| Cardiac disorder                                                              | 0                                              | (0.0)                                          | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 1                                                        | (0.0)                                                    |
| Cardio-respiratory alrest                                                     | 0                                              | (0.0)                                          | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 |                                                          | (0.0)                                                    |
| Myocarditis                                                                   | 1                                              | (0.2)                                          | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 4                                                        | (0.1)                                                    |
| Pericardial effusion                                                          | 0                                              | (0.0)                                          | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 1                                                        | (0.0)                                                    |
| Prosthetic cardiac valve thrombosis                                           | 0                                              | (0.0)                                          | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 |                                                          | (0.0)                                                    |
| Endocrine disorders                                                           | 2                                              | (0.3)                                          | 0                                         | (0.0)                                     | 1                                                     | (0.2)                                                 | 17                                                       | (0.3)                                                    |
| Addison's disease                                                             | 0                                              | (0.0)                                          | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 1                                                        | (0.0)                                                    |
| Adrenal insufficiency                                                         | 1                                              | (0.2)                                          | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 4                                                        | (0.1)                                                    |
| Hyperthyroidism                                                               | 0                                              | (0.0)                                          | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 3                                                        | (0.1)                                                    |
| Hypophysitis                                                                  | 0                                              | (0.0)                                          | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 4                                                        | (0.1)                                                    |
| Hypopituitarism                                                               | 0                                              | (0.0)                                          | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 4                                                        | (0.1)                                                    |
| Hypothyroidism                                                                | 1                                              | (0.2)                                          | 0                                         | (0.0)                                     | 1                                                     | (0.2)                                                 |                                                          | (0.0)                                                    |
| Eye disorders                                                                 | 1                                              | (0.2)                                          | 0                                         | (0.0)                                     | 0                                                     | (0.0)                                                 | 3                                                        | (0.1)                                                    |
| Cystoid macular oedema                                                        | 1                                              | (0.2)                                          | 0                                         |                                           |                                                       | (0.0)                                                 | 0                                                        |                                                          |
| Inidocyclitis                                                                 | 0                                              | (0.0)                                          | 0                                         | (0.0) (0.0)                               | 0 0                                                   | (0.0) (0.0)                                           | 1                                                        | (0.0) (0.0)                                              |
| Uveitis                                                                       | 0                                              | (0.0)                                          | 0                                         | (0.0)                                     | 0                                                     |                                                       | 2                                                        | (0.0)                                                    |
|                                                                               |                                                |                                                | 0                                         | (0.0)                                     |                                                       | (0.2)                                                 |                                                          | (1.0)                                                    |
| Gastrointestinal disorders                                                    |                                                | (0.8)                                          |                                           |                                           | 1                                                     |                                                       | 58                                                       |                                                          |

<div style=\"page-break-after: always\"></div>

|                                                          | KN355 Data for Pembrolizmab+ Chemotherapylt   | KN355Data for Placebo + Chemotherapyll   | mTNBC Safety Dataset for Pembrolizmab Monotherapyit   | Reference Safety Dataset for Pembrolizmab Monotherapyis   |
|----------------------------------------------------------|-----------------------------------------------|------------------------------------------|-------------------------------------------------------|-----------------------------------------------------------|
|                                                          | n (%)                                         | n (%)                                    | n (%)                                                 | n (%)                                                     |
| Gastrointestinal disorders                               | 5 (0.8)                                       | 0 (0.0)                                  | 1 (0.2)                                               | 58 (1.0)                                                  |
| Aptyalism                                                | 0 (0.0)                                       | 0 (0.0)                                  | 0 (0.0)                                               | 1 (0.0)                                                   |
| Autoimmume pancreatitis                                  | 0 (0.0)                                       | 0 (0.0)                                  | 0 (0.0)                                               | 1 (0.0)                                                   |
| Cheilitis                                                | 1 (0.2)                                       | 0 (0.0)                                  | 0 (0.0)                                               | 0 (0.0)                                                   |
| Colitis                                                  | 1 (0.2)                                       | 0 (0.0)                                  | 0 (0.0)                                               | 27 (0.5)                                                  |
| Colitismicroscopic                                       | 0 (0.0)                                       | 0 (0.0)                                  | 0 (0.0)                                               | 1 (0.0)                                                   |
| Dianhoea                                                 | 1 (0.2)                                       | 0 (0.0)                                  | 1 (0.2)                                               | 11 (0.2)                                                  |
| Enteritis                                                | 0 (0.0)                                       | 0 (0.0)                                  | 0 (0.0)                                               | 1 (0.0)                                                   |
| Enterocolitis                                            | 0 (0.0)                                       | 0 (0.0)                                  | 0 (0.0)                                               | 2 (0.0)                                                   |
| Gastitis                                                 | 0 (0.0)                                       | 0 (0.0)                                  | 0 (0.0)                                               | 2 (0.0)                                                   |
| Impaired gastric emptying                                | 0 (0.0)                                       | 0 (0.0)                                  | 0 (0.0)                                               | 1 (0.0)                                                   |
| Large intestine perforation                              | 0 (0.0)                                       | 0 (0.0)                                  | 0 (0.0)                                               | (0.0)                                                     |
| Oesophageal fistula                                      | 0 (0.0)                                       | 0 (0.0)                                  | 0 (0.0)                                               | 1 (0.0)                                                   |
| Oesophagitis                                             | 0 (0.0)                                       | 0 (0.0)                                  | 0 (0.0)                                               | 1 (0.0)                                                   |
| Oral lichen planus                                       | 0 (0.0)                                       | 0 (0.0)                                  | 0 (0.0)                                               | 1 (0.0)                                                   |
| Pancreatitis                                             | 1 (0.2)                                       | 0 (0.0)                                  | 0 (0.0)                                               | 3 (0.1)                                                   |
| Salivary gland disorder                                  | 0 (0.0)                                       | 0 (0.0)                                  | 0 (0.0)                                               | 1 (0.0)                                                   |
| Small intestinal perforation                             | 0 (0.0)                                       | 0 (0.0)                                  | 0 (0.0)                                               | (0.0)                                                     |
| Stomatitis                                               | 0 (0.0)                                       | 0 (0.0)                                  | 0 (0.0)                                               | 1 (0.0)                                                   |
| Vomiting                                                 | 1 (0.2)                                       | 0 (0.0)                                  | 0 (0.0)                                               | 1 (0.0)                                                   |
| Generaldisorders andadministration site conditions       | 5 (0.8)                                       | 2 (0.7)                                  | 1 (0.2)                                               | 27 (0.5)                                                  |
| Asthenia                                                 | 0 (0.0)                                       | 1 (0.4)                                  | 0 (0.0)                                               | 0 (0.0)                                                   |
| Death                                                    | 0 (0.0)                                       | 0 (0.0)                                  | 0 (0.0)                                               | 3 (0.1)                                                   |
| Fatigue                                                  | 2 (0.3)                                       | 1 (0.4)                                  | 0 (0.0)                                               | 11 (0.2)                                                  |
| General physical health deterioration                    | 0 (0.0)                                       | 0 (0.0)                                  | 1 (0.2)                                               | 0 (0.0)                                                   |
| Generalised oedema                                       | 0 (0.0)                                       | 0 (0.0)                                  | 0 (0.0)                                               | 3 (0.1)                                                   |
| Malaise                                                  | 0 (0.0)                                       | 0 (0.0)                                  | 0 (0.0)                                               | (0.0)                                                     |
| Mucosal inflammation                                     | 1 (0.2)                                       | 0 (0.0)                                  | 0 (0.0)                                               | 1 (0.0)                                                   |
| Oedema                                                   | 0 (0.0)                                       | 0 (0.0)                                  | 0 (0.0)                                               | 2 (0.0)                                                   |
| Oedema penipheral                                        | 1 (0.2)                                       | 1 (0.4)                                  | 0 (0.0)                                               | 0 (0.0)                                                   |
| Papillitis                                               | 0 (0.0)                                       | 0 (0.0)                                  | 0 (0.0)                                               | 1 (0.0)                                                   |
|                                                          | 1                                             | 0                                        | 0                                                     |                                                           |
| Pyrexia                                                  | (0.2)                                         | (0.0)                                    | (0.0)                                                 | 0 (0.0)                                                   |
| Sudden death Swellingface Systemic inflammatory response | 0 (0.0) 0 (0.0) 0 (0.0)                       | 0 (0.0) 0 (0.0) 0 (0.0)                  | 0 (0.0) 0 (0.0) 0 (0.0)                               | (0.0) 2 (0.0) 1 (0.0)                                     |

|                                              | KN355 Data for Pembrolizmab + Chemotherapylt   | KN355 Data for Placebo+ Chemotherapyll   | mINBC Safety Dataset for Pembrolizumab Monotherapyit   | Reference Safety Dataset for Pembrolizmab Monotherapy   |
|----------------------------------------------|------------------------------------------------|------------------------------------------|--------------------------------------------------------|---------------------------------------------------------|
|                                              | n (%)                                          | n (%)                                    | n (%)                                                  | n (%)                                                   |
| Hepatobiliarydisorders                       | 7 (1.2)                                        | 0 (0.0)                                  | 1 (0.2)                                                | 25 (0.4)                                                |
| Autoimmume hepatitis                         | 1 (0.2)                                        | 0 (0.0)                                  | 0 (0.0)                                                | 11 (0.2)                                                |
| Cholangitis                                  | 0 (0.0)                                        | 0 (0.0)                                  | 0 (0.0)                                                | 1 (0.0)                                                 |
| Dug-induced liver injuy                      | 0 (0.0)                                        | 0 (0.0)                                  | 0 (0.0)                                                | 1 (0.0)                                                 |
| Hepatic fimction abnormal                    | 3 (0.5)                                        | 0 (0.0)                                  | 0 (0.0)                                                | 1 (0.0)                                                 |
| Hepatitis                                    | 2 (0.3)                                        | 0 (0.0)                                  | 0 (0.0)                                                | 7 (0.1)                                                 |
| Hepatitis toxic                              | 0 (0.0)                                        | 0 (0.0)                                  | 0 (0.0)                                                | 1 (0.0)                                                 |
| Hyperbilirubinaemia                          | 0 (0.0)                                        | 0 (0.0)                                  | 0 (0.0)                                                | 1 (0.0)                                                 |
| Immue-mediated hepatitis                     | 0 (0.0)                                        | 0 (0.0)                                  | 0 (0.0)                                                | 1 (0.0)                                                 |
| Liver disorder                               | 1 (0.2)                                        | 0 (0.0)                                  | 1 (0.2)                                                | 0 (0.0)                                                 |
| Liver injuy                                  | 0 (0.0)                                        | 0 (0.0)                                  | 0 (0.0)                                                | 1 (0.0)                                                 |
| Immune system disorders                      | 4 (0.7)                                        | 2 (0.7)                                  | 0 (0.0)                                                | 9 (0.2)                                                 |
| Anaphylactoidreaction                        | 0 (0.0)                                        | 0 (0.0)                                  | 0 (0.0)                                                | 1 (0.0)                                                 |
| Autoimmume disorder                          | 0 (0.0)                                        | 0 (0.0)                                  | 0 (0.0)                                                | 1 (0.0)                                                 |
| Autoinflammatorydisease                      | 0 (0.0)                                        | 0 (0.0)                                  | 0 (0.0)                                                | 1 (0.0)                                                 |
| Cytokine release syndrome                    | 0 (0.0)                                        | 0 (0.0)                                  | 0 (0.0)                                                | 1 (0.0)                                                 |
| Drug hypersensitivity                        | 2 (0.3)                                        | 0 (0.0)                                  | 0 (0.0)                                                | 1 (0.0)                                                 |
| Hypersensitivity                             | 2 (0.3)                                        | 2 (0.7)                                  | 0 (0.0)                                                | 0 (0.0)                                                 |
| Sarcoidosis                                  | 0 (0.0)                                        | 0 (0.0)                                  | 0 (0.0)                                                | 3 (0.1)                                                 |
| Serm sickness                                | 0 (0.0)                                        | 0 (0.0)                                  | 0 (0.0)                                                | (0.0)                                                   |
| Infections and infestations                  | 3 (0.5)                                        | 0 (0.0)                                  | 0 (0.0)                                                | 6 (0.1)                                                 |
| Bronchitis                                   | 0 (0.0)                                        | 0 (0.0)                                  | 0 (0.0)                                                | 1 (0.0)                                                 |
| Device related sepsis                        | 1 (0.2)                                        | 0 (0.0)                                  | 0 (0.0)                                                | 0 (0.0)                                                 |
| Encephalitis                                 | 0 (0.0)                                        | 0 (0.0)                                  | 0 (0.0)                                                | 1 (0.0)                                                 |
| Myelitis                                     | 0 (0.0)                                        | 0 (0.0)                                  | 0 (0.0)                                                | 1 (0.0)                                                 |
| Paronychia                                   | 1 (0.2)                                        | 0 (0.0)                                  | 0 (0.0)                                                | 0 (0.0)                                                 |
| Pneumonia                                    | 1 (0.2)                                        | 0 (0.0)                                  | 0 (0.0)                                                | (0.0)                                                   |
| Pneumonia klebsiella                         | 0 (0.0)                                        | 0 (0.0)                                  | 0 (0.0)                                                | 1 (0.0)                                                 |
| Injuy,poisoning and procedural complications | 3 (0.5)                                        | 2 (0.7)                                  | 0 (0.0)                                                | 3 (0.1)                                                 |
| Alcohol poisoning                            | 1 (0.2)                                        | 0                                        | 0 (0.0)                                                | 0 (0.0)                                                 |
| Infusion related reaction                    | 2 (0.3)                                        | (0.0) 1 (0.4)                            | 0 (0.0)                                                | 2 (0.0)                                                 |
| Pneumonitis chemical                         | 0 (0.0)                                        | 0 (0.0)                                  | 0 (0.0)                                                | 1 (0.0)                                                 |
| Recall phenomenon                            | 0 (0.0)                                        | 1 (0.4)                                  | 0 (0.0)                                                | 0 (0.0)                                                 |
| Investigations                               | 27 (4.5)                                       | 11 (3.9)                                 | 5 (0.8)                                                | 41 (0.7)                                                |

<div style=\"page-break-after: always\"></div>

|                                                 | KN355 Data for Pembrolizmab+ Chemotherapylt   | KN355 Data for Placebo + Chemotherapyll   | mINBC Safety Dataset for Pembrolizumab Monotherapyit   | Reference Safety Dataset for Pembrolizmab Monotherapy   | Reference Safety Dataset for Pembrolizmab Monotherapy   |
|-------------------------------------------------|-----------------------------------------------|-------------------------------------------|--------------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|
|                                                 | n (%)                                         | n (%)                                     | n (%)                                                  | n                                                       | (%)                                                     |
| Investigations                                  | 27 (4.5)                                      | 11 (3.9)                                  | 5 (0.8)                                                | 41                                                      | (0.7)                                                   |
| Alanine aminotransferase increased              | 12 (2.0)                                      | 4 (1.4)                                   | 4 (0.7)                                                | 18                                                      | (0.3)                                                   |
| Aspartate aminotransferase increased            | 9 (S1)                                        | 2 (0.7)                                   | 4 (0.7)                                                | 16                                                      | (0.3)                                                   |
| Bilirubin conjugated increased                  | 1 (0.2)                                       | 0 (0.0)                                   | 0 (0.0)                                                | 0                                                       | (0.0)                                                   |
| Blood akaline phosphatase increased             | 1 (0.2)                                       | 0 (0.0)                                   | 0 (0.0)                                                |                                                         | 2 (0.0)                                                 |
| Blood bilirubin increased                       | 1 (0.2)                                       | 0 (0.0)                                   | 0 (0.0)                                                |                                                         | 3 (0.1)                                                 |
| Blood creatine increased                        | 1 (0.2)                                       | 0 (0.0)                                   | 0                                                      | (0.0)                                                   | 0 (0.0)                                                 |
| Blood creatine phosphokinase increased          | 0 (0.0)                                       | 0 (0.0)                                   | 0                                                      | (0.0)                                                   | 1 (0.0)                                                 |
| Blood creatinine increased                      | 1 (0.2)                                       | 2 (0.7)                                   | 0                                                      | (0.0)                                                   | 1 (0.0)                                                 |
| Blood lactate dehydrogenase increased           | 1 (0.2)                                       | 0 (0.0)                                   | 1                                                      | (0.2)                                                   | 0 (0.0)                                                 |
| Blood uric acidincreased                        | 0 (0.0)                                       | 0 (0.0)                                   | 0                                                      | (0.0)                                                   | 1 (0.0)                                                 |
| Gamma-glutamyltransferase increased             | 0 (0.0)                                       | 0 (0.0)                                   | 0                                                      | (0.0)                                                   | 3 (0.1)                                                 |
| Intraocular pressure decreased                  | 0 (0.0)                                       | 0 (0.0)                                   | 0                                                      | (0.0)                                                   | 1 (0.0)                                                 |
| Lipase increased                                | 0 (0.0)                                       | 0 (0.0)                                   | 0                                                      | (0.0)                                                   | 2 (0.0)                                                 |
| Liver fiuction test abnormal                    | 1 (0.2)                                       | 0 (0.0)                                   | 0                                                      | (0.0)                                                   | 0 (0.0)                                                 |
| Liver fuction test increased                    | 0 (0.0)                                       | 0 (0.0)                                   | 0                                                      | (0.0)                                                   | (0.0)                                                   |
| Neutrophil count decreased                      | 7 (1.2)                                       | 3 (1.1)                                   | 0                                                      | (0.0)                                                   | 1 (0.0)                                                 |
| Platelet count decreased                        | S (0.8)                                       | 1 (0.4)                                   | 0                                                      | (0.0)                                                   | 0 (0.0)                                                 |
| Transaminases increased                         | 0 (0.0)                                       | 0 (0.0)                                   | 0                                                      | (0.0)                                                   | 2 (0.0)                                                 |
| Weight decreased                                | 0 (0.0)                                       | 0 (0.0)                                   | 0                                                      | (0.0)                                                   | 2 (0.0)                                                 |
| Metabolismandnutritiondisorders                 | 1 (0.2)                                       | 0 (0.0)                                   | 0                                                      | (0.0)                                                   | 12 (0.2)                                                |
| Decreased appetite                              | 0 (0.0)                                       | 0 (0.0)                                   | 0                                                      | (0.0)                                                   | 2 (0.0)                                                 |
| Diabetes mellitus                               | 0 (0.0)                                       | 0 (0.0)                                   | 0                                                      | (0.0)                                                   | 1 (0.0)                                                 |
| Diabetic ketoacidosis                           | 0 (0.0)                                       | 0 (0.0)                                   | 0                                                      | (0.0)                                                   | 2 (0.0)                                                 |
| Hyponatraemia                                   | 0 (0.0)                                       | 0 (0.0)                                   | 0                                                      | (0.0)                                                   | 2 (0.0)                                                 |
| Insulin resistant diabetes                      | 0 (0.0)                                       | 0 (0.0)                                   | 0                                                      | (0.0)                                                   | 1 (0.0)                                                 |
| Type 1 diabetes mellitus                        | 1 (0.2)                                       | 0 (0.0)                                   | 0                                                      | (0.0)                                                   | 4 (0.1)                                                 |
| Musculoskeletal and connective tissue disorders | 4 (0.7)                                       | 1 (0.4)                                   | 3                                                      | (0.5) 25                                                | (0.4)                                                   |
| Arthralgia                                      | 1 (0.2)                                       | 0 (0.0)                                   | 2                                                      | (0.3)                                                   | 6 (0.1)                                                 |
| Arthritis                                       | 0 (0.0)                                       | 0 (0.0)                                   | 0 (0.0)                                                | 2                                                       | (0.0)                                                   |
| Joint stiffhess Muscle necrosis                 | 0 (0.0) 0 (0.0)                               | 0 (0.0)                                   | 0                                                      | (0.0)                                                   | 1 (0.0) 1                                               |
|                                                 | 1 (0.2)                                       | (0.0) 0 (0.0)                             | 0                                                      | (0.0)                                                   | (0.0)                                                   |
| Musculoskeletal pain                            |                                               | 0                                         | 0                                                      | (0.0)                                                   | (0.0) 0                                                 |
| Myalgia                                         | 1 (0.2)                                       | 0 (0.0)                                   | 0                                                      | (0.0)                                                   | 1 (0.0)                                                 |
| Myopathy                                        | 0 (0.0)                                       | 0 (0.0)                                   | 0                                                      | (0.0)                                                   | 1 (0.0)                                                 |

|                                                                   | KN355 Data for Pembrolizumab + Chemotherapylt   | KN355 Data for Placebo + Chemotherapyll   | mINBC Safety Dataset for Pembrolizmab Monotherapyit   | mINBC Safety Dataset for Pembrolizmab Monotherapyit   | Reference Safety Dataset for Pembrolizmab Monotherapy$   | Reference Safety Dataset for Pembrolizmab Monotherapy$   |
|-------------------------------------------------------------------|-------------------------------------------------|-------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|
|                                                                   | n (%)                                           | n (%)                                     | n                                                     | (%)                                                   | n                                                        | (%)                                                      |
| Musculoskeletalandconnective tissue disorders                     | (0.7)                                           | 1 (0.4)                                   | 3                                                     | (0.5)                                                 | 25                                                       | (0.4)                                                    |
| Myositis                                                          | 0 (0.0)                                         | 0 (0.0)                                   | 0                                                     | (0.0)                                                 | 6                                                        | (0.1)                                                    |
| Polyarthritis                                                     | 1 (0.2)                                         | 0 (0.0)                                   | 0                                                     | (0.0)                                                 | 2                                                        | (0.0)                                                    |
| Polymyalgia theumatica                                            | 0 (0.0)                                         | 0 (0.0)                                   | 0                                                     | (0.0)                                                 | 1                                                        | (0.0)                                                    |
| Rhabdomyolysis                                                    | 0 (0.0)                                         | 0 (0.0)                                   | 0                                                     | (0.0)                                                 | 1                                                        | (0.0)                                                    |
| Rheumatoid arthritis                                              | 0 (0.0)                                         | 0 (0.0)                                   | 1                                                     | (0.2)                                                 | 1                                                        | (0.0)                                                    |
| Sclerodema                                                        | 0 (0.0)                                         | 1 (0.4)                                   | 0                                                     | (0.0)                                                 | 0                                                        | (0.0)                                                    |
| Sjogren's syndrome                                                | 0 (0.0)                                         | 0                                         | 0                                                     |                                                       | 1                                                        | (0.0)                                                    |
| Soft tissue haemonhage                                            | 0 (0.0)                                         | (0.0) 0 (0.0)                             | 0                                                     | (0.0) (0.0)                                           | 1                                                        | (0.0)                                                    |
| Tenosynovitis                                                     | 0 (0.0)                                         | 0 (0.0)                                   | 0                                                     | (0.0)                                                 | 1                                                        | (0.0)                                                    |
| Neoplasms benign, malignant and uspecifed (incl cysts and polyps) | 0 (0.0)                                         | 1 (0.4)                                   | 0                                                     | (0.0)                                                 | 6                                                        | (0.1)                                                    |
| Haemangioma                                                       | 0 (0.0)                                         | (0.4)                                     | 0                                                     | (0.0)                                                 | 0                                                        | (0.0)                                                    |
| Infected neoplasm                                                 | 0 (0.0)                                         | 0 (0.0)                                   | 0                                                     | (0.0)                                                 | 1                                                        | (0.0)                                                    |
| Malignant neoplasm progression                                    | 0 (0.0)                                         | 0 (0.0)                                   | 0                                                     | (0.0)                                                 | 5                                                        | (0.1)                                                    |
| Nervoussystem disorders                                           | 22 (3.7)                                        | 7 (2.5)                                   | 0                                                     | (0.0)                                                 | 19                                                       | (0.3)                                                    |
| Ataxia                                                            | 0 (0.0)                                         | 0 (0.0)                                   | 0                                                     | (0.0)                                                 | 1                                                        | (0.0)                                                    |
| Autoimmume neuropathy                                             | 0 (0.0)                                         | 0                                         | 0                                                     | (0.0)                                                 | 1                                                        | (0.0)                                                    |
| Cerebrovascular accident                                          | 0 (0.0)                                         | (0.0) 0 (0.0)                             | 0                                                     | (0.0)                                                 | 1                                                        | (0.0)                                                    |
| Chronic inflammatory demyelinating polyradiculoneuropathy         | 0 (0.0)                                         | (0.4)                                     | 0                                                     | (0.0)                                                 | 0                                                        | (0.0)                                                    |
| Cognitive disorder                                                | 0 (0.0)                                         | 0 (0.0)                                   | 0                                                     | (0.0)                                                 | 1                                                        | (0.0)                                                    |
| Demyelinating polymeuropathy                                      | 0 (0.0)                                         | 0 (0.0)                                   | 0                                                     | (0.0)                                                 |                                                          | (0.0)                                                    |
| Encephalopathy                                                    | 0 (0.0)                                         | 0 (0.0)                                   | 0                                                     | (0.0)                                                 | 2                                                        | (0.0)                                                    |
| Epilepsy                                                          | 0 (0.0)                                         | 0 (0.0)                                   | 0                                                     | (0.0)                                                 | 1                                                        | (0.0)                                                    |
| Guillain-Bare syndrome                                            | 1 (0.2)                                         | 0 (0.0)                                   | 0                                                     | (0.0)                                                 | 1                                                        | (0.0)                                                    |
| Lethargy                                                          | 1 (0.2)                                         | 0 (0.0)                                   | 0                                                     | (0.0)                                                 | 0                                                        | (0.0)                                                    |
| Myasthenia gravis                                                 | 0 (0.0)                                         | 0 (0.0)                                   | 0                                                     | (0.0)                                                 |                                                          | (0.0)                                                    |
| Myelitis transverse                                               | 0 (0.0)                                         | 0 (0.0)                                   | 0                                                     | (0.0)                                                 | 1                                                        | (0.0)                                                    |
| Neuralgia                                                         | 0 (0.0)                                         | 0 (0.0)                                   | 0                                                     | (0.0)                                                 | 1                                                        | (0.0)                                                    |
| Neuropathy peripheral                                             | 8 (1.3)                                         | 3                                         | (1.1) 0                                               | (0.0)                                                 | 0                                                        | (0.0)                                                    |
| Neurotoxicity                                                     | (0.3)                                           | 1                                         | 0                                                     | (0.0)                                                 | 0                                                        | (0.0)                                                    |
| Optic neuritis                                                    | 0 (0.0)                                         | (0.4) 0 (0.0)                             | 0                                                     | (0.0)                                                 | 1                                                        | (0.0)                                                    |
| Paraesthesia                                                      | 1 (0.2)                                         | 0 (0.0)                                   | 0                                                     | (0.0)                                                 | 0                                                        | (0.0)                                                    |
| Partial seizures                                                  | 0 (0.0)                                         | 0 (0.0)                                   | 0                                                     | (0.0)                                                 | 1                                                        | (0.0)                                                    |
| Peripheral motor neuropathy                                       | 1 (0.2)                                         | 0                                         | (0.0) 0                                               | (0.0)                                                 | 0                                                        | (0.0)                                                    |

<div style=\"page-break-after: always\"></div>

|                                                 | KN355 Data for Pembrolizmab + Chemotherapyl!   | KN355 Data for Placebo + Chemotherapyll   | mTNBC Safety Dataset for Pembrolizmab Monotherapyit   | Reference Safety Dataset for Pembrolizmab Monotherapy$   |
|-------------------------------------------------|------------------------------------------------|-------------------------------------------|-------------------------------------------------------|----------------------------------------------------------|
|                                                 | n (%)                                          | n (%)                                     | n (%)                                                 | n (%)                                                    |
| Nervoussystemdisorders                          | 22 (3.7)                                       | 7 (2.5)                                   | 0 (0.0)                                               | 19 (0.3)                                                 |
| Peripheral sensory neuropathy                   | 6 (1.0)                                        | 2 (0.7)                                   | 0 (0.0)                                               | 2 (0.0)                                                  |
| Polymeuropathy                                  | 2 (0.3)                                        | 0 (0.0)                                   | 0 (0.0)                                               | 1 (0.0)                                                  |
| Seizure                                         | 0 (0.0)                                        | 0 (0.0)                                   | 0 (0.0)                                               | 2 (0.0)                                                  |
| Toxic leukoencephalopathy                       | 0 (0.0)                                        | 0 (0.0)                                   | 0 (0.0)                                               | (0.0)                                                    |
| Psychiatric disorders                           | 0 (0.0)                                        | 0 (0.0)                                   | 0 (0.0)                                               | 1 (0.0)                                                  |
| Disorientation                                  | 0 (0.0)                                        | 0 (0.0)                                   | 0 (0.0)                                               | 1 (0.0)                                                  |
| Renalandurinarydisorders                        | 2 (0.3)                                        | 0 (0.0)                                   | 0 (0.0)                                               | 16 (0.3)                                                 |
| Acute kidney injuy                              | 0 (0.0)                                        | 0 (0.0)                                   | 0 (0.0)                                               | 5 (0.1)                                                  |
| Autoimmume nephritis                            | 0 (0.0)                                        | 0 (0.0)                                   | 0 (0.0)                                               | (0.0)                                                    |
| Glomerulonephritis membranous                   | 0 (0.0)                                        | 0 (0.0)                                   | 0 (0.0)                                               | (0.0)                                                    |
| Nephritis                                       | 1 (0.2)                                        | 0 (0.0)                                   | 0 (0.0)                                               | (0.0)                                                    |
| Nephrotic syndrome                              | 0 (0.0)                                        | 0 (0.0)                                   | 0 (0.0)                                               | (0.0)                                                    |
| Renal failure                                   | 1 (0.2)                                        | 0 (0.0)                                   | 0 (0.0)                                               | 2 (0.0)                                                  |
| Tubulointerstitial nephritis                    | 0 (0.0)                                        | 0 (0.0)                                   | 0 (0.0)                                               | 4 (0.1)                                                  |
| Urinary tract obstuction                        | 0 (0.0)                                        | 0 (0.0)                                   | 0 (0.0)                                               | (0.0)                                                    |
| Reproductive system and breast disorders        | 1 (0.2)                                        | 0 (0.0)                                   | 0 (0.0)                                               | 0 (0.0)                                                  |
| Pelvic pain                                     | 1 (0.2)                                        | 0 (0.0)                                   | 0 (0.0)                                               | 0 (0.0)                                                  |
| Respiratory, thoracic and mediastinal disorders | 9 (1.5)                                        | 0 (0.0)                                   | 6 (1.0)                                               | 106 (1.8)                                                |
| Cough                                           | 0 (0.0)                                        | 0 (0.0)                                   | 0 (0.0)                                               | 1 (0.0)                                                  |
| Dyspnoea                                        | (0.2)                                          | 0 (0.0)                                   | 0 (0.0)                                               | 1 (0.0)                                                  |
| Hypoxia                                         | 0 (0.0)                                        | 0 (0.0)                                   | 0 (0.0)                                               | 1 (0.0)                                                  |
| Interstitial lug disease                        | 0 (0.0)                                        | 0 (0.0)                                   | (0.2)                                                 | 8 (0.1)                                                  |
| Organising pneumonia                            | 0 (0.0)                                        | 0 (0.0)                                   | (0.2)                                                 | 0 (0.0)                                                  |
| Pleural effusion                                | 0 (0.0)                                        | 0 (0.0)                                   | 0 (0.0)                                               | 2 (0.0)                                                  |
| Pneumonitis                                     | 7 (71)                                         | 0 (0.0)                                   | 4 (0.7)                                               | 16 (1.5)                                                 |
| Pulmonary embolism                              | 1 (0.2)                                        | 0 (0.0)                                   | 0 (0.0)                                               | 3 (0.1)                                                  |
| Respiratory failure                             | 0 (0.0)                                        | 0 (0.0)                                   | 0 (0.0)                                               | 1 (0.0)                                                  |
| Skinandsubcutaneoustissuedisorders              | 3 (0.5)                                        | 0 (0.0)                                   | 1 (0.2)                                               | 25 (0.4)                                                 |
| Dermatitis allergic                             | 1 (0.2)                                        | 0 (0.0)                                   | 0 (0.0)                                               | 1 (0.0)                                                  |
| Erythema multifome                              | 0 (0.0)                                        | 0 (0.0)                                   | 0 (0.0)                                               | (0.0)                                                    |

|                                             | KN355Data for Pembrolizmab+ Chemotherapylt   | KN355 Data for Placebo+ Chemotherapyll   | mINBC Safety Dataset for Pembrolizmab Monotherapyit   | Reference Safety Dataset for Pembrolizmab Monotherapy\"$   |
|---------------------------------------------|----------------------------------------------|------------------------------------------|-------------------------------------------------------|-----------------------------------------------------------|
|                                             | n (%)                                        | n (%)                                    | n (%)                                                 | n (%)                                                     |
| Skinandsubcutaneoustissuedisorders          | 3 (0.5)                                      | 0 (0.0)                                  | 1 (0.2)                                               | 25 (0.4)                                                  |
| Hyperkeratosis                              | 0 (0.0)                                      | 0 (0.0)                                  | 0 (0.0)                                               | 1 (0.0)                                                   |
| Lichen planus                               | 0 (0.0)                                      | 0 (0.0)                                  | 0 (0.0)                                               | 1 (0.0)                                                   |
| Palmar-plantar erythrodysaesthesia syndrome | 1 (0.2)                                      | 0 (0.0)                                  | 1 (0.2)                                               | 1 (0.0)                                                   |
| Pemphigus                                   | 0 (0.0)                                      | 0 (0.0)                                  | 0 (0.0)                                               | 1 (0.0)                                                   |
| Pnuitus                                     | 0 (0.0)                                      | 0 (0.0)                                  | 0 (0.0)                                               | 5 (0.1)                                                   |
| Psoriasis                                   | 0 (0.0)                                      | 0 (0.0)                                  | 0 (0.0)                                               | 2 (0.0)                                                   |
| Rash                                        | 0 (0.0)                                      | 0 (0.0)                                  | 0 (0.0)                                               | 6 (0.1)                                                   |
| Rash maculo-papular                         | 1 (0.2)                                      | 0 (0.0)                                  | 0 (0.0)                                               | 1 (0.0)                                                   |
| Sebonhoeicdermatitis                        | 0 (0.0)                                      | 0 (0.0)                                  | 0 (0.0)                                               | 1 (0.0)                                                   |
| Skin ulcer                                  | 0 (0.0)                                      | 0 (0.0)                                  | 0 (0.0)                                               | 1 (0.0)                                                   |
| Stevens-Johnson syndrome                    | 0 (0.0)                                      | 0 (0.0)                                  | 0 (0.0)                                               | 3 (0.1)                                                   |
| Viiligo                                     | 0 (0.0)                                      | 0 (0.0)                                  | 0 (0.0)                                               | 1 (0.0)                                                   |
| Vascular disorders                          | 3 (0.5)                                      | 0 (0.0)                                  | 0 (0.0)                                               | 3 (0.1)                                                   |
| Arterial thrombosis                         | 0 (0.0)                                      | 0 (0.0)                                  | 0 (0.0)                                               | 1 (0.0)                                                   |
| Hypertension                                | 1 (0.2)                                      | 0 (0.0)                                  | 0 (0.0)                                               | 0 (0.0)                                                   |
| Hypertensive emergency                      | 1 (0.2)                                      | 0 (0.0)                                  | 0 (0.0)                                               | 0 (0.0)                                                   |
| Peripheral ischaemia                        | 0 (0.0)                                      | 0 (0.0)                                  | 0 (0.0)                                               | 1 (0.0)                                                   |
| Superior vena cava syndrome                 | 0 (0.0)                                      | 0 (0.0)                                  | 0 (0.0)                                               | 1 (0.0)                                                   |

|                        | KN355 Data for Pembrolizmab + Chemotherapylt (%)   | KN355 Data for Placebo + Chemotherapyll (%)   | mTNBC Safety Dataset for Pembrolizmab Monotherapyit (%)   | Reference Safety Dataset for Pembrolizmab Monotherapy$ (%)   |
|------------------------|----------------------------------------------------|-----------------------------------------------|-----------------------------------------------------------|--------------------------------------------------------------|
| Vasculardisorders      | 3 (0.5)                                            | 0 (0.0)                                       | 0 (0.0)                                                   | 3 (0.1)                                                      |
| Venous thrombosis limb | 1 (0.2)                                            | 0 (0.0)                                       | 0 (0.0)                                                   | 0 (0.0)                                                      |

<div style=\"page-break-after: always\"></div>

## UPDATED SAFETY RESULTS - FINAL ANALYSIS

During the procedure, the MAH submitted the results of the final analysis (FA) for OS with data cut-off date 15 Jun 2021.

The safety profile of pembrolizumab in combination chemotherapy observed at the FA is generally consistent with the known safety profiles of pembrolizumab monotherapy and the chemotherapies administered and is consistent with safety at IA2. No new safety concerns were identified at the FA for pembrolizumab.

A summary of the updated safety data is presented in the tables below:

## Summary of Drug Exposure (Part 2 All Subjects) (ASaT Population)

|                                      | Pembrolizumab + Chemotherapy   | Placebo + Chemotherapy   |
|--------------------------------------|--------------------------------|--------------------------|
| Subjects in population               | 562                            | 281                      |
| All Drugs                            |                                |                          |
| Number of Weeks on Therapy (weeks) n | 562                            | 281                      |
| Mean                                 | 39.1                           | 33.9                     |
| SD                                   | 36.6                           | 35.0                     |
| Median                               | 26.4                           | 23.1                     |
| Range                                | 0.1 to 212.1                   | 0.1 to 224.1             |
| Pembrolizumab/Placebo                |                                |                          |
| Number of Weeks on Therapy (weeks) n | 562                            | 281                      |
| Mean                                 | 35.9                           | 31.3                     |
| SD                                   | 32.0                           | 28.0                     |
| Median                               | 24.2                           | 22.1                     |
| Range                                | 0.1 to 140.1                   | 0.1 to 119.6             |
| Number of Administrations            |                                |                          |
| n                                    | 562                            | 281                      |
| Mean                                 | 12.0                           | 10.6                     |
| SD                                   | 9.9                            | 8.7                      |
| Median                               | 8.0                            | 8.0                      |
| Range                                | 1.0 to 35.0                    | 1.0 to 35.0              |

<div style=\"page-break-after: always\"></div>

| Nab-Paclitaxel                     |              |              |
|------------------------------------|--------------|--------------|
| Number of Weeks on Therapy (weeks) |              |              |
| n                                  | 174          | 95           |
| Mean                               | 35.4         | 30.3         |
| SD                                 | 37.2         | 34.5         |
| Median                             | 23.1         | 18.1         |
| Range                              | 0.1 to 212.1 | 0.1 to 208.1 |
| Number of Administrations          |              |              |
| n                                  | 174          | 95           |
| Mean                               | 25.5         | 22.6         |
| SD                                 | 25.7         | 24.2         |
| Median                             | 18.0         | 14.0         |
| Range                              | 1.0 to 159.0 | 1.0 to 143.0 |
| Paclitaxel                         |              |              |
| Number of Weeks on Therapy (weeks) |              |              |
| n                                  | 81           | 32           |
| Mean                               | 29.3         | 26.5         |
| SD                                 | 23.9         | 38.2         |
| Median                             | 21.6         | 17.4         |
| Range                              | 1.1 to 108.9 | 0.1 to 224.1 |
| Number of Administrations          |              |              |
| n                                  | 81           | 32           |
| Mean                               | 20.9         | 19.8         |
| SD                                 | 15.5         | 28.2         |
| Median                             | 16.0         | 13.5         |
| Range                              | 2.0 to 79.0  | 1.0 to 167.0 |
| Gemcitabine                        |              |              |
| Number of Weeks on Therapy (weeks) |              |              |
| n                                  | 309          | 154          |
| Mean                               | 32.6         | 30.8         |
| SD                                 | 32.3         | 30.2         |
| Median                             | 22.1         | 23.1         |
| Range                              | 0.1 to 199.1 | 0.1 to 215.7 |
| Number of Administrations          |              |              |
| n                                  | 309          | 154          |
| Mean                               | 16.4         | 16.6         |
| SD                                 | 13.9         | 16.1         |
| Median                             | 12.0         | 13.0         |
| Range                              | 1.0 to 98.0  | 1.0 to 137.0 |
| Carboplatin                        |              |              |
| Number of Weeks on Therapy (weeks) |              |              |

<div style=\"page-break-after: always\"></div>

| n                            | 309                          | 154                          |
|------------------------------|------------------------------|------------------------------|
| Mean                         | 31.4                         | 30.6                         |
| SD                           | 30.6                         | 30.1                         |
| Median                       | 22.1                         | 22.9                         |
| Range                        | 0.1 to 199.1                 | 0.1 to 215.7                 |
| NumberofAdministrations      |                              |                              |
| n                            | 309                          | 154                          |
| Mean                         | 15.8                         | 16.5                         |
| SD                           | 13.0                         | 16.0                         |
| Median                       | 12.0                         | 13.0                         |
| Range                        | 1.0 to 98.0                  | 1.0 to 137.0                 |
| DatabaseCutoffDate:15JUN2021 | DatabaseCutoffDate:15JUN2021 | DatabaseCutoffDate:15JUN2021 |

## Adverse Event Summary (Part 2 All Subjects) (ASaT Population)

|                                                                    | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Placebo + Chemotherapy   | Placebo + Chemotherapy   |
|--------------------------------------------------------------------|--------------------------------|--------------------------------|--------------------------|--------------------------|
|                                                                    | n                              | (%)                            | n                        | (%)                      |
| Subjects in population                                             | 562                            |                                | 281                      |                          |
| withoneormoreadverseevents                                         | 554                            | (98.6)                         | 276                      | (98.2)                   |
| with no adverse event                                              | 8                              | (1.4)                          | 5                        | (1.8)                    |
| with drug-relatedf adverse events                                  | 541                            | (96.3)                         | 267                      | (95.0)                   |
| with toxicity grade 3-5 adverse events                             | 438                            | (77.9)                         | 207                      | (73.7)                   |
| with toxicity grade 3-5 drug-related adverse events                | 383                            | (68.1)                         | 188                      | (66.9)                   |
| withserious adverseevents                                          | 169                            | (30.1)                         | 67                       | (23.8)                   |
| with serious drug-related adverse events                           | 100                            | (17.8)                         | 34                       | (12.1)                   |
| withanydosemodificationtduetoanadverse event                       | 429                            | (76.3)                         | 209                      | (74.4)                   |
| pembrolizumab/placebo dose modification                            | 313                            | (55.7)                         | 133                      | (47.3)                   |
| nab-paclitaxel dose modification                                   | 101                            | (18.0)                         | 45                       | (16.0)                   |
| paclitaxel dose modification                                       | 52                             | (9.3)                          | 21                       | (7.5)                    |
| gemcitabine dose modification                                      | 264                            | (47.0)                         | 138                      | (49.1)                   |
| carboplatin dose modification                                      | 261                            | (46.4)                         | 140                      | (49.8)                   |
| who died                                                           | 17                             | (3.0)                          | 5                        | (1.8)                    |
| whodieddueto a drug-related adverseevent                           | 2                              | (0.4)                          | 0                        | (0.0)                    |
| discontinued any drug due to an adverse event                      | 115                            | (20.5)                         | 38                       | (13.5)                   |
| discontinuedpembrolizumab/placebo                                  | 60                             | (10.7)                         | 15                       | (5.3)                    |
| discontinued nab-paclitaxel                                        | 22                             | (3.9)                          | 5                        | (1.8)                    |
| discontinued paclitaxel                                            | 16                             | (2.8)                          | 6                        | (2.1)                    |
| discontinuedgemcitabine                                            | 37                             | (6.6)                          | 16                       | (5.7)                    |
| discontinuedcarboplatin                                            | 42                             | (7.5)                          | 17                       | (6.0)                    |
| discontinued any drug due to a drug-related                        | 103                            | (18.3)                         | 31                       | (11.0)                   |
| discontinuedpembrolizumab/placebo                                  | 51                             | (9.1)                          | 9                        | (3.2)                    |
| discontinued nab-paclitaxel                                        | 18                             | (3.2)                          | 4                        | (1.4)                    |
| discontinued paclitaxel                                            | 16                             | (2.8)                          | 3                        | (1.1)                    |
| discontinuedgemcitabine                                            | 33                             | (5.9)                          | 15                       | (5.3)                    |
| discontinued carboplatin                                           | 37                             | (6.6)                          | 15                       | (5.3)                    |
| discontinued any drug due to a serious adverse event               | 44                             | (7.8)                          | 9                        | (3.2)                    |
| discontinuedpembrolizumab/placebo                                  | 40                             | (7.1)                          | 8                        | (2.8)                    |
| discontinued nab-paclitaxel                                        | 9                              | (1.6)                          | 1                        | (0.4)                    |
| discontinued paclitaxel                                            | 4                              | (0.7)                          | 4                        | (1.4)                    |
| discontinuedgemcitabine                                            | 9                              | (1.6)                          | 0                        | (0.0)                    |
| discontinued carboplatin                                           | 8                              | (1.4)                          | 1                        | (0.4)                    |
| discontinued any drug due to a serious drug- related adverse event | 36                             | (6.4)                          | 3                        | (1.1)                    |
| discontinued pembrolizumab/placebo                                 | 32                             | (5.7)                          | 2                        | (0.7)                    |

<div style=\"page-break-after: always\"></div>

| discontinuednab-paclitaxel   | 5       | (0.9) 0 (0.0)   |
|------------------------------|---------|-----------------|
| discontinuedpaclitaxel       | 4 (0.7) | 1 (0.4)         |
| discontinuedgemcitabine      | 7 (1.2) | 0 (0.0)         |
| discontinuedcarboplatin      | 6 (1.1) | 0 (0.0)         |

Determined by theinvestigator toberelated to the drug.

+ Defined as an action taken of dose reduced, drug interrupted or drug withdrawn.

GradesarebasedonNCICTCAEversion4.03.

Non-serious adverseeventsupto30days afterlastdose andserious adverseeventsupto90days afterlast dose are included.

MedDRApreferred terms\"Neoplasmprogression\",\"Malignantneoplasmprogression\"and\"Diseaseprogression\" notrelatedtothedrugareexcluded.

DatabaseCutoffDate:15JUN2021

Subjects With Adverse Events by Decreasing Incidence (Incidence ≥ 10% in One or More Treatment Groups) (Part 2 All Subjects) (ASaT Population)

|                                      | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   |   Placebo + Chemotherapy | Placebo + Chemotherapy   |
|--------------------------------------|--------------------------------|--------------------------------|--------------------------|--------------------------|
|                                      | n                              | (%)                            |                        1 | (%)                      |
| Subjects in population               | 562                            |                                |                      281 |                          |
| with one or more adverseevents       | 554                            | (98.6)                         |                      276 | (98.2)                   |
| with no adverse events               | 8                              | (1.4)                          |                        5 | (1.8)                    |
| Anaemia                              | 300                            | (53.4)                         |                      143 | (50.9)                   |
| Nausea                               | 251                            | (44.7)                         |                      132 | (47.0)                   |
| Neutropenia                          | 233                            | (41.5)                         |                      109 | (38.8)                   |
| Alopecia                             | 190                            | (33.8)                         |                       97 | (34.5)                   |
| Fatigue                              | 180                            | (32.0)                         |                       97 | (34.5)                   |
| Diarrhoea                            | 157                            | (27.9)                         |                       66 | (23.5)                   |
| Constipation                         | 155                            | (27.6)                         |                       77 | (27.4)                   |
| Vomiting                             | 145                            | (25.8)                         |                       63 | (22.4)                   |
| Alanine aminotransferase increased   | 142                            | (25.3)                         |                       55 | (19.6)                   |
| Aspartate aminotransferase increased | 134                            | (23.8)                         |                       47 | (16.7)                   |
| Neutrophil count decreased           | 128                            | (22.8)                         |                       75 | (26.7)                   |
| Arthralgia                           | 121                            | (21.5)                         |                       50 | (17.8)                   |
| Decreased appetite                   | 120                            | (21.4)                         |                       40 | (14.2)                   |
| Cough                                | 117                            | (20.8)                         |                       49 | (17.4)                   |
| Thrombocytopenia                     | 116                            | (20.6)                         |                       57 | (20.3)                   |
| Leukopenia                           | 114                            | (20.3)                         |                       50 | (17.8)                   |
| Headache                             | 112                            | (19.9)                         |                       67 | (23.8)                   |
| Rash                                 | 011                            | (19.6)                         |                       34 | (12.1)                   |
| Asthenia                             | 107                            | (19.0)                         |                       48 | (17.1)                   |
| White blood cell count decreased     | 106                            | (18.9)                         |                       54 | (19.2)                   |
| Pyrexia                              | 104                            | (18.5)                         |                       56 | (19.9)                   |
| Platelet count decreased             | 90                             | (16.0)                         |                       44 | (15.7)                   |
| Hypothyroidism                       | 89                             | (15.8)                         |                        9 | (3.2)                    |
| Pruritus                             | 85                             | (15.1)                         |                       32 | (11.4)                   |
| Back pain                            | 73                             | (13.0)                         |                       42 | (14.9)                   |
| Dyspnoea                             | 69                             | (12.3)                         |                       38 | (13.5)                   |
| Oedema peripheral                    | 66                             | (11.7)                         |                       29 | (10.3)                   |
| Neuropathy peripheral                | 62                             | (11.0)                         |                       35 | (12.5)                   |
| Upper respiratory tract infection    | 59                             | (10.5)                         |                       25 | (8.9)                    |
| Myalgia                              | 58                             | (10.3)                         |                       34 | (12.1)                   |

Pain in extremity

57

(10.1)

Every subject is counted a single time for each applicable row and column.

A specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

Non-serious adverse events up to 30 days after last dose and serious adverse events up to 90 days after last dose are included.

MedDRA preferred terms \"Neoplasm progression\", \"Malignant neoplasm progression\" and \"Disease progression' not related to the drug are excluded.

Database Cutoff Date: 15JUN2021

41

(14.6)

<div style=\"page-break-after: always\"></div>

## Between-Treatment Comparisons in Adverse Events (Incidence ≥ 10% in One or More Treatment Groups)

## Sorted by Risk Difference (Part 2 All Subjects) (ASaT Population)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Subjects With Drug-Related Adverse Events by Decreasing Incidence (Incidence ≥ 5% in One or More Treatment Groups) (Part 2 All Subjects) (ASaT Population)

|                                      | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Placebo+Chemotherapy   | Placebo+Chemotherapy   |
|--------------------------------------|--------------------------------|--------------------------------|------------------------|------------------------|
|                                      |                                | (%)                            |                        | (%)                    |
| Subjects in population               | 562                            |                                | 281                    |                        |
| withoneormore adverseevents          | 541                            | (96.3)                         | 267                    | (95.0)                 |
| with no adverse events               | 21                             | (3.7)                          | 14                     | (5.0)                  |
| Anaemia                              | 276                            | (49.1)                         | 129                    | (45.9)                 |
| Neutropenia                          | 231                            | (41.1)                         | 107                    | (38.1)                 |
| Nausea                               | 221                            | (39.3)                         | 116                    | (41.3)                 |
| Alopecia                             | 186                            | (33.1)                         | 94                     | (33.5)                 |
| Fatigue                              | 161                            | (28.6)                         | 84                     | (29.9)                 |
| Neutrophil count decreased           | 126                            | (22.4)                         | 74                     | (26.3)                 |
| Alanine aminotransferase increased   | 115                            | (20.5)                         | 46                     | (16.4)                 |
| Diarrhoea                            | 111                            | (19.8)                         | 46                     | (16.4)                 |
| Leukopenia                           | 111                            | (19.8)                         | 49                     | (17.4)                 |
| Thrombocytopenia                     | 109                            | (19.4)                         | 54                     | (19.2)                 |
| Aspartate aminotransferase increased | 108                            | (19.2)                         | 42                     | (14.9)                 |
| Vomiting                             | 107                            | (19.0)                         | 42                     | (14.9)                 |
| White blood cell count decreased     | 103                            | (18.3)                         | 54                     | (19.2)                 |
| Decreased appetite                   | 95                             | (16.9)                         | 26                     | (9.3)                  |
| Plateletcountdecreased               | 90                             | (16.0)                         | 43                     | (15.3)                 |
| Rash                                 | 87                             | (15.5)                         | 26                     | (9.3)                  |
| Asthenia                             | 78                             | (13.9)                         | 37                     | (13.2)                 |
| Constipation                         | 78                             | (13.9)                         | 37                     | (13.2)                 |
| Hypothyroidism                       | 75                             | (13.3)                         | 8                      | (2.8)                  |
| Pruritus                             | 57                             | (10.1)                         | 26                     | (9.3)                  |
| Neuropathy peripheral                | 56                             | (10.0)                         | 32                     | (11.4)                 |
| Pyrexia                              | 56                             | (10.0)                         | 23                     | (8.2)                  |
| Peripheral sensory neuropathy        | 49                             | (8.7)                          | 20                     | (7.1)                  |
| Dysgeusia                            | 47                             | (8.4)                          | 12                     | (4.3)                  |
| Arthralgia                           | 46                             | (8.2)                          | 24                     | (8.5)                  |
| Stomatitis                           | 46                             | (8.2)                          | 17                     | (6.0)                  |
| Myalgia                              | 41                             | (7.3)                          | 21                     | (7.5)                  |
| Headache                             | 38                             | (6.8)                          | 24                     | (8.5)                  |
| Blood alkaline phosphatase increased | 34                             | (6.0)                          | 13                     | (4.6)                  |
| Weight decreased                     | 31                             | (5.5)                          | 7                      | (2.5)                  |
| Oedema peripheral                    | 29                             | (5.2)                          | 13                     | (4.6)                  |
| Lymphopenia                          | 28                             | (5.0)                          | 4                      | (1.4)                  |

Dizziness

14

(2.5)

Every subject is counted a single time foreach applicable row and column.

A specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

Non-serious adverse events upto30 days afterlast dose andserious adverse events up to90 days afterlast dose are included.

DatabaseCutoffDate:15JUN2021

15

(5.3)

<div style=\"page-break-after: always\"></div>

Subjects With Grade 3-5 Adverse Events by Decreasing Incidence (Incidence ≥ 5% in One or More Treatment Groups) (Part 2 All Subjects) (ASaT Population)

|                                     | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   |   Placebo + Chemotherapy | Placebo + Chemotherapy   |
|-------------------------------------|--------------------------------|--------------------------------|--------------------------|--------------------------|
|                                     | n                              | (%)                            |                       11 | (%)                      |
| Subjects in population              | 562                            |                                |                      281 |                          |
| with one or more adverse events     | 438                            | (77.9)                         |                      207 | (73.7)                   |
| with no adverse events              | 124                            | (22.1)                         |                       74 | (26.3)                   |
| Neutropenia                         | 169                            | (30.1)                         |                       85 | (30.2)                   |
| Anaemia                             | 101                            | (18.0)                         |                       46 | (16.4)                   |
| Neutrophil count decreased          | 101                            | (18.0)                         |                       57 | (20.3)                   |
| Thrombocytopenia                    | 63                             | (11.2)                         |                       33 | (11.7)                   |
| White blood cell count decreased    | 59                             | (10.5)                         |                       29 | (10.3)                   |
| Leukopenia                          | 57                             | (10.1)                         |                       31 | (11.0)                   |
| Alanine aminotransferase increased  | 44                             | (7.8)                          |                       16 | (5.7)                    |
| Platelet count decreased            | 36                             | (6.4)                          |                       20 | (7.1)                    |
| Aspartate aminotransferaseincreased | 32                             | (5.7)                          |                       11 | (3.9)                    |

Every subject is counted a single timefor each applicablerow and column.

A specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

Non-serious adverse events up to 30 days after last dose and serious adverse events up to 90 days after last dose are included.

MedDRA preferred terms \"Neoplasm progression\", \"Malignant neoplasm progression\" and \"Disease progression\" not related to the drug are excluded.

Grades are based on NCI CTCAE version 4.03.

DatabaseCutoffDate:15JUN2021

Subjects With Drug-Related Grade 3-5 Adverse Events by Decreasing Incidence (Incidence ≥ 5% in One or More Treatment Groups) (Part 2 All Subjects) (ASaT Population)

|                                   | Pembrolizumab+ Chemotherapy   | Pembrolizumab+ Chemotherapy   | Placebo+ Chemotherapy   | Placebo+ Chemotherapy   |
|-----------------------------------|-------------------------------|-------------------------------|-------------------------|-------------------------|
|                                   | 1n                            | (%)                           | n                       | (%)                     |
| Subjects in population            | 562                           |                               | 281                     |                         |
| with one or more adverse events   | 383                           | (68.1)                        | 188                     | (66.9)                  |
| with no adverseevents             | 179                           | (31.9)                        | 93                      | (33.1)                  |
| Neutropenia                       | 167                           | (29.7)                        | 84                      | (29.9)                  |
| Neutrophil count decreased        | 98                            | (17.4)                        | 57                      | (20.3)                  |
| Anaemia                           | 93                            | (16.5)                        | 41                      | (14.6)                  |
| Thrombocytopenia                  | 57                            | (10.1)                        | 31                      | (11.0)                  |
| Whiteblood cell count decreased   | 57                            | (10.1)                        | 29                      | (10.3)                  |
| Leukopenia                        | 56                            | (10.0)                        | 30                      | (10.7)                  |
| Platelet count decreased          | 36                            | (6.4)                         | 20                      | (7.1)                   |
| Alanine aminotransferaseincreased | 34                            | (6.0)                         | 13                      | (4.6)                   |

Everysubject iscounted a singletimefor each applicablerow and column.

A specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

Non-serious adverse events up to 30 days after last dose and serious adverse events up to 90 days after last dose are included.

Grades are based on NCI CTCAE version 4.03.

DatabaseCutoffDate:15JUN2021

<div style=\"page-break-after: always\"></div>

Subjects With Adverse Events Resulting in Death by Decreasing Incidence (Incidence &gt; O% in One or More Treatment Groups) (Part 2 All Subjects) (ASaT Population)

|                                     | Pembrolizumab+Chemotherapy   | Pembrolizumab+Chemotherapy   | Placebo+ Chemotherapy   | Placebo+ Chemotherapy   |
|-------------------------------------|------------------------------|------------------------------|-------------------------|-------------------------|
|                                     | 1n                           | (%)                          | n                       | (%)                     |
| Subjects in population              | 562                          |                              | 281                     |                         |
| with one ormore adverse events      | 17                           | (3.0)                        | 5                       | (1.8)                   |
| with no adverse events              | 545                          | (97.0)                       | 276                     | (98.2)                  |
| Cardio-respiratory arrest           | 2                            | (0.4)                        | 0                       | (0.0)                   |
| Pneumonia                           | 2                            | (0.4)                        | 1                       | (0.4)                   |
| Septic shock                        | 2                            | (0.4)                        | 0                       | (0.0)                   |
| Acute kidney injury                 | 1                            | (0.2)                        | 0                       | (0.0)                   |
| Acute myocardial infarction         | 1                            | (0.2)                        | 0                       | (0.0)                   |
| Assisted suicide                    | 1                            | (0.2)                        | 0                       | (0.0)                   |
| Cardiac arrest                      | 1                            | (0.2)                        | 0                       | (0.0)                   |
| Cardiopulmonary failure             | 1                            | (0.2)                        | 0                       | (0.0)                   |
| Death                               | 1                            | (0.2)                        | 0                       | (0.0)                   |
| Hepatic encephalopathy              | 1                            | (0.2)                        | 0                       | (0.0)                   |
| Multiple organ dysfunction syndrome | 1                            | (0.2)                        | 0                       | (0.0)                   |
| Pulmonary embolism                  | 1                            | (0.2)                        | 0                       | (0.0)                   |
| Sepsis                              | 1                            | (0.2)                        | 0                       | (0.0)                   |
| Shock haemorrhagic                  | 1                            | (0.2)                        | 0                       | (0.0)                   |
| Cardiac failure                     | 0                            | (0.0)                        | 1                       | (0.4)                   |
| Haemorrhagic stroke                 | 0                            | (0.0)                        | 1                       | (0.4)                   |
| Respiratory failure                 | 0                            | (0.0)                        | 1                       | (0.4)                   |
| Vascular device infection           | 0                            | (0.0)                        |                         | (0.4)                   |

Everysubject is counted asingletimeforeach applicablerow andcolumn.

Non-serious adverse events up to30 days after last dose and serious adverse events up to90 days after last dose are included.

MedDRA preferred terms \"Neoplasm progression\", \"Malignant neoplasm progression\" and\"Disease progression\" not related to the drug are excluded.

DatabaseCutoffDate:15JUN2021

Subjects With Serious Adverse Events up to 90 Days After Last Dose by Decreasing Incidence (Incidence ≥ 1% in One or More Treatment Groups) (Part 2 All Subjects) (ASaT Population)

|                              | Pembrolizumab+Chemotherapy   | Pembrolizumab+Chemotherapy   | Placebo + Chemotherapy   | Placebo + Chemotherapy   |
|------------------------------|------------------------------|------------------------------|--------------------------|--------------------------|
|                              |                              | (%)                          | n                        | (%)                      |
| Subjects in population       | 562                          |                              | 281                      |                          |
| withone ormore adverseevents | 169                          | (30.1)                       | 67                       | (23.8)                   |
| withno adverseevents         | 393                          | (69.9)                       | 214                      | (76.2)                   |
| Anaemia                      | 11                           | (2.0)                        | 6                        | (2.1)                    |
| Pneumonia                    | 11                           | (2.0)                        | 7                        | (2.5)                    |
| Thrombocytopenia             | 11                           | (2.0)                        | 4                        | (1.4)                    |
| Vomiting                     | 10                           | (1.8)                        | 6                        | (2.1)                    |
| Febrile neutropenia          | 7                            | (1.2)                        | 3                        | (1.1)                    |
| Pulmonary embolism           | 7                            | (1.2)                        | 3                        | (1.1)                    |
| Pyrexia                      | 7                            | (1.2)                        | 4                        | (1.4)                    |
| Pneumonitis                  | 6                            | (1.1)                        | 0                        | (0.0)                    |
| Sepsis                       | 6                            | (1.1)                        | 3                        | (1.1)                    |
| Neutropenia                  | 5                            | (0.9)                        | 4                        | (1.4)                    |
| Pleural effusion             | 5                            | (0.9)                        | 3                        | (1.1)                    |
| Nausea                       | 3                            | (0.5)                        | 3                        | (1.1)                    |

Every subjectiscounted asingletimeforeach applicablerow and column.

A specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidencecriterion in thereport title,after rounding.

Serious adverse events up to 90 days after last dose are included.

MedDRA preferred terms \"Neoplasm progression\", \"Malignant neoplasm progression\" and \"Disease progression\" not related to the drug are excluded.

DatabaseCutoff Date:15JUN2021

<div style=\"page-break-after: always\"></div>

## Subjects With Drug-Related Serious Adverse Events up to 90 Days After Last Dose by

## Decreasing Incidence

(Incidence &gt; O% in One or More Treatment Groups)

(Part 2 All Subjects)

(ASaT Population)

|                                      | Pembrolizumab + Chemotherapy   | Pembrolizumab + Chemotherapy   | Placcbo + Chemotherapy   | Placcbo + Chemotherapy   |
|--------------------------------------|--------------------------------|--------------------------------|--------------------------|--------------------------|
|                                      | n                              | (%)                            | n                        | (%)                      |
| Subjects in population               | 562                            |                                | 281                      |                          |
| with one or more adverse cvents      | 100                            | (17.8)                         | 34                       | (12.1)                   |
| with no adverse events               | 462                            | (82.2)                         | 247                      | (87.9)                   |
| Anaemia                              | 11                             | (2.0)                          | 4                        | (1.4)                    |
| Thrombocytopenia                     | 9                              | (1.6)                          | 3                        | (1.1)                    |
| Vomiting                             | 8                              | (1.4)                          | 3                        | (1.1)                    |
| Febrile neutropenia                  | 6                              | (1.1)                          | 3                        | (1.1)                    |
| Pneumonitis                          | 6                              | (1.1)                          | 0                        | (0.0)                    |
| Pyrexia                              | 6                              | (1.1)                          | 3                        | (1.1)                    |
| Neutropenia                          | 5                              | (0.9)                          | 4                        | (1.4)                    |
| Platelet coumt decrcased             | 5                              | (0.9)                          | 2                        | (0.7)                    |
| Alanine aminotransferase increased   | 4                              | (0.7)                          | 1                        | (0.4)                    |
| Aspartate aminotransferase increascd | 4                              | (0.7)                          | 1                        | (0.4)                    |
| Leukopenia                           | 4                              | (0.7)                          | 0                        | (0.0)                    |
| Adrenal insufficiency                | 3                              | (0.5)                          | 0                        | (0.0)                    |
| Hepatitis                            | 3                              | (0.5)                          | 0                        | (0.0)                    |
| Nausca                               | 3                              | (0.5)                          | 2                        | (0.7)                    |
| Acute kidney injury                  | 2                              | (0.4)                          | 1                        | (0.4)                    |
| Decrcascd appctite                   | 2                              | (0.4)                          | 1                        | (0.4)                    |
| Diarhoca                             | 2                              | (0.4)                          | 0                        | (0.0)                    |
| Hepatic function abnormal            | 2                              | (0.4)                          | 1                        | (0.4)                    |
| Pneumonia                            | 2                              | (0.4)                          | 1                        | (0.4)                    |
| Pulmonary cmbolism                   | 2                              | (0.4)                          | 0                        | (0.0)                    |
| Renal failurc                        | 2                              | (0.4)                          | 0                        | (0.0)                    |
| Sepsis                               | 2                              | (0.4)                          | 2                        | (0.7)                    |
| Autoimmume hepatitis                 | 1                              | (0.2)                          | 0                        | (0.0)                    |
| Bone pain                            | 1                              | (0.2)                          | 0                        | (0.0)                    |
| Breast pain                          | 1                              | (0.2)                          | 0                        | (0.0)                    |
| Cardiac failure                      | 1                              | (0.2)                          | 0                        | (0.0)                    |
| Cheilitis                            | 1                              | (0.2)                          | 0                        | (0.0)                    |
| Colitis                              | 1                              | (0.2)                          | 0                        | (0.0)                    |
| Device related sepsis                |                                | (0.2)                          | 0                        | (0.0)                    |
| Dysphagia                            | 1                              | (0.2)                          | 0                        | (0.0)                    |
| Electrolyte imbalance                | 1                              | (0.2)                          | 0                        | (0.0)                    |
| Gastric ulcer haemonrhage            |                                | (0.2)                          | 0                        | (0.0)                    |
| Gastroenteritis                      |                                | (0.2)                          | 0                        | (0.0)                    |

<div style=\"page-break-after: always\"></div>

| Guillain-Barre syndrome                                                    |                                                                            | (0.2)                                                                      | 0                                                                          | (0.0)                                                                      |
|----------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|
| Hypertension                                                               | 1                                                                          | (0.2)                                                                      | 0                                                                          | (0.0)                                                                      |
| Hypertensive emergency                                                     | 1                                                                          | (0.2)                                                                      | 0                                                                          | (0.0)                                                                      |
| Hyponatraemia                                                              | 1                                                                          | (0.2)                                                                      | 1                                                                          | (0.4)                                                                      |
| Inappropriate antidiuretic hormone secretion                               | 1                                                                          | (0.2)                                                                      | 0                                                                          | (0.0)                                                                      |
| Limb injury                                                                |                                                                            | (0.2)                                                                      | 0                                                                          | (0.0)                                                                      |
| Liver disorder                                                             |                                                                            | (0.2)                                                                      | 0                                                                          | (0.0)                                                                      |
| Liver function test abnormal                                               | 1                                                                          | (0.2)                                                                      | 0                                                                          | (0.0)                                                                      |
| Lower gastrointestinal haemorrhage                                         | 1                                                                          | (0.2)                                                                      | 0                                                                          | (0.0)                                                                      |
| Lymphopenia                                                                | 1                                                                          | (0.2)                                                                      | 0                                                                          | (0.0)                                                                      |
| Malaise                                                                    | 1                                                                          | (0.2)                                                                      | 0                                                                          | (0.0)                                                                      |
| Meningitis aseptic                                                         | 1                                                                          | (0.2)                                                                      | 0                                                                          | (0.0)                                                                      |
| Myelopathy                                                                 | 1                                                                          | (0.2)                                                                      | 0                                                                          | (0.0)                                                                      |
| Myelosuppression                                                           | 1                                                                          | (0.2)                                                                      | 0                                                                          | (0.0)                                                                      |
| Myocarditis                                                                | 1                                                                          | (0.2)                                                                      | 0                                                                          | (0.0)                                                                      |
| Myositis                                                                   | 1                                                                          | (0.2)                                                                      | 0                                                                          | (0.0)                                                                      |
| Neutropenic sepsis                                                         | 1                                                                          | (0.2)                                                                      | 0                                                                          | (0.0)                                                                      |
| Neutrophil count decreased                                                 | 1                                                                          | (0.2)                                                                      | 0                                                                          | (0.0)                                                                      |
| Palmar-plantar erythrodysaesthesia syndrome                                | 1                                                                          | (0.2)                                                                      | 0                                                                          | (0.0)                                                                      |
| Pancreatic enzymes increased                                               | 1                                                                          | (0.2)                                                                      | 0                                                                          | (0.0)                                                                      |
| Pancreatitis                                                               | 1                                                                          | (0.2)                                                                      | 0                                                                          | (0.0)                                                                      |
| Pancytopenia                                                               | 1                                                                          | (0.2)                                                                      | 1                                                                          | (0.4)                                                                      |
| Peripheral motor neuropathy                                                | 1                                                                          | (0.2)                                                                      | 1                                                                          | (0.4)                                                                      |
| Peripheral sensory neuropathy                                              | 1                                                                          | (0.2)                                                                      | 2                                                                          | (0.7)                                                                      |
| Pleural effusion                                                           | 1                                                                          | (0.2)                                                                      | 0                                                                          | (0.0)                                                                      |
| Pneumonia bacterial                                                        | 1                                                                          | (0.2)                                                                      | 0                                                                          | (0.0)                                                                      |
| Pneumonia streptococcal                                                    | 1                                                                          | (0.2)                                                                      | 0                                                                          | (0.0)                                                                      |
| Polyarthritis                                                              | 1                                                                          | (0.2)                                                                      | 0                                                                          | (0.0)                                                                      |
| Pulmonary hypertension                                                     | 1                                                                          | (0.2)                                                                      | 0                                                                          | (0.0)                                                                      |
| Rash maculo-papular                                                        | 1                                                                          | (0.2)                                                                      | 0                                                                          | (0.0)                                                                      |
| Respiratory tract infection                                                | 1                                                                          | (0.2)                                                                      | 0                                                                          | (0.0)                                                                      |
| Sinus bradycardia                                                          | 1                                                                          | (0.2)                                                                      | 0                                                                          | (0.0)                                                                      |
| Soft tissue infection                                                      | 1                                                                          | (0.2)                                                                      | 0                                                                          | (0.0)                                                                      |
| Steatohepatitis                                                            | 1                                                                          | (0.2)                                                                      | 0                                                                          | (0.0)                                                                      |
| Thromboticmicroangiopathy                                                  | 1                                                                          | (0.2)                                                                      | 0                                                                          | (0.0)                                                                      |
| Transaminases increased                                                    | 1                                                                          | (0.2)                                                                      | 0                                                                          | (0.0)                                                                      |
| Upper respiratory tract infection                                          | 1                                                                          | (0.2)                                                                      | 0                                                                          | (0.0)                                                                      |
| Venous thrombosis limb                                                     | 1                                                                          | (0.2)                                                                      | 0                                                                          | (0.0)                                                                      |
| Chronic inflammatory demyelinating polyradiculoneuropathy                  | 0                                                                          | (0.0)                                                                      | 1                                                                          | (0.4)                                                                      |
| Deep vein thrombosis                                                       | 0                                                                          | (0.0)                                                                      | 1                                                                          | (0.4)                                                                      |
| Dyspnoea                                                                   | 0                                                                          | (0.0)                                                                      | 1                                                                          | (0.4)                                                                      |
| Fatigue                                                                    | 0                                                                          | (0.0)                                                                      | 1                                                                          | (0.4)                                                                      |
| Haematemesis                                                               | 0                                                                          | (0.0)                                                                      | 1                                                                          | (0.4)                                                                      |
| Hepatotoxicity                                                             | 0                                                                          | (0.0)                                                                      | 1                                                                          | (0.4)                                                                      |
| Hypocalcaemia                                                              | 0                                                                          | (0.0)                                                                      | 1                                                                          | (0.4)                                                                      |
| Pulmonaryfibrosis                                                          | 0                                                                          | (0.0)                                                                      | 1                                                                          | (0.4)                                                                      |
| Scleroderma                                                                | 0                                                                          | (0.0)                                                                      | 1                                                                          | (0.4)                                                                      |
| Urinary retention                                                          | 0                                                                          | (0.0)                                                                      | 1                                                                          | (0.4)                                                                      |
| Uterine haemorrhage                                                        | 0                                                                          | (0.0)                                                                      | 1                                                                          | (0.4)                                                                      |
| Every subject is counted a single time for each applicable row and column. | Every subject is counted a single time for each applicable row and column. | Every subject is counted a single time for each applicable row and column. | Every subject is counted a single time for each applicable row and column. | Every subject is counted a single time for each applicable row and column. |
| Serious adverse events up to 90 days after last dose are included.         | Serious adverse events up to 90 days after last dose are included.         | Serious adverse events up to 90 days after last dose are included.         | Serious adverse events up to 90 days after last dose are included.         | Serious adverse events up to 90 days after last dose are included.         |
| Database Cutoff Date: 15JUN2021                                            | Database Cutoff Date: 15JUN2021                                            | Database Cutoff Date: 15JUN2021                                            | Database Cutoff Date: 15JUN2021                                            | Database Cutoff Date: 15JUN2021                                            |

<div style=\"page-break-after: always\"></div>

## AdverseEventSummary Adverse Event of Special Interest (AEOSI) (Part 2 All Subjects) (ASaT Population)

|                                                                                   | Pembrolizumab+                                                                    | Pembrolizumab+                                                                    | Placebo + Chemotherapy                                                            | Placebo + Chemotherapy                                                            |
|-----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
|                                                                                   | Chemotherapy n                                                                    | (%)                                                                               |                                                                                   | (%)                                                                               |
| Subjects in population                                                            | 562                                                                               |                                                                                   | 281                                                                               |                                                                                   |
| with one ormore adverse events                                                    | 157                                                                               | (27.9)                                                                            | 31                                                                                | (11.0)                                                                            |
| with noadverse event                                                              | 405                                                                               | (72.1)                                                                            | 250                                                                               | (89.0)                                                                            |
| withdrug-relatedfadverseevents                                                    | 143                                                                               | (25.4)                                                                            | 26                                                                                | (9.3)                                                                             |
| with toxicity grade 3-5 adverse events                                            | 32                                                                                | (5.7)                                                                             | 0                                                                                 | (0.0)                                                                             |
| with toxicity grade 3-5 drug-related adverse events                               | 31                                                                                | (5.5)                                                                             | 0                                                                                 | (0.0)                                                                             |
| withserious adverse events                                                        | 19                                                                                | (3.4)                                                                             | 0                                                                                 | (0.0)                                                                             |
| withseriousdrug-relatedadverseevents                                              | 17                                                                                | (3.0)                                                                             | 0                                                                                 | (0.0)                                                                             |
| with anydosemodificationduetoan adverse event                                     | 59                                                                                | (10.5)                                                                            | 12                                                                                | (4.3)                                                                             |
| pembrolizumab/placebo dose modification                                           | 44                                                                                | (7.8)                                                                             | 2                                                                                 | (0.7)                                                                             |
| nab-paclitaxel dose modification                                                  | 15                                                                                | (2.7)                                                                             | 0                                                                                 | (0.0)                                                                             |
| paclitaxel dose modification                                                      | 7                                                                                 | (1.2)                                                                             | 1                                                                                 | (0.4)                                                                             |
| gemcitabine dose modification                                                     | 21                                                                                | (3.7)                                                                             | 6                                                                                 | (2.1)                                                                             |
| carboplatindose modification                                                      | 22                                                                                | (3.9)                                                                             | 10                                                                                | (3.6)                                                                             |
| whodied                                                                           | 0                                                                                 | (0.0)                                                                             | 0                                                                                 | (0.0)                                                                             |
| whodiedduetoa drug-related adverseevent                                           | 0                                                                                 | (0.0)                                                                             | 0                                                                                 | (0.0)                                                                             |
| discontinued any drug due to an adverse event                                     | 23                                                                                | (4.1)                                                                             | 3                                                                                 | (1.1)                                                                             |
| discontinued pembrolizumab/placebo                                                | 14                                                                                | (2.5)                                                                             | 0                                                                                 | (0.0)                                                                             |
| discontinuednab-paclitaxel                                                        | 3                                                                                 | (0.5)                                                                             | 0                                                                                 | (0.0)                                                                             |
| discontinued paclitaxel                                                           | 1                                                                                 | (0.2)                                                                             | 0                                                                                 | (0.0)                                                                             |
| discontinued gemcitabine                                                          | 6                                                                                 | (1.1)                                                                             | 0                                                                                 | (0.0)                                                                             |
| discontinued carboplatin                                                          | 6                                                                                 | (1.1)                                                                             | 3                                                                                 | (1.1)                                                                             |
| discontinued any drug due to a drug-related                                       | 23                                                                                | (4.1)                                                                             | 3                                                                                 | (1.1)                                                                             |
| adverseevent                                                                      |                                                                                   |                                                                                   |                                                                                   |                                                                                   |
| discontinuedpembrolizumab/placebo                                                 | 14                                                                                | (2.5)                                                                             | 0                                                                                 | (0.0)                                                                             |
| discontinued nab-paclitaxel                                                       | 3                                                                                 | (0.5)                                                                             | 0                                                                                 | (0.0)                                                                             |
| discontinued paclitaxel                                                           | 1                                                                                 | (0.2)                                                                             | 0                                                                                 | (0.0)                                                                             |
| discontinuedgemcitabine                                                           | 6                                                                                 | (1.1)                                                                             | 0                                                                                 | (0.0)                                                                             |
| discontinued carboplatin                                                          | 6                                                                                 | (1.1)                                                                             | 3                                                                                 | (1.1)                                                                             |
| discontinued any drug due to a serious adverse                                    | 13                                                                                | (2.3)                                                                             | 0                                                                                 | (0.0)                                                                             |
| event discontinuedpembrolizumab/placebo                                           | 12                                                                                | (2.1)                                                                             | 0                                                                                 | (0.0)                                                                             |
| discontinued nab-paclitaxel                                                       | 2                                                                                 | (0.4)                                                                             | 0                                                                                 | (0.0)                                                                             |
| discontinued paclitaxel                                                           | 1                                                                                 | (0.2)                                                                             | 0                                                                                 | (0.0)                                                                             |
| discontinued gemcitabine                                                          | 1                                                                                 | (0.2)                                                                             | 0                                                                                 | (0.0)                                                                             |
| discontinued carboplatin                                                          | 1                                                                                 | (0.2)                                                                             | 0                                                                                 | (0.0)                                                                             |
| discontinued any drug due to a serious drug-                                      | 13                                                                                | (2.3)                                                                             | 0                                                                                 | (0.0)                                                                             |
| related adverse event                                                             |                                                                                   |                                                                                   |                                                                                   |                                                                                   |
| discontinuedpembrolizumab/placebo                                                 | 12                                                                                | (2.1)                                                                             | 0                                                                                 | (0.0)                                                                             |
| discontinued nab-paclitaxel                                                       | 2                                                                                 | (0.4)                                                                             | 0                                                                                 | (0.0)                                                                             |
| discontinued paclitaxel                                                           | 1                                                                                 | (0.2)                                                                             | 0                                                                                 | (0.0)                                                                             |
| discontinued gemcitabine                                                          | 1                                                                                 | (0.2)                                                                             | 0                                                                                 | (0.0)                                                                             |
| discontinuedcarboplatin                                                           |                                                                                   | (0.2)                                                                             | 0                                                                                 | (0.0)                                                                             |
| Determined by the investigator to be related to the drug.                         | Determined by the investigator to be related to the drug.                         | Determined by the investigator to be related to the drug.                         | Determined by the investigator to be related to the drug.                         | Determined by the investigator to be related to the drug.                         |
| ↓ Defined as an action taken of dose reduced, drug interrupted or drug withdrawn. | ↓ Defined as an action taken of dose reduced, drug interrupted or drug withdrawn. | ↓ Defined as an action taken of dose reduced, drug interrupted or drug withdrawn. | ↓ Defined as an action taken of dose reduced, drug interrupted or drug withdrawn. | ↓ Defined as an action taken of dose reduced, drug interrupted or drug withdrawn. |
| Grades are based on NCI CTCAE version 4.03.                                       | Grades are based on NCI CTCAE version 4.03.                                       | Grades are based on NCI CTCAE version 4.03.                                       | Grades are based on NCI CTCAE version 4.03.                                       | Grades are based on NCI CTCAE version 4.03.                                       |
| Database Cutoff Date:15JUN2021                                                    | Database Cutoff Date:15JUN2021                                                    | Database Cutoff Date:15JUN2021                                                    | Database Cutoff Date:15JUN2021                                                    | Database Cutoff Date:15JUN2021                                                    |

<div style=\"page-break-after: always\"></div>

## Subjects With Adverse Events of Special Interest (AEOSI) by AEOSI Category and

## Preferred Term

## (Incidence &gt; 0% in One or More Treatment Groups) (Part 2 All Subjects) (ASaT Population)

|                                                                     | Pembrolizumab + Chemotherapy                                        | Pembrolizumab + Chemotherapy                                        | Placebo + Chemotherapy                                              | Placebo + Chemotherapy   |
|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|--------------------------|
|                                                                     | n                                                                   | (%)                                                                 | n                                                                   | (%)                      |
| Subjects in population                                              | 562 157                                                             | (27.9)                                                              | 281 31                                                              | (11.0)                   |
| withoneormoreadverseevents with no adverse events                   | 405                                                                 | (72.1)                                                              | 250                                                                 | (89.0)                   |
| Adrenal Insufficiency                                               | 8                                                                   | (1.4)                                                               | 0                                                                   | (0.0)                    |
| Adrenal insufficiency                                               | 8                                                                   | (1.4)                                                               | 0                                                                   | (0.0)                    |
| Colitis                                                             | 10                                                                  | (1.8)                                                               | 4                                                                   | (1.4)                    |
| Colitis                                                             | 9                                                                   | (1.6)                                                               | 3                                                                   | (1.1)                    |
| Enterocolitis                                                       | 1                                                                   | (0.2)                                                               | 1                                                                   | (0.4)                    |
| Guillain-Barre Syndrome                                             | 1                                                                   | (0.2)                                                               | 0                                                                   | (0.0)                    |
| Guillain-Barre syndrome                                             | 1                                                                   | (0.2)                                                               | 0                                                                   | (0.0)                    |
| Hepatitis                                                           | 5                                                                   | (0.9)                                                               | 2                                                                   | (0.7)                    |
| Autoimmunehepatitis                                                 | 1                                                                   | (0.2)                                                               | 0                                                                   | (0.0)                    |
| Hepatitis                                                           | 3                                                                   | (0.5)                                                               | 2                                                                   | (0.7)                    |
| Immune-mediated hepatitis                                           | 1                                                                   | (0.2)                                                               | 0                                                                   | (0.0)                    |
| Hyperthyroidism                                                     | 24                                                                  | (4.3)                                                               | 3                                                                   | (1.1)                    |
| Hyperthyroidism                                                     | 24                                                                  | (4.3)                                                               | 3                                                                   | (1.1)                    |
| Hypothyroidism                                                      | 89                                                                  | (15.8)                                                              | 9                                                                   | (3.2)                    |
| Hypothyroidism                                                      | 89                                                                  | (15.8)                                                              | 9                                                                   | (3.2)                    |
| Infusion Reactions                                                  | 21                                                                  | (3.7)                                                               | 14                                                                  | (5.0)                    |
| Anaphylactic reaction                                               | 1                                                                   | (0.2)                                                               | 0                                                                   | (0.0)                    |
| Drug hypersensitivity                                               | 3                                                                   | (0.5)                                                               | 1                                                                   | (0.4)                    |
| Hypersensitivity                                                    | 8                                                                   | (1.4)                                                               | 8                                                                   | (2.8)                    |
| Infusionrelatedreaction                                             | 9                                                                   | (1.6)                                                               | 6                                                                   | (2.1)                    |
| Myocarditis                                                         | 1                                                                   | (0.2)                                                               | 0                                                                   | (0.0)                    |
| Myocarditis                                                         | 1                                                                   | (0.2)                                                               | 0                                                                   | (0.0)                    |
| Myositis                                                            | 3                                                                   | (0.5)                                                               | 0                                                                   | (0.0)                    |
| Dermatomyositis                                                     | 1                                                                   | (0.2)                                                               | 0                                                                   | (0.0)                    |
| Myositis                                                            | 2                                                                   | (0.4)                                                               | 0                                                                   | (0.0)                    |
| Nephritis                                                           | 3                                                                   | (0.5)                                                               | 0                                                                   | (0.0)                    |
| Pancreatitis                                                        | 1                                                                   | (0.2)                                                               |                                                                     | (0.0)                    |
|                                                                     |                                                                     |                                                                     | 0                                                                   |                          |
| Pancreatitis                                                        | 1                                                                   | (0.2)                                                               | 0                                                                   | (0.0)                    |
| Pneumonitis                                                         | 14                                                                  | (2.5)                                                               | 0                                                                   | (0.0)                    |
| Organising pneumonia                                                | 1                                                                   | (0.2)                                                               | 0                                                                   | (0.0)                    |
| Pneumonitis                                                         | 13                                                                  | (2.3)                                                               | 0                                                                   | (0.0)                    |
| SevereSkinReactions                                                 | 10                                                                  | (1.8)                                                               | 1                                                                   | (0.4)                    |
| Erythema multiforme                                                 | 0                                                                   | (0.0)                                                               | 1                                                                   | (0.4)                    |
| Pruritus                                                            | 1                                                                   | (0.2)                                                               | 0                                                                   | (0.0)                    |
| Rash                                                                | 4                                                                   | (0.7)                                                               | 0                                                                   | (0.0)                    |
| Rash maculo-papular                                                 | 6                                                                   | (1.1)                                                               | 0                                                                   | (0.0)                    |
| Thyroiditis                                                         | 7                                                                   | (1.2)                                                               | 0                                                                   | (0.0)                    |
|                                                                     | 6                                                                   | (1.1)                                                               | 0                                                                   | (0.0)                    |
| Thyroiditis Thyroiditis acute                                       | 1                                                                   | (0.2)                                                               | 0                                                                   | (0.0)                    |
| Type1 Diabetes Mellitus                                             | 1                                                                   | (0.2)                                                               | 0                                                                   | (0.0)                    |
| Type 1 diabetes mellitus                                            | 1                                                                   | (0.2)                                                               | 0                                                                   | (0.0)                    |
| Uveitis                                                             | 2                                                                   | (0.4)                                                               | 0                                                                   | (0.0)                    |
| Uveitis                                                             | 2                                                                   | (0.4)                                                               | 0                                                                   | (0.0)                    |
| Vasculitis                                                          | 2                                                                   | (0.4)                                                               | 1                                                                   | (0.4)                    |
| Vasculitis                                                          | 2                                                                   | (0.4)                                                               | 1                                                                   | (0.4)                    |
| Everysubjectiscounted asingletimefor each applicablerow and column. | Everysubjectiscounted asingletimefor each applicablerow and column. | Everysubjectiscounted asingletimefor each applicablerow and column. | Everysubjectiscounted asingletimefor each applicablerow and column. |                          |

Non-serious adverse events up to30 days afterlast dose and serious adverse events up to90days afterlast dose are included.

DatabaseCutoffDate:15JUN2021

<div style=\"page-break-after: always\"></div>

## Post marketing experience

The safety profile of pembrolizumab was summarized in the Periodic Safety Update Report covering the period 04-SEP-2019 through 03-SEP-2020. There are no records of any pembrolizumab registration being revoked or withdrawn for safety reasons in any country.

## 2.5.1. Discussion on clinical safety

The safety data in support of the new indication of pembrolizumab (KEYTRUDA ® , MK-3475) in combination with chemotherapy (nab-paclitaxel, paclitaxel, or gemcitabine/carboplatin) for the treatment of patients with locally recurrent inoperable or metastatic TNBC, derive from the pooled data from Part 1 and Part 2 of study KEYNOTE-355. With a cutoff date of 11 DEC 2019, the safety database includes a total of 596 participants who were exposed to the drug combination for a median length of 6.2 months (50.7% had &gt; 6-month exposure), compared to a total of 281 subjects recruited in the placebo arm for which exposure slightly shorter, i.e. 5.3 months in median (44.5% had &gt;6-month exposure).

As an indirect comparative analysis, the MAH also presented data on pembrolizumab monotherapy in participants with metastatic TNBC as derived from studies KEYNOTE-012, KEYNOTE-086, and KEYNOTE119, for a total of 595 subjects who, however, received treatment for a considerably short time course of only 2.1 months in median (only 17.6% of total subjects has exposure &gt;6 months). Therefore, the information provided by this safety dataset is limited to a short-term estimation of the safety profile of pembrolizumab as add-on to chemotherapy vs pembrolizumab alone in the target population. More informative, for the long-term evaluation, is the reference safety dataset (RSD, N=5884) including all currently approved indications for pembrolizumab monotherapy, that provides data for an exposure median length of 4.9 months. However, given the underlying disease, study KEYNOTE-355 offers a safety analysis specifically restricted to female subjects who generally constituted a minority of previous safety database (33.9% of RSD), and younger patients than previously treated (median age of 54 and 53 years in the pembrolizumab and placebo arm, respectively, vs 62 years in RSD).

In the pivotal trial, the main demographic characteristics appeared generally well-balanced between pembrolizumab+ chemotherapy and placebo+chemotherapy groups. Overall features were: 100% females, 78% &lt;65 years, 68% White race, 60% ECOG PS 1. When compared to the pooled pembrolizumab monotherapy RSD, TNBC patients were younger.

The majority of patients (55%) received pembrolizumab in combination with carboplatin/gemcitabine, 32% of the patients were treated with the combination of pembrolizumab and nab-paclitaxel and only 13% of the patients were treated with pembrolizumab and paclitaxel.

The analysis of summary of adverse events revealed an unfavourable toxicity profile for the experimental therapy, based on significant between-treatment arm differences in terms of SAEs (30.4% vs 23.8%), drug-related SAEs (17.6% vs 12.1%), pembrolizumab/placebo dose modifications (52.7% vs 47.7%) and paclitaxel dose modification (10.1% vs 7.5%), any drug discontinuation due to adverse events (21.5% vs 13.2%) with particular reference to pembrolizumab/placebo (10.1% vs 5.3%) and, to a less extent, nab-paclitaxel (4.4% vs 1.4%), paclitaxel (3.2% vs 2.1%), gemcitabine (6.5% vs 5.7%) and carboplatin (7.4% vs 6.0%) discontinuations; a similar trend was observable for drug discont inuations due to drug-related adverse events (18.6% vs 11%), including serious drug-related adverse events (8.6% vs 3.2%). Of note, fatalities (2.5% vs 1.8%) were also more frequent in the experimental vs control arm.

In the comparison with pembrolizumab monotherapy as based on the RSD, all the above mentioned AE categories occurred at higher rate in the pembrolizumab+chemotherapy arm of KEYNOTE-355, with the exception of SAEs (38.3% in RSD) and deaths (5.3% in RSD), likely due to the older age of patients and

<div style=\"page-break-after: always\"></div>

the different tumour-related symptoms and severity of disease of the RSD database. These finding were confirmed in the exposure-adjusted analysis.

The most common AEs (incidence ≥40%) that occurred at a similar rate in both arms were anaemia, nausea and neutropenia, likely associated to chemotherapy side effects. Alopecia, fatigue, diarrhoea, constipation and vomiting were also very common (incidence ≥20%) and comparable between treatment groups. Significantly more frequent in the pembrolizumab+chemotherapy arm were alanine (24.5% vs 19.6%) and aspartase (23% vs 16.7%) aminotransferase increase, decreased appetite (21.5% vs 13.9%), cough (21.1% vs 17.4%), rash (19.6% vs 11.7%), pruritus (15.6% vs 11.4%), hypothyroidism (15.9% vs 3.2%) and upper respiratory tract infections (11.4% vs 8.9%). Data suggest a potentiating effect of pembrolizumab on chemotherapy-associated toxicities, as previously observed in other indications.

The drug-related AEs observed for participants treated with pembrolizumab + chemotherapy (96.3% vs 95%) were consistent with the known safety profiles of chemotherapy, being blood disorders (anemia, neutropenia, thrombocytopenia), nausea, alopecia and liver toxicity (ALT and AST increase) the prevailing reported events in both arms; r ash (15.4% vs 9.3%) and hypothyroidism (13.4% vs 2.8%), that are known side effects of pembrolizumab, also presented with common frequency (&gt;10% in rate) in the experimental but not the placebo arm; and with higher frequency than the RSD (11.4% and 9.5% fo r rash and hypothyroidism, respectively).

In terms of severity, the majority of patients experienced Grade 3-5 AEs (78% vs 73.7% in pembrolizumab+chemotherapy and placebo+chemotherapy, respectively). Blood disorders and liver toxicity were the most frequently reported AEs with a comparable rate (&gt;5% incidence rate) in both arms.  Most of these were drug-related Grade 3-5 AEs (68.3% vs 66.9%). Their incidence was substantially higher than what observed in the RSD (47.8% and 15.4% for grade 3-5 AEs and drugrelated grade 3-5 AEs, respectively).

As regards SAEs (30.4% vs 23.8%) , events demonstrated a pattern that is consistent with chemotherapy-associated toxicities (anaemia, neutropenia, thrombocytopenia, vomiting, sepsis, pneumonia were among the most prevale nt cases); colitis, which is a known AEOSI for pembrolizumab, occurred with an incidence of 0.2%, below the previously reported rate of 1% in the RSD. Drug-related SAEs occurred more frequently in the pembrolizumab+chemotherapy arm than chemotherapy alone; they were mostly related to the blood disorder (5.7% vs 4.6%), gastrointestinal (2.9% vs 2.1%), laboratory investigation (2.5% vs 1.4%) and liver (1.3% vs 0.7%) categories; however, also, renal (0.8% vs 0.7%) and endocrine (0.5% vs 0%) toxicities were registered with higher rate in the experimental arm than either control of KN-355 or RSD, except for endocrine disorders that were more frequent in RSD (1%).

The overall incidence of AEs resulting in death was worse in the combination pembrolizumab + chemotherapy compared to chemotherapy alone (15 vs 5 patients, 2.5% vs 1.8%). The majority of fatal AEs were related to cardiovascular events, but also septic shock and acute kidney injury occurred, both of them in the experimental arm and none in the placebo group. Two deaths in the pembrolizumab plus chemotherapy group were considered drug-related by the investigator. One event (pneumonia) was considered related to pembrolizumab and nab-paclitaxel and one event (acute kidney injury) was considered related to pembrolizumab.

The incidence of AEOSI in the pembrolizumab plus chemotherapy group was 28.2% (vs 10.7% in the control arm), which is similar to the previous experience with pembrolizumab monotherapy (24.9%). In study KEYNOTE-355, less SAEs (3.4% vs 6.4%) and drug-related SAEs (3% vs 5.7%) were reported in the experimental arm compared to the RSD. There were no deaths related to AEOSIs. The rate of any study drug dose modification (10.2% vs 8.9%) or discontinuation (4% vs 3.9%) was similar between pembrolizumab+chemotherapy and pembrolizumab monotherapy as reported in the RSD. The addition of

<div style=\"page-break-after: always\"></div>

chemotherapy apparently did not increase the risk and severity of AEOSI related to pembrolizumab compared to pembrolizumab monotherapy. The pattern of events is typical of pembrolizumab monotherapy; this consideration also applies to time of onset and event duration of events. There is, however, a higher incidence of hypothyroidism (15.9% vs 11%), with more events requiring corticosteroids (5.3% vs 1.5%) in KEYNOTE-355 relative to RSD. The exposure and sex-adjusted analysis confirmed no differences in the rate of AEOSI between KEYNOTE-355 and RSD. In terms of laboratory finding, blood cell count decrease and transaminase increase were the prevailing events, that were more marked in the pembrolizumabchemotherapy group than in control; the pattern is typical of chemotherapy-induced toxicities, so they occurred significantly more frequently than what observed in the RSD with pembrolizumab monotherapy.

Discontinuation of any study intervention due to drug-related AEs was higher in the pembrolizumab + chemotherapy group (18.6%) compared with the placebo + chemotherapy group (11.0%); the comparison with pembrolizumab monotherapy also demonstrated a worse profile in the experimental arm than previously reported in the RSD (6.9%). Neutropenia (1.7% vs 0%), increased ALT (2.0% vs 0.3%), increased AST (1.5% vs 0.3%), decreased neutrophil count (1.2% vs 0%), neuropathy peripheral (1.3% vs 0%), and peripheral sensory neuropathy (1.0% vs 0%) were the most common reasons for drug discontinuation, which is consistent with the safety profile of chemotherapeutics co-administrated. However, the tolerability of pembrolizumab +paclitaxel compared to pembrolizumab+ nab-paclitaxel and also to pembrolizumab +platinum-based chemotherapy is worrisome. 29.6% of the subjects discontinued any drug in the pembrolizumab + paclitaxel group (compared to 12.5% in the placebo + paclitaxel group). 16% discontinued pembrolizumab which is twice as high as the proportion of pembrolizumab discontinuations in the pembrolizumab + nab-paclitaxel group (7.6%) and the pembrolizumab + carboplatin/gemcitabine group (8.1%). The incidences of AEs and drug-related AEs leading to discontinuation of pembrolizumab were higher in the pembrolizumab + paclitaxel group compared to the pembrolizumab + nab-paclitaxel group. This was primarily driven by AEs of ALT increased (3.7% vs 1.7%) and AST increased (6.2% vs 1.7%), which all occurred in ≤5 participants. Overall, the addition of pembrolizumab to paclitaxel is less tolerable than the addition of pembrolizumab to nab-paclitaxel. However, as the numbers are limited this should be interpreted with caution.

## Safety profile by subgroups

Age : In study KN-355, a similar age-dependent increase in toxicity can be observed in both treatment arms when safety is analysed by using a cut-off of 65 years. The analysis by age groups &lt;65, 65-74, 7584, 85+ revealed that pembrolizumab augmented the rate of CNS disorders, AEs related to falling and infections across all patient categories; particularly marked is the increase in CNS (24.1% vs 0%), AEs related falling (24.1% vs 0%) and infections (79.3% vs 44.4%) that is observable in the oldest patient group receiving the combined therapy compared to the corrispective in the chemotherapy arm. The comparison between pembrolizumab + chemotherapy and pembrolizumab monotherapy revealed an increase in events across all AEs categories, which is particularly evident marked for the group of &gt;75year old. As previously observed in other indications for which combined regimens have been approved or are currently under review, the tolerability of pembrolizumab + chemotherapy is a concern for patients aged ≥75 years.  Given the limited number of sub jects in this category within individual trials, a pooled analyses of pembrolizumab + chemotherapy across indications was requested. Data suggested that pembrolizumab as addon to chemotherapeutic agents is less tolerated in patients ≥75 years of age than their younger counterpart. The pooled analysis corroborates the consistent trend observed across individual studies showing increased toxicity of pembrolizumab as add-on to chemotherapy by age. On this basis, a revision of section 4.4 and 5.1 of the SmPC was deemed necessary.

Chemotherapy : Pembrolizumab generally increased the toxicity of all chemotherapeutic agents tested in the trial. The different drug combinations were overall comparable in terms of incidence of AEs. However, given the better tolerability of nab-paclitaxel compared to the other agents when used alone, the most

<div style=\"page-break-after: always\"></div>

relevant impact of pembrolizumab on safety appears within the nab-paclitaxel groups, with a worsening in toxicity grade 3-5 events (62.8% vs 49.5%), drug-related grade 3-5 events (48.3% vs 36.8%), SAEs events (30.2% vs 17.9%) and drug-related SAEs (14.5% vs 7.4%), discontinuation due to adverse (16.3% vs 5.3%) or drug-related events (14% vs 4.2%) in patients treated with pembrolizumab+nabpaclitaxel versus nab-paclitaxel alone. The frequency of these events, however, was similar compared to the other combinations.

ECOG score : As expected, participants with a higher (1 vs 0) ECOG PS at baseline reported higher frequencies AEs across all categories and in both treatment arms; pembro lizumab slightly augmented the toxicity of therapy in both ECOG score categories.

Race : Race does not seem to influence the toxicity profile of either regimens since similar rate of events is observable in white and nonwhite across all AEs categories; pe mbrolizumab worsened the toxicity of chemotherapy regardless of race.

Region : the pattern of AEs as stratified by EU vs non-EU is similar.

## Updated safety data

During the procedure, the MAH submitted the results of the final analysis for OS (data cut-off date 15 Jun 2021). Overall, the updated safety results at the FA were generally consistent with those observed at IA2, with no new safety concerns identified.

## 2.5.2. Conclusions on clinical safety

Pembrolizumab as adds-on to chemotherapy presents an unfavourable profile compared to chemotherapy alone or pembrolizumab in monotherapy. The pattern of observed AEs is consistent with chemotherapyrelated toxicities; AEOSIs associated to the known safety profile of pembrolizumab were also observed and generally occurred at a similar rate than previously reported. The tolerability of the combined regimen appears worse in the oldest group of patients.

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.6. Risk management plan

The MAH submitted/was requested to submit an updated RMP version with this application.

The PRAC considered that the risk management plan version 32 is acceptable.

The CHMP endorsed this advice without changes.

The CHMP endorsed the Risk Management Plan version 32 with the following content:

<div style=\"page-break-after: always\"></div>

## Safety concerns

Table: List of safety concerns

| List of safety concerns    | List of safety concerns                                                                                                                                                                                                                                                                                           |
|----------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks | Immune-related adverse reactions (including immune-related pneumonitis, colitis, hepatitis, nephritis, and endocrinopathies)                                                                                                                                                                                      |
| Important potential risks  | For hematologic malignancies: increased risk of severe complications of allogeneic stem cell transplantation (SCT) in patients who have previously received pembrolizumab Graft versus host disease (GVHD) after pembrolizumab administration in patients with a history of allogeneic stem cell transplant (SCT) |
| Missing information        | None                                                                                                                                                                                                                                                                                                              |

## Pharmacovigilance plan

There are no ongoing or planned additional pharmacovigilance studies that are required for pembrolizumab

## Risk minimisation measures

Table : Summary Table of Pharmacovigilance Activities and Risk Minimisation Activities by Safety Concern

| Safety Concern                                                                                                               | Risk minimisation Measures                                                                                                                                                                                                                                                                                                                             | Pharmacovigilance Activities                                                                                                                                                                                          |
|------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important Identified Risks: Immune-Related Adverse Reactions                                                                 | Important Identified Risks: Immune-Related Adverse Reactions                                                                                                                                                                                                                                                                                           | Important Identified Risks: Immune-Related Adverse Reactions                                                                                                                                                          |
| Immune-related adverse reactions (including immune- related pneumonitis, colitis, hepatitis, nephritis and endocrinopathies) | Routine risk minimisation measures: • The risk of the immune- related adverse reactions (including immune-related pneumonitis colitis, hepatitis, nephritis, and endocrinopathies) associated with the use of pembrolizumab is described in the SmPC, Section 4.2, 4.4, 4.8 and appropriate advice is provided to the prescriber to minimize the risk. | Routine pharmacovigilance activities Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Targeted questionnaire for spontaneous postmarketing reports of all adverse events |
|                                                                                                                              | Additional risk minimisation measures: Patient educational materials                                                                                                                                                                                                                                                                                   | Additional pharmacovigilance including: • Safety monitoring in all ongoing MAH-sponsored clinical trials for pembrolizumab in various tumor types                                                                     |

<div style=\"page-break-after: always\"></div>

Table : Summary Table of Pharmacovigilance Activities and Risk Minimisation Activities by Safety Concern

| Safety Concern                                                                                                                                | Risk minimisation Measures                                                                                                                                                                                                                                                                                                                                       | Pharmacovigilance Activities                                                                                                                                                           |
|-----------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important Potential Risks                                                                                                                     | Important Potential Risks                                                                                                                                                                                                                                                                                                                                        | Important Potential Risks                                                                                                                                                              |
| For hematologic malignancies: increased risk of severe complications of allogeneic SCT in patients who have previously received pembrolizumab | Routine risk minimisation measures: • For Hematologic malignancies: the increased risk of severe complications of allogeneic SCT in patients who have previously received pembrolizumab is described in the SmPC, Section 4.4, 4.8 and appropriate advice is provided to the prescriber to minimize the risk. No additional risk minimisation measures warranted | Routine pharmacovigilance activities Additional pharmacovigilance including: • Safety monitoring in the ongoing HL trials (KN087, KN204).                                              |
| GVHD after pembrolizumab administration in patients with a history of allogeneic SCT                                                          | Routine risk minimisation measures: • GVHD after pembrolizumab administration in patients with a history of allogeneic SCT is described in the SmPC, Section 4.4 and appropriate advice is provided to the prescriber to minimize the risk. No additional risk minimisation measures warranted                                                                   | Routine pharmacovigilance activities Additional pharmacovigilance including: • Safety monitoring in all ongoing MAH-sponsored clinical trials for pembrolizumab in various tumor types |

## 2.7. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC have been updated. The Package Leaflet has been updated accordingly.

## 2.7.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable for the following reasons:

- -no significant changes are made to the package leaflet; in particular, the key messages for the safe use of the medicinal product are not impacted.
- the design, layout and format of the package leaflet will not be affected.

<div style=\"page-break-after: always\"></div>

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

The sought indication is for Keytruda, in combination with chemotherapy, for the treatment of locally recurrent unresectable or metastatic triple negative breast cancer in adults whose tumours express PD-L1 with a CPS ≥ 10 and who have not received prior chemotherapy for metastatic disease.

## 3.1.2. Available therapies and unmet medical need

Due to the ER, PgR and HER-2 negativity, treatment of TNBC is challenging due to the lack of therapeutic target. In the sought locally advanced unresectable/metastatic first line setting, chemotherapy remains the only available non-investigational systemic treatment option for non-BRCA-mutated patients, with no specific recommendations regarding types of agents, with the possible exception of platinum compounds for BRCA-mutated patients. Anthracyclines and taxanes are preferred (depending on prior use), single agent capecitabine, vinorelbine or eribulin are also possible choices. In 2019, Tecentriq in combination with nab-paclitaxel was approved in the 1L TNBC setting for tumours having PDL1 expression ≥1%, based on PFS advantage and positive OS trend shown in the pivotal IMpassion130 study 30 .

## 3.1.3. Main clinical studies

KEYNOTE-355: A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) plus Chemotherapy vs Placebo plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer. Results of Interim Analysis 2 (IA2, i.e. final for PFS, interim for OS) with data cut-off date 11 Dec 2019, median follow up of 19.2 months (range 0.3, 35) in the CPS ≥ 10 population, have been submitted. During the procedure, the final analysis (FA) for OS was also submitted (data cut-off date 15 Jun 2021), with median follow up of 20.2 months (range 0.3, 53.1) in the CPS ≥ 10 population.

## 3.2. Favourable effects

In participants whose tumors express PDL1 CPS≥10 , pembrolizumab plus chemotherapy provided:

- Statistically significant PFS by BICR per RECIST 1.1 benefit of pembrolizumab+chemotherapy vs placebo+chemotherapy: HR=0.65, 95%CI 0.49, 0.86, p=0.0012, corresponding to gain in median PFS of about 4 months (9.7 vs 5.6 months) at the IA2 (final for PFS), confirmed in an updated PFS analysis.
- Statistically significant OS results at the FA, with a gain in median survival of about 7 months: OS HR of 0.73 (95% CI: 0.55, 0.95), median OS 23 months (95%CI 19, 26.3) vs 16.1 (95%CI 12.6, 18.8). KM curves separate at month 6 and remain separated over time.
- Numerical advantage in ORR based on BICR assessment (52.7% vs 40.8%), including higher CRs (16.8% vs 12.6%).

30  Tecentriq-H-C-004143-X-0017 EPAR (EMA/CHMP/425313/2019)

<div style=\"page-break-after: always\"></div>

- Median DOR longer in the CPS ≥ 10 (12.1 months) than in the ITT population (7.3 months).
- Supportive PFS2 trend: HR 0.69 (95%CI 0.49, 0.87), median PFS2 16.9 vs 10.9 months.
- No relevant differences were observed between treatment arms in the various PRO scores and parameters examined, neither supporting a benefit nor indicating a detrimental effect of additional toxicity by the addition of pembrolizumab

## 3.3. Uncertainties and limitations about favourable effects

- There are many uncertainties around the observation in KEYNOTE-355 that gemcitabine/carboplatin would be less effective than pembrolizumab + taxanes and maybe available data are finally not sufficient to draw reliable conclusions.
- A post-hoc analysis on EU patients showed PFS and OS HR &gt;1 and negative ORR difference. The small number of patients however (64 vs 28 in the CPS≥10 population) preclude further investigation, and it could be agreed that differences noted are likely due to random variation.
- The treatment benefit is uncertain for patients with disease free interval &lt;12 months [n=66]: PFS HR 1.0, OS HR 1.19, ORR diff. minus 14.2%. Numbers are limited (especially in the control arm n=17), and there is no support from external studies, therefore no conclusions can be drawn in this population.
- A smaller treatment effect was also observed for patients with prior (neo)adjuvant treatment (n=193): PFS HR 0.78, OS HR 0.90, ORR difference 3.8%, similarly observed in the IMpower130 study in the same setting.

## 3.4. Unfavourable effects

- Overall AEs were more frequent with the addition of pembrolizumab to chemotherapy compared to chemotherapy alone, based on significant between-treatment arm differences in terms of SAEs (30.4% vs 23.8%), drug-related SAEs (17.6% vs 12.1%), pembrolizumab/placebo dose modifications (52.7% vs 47.7%) and paclitaxel dose modification (10.1% vs 7.5%), any drug discontinuation due to adverse events (21.5% vs 13.2%) with particular reference to pembrolizumab/placebo (10.1% vs 5.3%) and, to a less extent, nab-paclitaxel (4.4% vs 1.4%), paclitaxel (3.2% vs 2.1%), gemcitabine (6. 5% vs 5.7%) and carboplatin (7.4% vs 6.0%) discontinuations; a similar trend was observ ed for drug discontinuations due to drug-related adverse events (18.6% vs 11%), including serious drugrelated adverse events (8.6% vs 3.2%). Of note, fatalities (2.5% vs 1.8%) were also more frequent in the experimental vs control arm.
- The most common AEs (incidence ≥40%) that occurred at a similar rate in both arms were anaemia, nausea and neutropenia, likely associated to chemotherapy side effects. Alopecia, fatigue, diarreha, constipation and vomiting were also very common (incidence ≥20%) and comparable between treatment groups.
- Significantly more frequent in the pembrolizumab+chemotherapy arm were alanine (24.5% vs 19.6%) and aspartase (23% vs 16.7%) aminotransferase increase, decreased appetite (21.5% vs 13.9%), cough (21.1% vs 17.4%), rash (19.6% vs 11.7%), pruritus (15.6% vs 11.4%), hypothyroidism (15.9% vs 3.1%) and upper respiratory tract infections (11.4% vs 8.9%).
- The drug-related AEs observed for participants treated with pembrolizumab + chemotherapy (96.3% vs 95%) were consistent with the known safety profiles of chemotherapy, being blood disorders

<div style=\"page-break-after: always\"></div>

(anemia, neutropenia, thrombocytopenia), nausea, alopecia and liver toxicity (ALT and AST increase) the prevailing reported events in both arms; rash (15.4% vs 9.3%) and hypothyroidism (13.4% vs 2.8%), that are known side effects of pembrolizumab, also presented with common frequency (&gt;10% in rate) in the experimental but not the placebo arm;

- Drug-related SAEs occurred more frequently in the pembrolizumab+chemotherapy arm than chemotherapy alone; they were mostly related to the blood disorder (5.7% vs 4.6%), gastrointestinal (2.9% vs 2.1%), laboratory investigation (2.5% vs 1.4%) and liver (1.3% vs 0.7%) categories. The overall incidence of AEs resulting in death was worse in the combination pembrolizumab + chemotherapy compared to chemotherapy alone (15 vs 5 patients, 2.5% vs 1.8%). The majority of fatal AEs were related to cardiovascular events, but also septic shock and acute kidney injury occurred, both of them in the experimental arm and none in the placebo group.
- The incidence of AEOSI in the pembrolizumab plus chemotherapy group was 28.2% (vs 10.7% in the control arm), which is similar to the previous experience with pembrolizumab monotherapy (24.9%). In study KEYNOTE-355, less SAEs (3.4% vs 6.4%) and drug-related SAEs (3% vs 5.7%) were reported in the experimental arm compared to the RSD. There were no deaths related to AEOSIs.

## 3.5. Uncertainties and limitations about unfavourable effects

- Data demonstrate a potentiating effect of pembrolizumab on chemotherapy-associated toxicities, as previously observed on other indications for which combined regimens have been approved. The tolerability of pembrolizumab + chemotherapy is a concern for patients aged ≥ 75 years. Relevant wording in the SmPC has been included on this aspect.

## 3.6. Effects Table

Table 2. Effects Table for Keytruda in combination with chemotherapy for 1L locally advanced unresectable/metastatic TNBC with PD-L1 CPS ≥ 10 - KEYNOTE-355 IA2, 11 Dec 2019; FA 15 Jun 2021

| Effect                                                                                                                                                | Short description                         | Treatment Pembro +chemo (n=220)                      | Control Placebo +chemo (n=103)            | Uncertainties / Strength of evidence                                                                                                               | Unit Ref ere nc es                        |                                           |
|-------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------|------------------------------------------------------|-------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------|-------------------------------------------|
| Favourable Effects in the CPS≥10 subgroup                                                                                                             | Favourable Effects in the CPS≥10 subgroup | Favourable Effects in the CPS≥10 subgroup            | Favourable Effects in the CPS≥10 subgroup | Favourable Effects in the CPS≥10 subgroup                                                                                                          | Favourable Effects in the CPS≥10 subgroup | Favourable Effects in the CPS≥10 subgroup |
| Time from randomization to first documented disease progression per RECIST 1.1 based on blinded CIV or death due to any cause, whichever occurs first | months (95% CI) n/a                       | 9.7 (7.6, 11.3) HR 0.65 (95%CI (0.49, p-value 0.0012 | 5.6 (5.3, 7.5) 0.86)                      | At the IA2 (i.e. final analysis for PFS), statistically significant advantage in PFS in CPS≥10, supported by other endpoints. Treatment effect not | PFS (by CIV per RECIST 1.1) CSR KN- 355   |                                           |
| OS Time from randomization to death due to any cause                                                                                                  | months (95% CI) n/a                       | 23 (19, 26.3) HR 0.73 (95%CI p-value 0.0093          | 16.1 (12.6, 18.8) 0.55, 0.95)             | Limited data in ≥75 years At the FA for OS, statistically significant OS benefit in CPS ≥ 10                                                       |                                           |                                           |
| ORR Confirmed CR or PR (by BICR per RECIST 1.1)                                                                                                       | % (95% CI)                                | 53.2% (46.4, 59.9)                                   | 39.8 % (30.3, 49.9)                       | Trend towards higher ORR and CR/ less SD and more PD                                                                                               |                                           |                                           |
| DOR Time from first response to PD or death due to any cause, whichever occurs first, in subjects who achieve PR or CR                                | months (range)                            | 19.3 (1.6+ - 29.8)                                   | 7.3 (1.5 - 32.5+)                         | Durable responses                                                                                                                                  |                                           |                                           |
| Unfavourable Effects                                                                                                                                  | Unfavourable Effects                      | Unfavourable Effects                                 | Unfavourable Effects                      | Unfavourable Effects                                                                                                                               | Unfavourable Effects                      | Unfavourable Effects                      |

<div style=\"page-break-after: always\"></div>

| Effect     | Short description                                   | Unit   |   Treatment Pembro +chemo (n=220) |   Control Placebo +chemo (n=103) | Uncertainties / Strength of evidence                                                                                                                                                              | Ref ere nc es   |
|------------|-----------------------------------------------------|--------|-----------------------------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|
| AE summary | drug related G3-5 AE                                | %      |                              68.3 |                             66.9 | Safety of the combination consistent with the established safety profile of the chemotherapy and pembrolizumab. No new safety concern identified. Concern over toxicity in elderly ( ≥ 75 years). | CSR             |
| AE summary | drug related SAE                                    | %      |                              17.6 |                             12.1 | Safety of the combination consistent with the established safety profile of the chemotherapy and pembrolizumab. No new safety concern identified. Concern over toxicity in elderly ( ≥ 75 years). | KN-             |
| AE summary | death due to drug related AE                        | %      |                               0.3 |                              0   | Safety of the combination consistent with the established safety profile of the chemotherapy and pembrolizumab. No new safety concern identified. Concern over toxicity in elderly ( ≥ 75 years). | 355             |
| AE summary | discontinuation of any drug due to drug related AE  | %      |                              18.6 |                             11   | Safety of the combination consistent with the established safety profile of the chemotherapy and pembrolizumab. No new safety concern identified. Concern over toxicity in elderly ( ≥ 75 years). | 355             |
| AE summary | discontinuation of any drug due to drug related SAE | %      |                               6.7 |                              1.4 | Safety of the combination consistent with the established safety profile of the chemotherapy and pembrolizumab. No new safety concern identified. Concern over toxicity in elderly ( ≥ 75 years). | 355             |
| AEOSI      | Hypothyroidism                                      | %      |                              15.9 |                              3.2 | Safety of the combination consistent with the established safety profile of the chemotherapy and pembrolizumab. No new safety concern identified. Concern over toxicity in elderly ( ≥ 75 years). | 355             |
| AEOSI      | Pneumonitis                                         | %      |                               2.5 |                              0   | Safety of the combination consistent with the established safety profile of the chemotherapy and pembrolizumab. No new safety concern identified. Concern over toxicity in elderly ( ≥ 75 years). | 355             |
| AEOSI      | hyperthyroidism                                     | %      |                               5.2 |                              1.1 | Safety of the combination consistent with the established safety profile of the chemotherapy and pembrolizumab. No new safety concern identified. Concern over toxicity in elderly ( ≥ 75 years). | 355             |

Abbreviations: PFS: progression free survival; OS: overall survival; ORR: objective response rate; DOR: duration of response; CIV: central imaging vendor ; NR: not reached; CI: confidence interval; AE: adverse event; SAE: serious adverse event; AEOSI: Adverse Events of Special Interest; CRS: clinical study report

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

Pembrolizumab in combination with chemotherapy showed PFS and OS advantage compared to chemotherapy in the subgroup with PDL1 expression CPS≥10 as first line treatment of locally advanced unresectable/metastatic TNBC in the pivotal KEYNOTE-355 study. The statistically significant PFS benefit seen at the IA2 was later supported by a statistically significant OS at the FA, and supportive ORR, DOR and PFS2 results. The PFS and OS hypotheses in the CPS≥10 subgroup, defining about 38% of the ITT population, were however added with a protocol amendment one year after the IA1 conduction. The MAH claims that the choice o f the additional CPS≥10 cut off was based only on external results (KEYNOTE -119 and IMpassion130) and that no data from KEYNOTE-355 study itself was used. The biological rationale for an enriched pembrolizumab efficacy with higher PD-L1 expression is indeed considered supported by the above mentioned external data, whose timing is also compatible with Amendment 5 release, and by pembrolizumab study results in various diseases. At the same time, pembrolizumab monotherapy in pretreated TNBC in KEYNOTE-119 did not show outstanding results in this disease.

As expected, pembrolizumab as add-on to chemotherapy presents an unfavourable profile compared to chemotherapy alone or pembrolizumab in monotherapy. The pattern of observed AEs is consistent with chemotherapyrelated toxicities; AEOSIs associated to the known safety profile of pembrolizumab were also observed and generally occurred at a similar rate as previously reported. The tolerability of the combined regimen appears worse in the oldest group of patients.

## 3.7.2. Balance of benefits and risks

Pembrolizumab in combination with chemotherapy showed significant OS and PFS advantage compared to chemotherapy as 1L treatment in TNBC with PDL1 CPS≥10 based on KEYNOTE -355 study. This outweighs the unfavourable profile compared to chemotherapy alone or pembrolizumab in monotherapy, and it can be concluded that the benefit/risk balance is positive.

## 3.7.3. Additional considerations on the benefit-risk balance

The relevance of the generic wording 'pembrolizumab in combination with chemotherapy ' proposed in the indication was considered in view that the pivotal study KEYNOTE-355 was performed with

<div style=\"page-break-after: always\"></div>

pembrolizumab in combination with specific chemotherapy drugs. According to EMA guideline on the Wording of therapeutic indication (EMA/CHMP/483022/2019), ' From a regulatory point of view, the therapeutic indication should be clearly stated in section 4.1 of the SmPC to reflect in which disease/condition and target population the benefit/risk balance is established to be positive .' Furthermore, ' If there is a need to specify use in combination therapy in SmPC section 4.1: Is there a need to specify particular combinations (e.g. the studied combinations if it is expected that the benefit risk balance may differ with other combinations ) or could a general statement (\"in combination with other products\") be used (with information on combinations studied reflected in other parts of the SmPC)? If so, since the description of performed studies in section 5.1 cannot be seen as restricting or broadening the indication, restriction or extrapolation in section 4.1 in terms of combination therapy should be justified in the assessment report . ' The possibility to extrapolate the use of pembrolizumab in combination with any chemotherapy currently used in TNBC was supported by efficacy shown in available clinical trials in TNBC, although in different setting, such as KEYNOTE-522 (phase III, carboplatin-paclitaxel, doxorubicin or epirubicin-ciclophosphamide in the neoadjuvant setting) and ENHANCE-1 (phase Ib/II single arm, pembrolizumab+eribulin). It was agreed that there are no data to suggest that the benefit of adding pembrolizumab to any of recommended treatment regimens for patients with locally recurrent unresectable or metastatic TNBC would be altered depending on the chemotherapy backbone chosen.

According to current guidelines (ESMO ABC 5th) for most patients, 'chemotherapy remains the only available non-investigational systemic treatment option for non-BRCA-mutated triple-negative ABC, with no specific recommendations regarding types of agents, with the possible exception of platinum compounds for patients with BRCA-mutated triple-negative ABC.' Chemotherapy regimens that can be used include anthracyclines, taxanes, antimetabolite (capecitabine, gemcitabine), eribulin, platinum, and combination chemotherapies in patients with rapid clinical progression, life-threatening visceral metastases, or need for rapid symptom and/or disease control.

On the one hand, there are previous experiences in other trials (atezolizumab + nab-paclitaxel and atezolizumab + paclitaxel in IMpassion130 and IMpassion 131 studies) showing a different outcome according to backbone chemotherapy in the same setting, that could suggest caution in extrapolation. On the other hand, the pembrolizumab study KEYNOTE-355 study showed no concern over the use of paclitaxel in combination with pembrolizumab (contrary to atezolizumab), though based on subgroup data.

With regard to pembrolizumab in combination with carboplatin-gemcitabine, where a lower treatment effect was seen, it is considered that it is unlikely from a biological perspective to assume a lack of treatment effect with carboplatin/gemcitabine as backbone, given prior experience with this combination. The same reasoning could potentially apply to other chemotherapies. Although not all drugs have been combined with pembrolizumab, and there are not necessarily safety data available for each combination, it is not expected that the benefit/risk balance will differ with other combinations, therefore, in line with EMA guidelines, the use of 'chemotherapy' in SmPC 4.1 can be considered acceptable. A reference to SmPC 5.1 was added at the end of the wording of the indication to raise awareness of the chemotherapy drugs used in the pivotal KEYNOTE-355 study (see SmPC section 4.1). It can be expected that physicians will use the combinations for whom there is clinical trial experience, although as noted in the EMA guidelines, 5.1 section does not restrict the indication.

## 3.8. Conclusions

The overall B/R of Keytruda in combination with chemotherapy for the 1L treatment of locally recurrent unresectable or metastatic TNBC in subjects with PD-L1 positive tumours (CPS ≥ 10) is positive.

<div style=\"page-break-after: always\"></div>

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication for Keytruda to include in combination with chemotherapy, treatment of locally recurrent unresectable or metastatic triple negative breast cancer in adults whose tumours express PD L1 with a CPS ≥ 10 and who have not received prior chemotherapy for metastatic disease; as a consequence, sections 4.1, 4.2, 4.4, 4.8  and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 32 of the RMP has also been submitted.

## Amendments to the marketing authorisation

In view of the data submitted with the variation, amendments to Annex(es) I and IIIB and to the Risk Management Plan are recommended.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## Risk management plan (RMP)

The Marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.

In addition, an updated RMP should be submitted:

At the request of the European Medicines Agency;

Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.